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The liver is a vertebrate-specific structure essential for all member species of this 
subphylum, including humans, for detoxification, homeostasis, digestion and 
growth. It is an accessory digestive organ, producing bile (an alkaline fluid 
containing cholesterol and bile acids), which aids absorption of fat and fat-soluble 
micronutrients. The liver consists mostly of hepatocytes which perform a wide 
variety of high-volume biochemical reactions, including the synthesis and 
breakdown of small and complex biomolecules, many of which are necessary for 
normal vital functions. Estimates regarding the organ's total number of functions 
vary, but a common number listed in textbooks is it being around 500. Although, or 
maybe because of, being essential for life, it is also the location of many diseases. 
In this thesis I have pursued to obtain more insight in the disease of the liver. 
 
     Hepatitis C 
 
Liver disease often involves hepatitis (inflammation of the liver). Although there are 
many etiologies that underlie hepatitis, the viral infection is probably the most 
common cause of hepatitis. In this thesis I provide special attention to Hepatitis C 
virus (HCV), which can be labelled as an import global health problem as chronic 
HCV infection is the second most common risk factor for hepatocellular carcinoma 
(HCC) and is responsible for 10–25% of all HCC cases.1 Hence there is an urgent 
to better understand the dynamics of HCV infection and the factors that underlie 
HCC development in such patients. 
An important factor should be taken into account in this respect are developments 
with respect to treatment of HCV infection. Interferon (IFN)-α and pegylated (PEG) 
recombinant human IFN were approved for treating HCV infection in 90th century. 
Although not fully satisfactory, the rate of sustained virologic response (SVR) 
achieved more than 80% when using response-guided PEG-IFNα plus ribavirin (PR) 
therapy.2 Rapid advances in therapy with oral direct-acting antivirals (DAAs) have 
resulted in further significant improvements in SVR which exceed 95%.3 Reaching 
SVR significantly reduces the risk of developing hepatoma, as was already known 
from the IFN era, so one may have expected that with the newer DAAs, such a risk 
would be minimized to an occasional event, but several reports from the wider 
clinical applications of the new treatments were worrying.4-6 They observed much 
higher rate HCC development than previous reports on IFN responders which 
called more attention on the application of DAAs to HCV eradication. Therefor it 
was important to further investigate whether DAAs would affect HCC development 
and to evaluate the efficacy and safety in some special cohort of patients. 
 
    Hepatitis E 
Hepatitis E (HEV) is a single-strand positive-sense RNA virus belongs to the 
Orthohepevirus genus within the Hepeviridae family and at least four types can 
produce human infection. It is the most common causative agent for acute viral 
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hepatitis worldwide and although often hardly symptomatic, it is still estimated that 
there are around 56000 HEV-related deaths annually.7 HEV genotype 1 and 2 are 
indigenous predominantly in countries of the developing world, especially in Asia 
and Africa. They are transmitted via a fecal-oral route through contaminated water 
sources in conjunction with poor sanitary conditions, thus these genotypes 
responsible for many of the water-borne outbreaks of HEV. In contrast, HEV 
genotypes 3 and 4 infect humans and animals alike and with transmission to 
humans from animal reservoirs (like pigs) being responsible for the infectious 
pressure on the human population and human-to-human infection being not 
important if present at all.8 The latter strains are mainly restricted to developing 
countries.9 In general, HEV causes a self-limiting infection with low mortality. 
However, fulminant hepatitis may develop and a high mortality rate (as high as 
20%-30%) is reported in pregnant women.10, 11 Chronic HEV infections are 
increasingly documented in immunocompromised patients, individuals with HIV 
infection and hemodialysis patients. As thus, HEV constitutes as an important threat 
to global health and further research into the factors driving disease progression as 
well as how its best managed is required. 
 
     NAFLD and MAFLD 
Apart, from infections of pathogens, also lifestyle may be responsible for important 
pathology in the liver. Maybe nonalcoholic fatty liver disease (NAFLD, also called 
metabolic dysfunction-associated fatty liver disease [MAFLD]) is one of the most 
important liver diseases. This condition, to a certain extent, can be considered as 
a hepatic manifestation of metabolic syndrome, in turn the consequence of an 
unhealthy diet and sedentary behavioral style.12 Practically, NAFLD is defined as 
the presence of 5% of hepatic steatosis in the absence of competing liver disease 
etiologies, such as chronic viral hepatitis, use of medications that induce steatosis 
(such as amiodarone or tamoxifen), or other chronic liver diseases, such as 
autoimmune hepatitis, hemochromatosis, Wilson’s disease, or significant alcohol 
consumption. Although NAFLD is very common and not an overly serious condition, 
a subgroup of patients progresses to nonalcoholic steatohepatitis (NASH), which is 
a more serious type of liver disease. NASH is defined histologically by presence of 
hepatic steatosis with evidence for hepatocyte damage (ballooning hepatocytes).12 
NASH is associated with a multitude of pathological events, but hepatic fibrosis and 
cirrhosis are especially problematic.13-15 Indeed, NASH has been recognized as 
one of the leading causes of cirrhosis in adults in the United States.16-18  
Moreover, HCC has been linked to NAFLD. A comparative study from USA 
documented the yearly cumulative incidence of HCC was 2.6% in patients with 
NASH-associated cirrhosis.19 In parallel, a large US health care database study 
identified NAFLD or NASH as the most common underlying risk factor for HCC, 
being present in 59% of cases, and NAFLD-associated HCC was recognized as an 
emerging indication for liver transplantation in the USA.20, 21 Accordingly, the 
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number of individuals with NAFLD potentially at risk for developing HCC may be 
much larger than previously thought. This presents a compelling need to 
understand the epidemiological information of NAFLD and review potential 
strategies for HCC prevention and surveillance in the affected population. 
 
    Liver cancer 
Apart from viral infection and steatosis, genetic transformation and subsequent 
uncontrolled growth of tumor cells are also important sources of liver disease. Liver 
cancer has a relatively high prevalence and in combination with a paucity of curative 
and therapeutic options, it remains a leading cause of mortality worldwide.22 With 
increasing age, the incidence of liver cancer increases and thus the globally rising 
life expectancy will further provoke more cases of this deadly disease.23, 24 
According to the GLOBOCAN 2018 survey, an estimated 18.1 million new cases of 
liver cancer occurred, while 9.6 million cancer deaths were a consequence of this 
disease.25 It is thus evident that liver cancer is a major health problem warranting 
further research. 
Liver cancer is a term that groups various subtypes of disease, including HCC (the 
most prevalent form), cholangiocarcinoma (CCA) and various other rare types. In 
conjunction they constitute the fourth leading cause of cancer-related death.25 HCC 
accounts for 75% - 85% of liver cancer and is often the consequence of other 
etiologies that provoke chronic inflammatory liver diseases, finally culminating in 
oncogenic transformation including viral hepatitis and liver steatosis.26 In the 
principle this would provide a window for prevention and early diagnosis of disease 
at a potentially curative stage, but unfortunately effective prevention, timely 
diagnosis and treatment remain challenging. Main issues in this respect are the 
absence of symptoms and liver cancer progresses silently without specific 
manifestations, whereas once disease has been established it is highly resistant to 
therapy.27 Insights into the characteristics of the cells that initiate the disease, how 
the cells involved acquire their resistance towards therapeutic intervention, and 
how physiology of these cells is different from non-transformed cells may all proof 
necessary to devise novel avenues for the rational treatment of disease. These are 
all aspects of liver cancer I have aimed to explore in thesis.  
Based on the above I decided to explore in this thesis Hepatitis C, fatty liver disease 
and liver cancer. In order to be able the field forward (which is fairly competitive) I 
realized I had to exploit the possibilities provided by novel tools, which I shall 
discuss below.  
 
    LGR5 and Organoids 
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As also evident from the above, liver biology studies are required, but such studies 
are very challenging in animal models and particularly in humans. Use of immortal 
transformed cell lines has been abundant, also by my own host laboratory,28 but 
the general opinion among professionals is that their use has proven inadequate 
with respect to capturing the clinical situation as encountered by oncologists and 
other physicians. However, progress in stem cell culture achieved in the last decade 
has made it possible to derive in vitro 3D tissue cultures called organoids.29 
Although organoids are stem cell derived, they are organ-like in many respects. 
Their use has been extensively described by colleagues in various recent 
publications.30, 31 Organoids system not only offer a promising platform for stem cell 
study but could also be used for modeling a wide range of diseases.32 In the present 
thesis I shall do so for various liver diseases, including NAFLD. 
Stem cells in cancer are considered to be responsible for tumor initiation and growth, 
therapy resistance and tumor recurrence due to their unique feature of self-renewal 
capacity that enables such cells to give birth to offspring of which a substantial 
fraction retains the stemness.33 Their physiology remains only partly understood 
and also markers identifying these cells have not yet been conclusively defined. 
With regard to liver cancer, analogous to other systems, LGR5 (leucine-rich-repeat-
containing G-protein-coupled receptor 5) may mark a group of stem cells 
proliferating after liver injury induced by carbon tetrachloride (CCL4).31 Generally, 
this marked population has high tumorigenesis, evident by their remarkable 
capacity to form tumors when transplanted into immunodeficient mice.34 Although 
cancer stem cells fuel the tumor initiation and tumor growth, making them attractive 
cancer targets33, many adult stem cells resemble such cells with respect to marker 
expression, making it difficult to target cancer stem cells without killing important 
healthy cells. Encouraging results, however, have been obtained with antibody-
drug conjugates. Anti-LGR5-antibody-drug conjugates selectively target and 
deplete LGR5 stem cells in colon cancer and impede the growth of the primary 
tumor without a major effect on normal stem cell pool.35 These observations make 
LGR5-targeting an attractive novel strategy for combating cancer stem cells and 
the current thesis I have explored this possibility with respect to liver cancer. 
 
    Cancer associated fibroblasts 
Apart from cancer stem cells, supporting cell types may also represent a valuable 
novel target for therapy of liver cancer. In this context cancer-associated fibroblasts 
(CAFs) attract attention, as they are a major component of the tumor 
microenvironment. It is thought that they played an important role in cancer 
progression and drug resistance.36 Research of the interaction between CAFs and 
the cancer cells remained challenging. Potentially, in vitro models that involve co-
cultures of CAFs and cancer cells may be exploited to determine in a potentially 
more clinically relevant tumor model medication effects and such cultures may 
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better mimic the actual situation in vivo. Diverse sorts of co-culture systems 
exploiting the mutual interaction between CAFs and tumor cells have been 
investigated in previous studies and have gained interest in the cancer research 
field, stimulating me to further explore possibilities here.37-39 Important cellular 
interactions within the tumor microenvironment include the interaction between 
(presumptive) tumor cells and fibroblasts are known to further promote tumor 
initiation, progression and metastasis in much of the cancer types investigated.36, 
40, 41 Such models have also been implemented for testing anticancer agents, but 
unfortunately progress is impeded by the reliance on tumor cell lines and/or 
fibroblast cell lines and thus current experimentation has not permitted to fully 
capture the mechanistic details of the mutual interactions involved. Hence, in the 
present thesis I endeavored to determine how isolated CAFs promote the 
proliferation and also the angiogenesis of liver cancer in an organoid system that 
mimics tumors much better as compared to earlier approaches. I find that such 
organoid systems may be useful for imitating liver cancer and allow long-term 
cultures for expanding cancer cells, e.g. for precision medicine approaches aimed 
at extracting personalized information with respect to response to therapy and also 
for further exploring the properties of cancer cells in general especially the stem 
cell population defined by LGR5 positivity in particular. With respect to the latter, I 
addressed my hypothesis that targeting cancer stem cells directly potentially yields 
improved therapy. 
 
     Aim of the thesis 
Lipid droplets are an often-ignored ultrastructural feature of cells but may have 
important roles in explaining pathophysiological mechanisms. With regard to liver 
disease, their role remains undefined. Hence in chapter 2, I set out to perform a 
deep study with respect to the body of current biomedical literature in this respect. 
I find that lipid droplets are closely correlated to lipid storage, lipid metabolism, 
membrane biosynthesis, cell signaling, inflammation, pathogen-host interaction 
and cancer development.  
Hepatitis C, is the diseases in which lipid droplets may be involved. Recently, lipid 
droplets have been linked to the action of DAAs with respect to their action in 
Hepatitis C.42 Research into Hepatitis C is important as the number of HCV-related 
cirrhosis has doubled in the last 10 years and is projected to reach peak levels in 
the next decade. Although the number of decompensated cirrhotic patients has 
continued to increase, the organ donor pool has remained static over the last 
decade, resulting in increased liver transplant waitlist mortality. Moreover, HCV 
occurrence or recurrence is commonly observed in transplant recipients post liver 
transplantation. DAA therapies, however, have changed the landscape of HCV due 
to their excellent safety profile and cure rates. In chapter 3, I compared the efficacy 
and safety of different combinations of DAAs in transplant recipients with HCV 
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genotype 1 (GT1) infection in order to provide more information for clinical 
treatment.  
Inspired by my results described in chapter 3, in chapter 4 of this thesis, I further 
built on the observation that IFN-free all-oral DAAs have replaced IFN-based 
therapy as the standard of care for HCV infection worldwide because of the higher 
SVR rate and lower incidence of adverse effects. By using currently approved DAA 
regimens, HCV can be eradicated in more than 95% of infected hosts, regardless 
of their disease severity. Results with respect to the development of HCC in former 
HCV patients are, however, more ambiguous. Since 2016, the risk of de novo 
occurrence or recurrence of HCC in hepatitis C patients receiving DAAs has been 
debated following a report identifying an unexpected high early tumor recurrence 
rate in such patients. It is possible that alternative DAA regimens may improve 
outcomes, possibly also because of different interactions with lipid droplets (see 
chapter 2). Hence, I initiated an in vitro study on the effects of different 
concentrations of Sofosbuvir in tumor cells. Intriguingly, I observe a moderate 
stimulation of proliferation, possibly related to DAA effects with respect to liver 
cancer. 
DAAs (which I investigated in chapter 3 and 4) have revolutionized the 
management of Hepatitis C, but based on case reports, may have promise in 
Hepatitis E as well.43 In order to understand to which extent such strategies might 
become important, I decided to obtain more insight into the prevalence of Hepatitis 
E, and the study involved is described in chapter 5. Hepatitis E is the fifth known 
human viral hepatitis and is probably the most common cause of acute viral 
hepatitis in the world. Despite being an important cause of hepatitis and being 
widely studied, the HEV remains poorly understood, with little comprehension about 
its prevalence in general population, HIV infected individuals, people with acute 
hepatitis as well as hemodialysis patients. Although chronic HEV infection is not a 
classical cause of HCC, some case reports have indicated that HEV joins hepatitis 
B/C viruses as a potential cause of HCC in chronically infected patients.44 In 
Chapter 5, I performed a systematic review and meta-analysis in order to pooled 
estimate the prevalence of HEV in these subgroups. 
As explained above, not only viral infection is a substantial health problem, but the 
lifestyle-associated fatty liver disease is so as well, prompting investigation, 
especially as the pathophysiology of NAFLD relates to the lipid droplet research 
described in chapter 2. In chapters 6-8, thus NAFLD becomes the center of my 
attention. Fatty liver disease has gained high prevalence and a growing contribution 
to the burden of end-stage liver disease in the general population. In chapter 6 this 
notion is objectified by investigating the prevalence, incidence, and risk factors for 
NAFLD in the general population. In addition, I explored the disease progression 
and clinical outcomes of NAFLD. In view of the results obtained in chapter 7-8, I 
further investigated the MAFLD prevalence in overweight or obese children/adults. 
The results provide an up-to-date description of the problem of fatty liver disease 
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and rationalize further efforts to adequately model this disease for defining rational 
treatment. 
Potential sequela of both viral infection as well as fatty liver disease are the liver 
cancers that may develop in such patients. As explained above, the (cancer) stem 
cell compartment may be an attractive target for clinical management of liver cancer. 
Thus prompted, in chapter 9 and chapter 10, I aim to investigate the 
interrelationship of the proliferative LGR5 stem cells in liver cancer. In chapter 9, I 
aim to establish malignant organoids models from mouse injury primary liver tumors 
and whereas in chapter 10 I demonstrate their applications for liver cancer research. 
Unfortunately, however, I discovered that the studies involved did not yet fully 
capture the influence of stromal component in the liver cancer process and thus I 
decided to explore these aspects better in the last chapter of this thesis. 
In chapter 11, I decided to investigate the interaction of the cancer with the stroma 
and for this purpose I exploit an organoid-based co-culture model that combines 
CAFs with tumor organoids. CAFs that were activated by tumor cells in a co-culture 
condition, displayed increases in α-SMA expression and migratory activity. Tumor 
cell proliferation was significantly increased in the co-culture group when contrasted 
to the control group. I also showed the presence of a reciprocal interaction between 
fibroblasts and tumor organoids and their relation to the components of the 
microenvironment surrounding these two cell types. I conclude that the co-culture 
system might allow study of the tumor microenvironment and may permit evaluation 
of drug screening. Especially in combination with other strategies these findings 
may open the way for improved treatment. 
 
In conjunction, in this thesis I explore the epidemiology of inflammatory disease in 
liver, the stem cell compartment leading to liver cancer development and the 
interactions of liver cancer cells with environment (fibroblasts and immune system). 
I hope to with this multifaceted approach to have contributed to better 
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Abstract 
Lipid droplets (LDs) are cellular organelles for lipid storage with a hydrophobic core of 
neutral lipid enclosed by a phospholipid monolayer. Besides in fat tissue, LDs are also 
widely present in hepatocytes, and play key roles in health and disease of the liver. 
LDs dynamically interact with other cellular organelles to exert a variety of biological 
functions. Besides lipid storage, they are also involved in lipid metabolism, membrane 
biosynthesis, cell signaling, inflammation, pathogen-host interaction and cancer 
development. In this review, we aim to concisely decipher the interactions of LDs with 
other organelles and their functional implications in the important liver diseases, 
including fatty liver disease, viral hepatitis and liver cancer.  
 
Keywords: lipid droplet, lipid biogenesis, organelle, liver disease 
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1. Introduction 
Lipid droplets (LDs) are newly-recognized cellular organelles found in many types of 
cells and tissues [1]. It has a hydrophobic core with neutral lipid, usually consisting of 
triacylglycerols and sterol esters, and encircled by a phospholipid monolayer with 
integral and peripheral proteins (Fig. 1). Initially, LDs were thought only as lipid 
deposition in all organisms without biological functions, whereas accumulating 
research found that different proteins in the surface of LDs endow them various 
functions (Fig. 1). 
 
Figure 1. The structure and biogenesis of lipid droplets. 
 
Acting as a dynamic hub in lipid metabolism, energy homeostasis and cellular signaling 
[2], LDs play essential roles in health and diseases. Because of drastic changes in life 
style and environment, obesity has grown into a global pandemic during the past 
decades, accompanied with comorbidities including insulin resistance, type 2 diabetes 
mellitus, hypertension, cardiovascular disease and dyslipidemia [3]. Thus, research on 
LDs mainly focused on fat cells of adipose tissue, which is the largest energy reservoir 
of the body.  
In fact, the liver is a metabolically active organ serving as a center for lipid metabolism, 
and dysfunction of lipid metabolism is inevitably associated with hepatic 
physiopathology [4]. For example, hepatic impairment of lipid metabolism such as lipid 
overload attributes to the development of fatty liver disease. The epidemic of fatty liver 
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disease parallels the obesity pandemic. Intriguingly, LDs closely connect and interact 
with other cellular organelles including endoplasmic reticulum (ER), mitochondria, 
peroxisomes and lysosomes [5]. In this review, we aim to decipher LD biogenesis, their 
multifaceted interactions with other cellular organelles and functional implications in 
the context of the most important liver diseases. 
 
2. Biogenesis of lipid droplets  
The liver, in particular hepatocytes, plays a key role in lipid metabolism, and is 
considered as the hub of fatty acid synthesis and lipid circulation. Accumulation of LDs 
in hepatocytes is almost universal albert at variable amount. The level of LDs 
presenting in hepatocytes is intimately related to the metabolic status. The biogenesis 
and turnover of LDs in hepatocytes are highly regulated and coordinated. Although the 
exact process of LD biogenesis remains to be further defined, this roughly involves 
four main steps (Fig. 1) 
 
2.1 Lipid synthesis and lens formation 
Neutral lipids, as the core of LDs, are initially generated in ER. The classical model of 
LD biogenesis is based on ER-budding through multiple steps. Firstly, it is the 
synthesis of triacylglycerols and sterol esters in the ER, where enzymes for catalysis 
are located. For triacylglycerols synthesis, fatty acids use fatty acyl-CoA as acyl donors 
to synthesize diacylglycerols either via the glycerol phosphate or monoacylglycerol 
pathway. Diacylglycerols are catalyzed by diacylglycerol acyltransferase enzymes 
(DGAT) to produce triacylglycerols [6]. For synthesis of sterol esters, sterols are 
catalyzed by acyl-CoA:cholesterol acyl transferase (ACAT) [7]. Subsequently, when 
neutral lipid concentration increases, free neutral lipids distributed in the leaflets of ER 
bilayer will coalesce to form an oil len in the ER bilayer [8]. 
 
2.2 Expansion and budding of neutral lipid lens 
Upon neutral lipid accumulation, lens will grow and bud into a nearly spherical droplet 
from ER membrane. ER bilayer phospholipid composition and surface tension are key 
parameters in the process of budding. The different phospholipid composition of ER 
membrane and/or surface tension will form different sizes of LDs [9]. LD budding also 
facilitates the recruitment and function of many proteins. For example, seipin 
essentially involved in LD biogenesis is an ER membrane protein. Seipin is stably 
associated with nascent ER-LD contacts [10], which supports the formation of ER-LD 
contacts and promotes delivery of triacylglycerols from ER to LDs [11]. The cooperation 
between phospholipids and proteins contributes to LDs emergence. Their composition 
dictates ER membrane asymmetricity which guides directionality in the process of LD 
budding [12].  
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2.3 Proteins targeting to lipid droplets 
There are more than 100 proteins on the phospholipid monolayer surface of LDs which 
endow LDs distinct functions. How proteins specifically target to LDs remains largely 
elusive. Two major pathways help to understand the basic mechanisms of proteins 
targeting LDs, which are associated with two categories of proteins, including class I 
and II [13]. 
Class I proteins translocate from the ER bilayer with a hydrophobic hairpin structure to 
LDs via membrane bridges. These proteins, such as GPAT4, DGAT2, appear to lack 
ER luminal domains which may help them to insert into ER membrane or LD monolayer 
[13, 14, 15]. Class II proteins are translated in the cytosol, and subsequently bind to 
the LD surface. Most class II proteins, such as the perilipin/ADRP/TIP47 (PAT) proteins, 
bind to LDs through amphipathic helices or short stretches of hydrophobic residues 
[13, 16, 17, 18]. Amphipathic interfacial α-helical in monolayer-integrated proteins may 
be a common motif that directs membrane integration for monotopic integral proteins 
[19]. 
 
2.4 Growth of lipid droplets 
The sizes of LDs vary among different cell types. In white adipocytes, the size ranges 
from 0.1 µm to 100 µm in diameter [20]. There are two main pathways mediating LD 
growth, including triacylglycerol synthesis and LD fusion or coalescence. In the 
triacylglycerol synthesis pathway, newly synthesized triacylglycerols laterally diffuse to 
LDs attaching to ER. Triacylglycerols and proteins are transported via vesicular 
transport when LDs are separated from the ER [21]. In this pathway, GPAT4 and other 
triacylglycerol synthesis enzymes can relocalize from ER to LDs to mediate LD growth 
[14]. In the second pathway, many proteins contribute to LD growth. Fsp27, an LD-
associated protein, can promote LD growth via the LD contact sites [22]. 
CTP:phosphocholine cytidylyltransferase regulates phospholipid hemostasis to 
maintain LD expansion [23, 24]. 
 
3. Biological functions of lipid droplets and interactions with other organelles 
LDs were initially thought to merely deposit fat in adipose tissue without major 
biological functions. Later on, they were considered as cellular organelles that regulate 
storage and hydrolysis of neutral lipids and serve as a reservoir for cholesterol and 
acyl-glycerols for membrane formation and maintenance. Recently, LDs were 
recognized as highly dynamic organelles that essentially regulates intracellular lipid 
storage and metabolism, as well as many other functions. In non-adipocytes, such as 
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The development of stat-of-the-art imaging techniques has revealed new insight into 
physical interactions of LDs with other organelles with specific functional implications 
(Fig. 2). This has extended the understanding of LD biology beyond the classical lipid-
related functions, but also various other cellular signaling including inflammatory 
responses [25, 26].  
 
Figure 2. Interactions between lipid droplet and other cellular organelles. A) ER is the place to formate 
LDs, and LD-ER contacts transport lipid and proteins. B) Mitochondria can be divided into two 
subpopulations: peridroplet mitochondria that binds to LDs support triacylglycerol synthesis and 
conversely reduce β-oxidation activity, and cytoplasmic mitochondria that take place lipolysis to supply 
energy. C) Peroxisomes exert lipolysis through catabolization of fatty acid β-oxidation. D) Lysosomes 
degrade fatty acids by autophagy. ER: endoplasmic reticulum; LDs: lipid droplets. 
 
3.1 LD-ER interaction 
ER is the primary site for generating LDs. The interactions between ER and LD 
maintain lipid homeostasis and protect against lipotoxicity. LD-ER contacts not only 
transport lipids, but also proteins. Upon free fatty acids transported from ER and 
assembled in LDs, proteins bind with LDs to format a unique phospholipid monolayer 
[27]. After LD degradation, the level of neutral lipids declines. Some integral droplet 
proteins such as AAM-B and UBXD8 will return back to ER [28]. Some secretory 
proteins are transported to Golgi complex for assembly and secretion [29]. Other LD 
proteins are degraded via ubiquitin-proteasome system (UPS) or autophagy [30]. 
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3.2 LD-mitochondrion interaction 
Besides ER, mitochondrion is the most common interacting partner of LDs [31]. In 
mammalian cells, lipolysis of LD-derived fatty acids take place in mitochondrion 
through β-oxidation to supply energy [32, 33]. During nutrient starvation, LD-
mitochondrion interactions are further increased and LD-derived fatty acids are 
supplied to mitochondrial fatty acid oxidation via AMPK activation [34]. Direct 
connections between LDs and mitochondria are required to enable flux of fatty acids 
into mitochondria [35]. 
Based on whether or not interacting with LDs, mitochondria can be divided into two 
subpopulations, peridroplet mitochondria that binds to LDs and cytoplasmic 
mitochondria, with distinct role in lipid metabolism [36]. Peridroplet mitochondria are 
segregated with unique protein composition and structure. They can support 
triacylglycerol synthesis and conversely reduce β-oxidation activity [37].  
The perilipin protein family, belonging to PAT proteins, are surface scaffolds and 
regulators in LDs [38]. The members of perilipin family interact with mitochondrion to 
exert functions in lipid metabolism. Perilipin 5 (Plin5), only present in mammals, 
essentially mediates LD-mitochondrion interactions. Plin5 recruits mitochondria to the 
LD surface through a C-terminal region and protects mitochondrion from excessive 
fatty acid exposure by regulating LD hydrolysis and controlling local fatty acid flux [39]. 
In addition to lipid metabolism regulation and lipotoxicy defense, Plin5 also has 
antioxidant role to alleviate oxidative damage, whereas oxidative stress is intimately 
associated with mitochondrial electron transport chain [40].  
Some aspects of LD-mitochondrion interaction also involve ER. For example, MIGA2, 
an outer mitochondrial membrane protein links mitochondria to LDs, but also binds to 
the membrane proteins VAP-A or VAP-B of ER. Through multifaceted links among 
mitochondria, ER and LDs, MIGA2 promotes de novo lipogenesis from non-lipid 
precursors and stores lipids in LDs [41]. 
 
3.3 LD-peroxisome 
Peroxisomes are membrane-bound organelles present in the cytoplasm of all 
eukaryotic cells. They are essential in metabolism of lipids and reactive oxygen species. 
In the liver, peroxisomes also catabolize bile acid intermediates. Both LDs and 
peroxisomes are formed in the ER. This is thought to occur at the same ER 
subdomains where the reticulon homology domain of the multiple C2 domain 
containing transmembrane protein is located. This indicates intrinsic interactions 
between LDs and peroxisomes already during their biogenesis [42]. The best known 
example for illustrating the functional implication of LD-peroxisome interaction is 
probably β-oxidation of fatty acids. This crosstalk links lipolysis mediated by LDs to 
catabolize fatty acid β-oxidation within the peroxisomes [43].  
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Because both LDs and peroxisomes biogenesis occurs at ER, there could be 
communication and proteins/lipids trafficking among these three organelles [44]. 
Coordination and interaction among LDs, peroxisomes and mitochondria have been 
reported in adipocytes of mouse model to regulate energy consumption via CIDE-
ATGL-PPARα pathway [45]. These multi-organelle interactions are likely occur at the 
membrane contact sites, but their precise protein composition and physiological 
function remain largely undefined. 
 
3.4 LD-lysosome 
Lysosomes, the single-lipid-bilayer membrane organelles, are considered as waste 
disposal systems of the cells. They contain a variety of enzymes that enable to digest 
various engulfed biomolecules including lipids. Lysosomes are closely linked to one of 
the LD catabolism pathways. LD catabolism has two major pathways including lipolysis 
and autophagy. Autophagy is the degradation pathway in lysosome, and has been 
termed as lipophagy when referring to the specific degradation of lipids. Lysosome 
regulates lipid metabolism through autophagy, and inhibition of autophagy results in 
increased amount of triacylglycerols and LDs [46]. For example, defects in specific 
autophagy gene will lead to accumulation of LDs in cytoplasm because of defective 
lipid catabolism [46]. 
In the liver, involvement of autophagy in lipid catabolism is most prominent during 
fasting or nutrient deprivation, although lipophagy also maintains constitutive lipid 
degradation. Defects of key autophagy genes are associated with increased levels of 
triacylglycerols in liver [47, 48]. Conversely, accumulation of intracellular LDs promotes 
autophagy. LDs provide lipid precursors for autophagosome biogenesis, more 
specifically for autophagosomal membrane formation [49]. Furthermore, ER can also 
contribute to the interactions between LD and autophagy [50]. 
 
4. Lipid droplets in major liver diseases 
Dysregulation and imbalance of lipid metabolism in liver inevitably causes 
pathogenesis. The most prominently related disorder is fatty liver disease. Fatty liver 
disease is a leading etiology of primary liver cancer, and altered hepatic lipid 
metabolism can fuel hepatic carcinogenesis (Fig. 3). Interestingly, intracellular 
pathogens, including hepatitis viruses, can exploit LDs to sustain their life cycle.  
 
4.1 Metabolic dysfunction-associated fatty liver disease 
Metabolic dysfunction-associated fatty liver disease (MAFLD) is a new nomenclature 
updated from the previous known non-alcoholic fatty liver disease (NAFLD). Diagnosis 
of MAFLD is proposed to be based on detection of hepatic steatosis in addition to one 
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of the three conditions, including overweight/obesity, presence of type 2 diabetes 
mellitus, or evidence of metabolic dysregulation [51]. Although the precise 
epidemiology of MAFLD remains unknown as a new terminology, the prevalence of 
NAFLD has been estimated as 25% of the global population [52].  
 
Figure 3. Lipid droplets in major liver diseases. Excessive fatty acids lead to lipid metabolic disorder. 
Imbalance of lipid homeostasis will trigger LDs formation that promotes devolopment of metabolic 
dysfunction-associated fatty liver disease. Similarly, hepatitis virus infections, especially HBV and HCV, 
accelerate lipid accumulation and cause inflammation in liver. In turn, LDs support the life cycle of 
hepatitis viruses. Fatty acids sustain HCC cell growthand create a supportive microenvironment for 
cancer stem cells. LDs: lipid droplets; HBV: hepatitis B virus; HCV: hepatitis C virus; HCC: hepatocellular 
carcinoma. 
 
Steatosis, featured by lipid accumulation as either microvesicular or macrovesicular 
LDs in hepatocytes, is the hallmark of fatty liver disease. Fatty acids in the liver are 
derived from diet uptake, de novo lipogenesis and endogenous lipid catabolism. 
Imbalance in lipid anabolism and catabolism causes excessive fatty acids storage in 
hepatocytes as LDs, promoting the emergency of fatty liver disease. Fatty acids can 
also be converted to lipid intermediates that impair insulin signaling, referring as lipid-
induced insulin resistance and lipotoxicity. Hepatic steatosis is often associated with 
insulin resistance, which in turn exacerbates the pathogenesis of MAFLD [53]. 
Accumulated LDs will trigger further hepatic oxidative stress and inflammation, 
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At molecular level, several proteins are known to regulate LDs in fatty liver disease. 
The PAT family proteins located on LD surface include perilipin, adipophilin, TIP47, 
S3-12 and OXPAT. They differentially expressed in fatty compared to normal liver. 
Perilipin, adipophilin and TIP47 are associated with different sizes of LDs. TIP47 
affects nascent LDs, while perilipin and adipophilin are important for maturation and 
maintenance of LDs in hepatocytes [55]. CIDEA and Fsp27 are LD-associated proteins 
that promote LD fusion and regulate lipid storage. Their expression is dramatically 
upregulated in hepatic steatosis [56]. This process may be mediated by MKP5. 
Because loss of MKP5 in mice activates p38, resulting in increased expression of 
CIDEA and Fsp27 [57]. 17β-hydroxysteroid dehydrogenase-13 (17β-HSD13), a newly 
identified LD-associated protein, has been demonstrated as a pathogenic protein in 
MAFLD. 17β-HSD13 controls the number and size of LDs and is causative for fatty 
liver phenotype [58]. High expression of 17β-HSD13 in fatty liver has been shown to 
be induced by liver X receptor α through SREBP-1c [59]. 
 
4.2 Viral hepatitis  
Viral hepatitis are caused by the five hepatotropic viruses including hepatitis A, B, C, 
D and E. Globally, about 500 million people are chronically infected with hepatitis B 
(HBV) or C (HCV) virus. The link of HBV to LDs is mainly through the viral HBx protein, 
which causes lipid accumulation by upregulation of the liver X receptor and its lipogenic 
target genes [60, 61]. HBV viral particle production has been shown to impair LD 
expansion associated with inhibition of the expression of CIDE proteins. Because CIDE 
proteins support HBV production; this may serve as negative feedback loop for 
maintaining persistent infection [62]. 
HCV is the best known pathogen with close connections to LDs. LDs serve as putative 
sites for viral assembly during HCV replication [63]. The process of infectious HCV 
particle assembly consists of nucleocapsid formation, budding into the ER, and virion 
maturation. The capsid Core protein closely associates with LDs, and further recruits 
nonstructural proteins around LDs to participate in virus production [63]. HCV 
assembly likely takes place at the sites requiring interactions of ER and LDs [64]. 
Recent high-resolution imaging study indicates selective recruitment of ER 
membranes wrapping LDs to form membranous structure coupling HCV replication 
and assembly [65]. HCV Core can also be efficiently targeted to LDs outside the 
context of virion assembly, and induce LD redistribution and hepatic steatosis [66, 67]. 
This partially explains why MAFLD is a prominent feature of chronic hepatitis C patients, 
and eradication of HCV by antiviral treatment dramatically decreases liver steatosis 
[68].   
 
4.3 Liver cancer 
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MAFLD and viral hepatitis are the leading etiologies of primary liver cancer, namely 
hepatocellular carcinoma (HCC). Enhanced lipogenesis is a metabolic hallmark of 
cancer cells, and aberrant lipid metabolism universally occurs in HCC cells [69]. Fat-
containing liver lesions are commonly seen in HCC patients [70]. In HCC, lipogenesis 
pathway is activated, while fatty acid oxidation is downregulated [71, 72]. With a high 
rate of growth, HCC cells acquire fatty acids to support their proliferation [73]. Recent 
evidence indicate the essential involvement of lipid metabolism in cancer stem cells 
(CSCs). Activation of intrinsic lipid pathways in CSCs upregulates fatty acid de novo 
synthesis [74]. Furthermore, the lipid context in tumor microenvironment, in particular 
the stem cell niche, regulates CSC behavior [75]. Liver tumors are known to harbor 
CSCs [76], and the role of LDs and lipid metabolism in this unique cancer cell 
population deserves to be further studied.   
 
Conlusion 
LDs are highly dynamic organelles closely associated and interacting with other 
celleular organelles for exerting a variety of biological functions. The liver is a central 
organ in lipid metabolism and LDs are widely present in hepatocytes. LDs play key 
roles in health and diseases of the liver, involving in lipid metabolism, energy 
homeostasis, cell signaling, inflammation, pathogen-host interaction and 
carcinogenesis. Mechnistically decipering the role of LDs in liver shall help to better 
understand pathegensis of the major liver diseases inclduing MAFLD, viral hepattis 
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Abstract  
Background: Comprehensive evaluation of safety and efficacy of different 
combinations of direct-acting antivirals (DAAs) in liver transplant recipients with 
genotype 1 (GT1) hepatitis C virus (HCV) recurrence remains limited. Therefore, we 
performed this systematic review and meta-analysis in order to evaluate the clinical 
outcome of DAA treatment in liver transplant patients with HCV GT1 recurrence. 
Methods: Studies were included if they contained information of 12 weeks sustained 
virologic response (SVR12) after DAA treatment completion as well as treatment 
related complications for liver transplant recipients with GT1 HCV recurrence. 
Results: We identified 16 studies comprising 885 patients. The overall pooled estimate 
proportion of SVR12 was 93% (95% confidence interval (CI): 0.89, 0.96), with moderate 
heterogeneity observed (τ2=0.01, P<0.01, I2=75%). High tolerability was observed in 
liver transplant recipients reflected by serious adverse events (sAEs) with pooled 
estimate proportion of 4% (95% CI: 0.01, 0.07; τ2=0.02, P<0.01, I2=81%). For subgroup 
analysis, a total of five different DAA regimens were applied for treating these patients. 
Sofosbuvir/Ledipasvir (SOF/LDV) led the highest pooled estimate SVR12 proportion, 
followed by Paritaprevir/Ritonavir/Ombitasivir/Dasabuvir (PrOD), Daclatasvir 
(DCV)/Simeprevir (SMV) ± Ribavirin (RBV), and SOF/SMV ± RBV, Asunaprevir 
(ASV)/DCV. There was a tendency for favoring a higher pooled SVR12 proportion in 
patients with METAVIR Stage F0-F2 of 93% (95% CI: 0.89, 0.96) compared to 83% 
(95% CI: 0.75, 0.88) for stage F3-F4 (p<0.01). There was no significant difference 
between LT recipients treated with or without RBV (p=0.23). 
Conclusions: DAA treatment is highly effective and well tolerated in liver transplant 
recipients with recurrent GT1 HCV infection. 
Key words: Direct-acting antiviral; HCV; Liver transplantation; Genotype 1; Recurrence. 
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Introduction 
Liver cirrhosis and hepatocellular carcinoma (HCC) secondary to hepatitis C virus 
(HCV) infection are the leading causes for liver transplantation (LT) worldwide.(1, 2) 
However, recurrent HCV infection post LT is a unique and difficult medical dilemma 
which occurs in over 90% of patients, and severe recurrent infection is observed in 
nearly 30% of patients within 3 to 5 years.(3, 4) Thus, the allograft and recipient survival 
is closely correlated with the successful eradication of HCV. 
Until very recently, interferon-based therapy was the only treatment option and rate of 
sustained virological response (SVR) in these transplant recipients was merely 20%-
30%.(5, 6) The combination of direct-acting antiviral agents, in the form of a first 
generation protease inhibitor, telaprevir or boceprevir, doubled the SVR rate at the 
expense of a series of adverse events (AEs) and serious adverse events (sAEs).(7, 8) 
These included rashes, cytopenias, allograft rejection, severe anemia, and a mortality 
rate of 9% in one series. At the end of year of 2013, the US Food and Drug 
Administration (FDA) and European Medicines Agency (EMA) approvals of simeprevir 
(SMV) and sofosbuvir (SOF) heralded a new era in direct-acting antiviral (DAA) therapy 
of HCV-related liver diseases. Consequently, the launches of several other second 
generation of interferon-free DAAs have opened a new scenario which revolutionized 
the treatment of chronic HCV infection in the general infected population. With a very 
favorable safety profile and high rates of SVR of over 95%,(9) the newer and all-oral 
DAA-based regimens have provided an unprecedented opportunity to cure HCV. 
Although HCV disease burden remains substantial for the time being, however it is 
estimated that, within next decade, most patients with HCV infection would likely to 
attend SVR. Furthermore, SVR may forestall the progression of liver diseases with 
subsequent reduction in liver-related complications including hepatocellular carcinoma 
(HCC), hepatic decompensation, and both liver related as well as all-cause mortality. 
HCV genotype 1 (GT1) is the most prevalent recurrence affecting the majority of 
patients post LT.(10, 11) However, the effectiveness and tolerability of various of 
combinations of DAAs on specific genotype of HCV recurrence in LT recipients remain 
largely unknown.(12) In this study, we performed a systematic review and meta-
analysis in order to provide a comprehensive, reliable, and up-to-date assessment of 
DAA treatment for GT1 HCV recurrence post transplantation. Our results may provide 
additional guidance for clinical practice and future research. 
 
Materials and Methods 
Literature search 
 
We have conducted a systematic search of various electronic databases, including 
Ovid Medline, EMBASE, Web of Science, Cochrane Database and Google Scholar for 
relevant studies published from inception until July, 2018. The search was designed 
and conducted by an experienced medical librarian with input from the study 
investigators, using controlled vocabulary supplemented with keywords (“sofosbuvir” 
OR “ribavirin” OR “ritonavir” OR “asunaprevir” OR “simeprevir” OR “daclatasvir” OR 
“ombitasvir” OR “ledipasvir” OR “velpatasvir” OR “grazoprevir” OR “elbasvir” OR “DAA” 
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OR “direct-acting antivirals” AND “liver transplantation” AND “hepatitis C” OR “HCV” 
AND “Genotype 1” OR “GT1”) (Supplementary method 1). In addition, the 
bibliographies of relevant review articles and all included studies were manually 
reviewed to identify relevant studies. No restrictions were applied to language due to 
the limited number of manuscripts. Abstracts from conferences were excluded in our 
database search. Besides, the reference lists of included articles and relevant 
systematic reviews were manually searched. 
 
Inclusion and exclusion criteria   
All records identified through database searches were downloaded and duplicate 
records were removed. The title and abstract of remaining records were screened for 
relevance to liver disease and human subjects. After this initial screening, the lists of 
selected studies were cross-checked to resolve discrepancies. Subsequently, full 
articles were retrieved for detailed assessment. 
Reports were included if they were original studies which contained at least 5 patients, 
presented effectiveness of treatment of second generation of interferon-free DAA 
regimens for at least 12 weeks in adult LT recipients with GT1 HCV recurrence. In 
addition, these included studies should present proportion of SVR12 after the end of 
the treatment. We excluded studies that enrolled LT recipients featured coinfection with 
hepatitis A, B, D, E virus or human immunodeficiency virus (HIV). Besides, studies 
without reporting AEs and/or sAEs were also excluded.  
 
Study selection and data extraction 
Two reviewers (J.L. and B.M.) worked independently to determine whether a study met 
inclusion criteria, abstracted information to assess the methodological validity of each 
candidate study, and extracted data with structured data collection forms. The 
reviewers resolved discrepancies by jointly reviewing the study in question. If no 
consensus was reached, a third reviewer (Q.P.), unaware of prior determinations, 
functioned as an arbiter. 
Extracted information for this study include study design, immunosuppression 
protocols, dosage adjust, DAA combinations, collaboration (single or multicenter) and 
patient demographics including age, gender, ethnicity, viral load, degree of fibrosis. 
We also obtained data of treatment outcomes of SVR12. In addition, data about the 
tolerability of DAA treatment were also collected.  
 
Quality assessment 
The quality of included studies was rated using the institute of Health Economics (IHE) 
quality appraisal checklist, which is usually employed for assessment of the quality of 
case series. As all of the included studies were single-arm reports, an assessment tool 
for case series is more suitable than the Newcastle Ottawa Scale (NOS). In this 20-
item checklist, both risk of bias and quality of reporting were scored by yes, no or 
partial/unclear answers. Eight quality parameters including study objective (0-1 points), 
study design (0-3 points), study population (0-3 points), intervention and co-
intervention (0-2 points), outcome measure (0-4 points), statistical analysis (0-1 points), 
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results and conclusions (0-5 points) and competing interests and sources of support 
(0-1 points) were used to assess included studies. In our analysis, studies with 0-2, 3-
5, 6-8 and ≥9 points were considered as having low, moderate, high and very high risk 
of bias, respectively. Quality assessment was done by two independent authors (J.L. 
and B.M.), and disagreements were solved by the third author (Q.P.). 
 
Statistical analysis 
After checking for consistency, the Metaprop module in the R-3.4.2 statistical software 
package was used for the meta-analysis. Given that, the SVR12 proportion in many 
articles are close to 100%. So the proportion of SVR12 reported in each study was 
Free-Turkey double arcsine transformed prior to compute the pooled estimate rate. 95% 
confidence interval (CI) were estimated using Wilson score method. We performed 
meta-analysis of proportion to compute the pooled estimate proportions by using a 
random-effect model (DerSimonian-Laird Method). Heterogeneity across the included 
studies was assessed using the Cochran Q-statistics and I2 statistics, with I2 statistics 
25%-50%, 50%-75% and >75% considered as mild, moderate and severe 
heterogeneity, respectively. Based on the available data, subgroup meta-analysis were 
performed by using the Q test to determine whether the pooled estimate proportion of 
SVR12 varied by study type (retrospective study or perspective study), with or without 
Ribavirin (RBV), METAVIR score (F0-F2 or F3-F4), and different kinds of regimens 
SOF/SMV with or without RBV, SOF/Ledipasvir (LDV), Asunaprevir (ASV)/SMV, 
DCV/SMV with or without RBV and Paritaprevir/Ritonavir/Ombitasivir/Dasabuvir 
(PrOD). Funnel plots and Egger regression test were used to assess potential 
publication biases. 
Ethical approval or inform consent from patients was not required, because our data 
were extracted from previous studies. Nevertheless, the included studies in our review 




Our search strategy identified 2747 articles for inclusion. After removing duplicate 
studies, 2655 studies were further evaluated for eligibility. Of these, 1593 studies were 
excluded, which had no DAA, HCV GT1 or LT related items. After screening the titles 
and abstracts, another 950 studies were excluded; 744 studies of them included 
ineligible study participants, 206 with small sample size. 112 studies were retrieved 
and evaluated in full text. Of those reviewed in detail, 96 studies were excluded due to 
duplicate publication, improper study design, or incomplete information of 
effectiveness and tolerability. Eventually, 16 studies, published until July 2018, 
involving 885 patients were eligible for the qualitative and quantitative synthesis as 
detailed in Figure 1. Based on the Institute of Health Economics (IHE) quality appraisal 
checklist, six studies were of low risk of bias compared to 10 studies with moderate 
risk of bias. To date, no randomized controlled trial has been published exploring the 
efficacy and tolerability of DAAs on recurrence of post LT. The 16 included studies 
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were performed by five different countries. Among them, 62.5% were conducted in 
USA, 18.75% in Japan, 6.25% in UK, 6.25% in Germany and 6.25% in Spain. Ten of 
the included studies were multi-center studies and six were single-center studies. All 
of these studies were published in full text.  
 
Figure 1. Study selection. 
Baseline characteristics  
Table 1 and 2 summarize the baseline patient demographic and clinical characteristics. 
Except one study (13) that did not report patient ethnicity, the majority of patients were 
Caucasian, male, with a mean age of approximately 60-year-old, had GT1a HCV 
recurrence, and received tacrolimus as part of their immunosuppressive treatment. 
Five different DAA combination protocols were described: SOF/SMV with or without 
RBV (n=8);(13-20) SOF/LDV (n=3);(21-23) ASV/SMV (n=2);(24, 25) DCV/SMV with or 
without RBV (n=2);(26, 27) PrOD (n=1).(28) Detailed baseline characteristics of the 
included studies are provided in Table 1 and 2. 
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Table 1. Basic characteristic of studies included. 
 




Page | 35  
 
Outcomes 
The efficacy and tolerability of DAA treatment.  
 
Once DAA treatment completed, patients were followed up for evaluating SVR12 
proportion. In total, 805 out of 885 (91.0%) patients successfully achieved SVR12. The 
pooled estimate SVR12 proportion among all LT recipients were 93% (95% CI: 0.89, 
0.96), with moderate heterogeneity observed in a random-effects model (tau2=0.01, 
p<0.001, I2=75%, Figure 2). The expected shape observed in the funnel plots and 
results of the Egger’s test (p=0.44) indicated no significant publication bias 
(Supplementary Figure 1 and 2). AEs commonly occurred in these patients. General 
symptoms including fever, fatigue and dizziness were the most common AEs with 
pooled estimate rate of 37% (95% CI: 0.14, 0.64; tau2=0.30, p<0.01, I2 =98%, Random-
effects model, Supplementary figure 3). Pooled estimate incidence rate of 
gastrointestinal AEs was 10% (95% CI: 0.02, 0.23; tau2=0.11, p<0.01, I2 =96%, 
Random-effects model, Supplementary figure 4) and pooled estimate incidence rate of 
skin problems was 7% (95% CI: 0.02, 0.15; tau2=0.06, p<0.01, I2 =93%, Random-
effects model, Supplementary figure 5). SAEs were mainly associated with kidney 
injury, were reported in 45 patients, and 12 patients died during the treatment period 
(Table 3). The pooled estimate rate of sAEs was 4% (95% CI: 0.01, 0.07, tau2=0.02, 
p<0.01, I2 =81%, Random-effects model, Figure 3).  
 
Study Design 
Twelve retrospective and four prospective studies were included. There was no 
significant difference in pooled estimate SVR12 proportion when comparing studies of 
prospective, 91% (95% CI: 0.87, 0.95), versus retrospective, 93% (95% CI: 0.88, 0.97) 
(P=0.44, Figure S6, Random effects model). 
 
Figure 2. Pooled estimate proportion of 12 weeks sustained virological response after treatment 
completion and 95% confidence interval after directing-acting treatment of GT1 HCV recurrence post 
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liver transplantation from 16 studies. Abbreviations: Events, the number of patients who reached SVR12; 
Total, the number of patients analyzed. 
 
Figure 3. Pooed estimate proportion of serious adverse events and 95% confidence interval after direct-
acting antivirals of GT1 HCV recurrence post liver transplantation form 16 studies. Abbreviations: Events, 
the number of patients who reached SVR12; Total, the number of patients analyzed. 
3.3.3 Degree of liver cirrhosis. The METAVIR Fibrosis Score, simply put, is a 
evaluate system to determine the level of liver fibrosis.(29) The METAVIR Fibrosis 
Score grades the degree of fibrosis on a 5-point scale from 0 to 4. Fibrosis scores 
range from F0-F4 (F0 stage, no fibrosis; F1 stage, portal fibrosis without septa; F2 
stage, portal fibrosis with septa; F3 stage, numerous septa without cirrhosis; F4 stage, 
cirrhosis). A total of eight studies evaluated levels of fibrosis and cirrhosis of patients 
according to METAVIR Fibrosis Score. The pooled SVR12 rate estimates among 
patients with METAVIR Fibrosis Score F0-F2 stage was 93% (95% CI: 0.89, 0.96) 
compared to 83% (95% CI: 0.75, 0.88) for stage F3-F4. There was a trend for a higher 
SVR12 rate in patients with F0-F2 stage than patients with F3-F4 stage (p<0.01, Figure 
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Figure 4. Comparison of pooled estimate proportion of 12 weeks sustained virological response after 
treatment completion and 95% confidence interval between METAVIR Fibrosis Stages F0-F2 and F3-
F4 after direct-acting antivirals treatment of hepatitis C virus genotype 1 recurrence post liver 
transplantation. Abbreviations: Events, the number of patients who reached SVR12; Total, the number 
of patients analyzed. 
Different combination of DAA regimens 
Sixteen studies which contained five different DAA regimens were administered into clinical 
treatment of LT recipients with recurrent GT1 HCV infection. The pooled estimate SVR12 
proportion were 97% (95 CI: 0.89, 1.00), 81% (95% CI: 0.72, 0.89), 100% (95% CI: 0.98, 1.00), 
90% (95% CI: 0.80, 0.97), and 90% (95% CI: 0.87, 0.92) among patients who underwent 
treatment of PrOD, ASV/DCV, LDV/SOF, SMV/DCV with or without RBV and SMV/SOF with 
or without RBV, respectively (Figure S7, Random effects model). 
With or without RBV 
A total of 124 LT recipients used RBV as combinational treatment compared to 761 
recipients without. The pooled estimate SVR12 proportion of recipients treated with 
RBV was 90% (95%CI: 0.84, 0.94). For recipients treated without RBV, the pooled 
proportion was 94% (95%CI: 0.89, 0.97). There was no significant difference in SVR12 
proportion between LT recipients treated with or without RBV (P=0.23, Figure S8, 
Random effects model). 
 
Discussion 
The current systematic review and meta-analysis included 16 studies comprising 885 
patients to assess the outcome of DAA treatment for liver transplant recipients with 
recurrent GT1 HCV infection. Overall, the pooled SVR12 and sAEs proportion were 
93% and 4%, representing a rather good outcome. Subgroup analyses revealed clear 
difference in SVR12 rates for different treatment strategies. The pooled estimate 
proportion for combination of LDV/SOF appears much higher than the other four 
combinations. In addition, the efficacy of DAA treatment is closely associated with 
fibrosis or cirrhosis levels, which highlights the necessity of early initiation of DAA 
treatment in these patients. 
The pooled estimate results of SVR12 provided evidence that DAA treatment was 
clinically effective in eradicating GT1 HCV recurrence post LT. This is comparable to 
the pooled estimate results from a recent meta-analysis that contained all HCV 
GTs.(30) Of note, the unbalanced application of DAAs for GT1 HCV recurrence exists 
among different regions. There is a trend that the first-class of DAAs are commonly 
used in European or North American countries. For many countries, even like Japan, 
cost-effectiveness other than SVR rate is the first consideration for clinicians.(24, 25) 
However, in Asia-pacific or Africa countries, HCV has distinct epidemiology. 
Furthermore, DAA availability has been delayed due to economic constraints and 
regulatory rules.(31) Although two studies from Japan suggested that DAA treatment 
Page | 38 
 
is effective in Asian patients, multi-regional and systematic studies should be combined 
to further confirm the effectiveness of DAA treatment for different regions. 
The average time of progression from initial HCV infection to cirrhosis is about 30 years, 
but 20-30% of liver transplant recipients develop cirrhosis within 5 years.(32) Re-
transplantation is the only option to achieve long-term survival of patients with 
decompensated cirrhosis. However, due to organ shortage and poor clinical outcome, 
re-transplantation is clearly not a sustainable solution.(33) In our subgroup analysis of 
liver transplant recipients with SVR12 rate and fibrosis data (METAVIR Fibrosis Score), 
our detailed analysis supports the latest evidence-based guidelines that DAAs also can 
be effectively used in eradicating HCV in patients with advanced fibrosis or cirrhosis 
post LT.(34) We observed a higher SVR12 pooled estimate proportion in patients with 
mild fibrosis compared with those of advanced fibrosis or cirrhosis, with a trend favoring 
SVR12 in patients with mild fibrosis. Our results indicated that the capability of HCV 
eradication by DAAs may be correlated with the levels of liver fibrosis or cirrhosis. 
Therefore, DAA treatment is recommended to be initiated early after transplantation.  
Five different combinations of DAA treatment were identified in our systematic review 
and meta-analysis. There are important differences among the strategies, such as 
addition of RBV, duration of treatment and potential drug interactions. Among these 
regimens, SMV/SOF with or without RBV were most commonly used with a pooled 
estimate SVR12 proportion of 90%, which is comparable with a recent study reporting 
SVR12 rate of 88%.(30) A number of studies have pointed out that SMV may interact 
with Cyclosporine A (CsA), and therefore the immunosuppressant tacrolimus is 
recommended to be used.(35) In general, the combination of SMV and SOF with or 
without RBV seems to be a safe regimen even at the early stage of post-transplantation, 
when constant changes of immunosuppressive medication are often required and the 
patients are vulnerable to side effects. The combination of LDV and SOF has been 
used in three studies. The safety and efficacy of combination of LDV and SOF was 
firstly confirmed in a US-based SOLAR-2 study with a SVR12 rate of 96% and SVR24 
rate of 98%.(36) The pooled estimate SVR12 proportion of LDV and SOF from our 
study is as high as 100%. Only one study reported their results for the DAA 
combination regimen of PrOD in GT1 HCV recurrence post LT with SVR12 proportion 
of 97%. Unfortunately, PrOD is contraindicated in patients with cirrhosis and has a 
potential to increase the plasma cyclosporine A (CsA) levels by 5-6 folds and 
tacrolimus levels by 60-85 folds, which limited its clinical application.(28) In addition, 
efficacy and safety were not established for shorter duration therapy, or more 
advanced fibrosis/cirrhosis in a real world setting. Combination of ASV and DCV were 
administered by two Japanese studies with the lowest pooled estimate SVR12 
proportion of 81%. Although this combination had a cost-effective advantage, 
increased transaminase levels were commonly associated with ASV.(37, 38) Two 
studies have reported a pooled estimate SVR12 proportion of 90% with DAA 
combination of SMV/DCV with or without RBV. Although the pooled estimate SVR12 
proportion was satisfactory, two limitations including small sample size and prolonged 
treatment period of 24 weeks in these two studies should be noted.  
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There is ongoing debate whether adding RBV to interferon-free treatment strategy is 
necessary for treating HCV recurrence after LT.(16) RBV has been used for over 40 
years in combination for treating HCV with an obscure understanding of its mechanism-
of-action.(39, 40) What is clear, however, is adverse effects. Hemolytic anemia has 
been observed in about one third of the patients. Lymphopenias, pruritus and rash also 
commonly occur. Thus, patients treated with RBV often need a close monitoring and 
dose adjustment, especially for those with chronic kidney disease. It is also 
recommended that patients treated with RBV should undergo at least 6-month washout 
period due to the possible teratogenic and embryocidal effects.(40-42) In current study, 
we observed an increased pooled estimate incidence rate of sAEs in patients treated 
with RBV, in accordance with the results from previous studies. Given that a number 
of studies have pointed out RBV were not correlated with an increased SVR12 rate,(13, 
16, 20, 43) we compared patients treated or not treated with this medication. Our 
results also indicated that RBV was not correlated with an increased pooled estimate 
SVR12 proportion. We also assessed the tolerability of DAA treatment by analyzing 
pooled estimate proportion of AEs and sAEs. General symptoms, gastro-intestinal 
symptoms, and skin complaints were presented with a pooled estimate incidence rate 
of 37%, 10% and 7%, respectively. SAEs including death caused by hepatic or renal 
failure, pneumonia, bone marrow failure, acute kidney, liver or other major organ 
infection, hepatic decompensation, spontaneous bacterial peritonitis, and sepsis, were 
analyzed with a pooled estimate incidence rate of 4% (I2 =81%).  
Among them, renal dysfunction was reported in 45 patients, and 12 patients died during 
the treatment period. Impaired renal function commonly occurred in liver transplant 
recipients with the prevalence ranging from 17% to 95%.(44, 45) Approximately 40% 
of these patients had already experienced a hepatorenal syndrome pre-
transplantation.(46) In addition, toxic reasons, ischemia reperfusion and CNI-
associated nephropathy were account for renal dysfunction post-transplantation.(47) 
Although the exact pathophysiological mechanisms are not fully understood, HCV 
infection may influence renal function through different pathways.(48) A recent study 
documented that patients with HCV recurrence after LT will absolutely benefit from 
HCV elimination but will be at a higher risk for renal dysfunction or failure associated 
with antiviral drugs like SOF.(49) Unlike most DAAs, the nucleotide analogue NS5B 
polymerase inhibitor SOF was renally excreted. For area under the curves (AUCs) of 
SOF, patients with end-stage renal diseases was 45-fold and 35-fold higher compared 
to normal renal function when dosed 1 hour before or 1 hour after hemodialysis, 
respectively.(50) However, there are conflicting data about the application of SOF in 
clinical treatment. Saxena et al (51) evaluated the safety and efficacy of SOF-based 
therapy in HCV-infected patients with impaired renal function. High SVR rate of 83% 
was achieved with high rate of renal dysfunction and sAEs observed. A prospective 
multicenter cohort study enrolled 50 patients with GFR < 35 mL/min per 1.73 m2 for 
treatment with a SOF-based therapy. All genotypes were included and more than half 
of them were cirrhotic patients. The results indicated that there is no significant change 
in GFR for patients who were not on dialysis.(52) More recently, Teegen et al (49) also 
documented that a dose reduction for SOF did not seem to be necessary to prevent 
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further renal damage. Thus, additional data are still needed to further assess the safety 
of SOF in transplant recipients.  
CNIs are the backbone of immunosuppressive treatment of LT. Eighty percent of liver 
transplant recipients were using tacrolimus alone or in combination with 
mycophenolate 1 year post transplantation.(53) Although CNIs can reduce the 
incidence of acute injection and improve overall survival, they are inevitably associated 
with nephrotoxicity which is reflected in tubular atrophy, interstitial fibrosis, and 
glomerulosclerosis on kidney biopsy.(54) However, so far, the use of a CNI-free 
regimen is still challenging and the trend in LT was to use regimens that minimize the 
use of CNIs in combination with mycophenolate mofetil (MMF) or mammalian target of 
rapamycin inhibitors. One important observation, the use of everolimus with reduced 
tacrolimus exposure helped to preserve renal function after 3-year follow up which 
indicated that consideration should be given to minimize the dose of CNIs or switch to 
MMF or everolimus for these patients.(55, 56) 
This study has exclusively focused on the effectiveness and tolerability of DAA 
treatment. Thus, a control group is not included, such as patients treated with DAAs 
before LT or treated with interferon post LT. Thus, without such a control, we cannot 
conclude whether treatment post LT has any advantage than treatment prior to LT or 
interferon treated recipients. Besides, most studies were from developed regions, 
including North American or European countries. Hence, multi-regional studies are still 
needed to substantiate the comprehensive information for better clinical guidance 
globally. Last but not the least, the field of HCV treatment is a dynamic and constantly 
changing landscape. A number of new agents or combination approaches may still in 
clinical trials or just licensed.  
In summary, our results support DAAs as treatment for eradicating GT1 HCV 
recurrence in liver transplant recipients. They are highly effective and well-tolerated. 
However, fine-tuning is essential for achieving the optimal outcome, given 
considerations of drug availability, potential drug-drug interactions, the fibrotic or 
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Table 3. Incidence of adverse events and serious adverse events during direct-acting antivirals 
treatment for patients of hepatitis C virus genotype 1 recurrence post liver transplantation. 
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Supplementary method 1. Searching strategy for direct-acting antivirals for treatment of hepatitis 
C virus genotype 1 recurrence post liver transplantation. 
Embase.com 1106 
('direct acting antiviral'/exp OR 'sofosbuvir'/de OR 'ribavirin'/de OR 'ritonavir'/de OR 'asunaprevir'/de OR 
'simeprevir'/de OR 'daclatasvir'/de OR 'ombitasvir'/de OR 'dasabuvir plus ombitasvir plus paritaprevir 
plus ritonavir'/de OR 'ledipasvir'/de OR 'ledipasvir plus sofosbuvir'/de OR 'velpatasvir'/de  OR 'sofosbuvir 
plus velpatasvir'/de OR 'elbasvir plus grazoprevir'/de OR 'grazoprevir'/de OR 'elbasvir'/de OR ((direct* 
NEAR/3 (antiviral* OR anti-viral*)) OR daas OR daa OR sofosbuvir* OR ribavirin* OR Ritonavir* OR 
Asunaprevir* OR Simeprevir* OR daclatasvir* OR ombitasvir* OR prod OR ledipasvir* OR velpatasvir* 
OR Grazoprevir* OR Elbasvir* OR Sunvepra* OR interferon-free OR ifn-free):kw,de,ab,ti) AND ('liver 
transplantation'/exp OR 'organ transplantation'/de OR transplantation/de OR 'graft recipient'/de OR 
'patient history of liver transplantation'/de OR (((liver OR hepat* OR organ OR organs) AND (transplant* 
OR graft* OR allotransplant* OR allograft* OR autotransplant* OR autograft* OR recipient*))):kw,de,ab,ti) 
AND ('Hepatitis C virus genotype 1'/exp OR (('Hepatitis C virus'/exp OR 'Hepatitis C'/exp) AND 
genotype/de) OR (((Hepatitis-C OR hcv OR Hepacivirus) AND ((genotyp* OR gt OR subtyp*)) OR gt1 
OR g1)):kw,de,ab,ti) NOT ([Conference Abstract]/lim OR [Letter]/lim OR [Note]/lim OR [Editorial]/lim) 
AND [english]/lim 
Medline Ovid  662 
(sofosbuvir/ OR ribavirin/ OR ritonavir/ OR asunaprevir/ OR simeprevir/ OR daclatasvir/ OR ombitasvir/ 
OR ledipasvir/ OR ledipasvir plus sofosbuvir/ OR velpatasvir/  OR grazoprevir/ OR elbasvir/ OR ((direct* 
ADJ3 (antiviral* OR anti-viral*)) OR daas OR daa OR sofosbuvir* OR ribavirin* OR Ritonavir* OR 
Asunaprevir* OR Simeprevir* OR daclatasvir* OR ombitasvir* OR prod OR ledipasvir* OR velpatasvir* 
OR Grazoprevir* OR Elbasvir* OR Sunvepra* OR interferon-free OR ifn-free).kw,ab,ti.) AND (liver 
transplantation/ OR liver/tr OR organ transplantation/ OR transplantation/ OR graft recipient/ OR (((liver 
OR hepat* OR organ OR organs) AND (transplant* OR graft* OR allotransplant* OR allograft* OR 
autotransplant* OR autograft* OR recipient*))).kw,ab,ti.) AND (((Hepacivirus/ OR Hepatitis C/) AND 
genotype/) OR (((Hepatitis-C OR hcv OR Hepacivirus) AND ((genotyp* OR gt OR subtyp*)) OR gt1 OR 
g1)).kw,ab,ti.) NOT (letter OR news OR comment OR editorial OR congresses OR abstracts).pt. AND 
english.la. 
Cochrane CENTRAL 134 
(((direct* NEAR/3 (antiviral* OR anti-viral*)) OR daas OR daa OR sofosbuvir* OR ribavirin* OR 
Ritonavir* OR Asunaprevir* OR Simeprevir* OR daclatasvir* OR ombitasvir* OR prod OR ledipasvir* 
OR velpatasvir* OR Grazoprevir* OR Elbasvir* OR Sunvepra* OR interferon-free OR ifn-free):ab,ti) AND 
((((liver OR hepat* OR organ OR organs) AND (transplant* OR graft* OR allotransplant* OR allograft* 
OR autotransplant* OR autograft* OR recipient*))):ab,ti) AND ((((Hepatitis-C OR hcv OR Hepacivirus) 
AND ((genotyp* OR gt OR subtyp*)) OR gt1 OR g1)):ab,ti)  
Web of science  645 
TS=((((direct* NEAR/2 (antiviral* OR anti-viral*)) OR daas OR daa OR sofosbuvir* OR ribavirin* OR 
Ritonavir* OR Asunaprevir* OR Simeprevir* OR daclatasvir* OR ombitasvir* OR prod OR ledipasvir* 
OR velpatasvir* OR Grazoprevir* OR Elbasvir* OR Sunvepra* OR interferon-free OR ifn-free)) AND 
((((liver OR hepat* OR organ OR organs) AND (transplant* OR graft* OR allotransplant* OR allograft* 
OR autotransplant* OR autograft* OR recipient*)))) AND ((((Hepatitis-C OR hcv OR Hepacivirus) AND 
((genotyp* OR gt OR subtyp*)) OR gt1 OR g1))) ) AND DT=(article) AND LA=(english) 
Google scholar  
"direct antiviral"|"direct*antiviral"|"direct acting anti"|sofosbuvir|ribavirin|"interferon|ifn free" "liver|hepatic 
transplantation|graft|recipient" "Hepatitis-C"|Hepacivirus "genotype|gt|subtype 1" 
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Supplementary figure 1. The Begg funnel plot for 12 weeks sustained virologic response after direct-




Supplementary figure 2. The Egger regression test for 12 weeks sustained virologic response after 
direct-acting antivirals treatment of hepatitis C virus genotype 1 recurrence post liver transplantation 
from 16 studies. 
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Supplementary figure 3. Pooled estimate proportion of general symptoms incidence and 95% 
confidence interval after direct-acting antivirals of hepatitis C virus genotype 1 recurrence post liver 
transplantation from 16 studies. Abbreviations: CI, confidence interval; Events, the number of patients 
who reached SVR12; Total, the number of patients analyzed. 
 
Supplementary Figure 4. Pooled estimate proportion of gastrointestinal symptoms incidence and 95% 
confidence interval after direct-acting antivirals of hepatitis C virus genotype 1 recurrence post liver 
transplantation from 16 studies. Abbreviations: CI, confidence interval; Events, the number of patients 
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Supplementary figure 5. Pooled estimate proportion of skin problems incidence and 95% confidence 
interval after direct-acting antivirals of hepatitis C virus genotype 1 recurrence post liver transplantation 
from 16 studies. Abbreviations: CI, confidence interval; Events, the number of patients who reached 
SVR12; Total, the number of patients analyzed. 
 
 
Supplementary figure 6. Comparison of pooled estimate proportion of 12 weeks sustained virologic 
response after treatment completion and 95% confidence interval between prospective studies and 
retrospective studies after direct-acting antivirals treatment of hepatitis C virus genotype 1 recurrence 
post liver transplantation. Abbreviations: CI, confidence interval; Events, the number of patients who 
reached SVR12; Total, the number of patients analyzed. 
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Supplementary figure 7. Comparison of pooled estimate proportion of 12 weeks sustained virologic 
response after treatment completion and 95% confidence interval among five different direct-acting 
antivirals regimens for treatment of hepatitis C virus genotype 1 recurrence post liver transplantation. 
Abbreviations: CI, confidence interval; Events, the number of patients who reached SVR12; Total, the 
number of patients analyzed; PrOD, Paritaprevir/Ritonavir/Ombitasivir/Dasabuvir; ASV+DCV, 
Asunaprevir/Daclatavir; SOF+LDV, Sofosbuvir/Ledipasvir; DCV+SMV±RBV, Daclatavir/Simeprevir with 
or without Ribavirin; SOF+SMV±RBV, Sofosbuvir/Simeprevir with or without Ribavirin.  
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Supplementary figure 8. Comparison of pooled estimate proportion of 12 weeks sustained virologic 
response after treatment completion and 95% confidence interval for treatment with or without Ribavirin 
of hepatitis C virus genotype 1 recurrence post liver transplantation. Abbreviations: CI, confidence 







































Sofosbuvir Directly Promotes the Clonogenic 
Capability of Human Hepatocellular Carcinoma Cells 
 
Jiaye Liu, Wanlu Cao, Buyun Ma, Meng Li, Maikel P. Peppelenbosch and 
 Qiuwei Pan 
 
Clin Res Hepatol Gastroenterol. 2019 Oct;43(5). 
  



































Page | 55  
 
The recent launch of several types of direct-acting antiviral agents (DAAs) has opened 
a new scenario for treating chronic hepatitis C virus (HCV) infection. Extremely 
satisfactory sustained virological response (SVR) rates have been achieved in DAA 
treated HCV patients, leading to the extensive use of these regimens worldwide [1]. 
Because HCV is one of the leading causes of hepatocellular carcinoma (HCC), 
successful eradication of the infection is expected to dramatically reduce the risk of 
HCC development in these patients. Counterintuitively, several recent studies have 
reported an unexpected high rate of HCC development after DAA treatment [2,3]; 
whereas others did not observe such a risk [4]. However, it remains challenge to make 
definitive conclusion on this issue because of the heterogeneous populations and 
methodologies applied in the different studies. Regardless of this ongoing debate, a 
popular hypothesis has emerged that tumor development is likely attributed to the 
indirect effect of DAA treatment by disrupting cancer immunosurveillance, for instance 
through decreasing natural killer (NK) cell activation and inhibiting its cytotoxic function 
[5]. These immunological changes could be responsible for reduced 
immunosurveillance of neoplastic clone growing and spreading. Interestingly, a recent 
study [6] has profiled the levels of immune mediators including cytokines, growth 
factors and apoptosis markers in serum of HCV patients treated with DAA and studied 
the association with the development of HCC. They observed that the indirect effect of 
immune modulation by DAAs may have little impact on HCC development, although 
the immune background before treatment could already have a potential effect. In 
contrast, we have investigated whether DAAs have direct effect on HCC cells. 
Sofosbuvir (SOF), targeting the HCV RNA-dependent RNA polymerase, is widely used 
DAAs for HCV treatment. Importantly, most reported cases with HCC development 
were treated with SOF-based regimens. To evaluate the direct effect, four human HCC 
cell lines including Huh7, Huh6, HepG2 and SNU449 were treated with serial 
concentrations of SOF (0, 0.01, 0.1, 1M), which are clinically relevant. As expected, 
SOF potently inhibited HCV replication in Huh7-based subgenomic replicon 
(Supplementary Figure 1). No major effect was observed on the growth of bulk of HCC 
cells by SOF treatment for 48 or 72 hours determined by MTT and Alamar blue assays 
(Supplementary Figure 2 and 3). But, surprisingly, SOF increased single cell-based 
clonogenic capability in all four HCC cell lines. This is reflected by the significantly 
increased number and size of formed colonies (Fig. 1). In contrast, placebo treatment 
has no such effect (Supplementary Figure 4). Thus, we have clearly demonstrated a 
direct promoting effect of SOF on single HCC cell-based clonogenic initiation and 
expansion, but not on the growth of the bulk of HCC cells. We interpret that these 
unexpected results may bear important implications in explaining the clinical 
observations. In fact, higher risk of HCC development has been mostly observed from 
HCV patients with advanced diseases (e.g. cirrhosis), [3] or previously treated for HCC 
(e.g. ablation, resection, chemoembolization [2] or liver transplantation [7]). Although 
these studies are often blamed for the bias in selection of these particular patient 
groups, our results however may indicate a direct promoting effect of DAAs on the rare 
preexisting transformed tumor cells in the cirrhotic liver, the residual HCC cells that are 
not completely eradicated by treatment, or the circulating tumor cells in the transplant 
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patients. Despite the low number of these tumor cells, they are likely resemble the so 
called cancer stem cells that are resistance to chemo- or radiotherapy but responsible 
for tumor initiation, treatment relapse and recurrence after surgical operation [8]. Thus, 
DAAs are likely not to have a universal but rather specific effects on particular patients 
in respect to the risk of HCC development; whereas the current clinical studies are 
unable to fully resolve the ongoing debate. Nevertheless, neither our findings nor the 
previous study6 shall exclude the possibility of an indirect effect of DAAs on triggering 
HCC development, as tumor micro-environment was a complicated and evolving field. 
We believe that the joint efforts of future experimental and clinical research are 
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Figure 1. Sofosbuvir (SOF) treatment promotes the clonogenic capability of human hepatocellular 
carcinoma cells. (A, C, E, F) The number of colonies/1000 cells of HepG2, SNU449, Huh6 and Huh7 
after SOF treatment (mean ± SEM, n=9); (B, D, G, H). The diameters of colony formation units (CFUs). 
Every three random colonies from nine independent wells were measured (mean ± SEM, n=27). Mann-
Whitney test; *P<0.05, **P<0.01, ***P<0.001.  
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1 Supplementary materials and methods 
1.1 Reagents 
Sofosbuvir (SOF; PSI-7977) was purchased from Chemscene and were dissolved in dimethyl sulfoxide 
(DMSO) in a concentration of 10 mMol/L. Sorafenib was obtained from Bioconnect. 3-(4,5-
Dimethylthiazol-2-yl)-2,5-Diphenyltetrazolium Bromide (MTT) was from Sigma-Aldrich. Alamar blue 
reagent was from Invitrogen. 
1.2 HCC cells culture 
Human hepatocellular carcinoma cells (Huh7, Huh6, SNU449 and HepG2) were cultured with 
Dulbecco’s modified Eagle’s medium (Invitrogen, Carlsbad, CA) supplemented with 10% fetal bovine 
serum (Sigma-Aldrich) and 1% Penicillin/Streptomycin (Gibco, Bleiswijk, The Netherlands). 
1.3 HCV cell culture model 
HCV subgenomic replicon model (Huh7-HCV-Luc) was on the basis of Huh7 cells containing a 
subgenomic HCV bicistronic replicon (I389/NS3-3V/LucUbiNeo-ET) which contains the non-structural 
coding sequence of HCV and the firefly luciferase gene. Huh7-HCV-Luc cells were cultured in the 
presence of 250 μg/mL G418 (Sigma-Aldrich).  
1.4 Measurement of Luciferase activity 
Huh7-HCV-Luc luciferase activity was quantified by adding luciferin potassium salt (100 mM, Sigma-
Aldrich) to the cells and then incubating for 30 minutes at 37oC. Then firefly luciferase activities were 
quantified with a LumiStar Optima luminescence counter (BMG labTech, Offenburg, Germany). 
1.5 MTT assay 
The cells were seeded in a 96-well plate, at a concentration of 6×103 cells/well in 100 µl medium. Then 
they were incubated overnight to attach to the bottom of the wells and then treated with serials dilutions 
of SOF (0, 0.01, 0.1, 1 µM). Cell viability was analyzed by adding 10 mM MTT. Subsequently, the cells 
were incubated at 37 C with 5% CO2 for 4 hours. The culture medium was then replaced by 100 μl of 
DMSO for each well. The absorbance of each well was read in a microplate absorbance reader (Bio-
Rad, Japan) at wavelength of 490 nm. All measures performed in triplicates. 
1.6 Alamar blue assay 
The cells were harvested and then seeded in 96-well plate. Alamar blue reagent was firstly diluted into 
DMEM medium in 1:20 ratio. After removing supernatant, 100 µl diluted Alamar blue medium was added 
into each well. The plate was then moved to incubator at 37 C with 5% CO2 for 2 hours. Fluorescence 
was measured using Varioskan Flash Microplate Multimode Readers with an excitation wavelength of 
530 nm and an emission wavelength of 590 nm. All measures performed in triplicates. 
1.7 Colony formation assay 
The cells were harvested and suspended in medium, then seeded into 12 well plate (1000 cells/well). 
Cells were incubated overnight to attach to the bottom of the wells and then treated with serial dilutions 
of SOF (0, 0.01, 0.1, 1 µM). Formed colonies were stained by crystal violet solution (Sigmal-Aldrich). 
Colony numbers were counted and their diameters were measured microscopically trough digital image 
analysis.  
1.8 Statistical analysis 
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Statistical analysis was performed by using the nonpaired, nonparametric test (Mann-Whitney test; 
GraphPad Prism software, GraphPad Software Inc., La Jolla, CA). Difference were considered with 
significant difference at P values < 0.05. 
 
 
Supplementary figure 1. In the Huh7-HCV-Luc cells, treatment with clinically relevant concentrations of 
sofosbuvir (SOF) potently inhibited hepatitis C (HCV) replication-related luciferase activity (mean ± 
SEM, n = 5).  
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Supplementary figure 2. No major effect was observed on the metabolic activity of hepatocellular 
carcinoma (HCC) cells by sofosbuvir (SOF) treatment for 48 and 72 hours with clinically relevant 
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Supplementary figure 3. No major effect was observed on the growth of the bulk of hepatocellular 
carcinoma (HCC) cells by sofosbuvir (SOF) treatment for 48 and 72 hours with clinically relevant 
concentrations in Alamar blue assay (mean ± SEM, n = 9). 
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Supplementary figure 4. DMSO as placebo in accordance with the dilution contained in the sofosbuvir 
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Abstract 
Background and Aims: Hepatitis E virus (HEV) as an emerging zoonotic pathogen is 
a leading cause of acute viral hepatitis worldwide, with a high risk of developing chronic 
infection in immunocompromised patients. However, the global epidemiology of HEV 
infection has not been comprehensively assessed. This study aims to map the global 
prevalence and identify the risk factors of HEV infection by performing a systematic 
review and meta-analysis.  
 
Methods: A systematic searching of articles published in Medline, Embase, Web of 
science, Cochrane and Google scholar databases till July 2019 to identify studies with 
HEV prevalence data. Pooled prevalence among different countries and continents 
were estimated. HEV IgG seroprevalence of subgroups were compared and risk 
factors for HEV infection were evaluated using odd ratios. 
 
Results: We identified 419 related studies which comprised of 1519872 individuals. A 
total of 1099717 participants pooled from 287 studies of general population estimated 
a globally anti-HEV IgG seroprevalence of 12.47% (95% CI 10.42-14.67; I2=100%). 
Notably, the use of ELISA kits from different manufactures has a substantial impact on 
the global estimation of anti-HEV IgG seroprevalence. The pooled estimates of anti-
HEV IgM seroprevalence based on 98 studies is 1.47% (95% CI 1.14-1.85; I2=99%). 
The overall estimate of HEV viral RNA positive rate in general population is 0.20% (95% 
CI 0.15-0.25; I2=98%). Consumption of raw meat (p=0.0001), exposure to soil 
(p<0.0001), blood transfusion (p=0.0138), traveling to endemic areas (p=0.0244), 
contacting with dogs (p=0.0416), living in rural areas (p=0.0349) and receiving 
education less than elementary school (p<0.0001) were identified as risk factors for 
anti-HEV IgG positivity.  
 
Conclusions: Globally, approximately 939 million corresponding to 1 in 8 individuals 
have ever experienced HEV infection. 15-110 million individuals have recent or 
ongoing HEV infection. Our study highlights the substantial burden of HEV infection 


















Hepatitis E virus (HEV) as a single-stranded positive-sense RNA virus is a leading 
cause of acute viral hepatitis worldwide. The infection is usually asymptomatic or self-
limiting in the general population. However, acute infection in pregnant women may 
cause severe clinical outcomes, including fulminant hepatic failure with high mortality 
rate reaching up to 20-30%.1 These patients are mostly from resource-limited regions. 
In European countries, HEV infection has been frequently reported to bear high risk of 
developing into chronic hepatitis in immunocompromised individuals, in particular 
organ transplant patients.2,3 Thus, HEV is truly imposing a global health burden in both 
developing and developed countries.  
 
Currently, eight distinct genotypes of HEV have been classified.4 Genotype (GT) 1-4 
are known to be the main threat to humans. GT 1 and 2 are restricted to human and 
mainly transmit through contaminated water causing acute hepatitis. GT 3 and 4 are 
zoonotic and have been identified in a wide spectrum of hosts, including human, swine, 
wild boar, goat, cattle, deer, camel and yak.5 Both GT 3 and 4 can cause chronic 
infection in organ transplant patients,2,6 and consumption of raw or undercooked 
animal meat has been recognized as the main routes of causing sporadic cases in 
developed countries.7 In fact, the host range of HEV is ever expanding and the 
implications of the rare genotypes and the newly discovered strains in human health 
remain largely uncertain.7 This further complicates the transmission and the risk of 
HEV infection. In addition to the classical waterborne and foodborne transmission 
routes, blood transfusion-mediated transmission has been reported in organ transplant 
patients.8 Person-to-person transmission has also been proposed.9 Intriguingly, recent 
evidence has indicated that pet animals including dogs, cats, rabbits and horses might 
be accidental hosts for HEV and constitute a potential source for transmitting to 
human.10,11 Thus, there is an urgent need to comprehensively understand the risks for 
HEV infection, in order to device preventive measures. 
 
Globally, it has been roughly estimated that one third of the population are living in 
HEV endemic areas.12 More recently, substantial efforts have been dedicated to 
systematically evaluate HEV prevalence in different continents (e.g. the Americas and 
Europe),13,14 different countries (e.g. industrialized countries, China, Iran, Brazil and 
Somalia),15-17 and special populations or settings (e.g. blood donors, swine workers 
and outbreak setting).18-20 Most of these studies are based on seropositivity of anti-
HEV IgG antibody. Anti-HEV IgG antibody developed post-infection usually persists for 
many years, and is thus regarded as a marker for past infection.21,22 In contrast, anti-
HEV IgM antibody is short-lived up to a few months, thus considered as evidence of 
recent or current infection. Detection of HEV RNA is a bona fide marker for active 
ongoing infection. In this study, we aimed to systematically estimate the global burden 
of HEV infection. More specifically, we have mapped the global prevalence of past, 








Data sources and searches  
A systematic search was conducted in Medline, Embase, Web of science, Cochrane 
CENTRAL and Google scholar. Databases were searched for articles in the English 
language from inception until July 2019. All searches from database were performed 
by a biomedical information specialist of the medical library, with an exhaustive set of 
search terms related to hepatitis E virus infection and epidemiology (The full search 
strategies are provided in the Supplementary file S1). This study is reported in 
accordance with the Preferred Reporting Items for Systematic Reviews and Meta-
Analysis (PRISMA).23 No institutional review board approval was required for this 




Studies were included if they met following criteria: i) Studies which contained data 
about seroprevalence of anti-HEV IgG, anti-HEV IgM or HEV RNA positivity. ii) Studies 
contained mixed population were excluded unless they clearly and explicitly reported 
the prevalence for each group. iii) Studies contained information of risk factors related 
to HEV infection. iv) Studies which focused on the HEV prevalence in human beings. 
Studies were excluded if they met following criteria: i) Studies are systematic review, 
meta-analysis, case reports, perspectives and abstracts. ii) None human studies. iii) 
No primary data or incomplete data. iv) Duplicate data. v) Studies with less than 50 
individuals were excluded in order to decrease bias caused by small population. vi) 
Studies concerning about HEV outbreaks, since the prevalence and outcome of HEV 
infection in these studies would dramatically differ from those of the general population.  
Two reviewers (PL and JL) worked independently to determine whether a study met 
inclusion criteria, abstracted information to assess the methodological validity of each 
candidate study, and extracted data with structured data collection forms. The 
reviewers resolved discrepancies by jointly reviewing the study in question. If no 
consensus was reached, a third reviewer (QP), unaware of prior determinations, 
functioned as an arbiter. 
 
Data extraction and quality assessment  
Eligible studies were further divided into three study populations: general population, 
occupational population and special population. General population included people 
without apparent risk factors and could be comprised of blood donors, pregnant women, 
healthy individuals and hospital attendants. For general population, individuals were 
further divided into subgroups by gender, different age ranges, study period (1993-
2006 or 2007-2019), country development classification (developing and developed 
countries), gross national income classification of each country (high, upper-middle, 
lower middle and low income) and ELISA kit manufacturers. More importantly, odd 
ratios (OR) analysis of anti-HEV IgG seropositivity was conducted in possible risk 
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factors included living area (urban or rural), consumption of raw meat, exposure to soil, 
contacting with cat or dog, education level (elementary school or above elementary 
school), intravascular drug use (IDU), water source (tap, well or river), man having sex 
with man (MSM), transfusion history and travelling history to endemic areas. 
Occupational population represents people who had been in frequent contact with pigs 
or pig products, including veterinarians, swine workers, slaughterhouse workers and 
pork sellers. Special populations are further categorized into four groups as followings: 
patients with acute hepatitis (caused by hepatitis B virus, hepatitis C virus or other 
unknown hepatitis), individuals with human immunodeficiency virus (HIV) infection, 
people who underwent hemodialysis and organ transplant recipients. Two independent 
reviewers (PL and JY) extracted data, with discrepancies and disagreements resolved 
by discussion. We extracted data on first author, country, continent, publication date, 
anti-HEV IgG prevalence, anti-HEV IgM prevalence, HEV RNA positivity, subgroup 
information of anti-HEV IgG prevalence and HEV-related risk factors using data 
extracting forms. When multiple publications were identified that reported on the same 
populations and outcomes, only the most representative and comprehensive study 
was included for further meta-analysis in order to avoid duplicate data. The quality of 
studies was assessed using the Joanna Briggs Institute checklist for prevalence 
studies, which enabled assessment of included studies in relation to risk of bias, rigour, 
and transparency.24 Studies scoring 1-3 were defined as low quality, 4-6 as average 
quality, and 7-9 as high quality (Table S1). Studies were not excluded on the basis of 
their quality score to increase transparency and to ensure all available evidence in this 
area was reported.  
 
Statistics analysis 
After checking for consistency, the Metaprop module in the R-3.5.3 statistical software 
package was used for meta-analysis. A 95% confidence interval (95% CI) was 
estimated using Wilson score method, and pooled seroprevalence was calculated with 
the DerSimonian-Laird random-effects model with Freeman-Tukey double arcsine 
transformation. Heterogeneity across the included studies was assessed using the 
Cochran Q statistics and I2 statistics, with I2 statistics 25%-50%, 50%-75%, and >75% 
considered as mild, moderate, and severe heterogeneity, respectively. When 
heterogeneity was higher than 50%, a random-effect model will be used. ORs was 
used to report the risk factors for HEV infection. ORs and their 95% CI were extracted 
directly from studies when available, with adjusted ORs extracted preferentially over 
unadjusted ORs. If an included studies did not report ORs, crude ORs were calculated 
from extracted data. We then pooled the ORs using the DerSimonian and Laird random 
effect models, with the heterogeneity estimated from the Mantel-Haenszel model. 
Funnel plots and Egger regression test were used to assess potential publication 
biases. Additionally, we performed sensitivity analyses by using “metainf” in a random 
model to investigate the effects of population source and potentially unrepresentative 
samples. The estimated prevalence of anti-HEV IgG, IgM and HEV RNA infection was 
based on the global population of 7530000000 in 20th July, 2019 (https://population.io). 
 
 




Global prevalence of HEV infection  
Our search retuned 8153 records, of which 419 met the inclusion criteria (Fig. 1). In 
total, participants from 302 studies related to general population, 287 studies were 
pooled to estimate a global anti-HEV IgG seroprevalence of 12.47% (1099717 
individuals included; 95% CI 10.42-14.67; I2=100%) (Fig. 2A, Fig. S1). The pooled 
estimate of anti-HEV IgM seroprevalence based on 98 studies is 1.47% (479001 
individuals; 95% CI 1.14-1.85; I2=99%) (Fig. 2B, Fig. S2). The overall estimate of HEV 
RNA positive rate in the general population is 0.20% (3444752; 95% CI 0.15-0.25; 
I2=98%) (Fig. 2C, Fig. S3). We also stratified data to estimate the HEV prevalence in 
75 countries among six continents (excluding Antarctica). The highest anti-HEV IgG 
seropositivity rate was found in Africa (22377; 21.76%, 95% CI 13.05-31.98; I2=100%), 
followed by Asia (681373; 15.80%, 95% CI 13.29-18.49; I2=100%), Europe (132419; 
9.31%, 95% CI 7.35-11.48; I2=99%), North America (71989; 8.05%, 95% CI 5.47-11.09; 
I2=99%), South America (14586; 7.28%, 95% CI 4.83-10.19; I2=97%) and Oceania 
(1563; 5.99%, 95% CI 1.22-14.03; I2=96%) (Fig. S4). Besides, the anti-HEV IgM 
seroprevalence was 3.09% (5001; 95% CI 1.49-5.24; I2=93%), 1.86% (141565; 95% 
CI 1.34-2.46; I2=98%), 0.79% (146322; 95% CI 0.30-1.51; I2=99%), 0.22% (12197; 95% 
CI 0.00-0.74; I2=91%), 2.43% (2680; 95% CI 0.43-6.00; I2=96%) for Africa, Asia, 
Europe, North America and South America, respectively (Fig. S5). In addition, the HEV 
RNA positivity rate was 0.00% (278; 95% CI 0.00-0.35), 0.93% (727744; 95% CI 0.48-
1.52; I2=99%), 0.08% (2441774; 95% CI 0.05-0.11; I2=95%), 0.00% (34761; 95% CI 
0.00-0.02; I2=45%), 0.00% (74131; 95% CI 0.00-0.01), 0.18% (1054; 95% CI 0.00-1.36; 
I2=81%) for Africa, Asia, Europe, North America, Oceania and South America, 
respectively (Fig. S6). HEV prevalence varies substantially among countries, from 0.25% 
(Tanzania, 95% CI 0.00-0.97) to 74.76% (South Sudan, 95% CI 68.61-80.44) of anti-
HEV IgG, from 0.00% (Mongolia, 95% CI 0.00-0.08; Bulgaria, 95% CI 0.00-0.13) to 
19.83% (United Arab, 95% CI 16.35-23.56) of anti-HEV IgM, from 0.00% (Benin, 
Malawi, Australia, Canada, Brazil) to 6.75% (France, 95% CI 0.14-22.04) of HEV RNA 
positivity (Table 1, Fig. S1-S3). We also collected data of HEV genotypes, with the 
finding that HEV GT1 infection occasionally occurred in China and frequently in India, 
and GT3 was widely distributed in European countries. GT3 was also prevalent in 
Japan and Korea, whereas GT4 infection mainly emerged in China (Fig. 3, Table S2). 
Based on our comprehensive estimates, approximately 938991000 individuals 
corresponding to 1/8 of the global population have ever experienced HEV infection 
based on anti-HEV IgG positivity. Importantly, we estimated approximately 110691000 
global individuals with current or recent HEV infection and 15060000 individuals with 
ongoing HEV infection based on anti-HEV IgM or viral RNA positivity, respectively.  
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Figure 1. Study selection. 
We next performed subgroup analysis of anti-HEV IgG positivity rate in general 
population. General population of six different continents were further divided into 
seven age groups, including age range of 0-9, 10-19, 20-29, 30-39, 40-49, 50-59 and 
above 60-year old. The corresponding pooled anti-HEV IgG positive rates are 7.73% 
(6977 individuals included; 95% CI 2.29-16.02; I2=99%), 9.03% (14452 individuals; 95% 
CI 3.78-16.25; I2=99%), 10.78% (33365; 95% CI 7.44-14.64; I2=99%), 14.17% (23217; 
95% CI 10.27-18.57; I2=99%), 21.53% (21324; 95% CI 16.82-26.65; I2=99%), 24.48% 
(17474; 95% CI 18.56-30.93; I2=99%) and 27.47% (23924; 95% CI 21.07-34.36; 
I2=99%), respectively (Fig. 4, Fig. S7-8). The positive rate is slightly higher in male 
(129569; 13.39%, 95% CI 11.34-15.59; I2=99%) compared to female (120264; 12.25%, 
95% CI 10.05-14.63; I2=99%) (Fig. 4, Fig. S9). To clarify the HEV prevalence among 
regions with different levels of economic development, we firstly calculated the anti-
HEV IgG prevalence in high income countries, upper-middle income countries, lower 
middle income countries, and low income countries. We estimated the anti-HEV IgG 
positivity of 8.84% (424905; 95% CI 6.79-11.14; I2=100%) in high income countries, 
12.79% (618638; 95% CI 10.81-14.92; I2=100%) in upper-middle income countries, 
19.04% (40593; 95% CI 13.25%-25.60%; I2=100%) in lower middle income countries 
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and 30.44% (5781; 95% CI 16.60-46.39; I2=99%) in low income countries (Fig. 4, Fig. 
S10). The pooled estimate of anti-HEV IgG seroprevalence was 14.83% (689452; 95% 
CI 12.98-16.77; I2=100%) in developing countries compared to 8.59% (401513; 95% 
CI 6.46-10.99; I2=100%) in developed countries (Fig. 4, Fig. S11). Of the global HEV 
prevalence during the period of 1993-2019, we estimated anti-HEV IgG positive rate 
of 9.43% (79998; 95% CI 6.11-13.37; I2=100%) during 1993-2006 and 13.65% 
(1019719; 95% CI 11.15-16.35; I2=100%) during 2007-2019 (Fig. 4, Fig. S12). 
 
 
Figure 2. (A) The global seroprevalence of anti‐HEV IgG antibody (B) The global seroprevalence of 
anti‐HEV IgM antibody (C) The global prevalence of HEV RNA positivity. 
 
Page | 74 
 
 
Figure 3. Hepatitis E virus genotype distribution in our study. 
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3.2 Prevalence of HEV infection in occupational population and special 
population 
Anti-HEV IgG seroprevalence data from veterinarians, swine workers, slaughters, and 
pork sellers were collected to estimate the overall anti-HEV seroprevalence in 
occupational population. Based on 43 studies with 8776 occupational individuals, the 
overall seropositivity of anti-HEV IgG is 24.04% (95% CI 18.55-29.99; I2=97%) (Fig. 
S13). In total, 126 studies were extracted data to analyze the prevalence in special 
populations. The overall anti-HEV IgG, anti-HEV IgM and viral RNA positive rates are 
15.43% (95% CI 12.82-18.24; I2=98%), 3.21% (95% CI 1.77-5.06; I2=98%) and 1.10% 
(95% CI 0.53-1.87; I2=97%), respectively (Fig. S14-S16). Among these special 
populations, patients with acute hepatitis have the highest positive rate of anti-HEV 
IgG (21.49%, 95% CI 12.65-31.92; I2=99%), anti-HEV IgM (8.62%, 95% CI 4.16-14.51; 
I2=99%) and viral RNA (5.57%, 95% CI 2.26-10.21; I2=99%) (Fig. S17-S19). The anti-
HEV IgG positive rates in two special groups are higher than that in general population, 
with 16.91% (95% CI 12.64-21.67; I2=98%) in the HIV population, 13.10% (95% CI 
9.34-17.39; I2=96%) in hemodialysis population, while it is slightly lower in organ 
transplant recipients with 11.68% (95% CI 7.91-16.06; I2=97%) seropositivity (Fig. S20-
S27, Table S5). 
 
3.3 Risk factors of HEV 
We investigated the potential risk factors for HEV in the general population (Fig. S28). 
Significant rising effects on anti-HEV IgG seropositivity were observed in consumption 
of raw meat (OR 1.45, 95% CI 1.20-1.76, p=0.0001), exposure to soil (OR 1.52, 95% 
CI 1.24-1.86, p<0.0001), blood transfusion (OR 1.61, 95% CI 1.10-2.36, p=0.0138), 
travelling to endemic areas (OR 1.39, 95% CI 1.04-1.84, p=0.0244), contacting with 
dogs (OR 1.45, 95% CI 1.01-2.07, p=0.0416), living in rural areas (OR 0.80, 95% CI 
0.65-0.98, p=0.0349) and receiving education less than elementary school (OR 1.71, 
95% CI 1.41-2.07, p<0.0001). No statistically significant differences were identified for 
anti-HEV IgG positivity in respect to different water source (p=0.0909), IDU experience 
(p=0.4321), MSM experience (p=0.5576) and contacting with cats (p=0.4791) (Fig. 
S29-S39). Sensitivity analysis detected no study having an obvious effect influence the 
pooled estimates of HEV prevalence in the general population (Table S3). 
 
3.4 Anti-HEV IgG detection rate of different ELISA kits 
We finally analyzed the detection rates of the ELISA kits from six manufactures. The 
detection rates of anti-HEV IgG seropositivity vary dramatically, with the highest of 
Wantai assay (20.72%, 95% CI 2.07-9.84; I2=100%) followed by MP Diagnostics 
(10.75%, 95% CI 4.55-19.15; I2=100%), Dia.Pro (8.89%, 95% CI 6.68-11.38; I2=97%), 
Mikrogen (8.60%, 95% CI 4.65-13.62; I2=98%), Genelabs Diagnostics (6.22%; 95% CI 
3.42-9.77; I2=98%) and Abbott Laboratories (5.27%, 95% CI 2.07-9.84; I2=100%) (Fig. 
S40, Table S4). 
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It has been estimated that one third of the global population, representing over two 
billion people, live in HEV endemic areas at risk of infection.12 This has been widely 
misinterpreted as that 2.3 billion of the population have been infected with HEV.25 In 
fact, the true burden of hepatitis E remains largely unknown.26 In this study, we have 
systematically and comprehensively assessed the global HEV prevalence by retrieving 
data from 75 countries of the six continents. We estimated that 12.47% of the global 
population, corresponding to approximately 939 million individuals, have experienced 
past-infection of HEV based on their seropositivity of anti-HEV IgG antibody. Africa and 
Asia have been previously recognized for the high prevalence of HEV.27,28 Our 
estimates confirm the high seroprevalence rates of 21.76% and 15.80% in Africa and 
Asia, respectively. For Europe, we estimated a prevalence rate of 9.31%, which is 
substantially lower than a previous estimation of 16.90% from a meta-analysis 
performed in 2016.14 A possible explanation for the disparity could be that they 
collected fewer studies and included small size populations, and thus is prone to cause 
more bias. In Americas, we observed a slightly higher seroprevalence rate in North 
(8.05%) compared to South (7.28%) America, which is consistent with the results from 
a recent meta-analysis.13  
 
Of a technical note, it has been well-realized that there are substantial differences in 
sensitivity and specificity of the anti-HEV IgG ELISA kits from different 
manufactures.29,30 Our results largely agree with the literature that the Wantai assay 
has the best performance and has been most widely used.31 Thus, the use of different 
anti-HEV IgG ELISA kits may partially explain the disparities in estimates among 
different studies, and caution should be taken when interpreting the seroprevalence 
rate in this respect.  
 
The bona fide disease burden of HEV lies in the actively infected patients. The global 
burden caused by GT 1 and 2 HEV in Africa and Asia has been mathematically 
modeled for 2005. Among the 4.7 billion people in these regions corresponding to 72.8% 
of the global population in 2005, it has been estimated as 20 million incident HEV 
infections, 3.4 million symptomatic cases, 70000 deaths, and 3000 stillbirths.32 In 2011, 
WHO reported 14 million symptomatic cases annually worldwide with 300000 deaths 
and 5200 stillbirths.33 Hypothetically, if both estimates are accurate, there would be 
about 10 million symptomatic cases annually from developed countries, which are 
mainly caused by the zoonotic GT3 strains. This clearly disagrees with the vast majority 
of the current literature that we do not expect the burden in respect to symptomatic 
infection would be three-times in developed compared to developing countries. In this 
study, we have estimated approximately 110 million individuals with recent/current 
infection based on anti-HEV IgM antibody positivity and 15 million with ongoing 
infection based on HEV RNA positivity. As viral RNA persists for a few weeks and anti-
HEV IgM antibody for a few months,34 the annually global infections are probably at a 
range of hundred(s) millions. However, the available data regarding anti-HEV IgM 
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antibody or viral RNA positivity are very limited. Thus, our estimates may have biases, 
and we were not able to further sub-analyze regional prevalence, genotype-specific 
burden or clinical outcome, which require future studies in these aspects. 
 
Accumulating knowledge on HEV biology and transmission routes has facilitated the 
identification of risk factors for the infection. A wide range of domestic or wild animals 
have been recognized as reservoirs for the zoonotic strains. Consumption of uncooked 
meat or meat product from swine, wild boar or deer has been widely reported to cause 
GT3 HEV infection in European countries.35,36 As expected, consumption of raw meat 
is an important risk factor revealed by our meta-analysis. This is in line with previous 
reports that human with occupational exposure to pigs are at a high risk of HEV 
infection.37,38 In this study, we observed two-fold higher of anti-HEV seropositivity in 
occupational population who frequently contact with pig or pig products compared to 
the general population.  
 
The host range for HEV is ever expanding and cross-species infections commonly 
occur.7 Intriguingly, recent evidence has indicated that companion animals including 
dogs, cats, rabbits and horses might be accidental hosts for HEV and might constitute 
a source for HEV transmission to human.10,11,39 Transmission of rat HEV to human has 
been recently reported in Hong Kong.40 Dogs and cats are the most common 
household pets. Previous studies have reported that seroprevalence of HEV antibodies 
in dogs ranges from 0.8% in UK,41 6.79% in Brazil,42 17.8% to 36.55% in different 
regions of China,10,11 22.7% in India,43 and 56.6% in Germany.44 Interestingly, when 
comparing with the general population, veterinarians and dog farm staff who are 
frequently exposed to dogs have significantly higher anti-HEV antibody positivity.10 The 
anti-HEV seroprevalence rates in cats have been reported to be 6.28% in China,11 8.1% 
in Korea,45 and 33% in Japan.46 In this study, we found that people who frequently 
contact with dogs have higher anti-HEV IgG seropositivity. This was not found in 
people who contact with cats, but the number of studies are very limited. These results 
call more attention to address the potential role of pets in HEV zoonotic transmission, 
although currently it remains unconfirmed whether pets are reservoirs, requiring further 
investigation. 
 
Previous studies have indicated the differences of HEV seroprevalence between rural 
and urban areas.47-49 We found that rural compared to urban residents have higher risk 
of HEV infection. This largely agrees with our findings that high exposure to soil is also 
a risk factor. In addition, we observed the high risk of HEV infection in individuals with 
lower education levels, consistent with previous studies.50,51 Conceivably, this 
population are more likely living in rural arears with compromised sanitation conditions 
and more frequent exposure to animals or soil. Although we did not find differences of 
HEV prevalence in respect to different water source, this does not contradict to the fact 
that contaminated water is the main source of GT1 infection, especially during outbreak. 
In our study, we have excluded studies related to outbreak, and the number of included 
studies reporting water source is also very limited, which may cause bias. 
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Of note, there are some limitations of our study. Firstly, the number of available studies, 
in particular on anti-HEV IgM antibody and viral RNA positivity, are limited. We were 
also not able to further detailed sub-analyze regional prevalence, genotype-specific 
burden or clinical outcome. Secondly, we have focused on HEV prevalence, but did 
not estimate the incidence, which is also very relevant for assessing the disease 
burden. Thirdly, the assays used for HEV detection are heterogeneous in sensitivity 
and specificity, which may affect the estimates. Fourthly, publication bias existed in our 
study which was reflected in Funnel and Egger test (Fig. S41-S42).  
 
In summary, we found that 1/8 of the global population, corresponding to over 900 
million individuals, have ever encountered HEV infection. Importantly, 15-110 million 
individuals are experiencing recent or ongoing infection. Consuming raw meat, 
exposing to soil, blood transfusion, travelling to endemic areas, contacting with dogs, 
living in rural areas and receiving lower level of education were identified as risk 
factors for HEV infection. Thus, our results bear important implications for assessing 
the global burden and devising preventive measures for controlling HEV infection.  
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Abstract 
Background & Aims 
The increasing burden of non-alcoholic fatty liver disease (NAFLD) worldwide imposes 
an emerging public health issue. To obtain a comprehensive overview of NAFLD, we 
perform the current study with the aim to estimate the global prevalence, incidence, 
disease progression and clinical outcomes of NAFLD.  
Approach & Results 
A systematic search was conducted in five databases that screened articles in English 
language published from January 2000 to February 2020. Our search returned 59156 
records, of which 578 studies fulfilled our inclusion criteria. The overall prevalence of 
NAFLD was 29.38% (95% CI 28.09-30.69) regardless of the diagnostic techniques. 
Looking at the group in which the diagnosis was made by ultrasound exclusively, the 
pooled prevalence was 30.49% (95% CI 29.55-31.43). NAFLD has become more 
prevalent during the latest 10 years (31.63%, 95% CI 30.23-33.04) compared to the 
previous decade (27.94%, 95% CI 26.23-29.69). The pooled estimation of NASH 
prevalence was 8.26% (95% CI 1.13-21.01), 46.49% (95% CI 35.93-57.20), 46.72% 
(95% CI 37.57-55.98) in general population, NAFLD patients and severe/morbidly 
obese patients, respectively. Based on a total of 110142 newly developed NAFLD 
patients, the pooled incident rate was estimated as 46.2 cases per 1000 person-years 
(95% CI 43.2-49.3). In patients with NAFLD, the incident rate of hepatocellular 
carcinoma was 1.4 (95% CI 0.9-2.0) cases per 1000 person-years. The overall pooled 
estimate of mortality was 23.9 (95% CI 13.5-37.1) death per 1000 person-years.  
Conclusions 
The prevalence of NAFLD is increasing globally. It is contributing to poor clinical 
outcomes including hepatocellular carcinoma and death. Rising awareness and urgent 
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Introduction 
Non-alcoholic fatty liver disease (NAFLD), once considered a disease of western 
developed world, now is affecting the global population.1-5 Although NAFLD has a 
benign course in the majority of individuals, a subset of patients develop non-alcoholic 
steatohepatitis (NASH). NASH is a more serious form of liver damage which may 
further develop into end-stage liver diseases, including liver cirrhosis and 
hepatocellular carcinoma (HCC).6-9 Due to its high prevalence in general population, 
even a small proportion of NAFLD patients developing end-stage liver disease will 
represent a sizable number and impose an emerging global health burden.10-11 
Classical risk factors of NAFLD include age, sex, obesity resulted insulin resistance 
(IR), and development of metabolic syndromes (MetS).12 The rise in the prevalence of 
NAFLD/NASH parallels with the epidemics of obesity during the last two decades.13 
Obesity, especially central obesity, is highly predictive for hepatic steatosis and 
disease progression as the prevalence rate is doubled in obese in comparison with 
lean NAFLD patients.14 In morbid obesity, almost all patients have steatosis and more 
than one third present with NASH.15 Moreover, the association with type 2 diabetes 
mellitus (T2DM) is particularly strong, being 3-9 times more frequent in NAFLD and 5 
times higher in NASH patients as compared to the general population.16 On the other 
hand, more than two third of T2DM patients present with NAFLD.16-17 MetS is a cluster 
of metabolic abnormalities associated with cardiovascular mortality. One third of 
NAFLD patients have MetS and 80% have at least one of the components.18-19  
Early studies have highlighted the emergence of the NAFLD epidemic,3 but an up-to-
date comprehensive meta-analysis regarding the evolving epidemiology of NAFLD 
from a global perspective is lacking. Therefore, this study aims to comprehensively 
estimate the global prevalence, incidence, disease progression and clinical outcomes 
of NAFLD by a systematic review and meta-analysis.  
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Materials and methods 
Data source and searching strategy 
A systematic search was conducted in Medline, Embase, Web of science, google 
scholar and Cochrane CENTRAL. Databases were searched for articles in the English 
language from January 2000 to February 2020. All searches from database were 
performed by a biomedical information specialist of the medical library, with an 
exhaustive set of search terms related to “non-alcoholic fatty liver disease”, “non-
alcoholic steatohepatitis”, “prevalence”, “epidemiology” (The full search strategies are 
provided in the Supporting methods 1-3). Our analysis in this review was reported in 
accordance with PRISMA guidelines.20 
Eligibility criteria 
Inclusion criteria for the meta-analysis were as follows: (1) NAFLD diagnosed by 
imaging (ultrasound, computed tomography, and magnetic resonance 
imaging/spectroscopy, transient elastography), liver biopsy, and/or blood 
testing/predictive indices (fatty liver index or hepatic steatosis index); (2) the study was 
either a cross-sectional study or a baseline survey of longitudinal study; (3) the study 
provided information about sample size (> 30) and estimation of prevalence, incidence, 
disease progression or outcome (HCC or all-cause mortality, cancer-related, liver-
specific, cardiovascular-related mortality ) of NAFLD. Exclusion criteria for the meta-
analysis were as follows: (1) the study was a review article, abstract, case report, 
correspondence, conference papers; (2) the study did not identify individuals with 
NAFLD; (3) individuals <18 years. (4) the study did not exclude other causes of liver 
disease, such as viral hepatitis B and C (HBV/HCV); (5) the study without reporting 
screening for excess alcohol consumption; (6) for NAFLD prevalence, incidence 
pooled estimates in general population, studies performed in patients, individuals from 
outpatient service were excluded; (7) the study reporting that individuals with 
preexisting disease, for example, human immunodeficiency virus (HIV) co-infected; (8) 
the study diagnosed NAFLD postmortem; (9) NASH studies were excluded if the 
diagnosis was not made by histological assessment; (10) a study unable to provide 
sufficient information for data extraction. 
 
Data extraction, quality assessment and statistics analysis 
Studies were screened based on pre-specified decision rules. Initial title and abstract 
screening was done independently by two reviewers (JL, PL), with a random 10% of 
studies checked by another two investigators (WC, QY). Full-text review was done 
independently by two authors (any two of JL, PL, WC and QY), with any discrepancies 
resolved by consensus or by a third reviewer (QP); consensus was reached in all 
instances. We extracted data at all levels reported in the study, including time of 
publication, study period, country or region, country or region income, the level of 
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country development, study categories, gender, age, living area (urban or rural), 
diagnostic techniques and prevalence or incidence of disease. Data were then cross 
checked for accuracy against the original source by one of four authors (JL, PL, WC 
or QY). Two authors (any two of JL, PL, WC and QY) independent reviewed and 
extracted data from the included studies by using a data extraction form specifically 
designed for current study. When duplicate data were identified, the duplicate with the 
smallest sample size or shortest duration of follow-up was excluded. We assessed the 
quality of included studies using an assessment scale based on the Newcastle-Ottawa 
Scale, which is comprised of three domains including selection, comparability and 
outcome. The Newcastle-Ottawa Scale assigns a maximum score of five for selection, 
two for comparability, and two for outcome. Studies scoring 1-3 were defined as low 
quality, 4-6 as average quality, and 7-9 as high quality (Supporting Table 1).21 Studies 
were not excluded on the basis of their quality score to increase transparency and to 
ensure all available evidence in this area was reported. All statistics analysis were 
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Results 
Study and patient characteristics 
Our search retuned 59156 records, of which 578 studies fulfill our inclusion criteria 
(Figure 1). Among these included studies, 559 studies included epidemiological data, 
16 studies documented disease progression and 16 studies reported clinical outcomes. 
The quality assessment scores for included studies are displayed in the Supporting 
Table 1. The mean quality score of all studies was 7.96 (range from 6-9). As a result, 
553 high quality and 25 fair quality studies were further included in meta-analysis. The 
majority of these included studies had a cross-sectional design and most of them 
concerned data from health checkup’s assessments within general population. The 
mean or median age of all participants ranged from 19.7 to 80.3 years and 21.4 to 80.0 
years for NAFLD patients, respectively. The percentages of males ranged from 0% to 
100% for the total study population as well as for NAFLD patients. 
 
 
Figure 1. Study selection. 
NAFLD prevalence 
A total of 363 studies from 40 countries or regions (18 Asian countries and regions, 13 
European countries, 4 North American countries, 3 South American countries, 2 
African countries) comprised of 114406455 individuals reported NAFLD prevalence in 
general population. A total of 34347969 participants were diagnosed as NAFLD with a 
pooled estimated prevalence rate of 29.38% (95% CI 28.09-30.69) regardless of the 
diagnostic techniques (Supporting Table 2). By stratified data according to different 
continents, the highest NAFLD prevalence was found in South America with an 
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estimated rate of 31.31% (95% CI 25.81-37.08), followed by Europe (30.11%, 95% CI 
26.89-33.42), Asia (29.92.%, 95% CI 28.87-30.98.), North America (24.28%, 95% CI 
20.33.-28.47) and Africa (8.10%, 95% CI 0.85-21.72). NAFLD prevalence varied 
substantially among countries and regions, from 3.85% (Jamaica, 95% CI 0.75-9.21) 
to 59.85% (Guatemala, 55.08-64.54, Figure 2, Supporting Table 3). Clinical 
characteristics of participants in studies included for overall NAFLD prevalence 
analysis were listed in Supporting Table 4. Considering the diagnostic techniques for 
assessing NAFLD prevalence, 3 studies used liver biopsy (31.97%, 95% CI 14.12-
53.13), 12 used computed tomography (CT, 18.07%, 95% CI 13.50-23.16), 30 used 
fatty liver index or hepatic steatosis index (26.93%, 95% CI 22.38-31.73), 4 studies 
used magnetic resonance imaging (MRI, 27.01%, 95% CI 24.87-29.20), 7 studies used 
transient elastography (TE, 29.63%, 95% CI 16.17-45.20), 12 used elevated liver 
enzyme (22.47%, 95% CI 17.11-28.33), and 295 studies used abdominal ultrasound 
(30.49%, 95% CI 29.55-31.43, Figure 3, Supporting Table 5). Since ultrasound was 
the most commonly used diagnostic technique, only these studies were included for 
the remaining analysis unless otherwise specified. 
 
Figure 2. Prevalence of non-alcoholic fatty liver disease in general population regardless of diagnostic 
techniques. 
 
Figure 3. Prevalence of non-alcoholic fatty liver disease stratified by different diagnostic techniques. 
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Overall, 1045090 NAFLD patients from 31 countries or regions were diagnosed by 
ultrasound with overall prevalence rate of 30.49% (95% CI 29.55-31.43, Figure 4). USA 
had the highest prevalence rate of 51.11% (95% CI 46.25-55.95) and Nigeria with the 
lowest prevalence of 4.09% (95% CI 0.03-14.41). For countries or regions with more 
than three studies included, NAFLD was most prevalent in Taiwan (38.95%, 95% CI 
31.53-46.63) and least prevalent in Japan (25.22%, 95% CI 22.17-28.27, Figure 5). 
Stratified data by continents, North America had the highest prevalence (40.33%, 95% 
CI 21.13-61.21), followed by Europe (32.23%, 95% CI 29.82-34.70), South America 
(31.31%, 95% CI 25.81-37.08), Asia (30.58%, 95% CI 29.60-31.57) and Africa (8.10%, 
95% CI 0.85-21.72, Figure 5, Supporting Table 6). For subgroup analysis, NAFLD 
prevalence was further stratified by age, gender, sample size, country development, 
country income, study period and quality assessment score. The highest prevalence 
of NAFLD was found in the 40-60 age groups (38.10%, 95% CI 29.65-46.92, Figure 6 
and Supporting table 7). The reported NAFLD prevalence was about 1.5 fold higher in 
males (36.96%, 95% CI 34.82-39.12) compared to females (23.85%, 95% CI 21.24-
26.55, Figure 6 and Supporting table 7). The prevalence was slightly higher in 
developing countries (30.66%, 95% CI 29.01-32.33) than in developed countries 
(30.15%, 95% CI 28.99-31.31, Figure 6 and Supporting table 7). NAFLD prevalence 
was more prevalent in high income countries (31.19%, 95% CI 30.00-32.38) than in 
upper-middle income (30.53%, 95% CI 28.81-32.27) or lower-middle income countries 
(23.51%, 95% CI 16.80-30.97, Figure 6 and Supporting table 7). The prevalence had 
substantially increased from 27.94% (95% CI 26.23-29.69) during 2000-2009 to 31.63% 
(95% CI 30.23-33.04) during 2010-2020 (Figure 6, Supporting Table 7). Besides, we 
pooled estimates for the rate of comorbidities in NAFLD patients. Obesity was the most 
common comorbidity (67.36%, 95% CI 60.68-73.70), followed by Hypertriglyceridemia 
(52.36%, 95% CI 42.81-61.83), MetS (45.43%, 95% CI 38.75-52.18), hyperlipidemia 
(42.68%, 95% CI 40.38-45.00), hypertension (39.28%, 95% CI 37.59-40.98), 
cardiovascular disease (19.32%, 95% CI 8.06-33.96), diabetes (16.79%, 95% CI 
15.83-17.77), chronic obstructive pulmonary disease (5.53%, 95% CI 1.59-11.66) and 
stroke (2.00%, 95% CI 0.00-11.74, Supporting Table 8). In addition, pooled estimates 
of the risk factors correlating with NALD prevalence are listed in Supporting Table 9. 
Individual parameters including advanced age (OR 1.02, 95% CI 1.02-1.02) and male 
sex (OR 2.39, 95% CI 2.303-2.487) were correlated with a higher risk of NAFLD 
development. Metabolic and biochemical parameters, such as increased body mass 
index (BMI, OR 1.01, 95% CI 1.01-1.01), central obesity (OR 1.13, 95% CI 1.13-1.14), 
elevated alanine aminotransferase (ALT, OR 1.03, 95% CI 1.03-1.03), aspartate 
aminotransferase (AST, OR 1.05, 95% CI 1.05-1.06), total cholesterol (OR 1.01, 95% 
CI 1.01-1.01), triglyceride (OR 1.01, 95% CI 1.01-1.01), insulin resistance (OR 1.01, 
95% CI 1.01-1.01) are risk factors for NAFLD development. Furthermore, our pooled 
estimations indicated that obesity (OR 4.22, 4.13-4.30), diabetes (OR 1.86, 95% CI 
1.69-2.04), MetS (OR 3.86, 3.46-4.30), hypertension (OR 2.38, 95% CI 2.33-2.44) and 
hyperlipidemia (OR 1.37, 1.26-1.49) were strong risk factors of NAFLD development 
(Supporting Figure 1). 
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We also attempted to calculate pooled estimates of NAFLD prevalence in normal or 
non-obese and overweight or obese individuals. As the cut off value defining normal, 
non-obese,  
Figure 4. Prevalence of non-alcoholic fatty liver disease diagnosed by ultrasound. 
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overweight and obese vary among different countries and continents. In accordance 
with many original publications, we estimated the pooled data by combining the 
overweight and obese groups. This resulted in 48 studies comprising of 537358 normal 
or non-obese participants with a pooled rate of 12.08% (95% CI 10.70-13.53, 
Supporting Figure 2, Table 10-11) compared to 46 studies comprising of 111999 
overweight or obese participants with a rate of 54.49% (95% CI 50.94-58.02; 
Supporting Figure 3, Table 12-13). Moreover, we observed a particularly high NAFLD 
prevalence in severe or morbidly obese patients that had underwent bariatric surgery. 
A total of 7573 of such patients from 35 studies had underwent an intraoperative liver 
biopsy with a pooled NAFLD prevalence rate of 82.16% (95% CI 77.21-86.62; 
Supporting Figure 4, Table 14-15). 
In addition, 82 studies comprising of 93446 T2DM patients yielded a NAFLD 
prevalence rate of 57.85% (95% CI 55.03-60.66). South America revealed the highest 
prevalence rate (75.64%, 95% CI 62.37-86.78), followed by North America (62.50%, 
95% CI 49.55-74.59), Europe (62.42%, 95% CI 51.75-72.52), Asia (56.26%, 95% CI 
52.76-59.72) and Africa (41.76%, 95% CI 17.13-68.83). For countries in which more 
than three studies were performed, NAFLD was most prevalent in Brazil (76.81%, 95% 
CI 60.27-89.93) and least prevalent in Nigeria (28.89%, 95% CI 4.55-63.29, Supporting 
Figure 5 and Supporting Table 16-17). 
 
Figure 6. Subgroup analysis of prevalence of NAFLD diagnosed by ultrasound. 
NASH prevalence 
Diagnosis of NASH was based on histological features. Overall, there were 51 studies 
reporting NASH prevalence. Of these, 4 studies comprised of 1082 organ donor with 
a pooled NASH prevalence rate of 8.26% (95% CI 1.13-21.01) in general population 
(Supporting table 18-19). Twenty four studies including 108023 NAFLD patients with a 
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pooled prevalence rate of 46.49% (95% CI 35.93-57.20; Supporting figure 6 and 
Supporting Table 20-21). A total of 4574 severe or morbidly obese patients from 22 
studies reported NASH prevalence of 46.72% (95% CI 37.57-55.98; Supporting figure 
7 and Supporting Table 22-23). 
NAFLD incidence 
53 studies including 808713 individuals reported on the NAFLD incidence in the 
general population (mainland China [n=23], South Korea [n=20], Japan [n=5], Italy 
[n=2], Hong Kong [n=1], Israel [n=1], Germany [n=1], Table 1). Overall, 110142 newly 
developed NAFLD yielded a pooled incident rate of 46.2 cases per 1000 person-years 
(95% CI 43.2-49.3). The highest incident rate was reported in South Korea (49.1 cases 
per 1000 person-years, 95% CI 45.1-53.2) and lowest in Israel (28.0 cases per 1000 
person-years, 95% CI 18.7-39.1, Supporting Table 24).  
Disease progression and outcome 
There were 16 studies reporting disease progression of non-NASH NAFLD and NASH 
patients (Table 2). The mean follow-up time ranged from 1.7 to 9.9 years. The pooled 
estimates of NAFLD remission rate was 50.4 cases per 1000 person-years (95% CI 
37.9-64.5). The pooled newly developed rates of fibrosis, advanced fibrosis and 
cirrhosis were 93.7 (95% CI 55.4-140.8), 41.0 (95% CI 23.6-63.0), and 4.4 (95% CI 
2.4-7.0) cases per 1000 person-years, respectively (Supporting Table 25-26). Eleven 
studies reported on the development of HCC (USA [n=4], South Korea [n=1], Israel 
[n=1], Italy [n=1], Hong Kong [n=1], UK [n=1], Japan [n=1], France and Hong Kong 
[n=1] ), malignancy except HCC (South Korea [n=1], Italy [n=1], Israel [n=1], UK [n=1], 
France and Hong Kong [n=1]) or cardiovascular disease (Italy [n=1], UK [n=2], France 
and Hong Kong [n=1]) with the pooled rate of 1.4 (95% CI 0.9-2.0), 14.2 (95% CI 6.4-
24.9), 20.2 (95% CI 6.2-41.9) cases per 1000 person-years, respectively (Table 3, 
Supporting Table 27). The annual overall mortality rate among patients with NAFLD 
was 23.9 (95% CI 13.5-37.1) cases per 1000 person-years. In addition, there were 4 
studies that documented the overall cancer related mortality, 5 studies on liver-specific 
mortality and 8 studies on cardiovascular disease mortality with the rate of 1.5 (95% 
CI 0.2-3.9), 0.7 (95% CI 0.2-1.7) and 2.3 (95% CI 1.0-4.2) cases per 1000 person-
years, respectively (Table 4, Supporting Table 28).  
No significant publication bias was identified in the overall population (Egger’s test, 
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Table 1. Pooled NAFLD incidence rate, stratified by countries or regions. 
Country/Region Studies Incident cases of 
NAFLD 




China 23 24221 157394 49.0 (41.4-57.3) 99% 
Hong Kong 1 76 565 34.5 (27.3-42.5) - 
Germany 1 605 2623 32.5 (30.0-35.1) - 
Israel 1 28 147 28.0 (18.7-39.1) - 
Italy 2 115 359 37.5(31.1-44.5) 0 
Japan 5 3407 22407 32.8 (28.3-37.6) 89% 
South Korea 20 81690 625218 49.1 (45.1-53.2) 99% 
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Table 2. Incident rate of remission, fibrosis, advanced fibrosis and cirrhosis of non-



















Participants Incident cases 
per 1000 person-
years (95% CI) 
I2 
NAFLD remission      
China 5 565 2750 49.8 (32.9-700.0) 97% 
Japan 1 127 484 57.1 (47.8-67.1) - 
South Korea 3 315 1800 49.7 (24.4-83.2) 97% 
Fibrosis development      
Taiwan 1 5 10 294.1 (108.4-525.5) - 
Croatia 1 201 507 156.2 (136.9-176.5) - 
Malaysia 1 18 35 80.4 (48.5-119.4) - 
Turkey 1 82 468 67.4 (54.0-82.2) - 
UK 1 45 108 63.1(46.4-82.1) - 
Advanced fibrosis development  
Taiwan 1 1 10 58.8 (1.5-286.9) - 
Malaysia 1 9 35 46.9 (21.7-87.1) - 
UK 1 6 27 33.7 (12.5-71.9) - 
Cirrhosis development      
Iceland 1 10 151 7.0 (3.3-11.9) - 
Malaysia 1 2 35 8.9 (0.8-25.4) - 
Turkey 1 16 468 8.5 (4.9-13.2) - 
USA 2 479 19361 2.8 (1.0-5.5) 97% 
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Table 3. Incident rate of hepatocellular carcinoma, other cancer types except 
hepatocellular carcinoma and cardiovascular among patients with non-alcoholic fatty 














 Studies Incident 
cases 
Participants Incident cases 
per 1000 person-




     
Hong Kong 1 2 356 0.5 (0.1-1.6) - 
France and Hong Kong 1 21 2245 4.2 (2.6-6.1) - 
Israel 1 6 153 4.7 (1.7-9.1) - 
Italy 1 13 471 5.0 (2.7-8.1) - 
Japan 1 9 301 5.0 (2.3-8.8) - 
South Korea 1 13 8721 0.2 (0.1-0.4) - 
UK 1 19 1452 2.7 (1.6-4.0) - 
USA 4 983 571524 0.7 (0.3-1.2) 99% 
Malignancy except 
HCC 
     
France and Hong Kong 1 142 2245 28.1 (23.7-32.9) - 
Israel 1 14 153 10.9 (6.0-17.3) - 
Italy 1 17 471 6.6 (3.8-10.1) - 
South Korea 1 427 8721 7.6 (6.9-8.3) - 
UK 1 157 1452 23.4 (19.9-27.1) - 
Cardiovascular 
disease 
     
France and Hong Kong 1 151 2254 29.9 (25.4-34.8) - 
Italy 1 8 471 3.1 (1.3-5.6) - 
UK 2 352 1773 25.8 (6.7-56.8) 99% 
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Table 4. Overall mortality, cancer-related mortality, liver-disease related mortality and 
cardiovascular disease related mortality among patients with non-alcoholic fatty liver 












 Studies Incident 
cases 
Participants Incident cases 
per 1000 person-
years (95% CI) 
I2 
Overall mortality      
Hong Kong 1 47 356 12.8 (9.4-16.7) - 
France and Hong Kong 1 56 2245 11.5 (8.7-14.6) - 
Israel 1 19 153 14.8 (8.9-22.1) - 
Italy 2 156 471 95.0 (0-492.5) - 
Japan 1 179 4073 6.3 (5.4-7.2) - 
Sri Lanka 1 41 851 4.8 (3.5-6.4) - 
South Korea 1 500 82899 49.7 (24.4-83.2) 97% 
UK 2 309 1773 37.8 (28.7-48.0) 70% 
Cancer-related 
mortality 
     
Italy 1 2 471 0.8 (0.1-2.2) - 
Sri Lanka 1 9 851 1.1 (0.5-1.9) - 
South Korea 1 211 82899 0.4 (0.4-0.5) - 
UK 1 38 1452 5.4 (3.8-7.2) - 
Liver disease-related mortality  
Italy 1 12 471 4.7 (2.4-7.7) - 
Japan 1 9 4073 0.3 (0.1-0.6) - 
Sri Lanka 1 4 851 0.5 (0.1-1.0) - 
South Korea 1 16 82899 0 (0-0.1) - 
UK 1 8 1452 1.1 (0.5-2.0) - 
Cardiovascular-related mortality 
Hong Kong 1 9 356 2.4 (1.1-4.3) - 
Italy 1 2 471 0.8 (0.1-2.2)  
Japan 1 9 4073 0.3 (0.1-0.6) - 
Sri Lanka 1 17 851 2.0 (1.2-3.1) - 
South Korea 1 89 82899 0.2 (0.2-0.2) - 
UK 2 58 1773 6.3 (4.8-8.0) 0 
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Discussion 
In this systematic review and meta-analysis, we included 578 studies in order to 
comprehensively estimate the global prevalence, incidence, disease progression and 
outcomes of NAFLD. The overall prevalence of NAFLD in the general population is 
29.38% (95% CI 28.09-30.69) regardless of the diagnostic techniques used to 
establish the diagnosis. Looking at the group in which the diagnosis was made by 
ultrasound exclusively, the pooled prevalence was 30.49% (95% CI 29.55-31.43). 
Importantly, the prevalence of NAFLD has substantially increased during the latest 10 
years (31.63%, 95% CI 30.23-33.04) compared to the previous decade (27.94%, 95% 
CI 26.23-29.69). Except for Africa (8.10%, 95% CI 28.21-30.80) still maintaining a low 
prevalence, the other four continents show strikingly high NAFLD prevalence, 
regardless of the state of economic development. 
Extensive studies have highlighted the importance of techniques in diagnosing 
NAFLD.22-23 Arguments have been raised against the application of liver enzymes for 
diagnosing NAFLD because normal levels of these enzymes have been widely 
observed in the entire spectrum of NAFLD.3 In line with this, we also observed that the 
prevalence of NAFLD diagnosed by elevation of liver enzymes yielded a substantially 
lower rate compared to that of liver biopsy and imaging modality based diagnosis. 
Interestingly, we also observed that the prevalence rate diagnosed by CT was lower 
than those of other imaging methodologies. Most of these studies targeted young or 
middle aged population, as they can tolerate to longer time of body examination. This 
bias in selecting younger population may explain the lower NAFLD prevalence. 
Ultrasound is the first-line and most widely used imaging test for NAFLD diagnosis with 
satisfactory sensitivity and specificity.24-25 However, the accuracy of diagnosis by 
ultrasound substantially relies on the proficiency of the physician. Although liver biopsy 
is the gold standard, it is reserved for a specific patient population due to its 
invasiveness. Therefore, the uncertainty and variations in NAFLD diagnosis challenge 
the accurate estimation of the global prevalence.  
Our pooled estimates of the odds ratios of risk factors are largely in line with previous 
studies with some subtle differences.26-27 Male sex, obesity, development of MetS and 
hypertension are major risk factors. It has been proposed that lower prevalence in 
females may be attributable to the protective role of estrogen,28 but lipid metabolism 
and fat distribution may also play a role.29 Insulin resistance, diabetes, obesity, 
hypertension and hyperlipidemia are all conditions that may play a role in the 
development of MetS.30 There is strong relation between the total number of the MetS 
components and the prevalence and severity of NAFLD.31,32 A study from Japan 
proposed that MetS plays a central role in NAFLD development and remission.33 
Findings from Australia and Europe show that 85% NASH patients have at least three 
components of Mets.34,35 Some other risk factors, such as sedentary lifestyle, diet habit 
or amount of exercise, cannot be included in our meta-analysis due to limited studies. 
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Several studies have reported regional data on NAFLD incidence. In Asia, NAFLD 
incidence rate was estimated as 50.9 cases per 1000 person-years, with the highest 
incidence observed in mainland China (63.0 cases per 1000 person-years) and the 
lowest in Japan (29.0 cases per 1000 person-years).1 In Europe, a retrospective study 
including four countries observed doubled incidence rate comparing year 2015 with 
2007.36 In this study, the overall incidence was estimated as 46.2 cases per 1000 
person-years. 
Development of liver fibrosis or cirrhosis ultimately determine the clinical outcome of 
NAFLD patients. Although most NAFLD patients are not at risk of disease progression, 
a proportion will eventually progress to NASH. It has been estimated that 59.1% (95% 
CI 47.6-69.7) of NAFLD patients may develop with NASH.3 In the current study, pooled 
prevalence of NASH in NAFLD patients is 45.48% (95% CI 35.21-55.96). However, 
there may be a selection and ascertainment bias because most of these NAFLD 
patients have at least one indication for liver biopsy. The overall prevalence of NASH 
in morbidly obese patients parallels of the prevalence of NASH among NAFLD patients. 
This finding is in line with two previous studies that the prevalence of NAFLD was 76% 
and 93% in obese people, and 37% and 26% of them progress to NASH, 
respectively.37-38 Of note, we also estimated the pooled prevalence of NASH in organ 
donors showing a prevalence rate of 8.26% (95% CI 1.13-21.01), but numbers are 
small. 
We found that the annual incidence of HCC was 1.3 cases per 1000 person-years, 
indicating an increase as compared to previously published estimates.3 However, the 
exact HCC incidence is difficult to estimate because in some cases with NAFLD-related 
HCC the biological characteristics are distinctly different without preceding cirrhosis.39 
Also, some NAFLD/NASH patients that are co-infected with hepatitis B virus, hepatitis 
C virus or have other metabolic diseases cannot be included in this estimate of NALFD-
related HCC incidence. Given the already high and ever-increasing burden of NAFLD 
and NASH, the incidence of related HCC is expected to grow. NAFLD/NASH related 
cirrhosis or HCC are becoming the leading indication for liver transplantation.10,40 On 
another note, NAFLD is also associated with high incidence rate of other cancers (14.2 
cases 1000 person-years, 95% CI 6.4-24.9), as well as cardiovascular disease (20.2 
cases 1000 person-years, 95% CI 6.2-41.9). This may explain why a strikingly high 
overall death rate was observed in our study. 
This study has several strengths. To our knowledge, this is the most comprehensive 
and up-to-date meta-analysis on the global epidemiology of NAFLD. By including large 
number of studies and individuals using stringent inclusion criteria, our estimates 
maximally recapitulate the real-world situation. Furthermore, we were able to include 
additional estimations for specific subpopulations and conditions such as NAFLD 
prevalence in morbidly obese patients, incidence of non-HCC malignancies, incidence 
of cardiovascular disease, and liver-specific and cardiovascular disease related death 
rates. There are also limitations in this study. Limited data from Africa and Oceania 
provided made it challenging to arrive at the accurate estimation for these continents. 
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The high heterogeneity underlying some of the source data in the current study cannot 
be fully explained. For subgroup analysis, we were only able to divide individuals into 
two broad categories, that is ‘normal or non-obese’ and ‘overweight or obese’ groups 
because studies all used different definitions to subdivide their populations. Pertaining 
disease progression and clinical outcome, some studies included NAFLD/NASH 
patients that also suffer from related complications (e.g. diabetes or cardiovascular 
disease) which may over-estimate the incidence and death rate of cardiovascular 
disease as well as the overall mortality rate. Last but not the least, a new terminology, 
“Metabolic associated fatty liver disease (MAFLD)”, has recently been proposed to 
replace “NAFLD”.41-42 However, for this study, we decided not to adopt this new 
concept as it will take substantial debate and revision, before this new terminology will 
be fully accepted by the field.43 
In summary, this meta-analysis shows that the global prevalence rate of NAFLD, a 
metabolic disease closely associated with hypertension, hyperlipidemia and diabetes, 
has risen to 29.38%. Nearly half of the individuals with NAFLD will progress to NASH, 
and ensuing cases that develop associated liver fibrosis, cirrhosis and HCC will impose 
a high demand on the healthcare system. Therefore, this substantial and ever growing 
burden of NAFLD, irrespective of geographic and socio-economic status, calls for 
attention and dedicated action from primary care physicians, specialists, health policy 
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Summary 
Background Metabolic dysfunction-associated fatty liver disease (MAFLD) is a new 
terminology recently updated from non-alcoholic fatty liver disease (NAFLD). The 
discontinuity in nomenclature and disease definition hampers epidemiological 
understanding of MAFLD. In this study, we aim to perform a systematic review and 
meta-analysis to estimate the global prevalence of MAFLD in overweight or obese 
children and adolescents, by repurposing existing data on fatty liver disease. 
Methods A systematic search was conducted in Medline, Embase, Web of science, 
Cochrane CENTRAL Databases and google scholar. We screened relevant articles in 
English language published until May 2020. By transforming data according to the new 
diagnosis criteria, the global prevalence of MAFLD was estimated in general and 
clinical populations. A 95% confidence interval was estimated using Wilson score 
method, and pooled prevalence was calculated using the DerSimonian-Laird random-
effects model with Free-Tukey double arcsine transformations. 
Findings Our search returned 35441 records, of which 156 studies fulfilled our 
inclusion criteria. The overall prevalence of MAFLD was 34.76% (95% CI 27.78-42.08) 
in general and 45.33% (95% CI 40.74-49.96) in clinical populations of overweight or 
obese children and adolescents regardless of the diagnostic techniques. Based on the 
most used ultrasound diagnosis, the pooled prevalence was 35.07% (95% CI 27.76-
42.73) in general population and 46.82% (95% CI 41.47-51.20) in clinical population. 
For subgroup analysis, MAFLD prevalence was slightly higher in boys compared to 
girls (34.28% vs 25.48% in the general population; 51.33% vs 36.95% in a clinical 
setting). In the general population, higher prevalence was observed in developing 
compared to developed countries.  
Interpretation MAFLD is highly prevalent in overweight or obese children and 
adolescents. Rising awareness and urgent actions are warranted as control of the 
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Introduction 
Obesity has become a global pandemic, and especially the growing burden in pediatric 
population is more worrisome.1 Approximately 400 million children and adolescents 
were estimated to be overweight or obese in 2016,2 which will have substantial short- 
and long-term consequences. More specifically, these children are more likely to suffer 
from psychological comorbidities, cardiovascular disease, diabetes, cancers, 
musculoskeletal problems and liver complications.3-5 
Fatty liver disease is one of the most common co-morbidities to obesity in pediatric 
population. Previous studies established that the prevalence of non-alcoholic fatty liver 
disease (NAFLD) in pediatric population ranges from 3% to 12%, but this rate can 
become as high as 70-80% in obese children.6-7 Recently it has been proposed to 
revise the classical NAFLD definition and terminology in fatty liver disease to metabolic 
dysfunction-associated fatty liver disease (MAFLD).8-9 This revised nomenclature is 
expected to have major impact on the reporting of the dynamics in disease diagnosis, 
guidelines for patient management, therapeutic development and the management of 
public health with respect to fatty liver disease. One of the major changes is the shift 
towards inclusionary diagnostic criteria, a diagnosis of MAFLD being based on 
detection of hepatic steatosis by histology, imaging or blood biomarker in addition to 
the presence of at least one of the following three conditions: overweight/obesity, 
presence of type 2 diabetes mellitus (T2DM), or evidence for metabolic dysregulation.  
The resulting paradigm shift in disease definition urges re-assessing the burden of fatty 
liver disease, as many previous studies on NAFLD would become ineligible for 
estimating MAFLD epidemiology. A large proportion of existing data on fatty liver 
disease in overweight or obese population might, however, be repurposed for MAFLD 
epidemiology, by adjusting existing results to the new criteria. In this study, we 
performed a systematic review and meta-analysis to estimate the global prevalence of 
MAFLD in overweight and obese children and adolescents by exploring the existing 
epidemiological data of fatty liver disease.  
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Methods  
Searching strategy and selection criteria  
A systematic search was conducted in Medline, Embase, Web of science and 
Cochrane CENTRAL. Databases were searched for articles in the English language 
until May 2020. All searches from database were performed by a biomedical 
information specialist of the medical library, with an exhaustive set of search terms 
related to “fatty liver”, “hepatic steatosis”, “prevalence”, and “epidemiology” (The full 
search strategies are provided in the Appendix methods 1). We included studies that 
can be retrospectively transformed into reporting MAFLD prevalence in overweight or 
obese children or adolescents. The diagnosis of MAFLD was in accordance with the 
recent consensus on the criteria of diagnosing MAFLD. The detailed inclusion and 
exclusion criteria are provided in Appendix methods 2. Our analysis in this review was 
reported in accordance with PRISMA guidelines.10 
 
Screen and selection   
Studies were screened based on pre-specified decision rules. Initial title and abstract 
screening was done independently by two reviewers (JL, ZW), with a random 10% of 
studies checked by another two investigators (LW, YL). Full-text review was done 
independently by two authors (any two of JL, ZW, LW and YL), with any discrepancies 
resolved by consensus or by a third reviewer (QP); consensus was reached in all 
instances. We extracted data at all levels reported in the study, including time of 
publication, study period, country or region, country or region income based on World 
bank evaluation, the level of country development, study categories, gender, age, 
diagnostic techniques, body mass index (BMI) and prevalence of disease. Data were 
then crossly checked for accuracy against the original source by one of four authors 
(JL, ZW, LW or YL). 
 
Data analysis  
Two authors (any two of JL, ZW, LW and YL) independently reviewed and extracted 
data from the included studies by using a data extraction form specifically designed for 
this study. When duplicate data were identified, the duplicate with the smallest sample 
size or shortest duration of follow-up was excluded. We assessed the quality of 
included studies using an assessment scale based on the Newcastle-Ottawa Scale, 
which is comprised of three domains including selection, comparability and outcome. 
The Newcastle-Ottawa Scale assigns a maximum score of five for selection, two for 
comparability, and two for outcome.11 Studies scoring 1-3 were defined as low, 4-6 as 
average, and 7-9 as high quality (Appendix Table 1). Studies were not excluded on the 
basis of their quality score to increase transparency and to ensure that all available 
evidence of this topic will be reported. Egger’s test was used to assess publication bias. 
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The main outcomes for this study were the global MAFLD prevalence for overweight 
or obese children and adolescents. To calculate MAFLD prevalence for each country 
and region, we estimated the pooled rate by using DerSimonian-Laird random-effects 
model with Free-Tukey double arcsine transformations. Heterogeneity across the 
included studies was assessed using the Cochran Q statistics and I2 statistics, with I2 
statistics 25%-50%, 50%-75%, and >75% considered as mild, moderate, and severe 
heterogeneity, respectively. When heterogeneity was higher than 50%, a random-
effect model will be used. Given that abdominal ultrasound was the most commonly 
used diagnostic technique, we further pooled the prevalence in studies with ultrasound 
as main diagnostic technique for estimating a more accurate rate. Subgroup analysis 
was done to further explore the source of heterogeneity which estimated the pooled 
rate by dividing individuals into covariates. 
 
 




Page | 113  
 
Results 
Our search retuned 35441 records. After removing duplicates, 19223 studies were 
retained. By screening titles and abstracts, 18774 records were further excluded. Full 
text of the remaining 449 studies were assessed for eligibility, of which 293 were 
excluded. As a result, 156 studies from 32 countries and regions (Albania [n=1], 
Australia [n=2], Brazil [n=12], Mainland China [n=12], Canada [n=2], Chile [n=1], 
Colombia [n=2], Denmark [n=3], Egypt [n=4], Germany [n=5], Germany, Austria and 
Switzerland [n=1], Greece [n=2], Hong Kong [n=1], India [n=5], Iran [n=8], Israel [n=2], 
Italy [n=15], Japan [n=3], Malaysia [n=1], Mexico [n=2], Netherlands [n=4], Pakistan 
[n=1], Poland [n=5], Romania [n=2], Saudi Arabia [n=1], South Korea [n=7], Spain 
[n=6], Taiwan [n=8], Sri Lanka [n=1], Turkey [n=22], United Arab Emirates [n=1] and 
USA [n=14]) fulfill our inclusion criteria (Figure 1). The quality assessment score for 
included studies ranged from 6 to 9, with mean quality score as 7.46. A total of 147 
high quality and 9 fair quality studies were included in the meta-analysis (Appendix 
Table 1). Characteristics of all included studies were listed in Appendix Table 1. The 
majority of these included studies had a cross-sectional design and most of them 
reported data from hospital or outpatient clinic settings. The mean or median age of 
participants across different studies ranged from 7.00 to 17.01 years, and the 
percentages of males ranged from 19.60% to 100%.  
Among these included studies, 29 studies comprising 6095 individuals concerning 
MAFLD prevalence in overweight and obese children and adolescents from general 
population. The overall prevalence in this population was 34.76% (95% CI 27.78-42.08) 
regardless of diagnostic techniques. By stratifying data according to continents, the 
prevalence of MAFLD was 43.05% (95% CI 37.04-50.06), 40.89% (95% CI 34.54-
47.39), 38.39% (95% CI 29.01-48.23), 24.09% (95% CI 16.51-32.57), and 22.86% (95% 
CI 11.65-36.46) in North America, Oceania, Asia, Europe and South America, 
respectively. The highest rate was observed in India (60.92%, 95% CI 54.60-67.07) 
and the lowest in Pakistan (10.45%, 95% 4.08-19.07, Figure 2). The majority of studies 
(89.66%) used ultrasound diagnosing MAFLD with the pooled prevalence rate of 35.07% 
(95% CI 27.76-42.73, Table 1, Appendix Figure S1). Subgroup analysis revealed that 
MAFLD was more prevalent in developing countries (38.69%, 95% CI 29.28-48.54) 
than developed countries (25.97%, 95% CI 18.66-34.00). In respect of the income of 
countries or regions, the pooled estimate prevalence of high, upper-middle and lower-
middle countries or regions was 29.09% (95% 21.71-37.06), 40.94% (95% CI 27.92-
54.64) and 40.71% (95% CI 9.91-76.22). Moreover, the MAFLD prevalence was 27.06% 
(95% CI 20.20-34.51) in participants below 10 years old and 43.65% (95% CI 27.66-
60.34) in those above 10 years old. The pooled prevalence was 34.28% (95% CI 
21.33-48.50) and 25.48% (95% CI 16.64-35.41) in boys and girls, respectively. 
Stratified participants by BMI, MAFLD prevalence was 22.87% (95% CI 14.49-32.47) 
in overweight participants and 38.91% (95% CI 29.42-48.83, Table 2) in obese 
participants. 
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A total of 127 studies comprising 36357 individuals were included for estimating 
MAFLD prevalence in overweight and obese patients from hospital or outpatient 
settings. The overall prevalence rate regardless of diagnostic techniques used was 
45.33% (95% CI 40.74-49.96, Figure 3). The pooled regional prevalence estimates in 
this population were 59.82% (95% CI 43.61-56.02) for Asia, 38.69% (95% CI 31.09-
46.58) for Europe, 52.20% (95% CI 33.32-70.77) for Africa, 47.34% (95% CI 31.99-
62.95) for North America, 39.46% (95% CI 30.85-48.41) for South America and 67.44% 
(95% CI 59.08-75.28) for Oceania, though the number of studies for Oceania was 
limited. The prevalence varied substantially among different countries and regions, 
from 8.62% (Germany, Austria and Switzerland, 95% CI 8.09-9.18) to 86.67% (Japan, 
95% CI 74.94-95.29). For countries or regions with more than  
 
Figure 2. MAFLD prevalence in general population regardless of the diagnostic techniques. (A) Forest 
plot of MAFLD prevalence. (B) MAFLD prevalence in 14 countries and regions. 
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three studies included, MAFLD was most prevalent in Mainland China (54.09%, 95% 
CI 45.69-62.38) and the least in Germany (28.15%, 95% CI 25.76-30.60). Considering 
the diagnostic techniques, 96 studies used ultrasound (46.82%, 95% CI 41.47-52.20), 
15 studies used magnetic resonance imaging (MRI, 34.48%, 95% CI 29.60-39.53), 11 
studies used liver biopsy (46.94%, 95% CI 18.75-76.20), 5 studies used proton 
magnetic resonance spectroscopy (H-MRS, 50.23%, 95% CI 30.57-69.86), 1 studies 
used fatty liver index (FLI, 22.11%, 95% CI 16.60-28.16) and 1 studies used controlled 
attenuation parameter (CAP, 53.17%, 95% CI 44.41-61.85, Table 1). Since ultrasound 
was most commonly used, only these studies were included for the remaining analysis 
unless otherwise specified. For subgroup analysis, MAFLD was most prevalent in 
Mainland China (51.83%, 95% CI 41.98-61.62) and the least in Germany (28.15%, 95% 
CI 25.76-30.60, Appendix Figure S2). MAFLD prevalence was 48.44% (95% CI 42.58-
54.32) in developing and 44.50% (95% CI 36.03-53.13) in developed countries. The 
pooled estimates among high, upper-middle and lower-middle countries. 
 
Figure 3. MAFLD prevalence in clinical population regardless of the diagnostic techniques. (A) Forest 
plot of MAFLD prevalence. (B) MAFLD prevalence in 31 countries and regions. 
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 were 45.54% (95% CI 37.23-53.98), 47.76% (95% CI 41.62-53.92) and 48.81% (95% 
CI 19.01-79.09), respectively. Patients with age above 10 years old had a higher 
prevalence rate (46.12%, 95% CI 28.42-64.33) compared to those below 10 years old 
(34.00%, 95% CI 16.50-54.05). The prevalence was higher in boys (51.33%, 95% CI 
45.06-57.59) than in girls (36.95%, 95% CI 30.31-43.83). Pooled estimates from six 
studies revealed a prevalence of 27.41% (95% CI 12.10-46.01) in overweight patients. 
Pooled analysis of 75 studies resulted in a rate of 48.32% (95% CI 41.83-54.84) in 
obese patients. There is a slightly increase of MAFLD prevalence when comparing 
study period before and after year 2010 (44.32%, 95% CI 33.42-55.51 versus 47.77%, 
95% CI 42.32-53.25). MAFLD prevalence for studies with a quality assessment score 
above or below 8 points was 42.53% (95% CI 34.39-50.88) and 50.25% (95% CI 45.41-
55.08), respectively. Studies with sample size less than 100 (41.85%, 95% 35.65-
48.18) have a lower rate than those with over 100 participants (57.36%, 95% CI 51.15-
63.46, Table 2). 
Table 1. MAFLD prevalence by different diagnostic techniques in general and clinical 
populations. 
 Studies Individuals Prevalence (95% CI) I2 (%) 
General     
MRI 3 857 32.23% (9.44-60.78) 98% 
US 26 5238 35.07% (27.76-
42.73) 
97% 
Clinical*     
CAP 1 126 53.17% (44.41-
61.85) 
- 
FLI 1 199 22.11% (16.60-28.16) - 
H-MRS 5 363 50.23% (30.57-
69.86) 
92% 
Liver biopsy 9 2211 46.94% (18.75-
76.20) 
99% 
MRI 15 2797 34.48% (29.60-
39.53) 
85% 
US 96 30661 46.82% (41.47-
51.20) 
99% 
MRI, magnetic resonance imaging; US, ultrasound; CAP, Controlled attenuation parameter; FLI, fatty liver index; 
H-MRS, proton magnetic resonance spectroscopy; *P<0.001 for difference across diagnostic methods. 
 
Discussion 
In this study, we performed a systematic review and meta-analysis based on existing 
epidemiology data on fatty liver disease in overweight or obese children and 
adolescents, but transformed the data to the new diagnosis criteria of MAFLD. We 
found the global MAFLD prevalence to be about 45% in clinical settings and 35% in 
the general population among overweight or obese children and adolescents aged 
between 1 and 19 years, regardless of the diagnostic techniques used. Based on the 
commonly used ultrasound methodology for diagnosis, we estimated a prevalence rate 
of 22.87% (95% CI 14.49-32.47) in overweight and 38.91% (95% CI 29.42-48.83) in 
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obese children and adolescents from the general population. These rates are 27.41% 
(95% CI 12.10-46.01) and 48.32% (95% CI 41.83-54.84) in the clinical setting of 
overweight or obese children and adolescents, respectively. 
 
Table 2. Subgroup analysis of MAFLD prevalence in general and clinical populations based 
on ultrasound diagnosis. 
 General population Clinical population 
 Studies Prevalence 
(95% CI) 
I2 P Studies Prevalence 
(95% CI) 
I2 P 
Continents   97% <0.01   99% <0.01 
Asia 19 37.98% 
(28.32-
48.14) 




Europe 3 27.91% 
(19.85-
36.74) 




Oceania 1 40.89% 
(34.54-
47.39) 





















Development   97% 0.04   99% 0.46 
Developed 7 25.97% 
(18.66-
34.00) 




Developing 19 38.69% 
(29.28-
48.54) 




Income   97% 0.29   99% 0.91 
High 13 29.09% 
(21.71-
37.06) 




Upper-middle 10 40.94% 
(27.92-
54.64) 




Lower-middle 3 40.71% 
(9.91-76.22) 




Gender   90% 0.30   94% <0.01 
Boy 8 34.28% 
(21.33-
48.50) 




girl 8 25.48% 
(16.64-
35.41) 




Age   97% 0.07   99% 0.38 
1< and≤10 4 27.06% 
(20.20-
34.51) 
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10<and≤19 10 43.65% 
(27.66-
60.34) 




Study period    0.11   99% 0.59 
Before 2010 14 29.23% 
(21.35-
37.78) 




After 2010 10 43.61% 
(28.48-
59.37) 




Sample size   97% 0.56   99% <0.01 
<100  30.71% 
(15.27-
48.66) 




≥100 19 36.65% 
(28.29-
45.43) 




Quality    97% 0.60   99% 0.12 
<8 12 37.01 
(23.71-
51.37) 




≥8 14 32.77% 
(25.90-
40.02) 




BMI         
Overweight 10 22.87% 
(14.49-
32.47) 




Obese 20 38.91% 
(29.42-
48.83) 





The terminology describing NAFLD and non-alcoholic steatohepatitis (NASH) was 
defined now 40 years ago.12 This definition requires the exclusion of other causes of 
liver disease and the exclusion of detrimental alcohol consumption but the exact cut-
offs in respect remains open to debate. Because of this ambiguity, it is now recognized 
fatty liver disease needs redefinition and thus renaming.13 MAFLD is a new terminology 
recently proposed by a panel of international experts to replace NAFLD.8-9 This 
updated nomenclature shifts towards an inclusionary diagnosis that does not require 
exclusion of alcohol intake or that of other liver diseases. As proposed, a diagnosis of 
MAFLD should be based on detection of liver steatosis with one of the following three 
conditions, overweight/obesity and/or presence of T2DM, and/or evidence of metabolic 
dysregulation.8-9 A recent study has endeavored to compare MAFLD and NAFLD 
criteria in the real world using the large population-based National Health and Nutrition 
Examination Survey (NHANES) database. Although a diagnosis of MAFLD does not 
require exclusion of excessive alcohol consumption or other liver diseases, a similar 
prevalence rate as NAFLD was detected. However, MAFLD criteria were found to be 
more practical for identifying fatty liver disease patients with high risk of disease 
progression.14 There are strong indications of a global acceptance and endorsement 
of the term MAFLD,15 but the issue remains open to fierce debate. For example, it is 
reasonable to argue that currently there is no general consensus on the criteria to 
define ‘‘metabolic dysfunction”, and adding the new term “metabolic” does not fully 
 
 
Page | 119  
 
solve the ambiguity regarding etiologies of the disease.16 We noticed, however, that 
MAFLD is relatively straightforward to be defined in the overweight or obese population. 
Globally, over 1.9 billion adults and about 400 million children and adolescents were 
overweight or obese in 2016.2 
The prevalence of obesity has nearly tripled since 1975, and this parallels the growth 
of the fatty liver disease epidemic. Strong associations between obesity and 
prevalence of fatty liver disease are well-documented, both in children and 
adolescents.17 A previous study attempted to depict the dynamic changes of NAFLD 
prevalence in adolescents aged 12-19 years using data from different periods of the 
NHANES database. Strikingly, the prevalence of NAFLD has increased from 3.9% in 
1988-1994 to 10.7% in 2007-2010.18 A recent meta-analysis estimated that the NAFLD 
prevalence rate in overweight or obese children from general population was 12.5% 
and 36%, respectively. NAFLD prevalence among children based on child obesity 
clinics has been reported as 34%,7 but we observed a much higher (1.5-fold) rate of 
MAFLD in this population. This discrepancy may be attributed to differences in disease 
definition between NALFD and MAFLD, and/or population selection. NAFLD could 
represent an umbrella term for the multiple underlying sub-types which underestimates 
the prevalence of fatty liver disease.19,20 
Extensive studies have highlighted the importance of technique in the diagnosis of fatty 
liver disease. Ultrasound has been the most used diagnostic method in both clinical 
and general populations and majorly contributes to the satisfactory sensitivity and 
specificity.21,22 In the general population, we found no evidence of differences in 
MAFLD prevalence when analyzed with respect to different diagnostic techniques. In 
the clinical population, the prevalence of MAFLD diagnosed by H-MRS was higher than 
that by MRI or ultrasound. Interestingly, ultrasound and liver biopsy diagnoses yielded 
similar rates of MAFLD prevalence. Arguments have been raised against the 
application of liver enzymes for diagnosing fatty liver disease because occurrence of 
normal levels of these enzymes has been reported across the entire spectrum of 
NAFLD manifestations.23,24 In line with this, the new diagnostic criteria of MAFLD no 
longer adopt elevated ALT and AST as markers for assessing fatty liver disease.  
To our knowledge, this is the first study to comprehensively estimate the global 
epidemiology of MAFLD, even if clear limitations to our study exist. Firstly, there is a 
retrospective transformation of previous fatty liver disease data to the MAFLD 
epidemiological estimation. Any pre-existing bias in population selection will thus be 
copied to our results. Secondly, limited data are available for Africa and Oceania 
constituting a challenge to the accuracy for our estimates on these continents. There 
is limited data regarding race, ethnics, familial risk, epidemic factors and genetic 
variation, hence we could not perform further subgroup analysis. Fourthly, the high 
heterogeneity underlying some of the source data in the current study cannot be fully 
explained, and thus calls for caution. Finally, there are no consistent standards for 
defining overweight or obese across different countries and regions, which hampers 
interpretation.  
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In summary, this study has demonstrated a proof-of-concept on the feasibility of 
repurposing existing fatty liver disease data for estimating MAFLD burden. By including 
a large number of eligible studies across the globe, we a high prevalence rate of 
MAFLD in overweight or obese children and adolescents from both general or clinical 
populations. These findings should be interest for medical professionals and health 
policy makers interested in combating this disease. Given the retrospective nature of 
transforming previous data, future well-designed prospective studies are needed to 
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Supplementary file to 
Estimating global prevalence of metabolic dysfunction-associated fatty liver 
disease in overweight or obese children and adolescents 
 
Supplementary methods 1. Searching strategy for metabolic dysfunction-associated fatty liver 
disease in overweight or obese children and adolescents. 
 
Database searched Via Records Records after 
duplicates 
removed 
Embase  Embase.com 11248 11075 
Medline ALL  Ovid  10390 3157 
Web of Science Core 
Collection  
Web of Knowledge  8558 2260 
Cochrane Central Register of 
Controlled Trials 
Wiley  349 182 
Other sources: Google 
Scholar (200 top ranked) 
 200 32 
Additional By searching 
NAFLD 
4696  
Total  35441 19223 
 
Embase 
('fatty liver'/exp OR 'metabolic liver disease'/de OR 'steatohepatitis'/de OR (hepatosteato* OR 
steatohepat* OR AFLD OR NAFLD OR FLD OR ((fatty OR steato*) NEAR/3 (liver OR hepat*)) OR 
((metabol*) NEAR/3 (liver OR hepat*) NEAR/3 (diseas* OR syndrom*))):ab,ti,kw) AND ('epidemiological 
data'/de OR 'epidemiology'/de OR 'geographic distribution'/de OR 'patient volume'/de OR 
prevalence/exp OR geography/de OR 'geographic names'/exp OR 'cross-sectional study'/de OR 
(epidemiolog* OR ((geograph* OR global*) NEAR/3 (distribut*)) OR (patient* NEAR/3 volume*) OR 
prevalen* OR population-based* OR cross-sectional*):ab,ti,kw) NOT ([animals]/lim NOT [humans]/lim) 
NOT ('case report'/de OR 'case report*':ti) NOT ([Conference Abstract]/lim) AND [english]/lim 
Medline 
(exp Fatty Liver/ OR Liver Diseases/me OR (hepatosteato* OR steatohepat* OR AFLD OR NAFLD OR 
FLD OR ((fatty OR steato*) ADJ3 (liver OR hepat*)) OR ((metabol*) ADJ3 (liver OR hepat*) ADJ3 
(diseas* OR syndrom*))).ab,ti,kw.) AND (Epidemiological Monitoring/ OR Epidemiology/ OR 
Epidemiology.fs. OR exp Incidence/ OR exp Prevalence/ OR Geography/ OR exp Geographic 
Locations/ OR Epidemiologic Studies OR Cross-Sectional Studies/ OR (epidemiolog* OR ((geograph* 
OR global*) ADJ3 (distribut*)) OR (patient* ADJ3 volume*) OR prevalen* OR population-based* OR 
cross-sectional*).ab,ti,kw.) NOT (exp Animals/ NOT Humans/) NOT (Case Reports/ OR case report*.ti.) 
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NOT (news OR congres* OR abstract* OR book* OR chapter* OR dissertation abstract*).pt. AND 
english.la.  
Cochrane 
((hepatosteato* OR steatohepat* OR AFLD OR NAFLD OR FLD OR ((fatty OR steato*) NEAR/3 (liver 
OR hepat*)) OR ((metabol*) NEAR/3 (liver OR hepat*) NEAR/3 (diseas* OR syndrom*))):ab,ti) AND 
((epidemiolog* OR ((geograph* OR global*) NEAR/3 (distribut*)) OR (patient* NEAR/3 volume*) OR 
prevalen* OR population-based* OR cross-sectional*):ab,ti) 
Web of Science 
TS=(((hepatosteato* OR steatohepat* OR AFLD OR NAFLD OR FLD OR ((fatty OR steato*) NEAR/2 
(liver OR hepat*)) OR ((metabol*) NEAR/2 (liver OR hepat*) NEAR/2 (diseas* OR syndrom*)))) AND 
((epidemiolog* OR ((geograph* OR global*) NEAR/2 (distribut*)) OR (patient* NEAR/2 volume*) OR 
prevalen* OR population-based* OR cross-sectional*)) NOT ((animal* OR rat OR rats OR mouse OR 
mice OR murine OR dog OR dogs OR canine OR cat OR cats OR feline OR rabbit OR cow OR cows 
OR bovine OR rodent* OR sheep OR ovine OR pig OR swine OR porcine OR veterinar* OR chick* OR 
zebrafish* OR baboon* OR nonhuman* OR primate* OR cattle* OR goose OR geese OR duck OR 
macaque* OR avian* OR bird* OR fish*) NOT (human* OR patient* OR women OR woman OR men 
OR man))) AND DT=(Article OR Review) AND LA=(English) 
Google Scholar 
hepatosteatosis|steatohepatitis|AFLD|NAFLD|FLD|"fatty|steatotic liver"|"liver|hepatic 
steatosis"|"metabolic liver disease" epidemiology|prevalence|"geographic|global distribution"|"patient 
volume"|"population based"|"cross sectional" 
 
 
Additional searching for Non-alcoholic fatty liver disease 
embase.com  
('nonalcoholic fatty liver'/exp OR (((nonalcohol* OR non-alcohol*) NEAR/3 (fatty-liver* OR steatohepat* 
OR fld OR hepatosteato*)) OR ((nonalcohol* OR non-alcohol*) NEAR/3 steato* NEAR/3 (hepat* OR 
liver*)) OR nafld):ab,ti) AND ('epidemiological data'/de OR 'epidemiology'/de OR 'geographic 
distribution'/de OR incidence/exp OR 'patient volume'/de OR prevalence/exp OR geography/de OR 
'geographic names'/exp OR (epidemiolog* OR ((geograph* OR global*) NEAR/3 (distribut*)) OR 
incidenc* OR (patient* NEAR/3 volume*) OR prevalen*):ab,ti) NOT ([animals]/lim NOT [humans]/lim) 
NOT ('case report'/de OR 'case report*':ti) NOT ([Conference Abstract]/lim) AND [english]/lim  
Medline Ovid  
(Non-alcoholic Fatty Liver Disease/ OR (((nonalcohol* OR non-alcohol*) ADJ3 (fatty-liver* OR 
steatohepat* OR fld OR hepatosteato*)) OR ((nonalcohol* OR non-alcohol*) ADJ3 steato* ADJ3 (hepat* 
OR liver*)) OR nafld).ab,ti.) AND (Epidemiological Monitoring/ OR Epidemiology/ OR Epidemiology.fs. 
OR exp Incidence/ OR exp Prevalence/ OR Geography/ OR exp Geographic Locations/ OR 
(epidemiolog* OR ((geograph* OR global*) ADJ3 (distribut*)) OR incidenc* OR (patient* ADJ3 volume*) 
OR prevalen*).ab,ti.) NOT (exp animals/ NOT humans/) NOT (case report/ OR case report*.ti.) NOT 
(news OR congres* OR abstract* OR book* OR chapter* OR dissertation abstract*).pt. AND english.la.  
Web of science Core Collection 
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TS=(((((nonalcohol* OR non-alcohol*) NEAR/2 (fatty-liver* OR steatohepat* OR fld OR hepatosteato*)) 
OR ((nonalcohol* OR non-alcohol*) NEAR/2 steato* NEAR/2 (hepat* OR liver*)) OR nafld)) AND 
((epidemiolog* OR ((geograph* OR global*) NEAR/2 (distribut*)) OR incidenc* OR (patient* NEAR/2 
volume*) OR prevalen*)) NOT ((animal* OR rat OR rats OR mouse OR mice OR murine OR dog OR 
dogs OR canine OR cat OR cats OR feline OR rabbit OR cow OR cows OR bovine OR rodent* OR 
sheep OR ovine OR pig OR swine OR porcine OR veterinar* OR chick* OR zebrafish* OR baboon* OR 
nonhuman* OR primate* OR cattle* OR goose OR geese OR duck OR macaque* OR avian* OR bird* 
OR fish*) NOT (human* OR patient* OR women OR woman OR men OR man))) NOT TI=( "case report*") 
AND LA=(english) AND DT=(article) Cochrane CENTRAL ((((nonalcohol* OR non-alcohol*) NEAR/3 
(fatty-liver* OR steatohepat* OR fld OR hepatosteato*)) OR ((nonalcohol* OR non-alcohol*) NEAR/3 
steato* NEAR/3 (hepat* OR liver*)) OR nafld):ab,ti) AND ((epidemiolog* OR ((geograph* OR global*) 
NEAR/3 (distribut*)) OR incidenc* OR (patient* NEAR/3 volume*) OR prevalen*):ab,ti) 
 







































US 45 267 BMI>25 8 







US 23 42 Not specified 8 












































Khalkhali.HR8 Iran 2016 2013 
Cross-
sectional 


























Tominaga.K11 Japan 1995 1989 
Cross-
sectional 
School US 20 138 BMI>18 7 
























School US 16 89 Not specified 8 
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Ramzan.M15 Pakistan 2009 2009 
Cross-
sectional 





























MRI 97 223 BMI>25 8 





























Dai.DL22 China 2017 2017 
Cross-
sectional 





















US 9 40 BMI>25 7 























School US 50 148 
BMI z-
score > 1 
7 

































boys in the 
USA 
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Alp.H31 Turkey 2013 2006 
Cross-
sectional 




Arenaza.L32 Spain 2019 2017 
Cross-
sectional 









Arslan.N33 Turkey 2005 2005 
Cross-
sectional 
Hospital US 123 198 

































Atabek.ME36 Turkey 2014 2014 
Cross-
sectional 































Burgert.TS40 USA 2006 2004 
Cross-
sectional 
Hospital US 20 138 BMI>18 7 





























for age and 
sex 
7 
Das.MK44 India 2017 2017 
Cross-
sectional 
Hospital US 7 67 BMI>18.5 8 
Zusi.C45 Italy 2019 2019 
Cross-
sectional 




Costanzo.DI46 Italy 2019 2019 
Cross-
sectional 




Dursun.F47 Turkey 2019 2019 
Cross-
sectional 
Hospital MRI 97 223 BMI>25 8 
Karaksy.HM48 Egypt 2011 2011 
Cross-
sectional 













Erol.M50 Turkey 2016 2015 
Cross-
sectional 



























Hospital US 9 40 BMI>25 8 


















Han.XC56 China 2020 2020 
Cross-
sectional 
Hospital US 50 148 
BMI z-
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Hatipoglu.N57 Turkey 2016 2016 
Cross-
sectional 

















































































Kistler.KD64 USA 2010 2007 
Cross-
sectional 




Kodhelaj.K65 Albania 2014 2010 
Cross-
sectional 




Labayen.I66 Spain 2018 2018 
Cross-
sectional 
































De piano.A70 Brazil 2007 2007 
Cross-
sectional 
Hospital US 65 84 BMI>30 7 
Mohammed.R
Z71 
Malaysia 2020 2015 
Cross-
sectional 




Ardakali.AT72 Iran 2014 2012 
Cross-
sectional 
Hospital US 215 961 BMI>18.5 7 
Navarro.JM73 Spain 2013 2013 
Cross-
sectional 




Franzese.A74 Italy 1997 1997 
Cross-
sectional 




Guzzaloni.G75 Italy 2000 2000 
Cross-
sectional 














Ozhan.B77 Turkey 2016 2016 
Cross-
sectional 
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Radetti.G83 Italy 2006 2004 
Cross-
sectional 






Spain 2011 2011 
Cross-
sectional 




Schlieske.C85 Germany 2014 2014 
Cross-
sectional 




Damaso.AR86 Brazil 2008 2008 
Cross-
sectional 
















Sezer.OB88 Turkey 2016 2015 
Cross-
sectional 






















Cali.AMG91 USA 2007 2007 
Cross-
sectional 




Shi.JQ92 China 2017 2015 
Cross-
sectional 






























Trico.D96 USA 2018 2018 
Cross-
sectional 





















Hospital US 13 43 BMI>30 8 
Silveira.LS99 Brazil 2013 2013 
Cross-
sectional 






Poland 2018 2018 
Cross-
sectional 
















Grønbæk.H102 Denmark 2012 2011 
Cross-
sectional 














an IBW over 
120%. 





Hospital US 157 375 





Zou.CC104 China 2005 2005 
Cross-
sectional 
















Chiloiro.M106 Italy 2008 2008 
Cross-
sectional 













Denzer.C108 Germany 2009 2009 
Cross-
sectional 
Hospital MRI 14 60 







Turkey 2011 2011 
Cross-
sectional 




Kim.JS110 USA 2012 2012 
Cross-
sectional 






Egypt 2012 2012 
Cross-
sectional 




Ozkol.M112 Turkey 2010 2010 
Cross-
sectional 

















Italy 2006 2006 
Cross-
sectional 




Reinehr.T115 Germany 2008 2008 
Cross-
sectional 




Tock.L116 Brazil 2006 2006 
Cross-
sectional 














































Chociej.AB121 Spain 2018 2018 
Cross-
sectional 
















Brazil 2017 2015 
Cross-
sectional 




Goyal.P124 India 2018 2018 
Cross-
sectional 
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Yu.EL127 USA 2018 2018 
Cross-
sectional 




Szyboska.P128 Poland 2015 2015 
Cross-
sectional 






Mexico 2019 2019 
Cross-
sectional 






Egypt 2019 2019 
Cross-
sectional 





















Hospital US 48 104 
BMI z score 
of greater 
than 2 (95th 
percentile 
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Velez.RR138 Colombia 2018 2018 
Cross-
sectional 






Poland 2018 2018 
Cross-
sectional 




Bacha.F140 USA 2017 2017 
Cross-
sectional 






Romania 2018 2017 
Cross-
sectional 















Denmark 2017 2017 
Cross-
sectional 




Lee.SJ144 USA 2016 2016 
Cross-
sectional 






Colombia 2016 2016 
Cross-
sectional 









Jin.R146 USA 2015 2015 
Cross-
sectional 










Hospital Biopsy 114 144 
body mass 
index (BMI) 
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43.5 kg/m2 
























Santoro.N150 USA 2014 2014 
Cross-
sectional 













Turkey 2008 2004 
Case-
control 






USA 2008 2008 
Cross-
sectional 























Barretto.JR156 Brazil 2020 2019 
Cross-
sectional 




*US, ultrasound; CT, computed tomography; MRI, magnetic resonance imaging; FLI, fatty liver index; H-MRS, proton magnetic resonance spectroscopy; BMI, body mass 
index. 
 
Supplementary Table 2. Egger’s test for included studies. 
Groups P value 
Studies in general population regardless of diagnostic technique <0.01 
Studies in general population diagnosed by ultrasound 0.39 
Studies in special population from clinics regardless of diagnostic technique <0.01 
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Supplementary figure 2. MAFLD prevalence in clinical population diagnosed by ultrasound. 
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Background Metabolic dysfunction-associated fatty liver disease (MAFLD) is a new 
terminology recently updated from non-alcoholic fatty liver disease (NAFLD). The 
discontinuity in nomenclature and disease definition hampers epidemiological 
understanding of MAFLD. In this study, we aim to perform a systematic review and 
meta-analysis to estimate the global prevalence of MAFLD in overweight or obese 
adults from general population, by repurposing existing data on fatty liver disease. 
Methods A systematic search was conducted in Medline, Embase, Web of science, 
Cochrane CENTRAL Databases and google scholar. We screened relevant articles in 
English language published until May 2020. By transforming data according to the new 
diagnosis criteria, the global prevalence of MAFLD was estimated in general 
population. A 95% confidence interval was estimated using Wilson score method, and 
pooled prevalence was calculated using the DerSimonian-Laird random-effects model 
with Free-Tukey double arcsine transformations. 
Findings Our search returned 30745 records, of which 113 studies fulfilled our 
inclusion criteria. Based on the updated definition, we identified 1911077 overweight 
or obese adults who could be diagnosed as MAFLD. This resulted in an overall 
prevalence rate of 51.32% (95% CI 47.53-55.11) regardless of diagnostic techniques. 
Ultrasound was the most commonly used technique for the diagnosis with a prevalence 
rate of 52.72% (95% CI 50.38-55.06). 
Interpretation MAFLD is highly prevalent in overweight or obese adults from general 
populations. Rising awareness and urgent actions are warranted as control of the 
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Introduction 
Metabolic dysfunction-associated fatty liver disease (MAFLD) is a new terminology and 
is proposed to replace the older term non-alcoholic fatty liver disease (NAFLD), but 
involves a more broad definition of disease. This revised nomenclature appears to 
have major advantages for diagnosis, patient management, therapeutic development 
and public health when combating this disease. One of the major changes is shifting 
towards inclusionary diagnostic criteria, which removes ambiguity. As proposed, a 
positive diagnosis of MAFLD should be based on detection of hepatic steatosis by 
histology (biopsy), imaging or blood biomarker in addition to at least one of the 
following three criteria, namely overweight/obesity, presence of type 2 diabetes 
mellitus, or evidence of metabolic dysregulation.1-2 
The resulting paradigm shift in defining fatty liver disease requires re-assessment of 
existing epidemiological data to fit the MAFLD criteria. The vast majority of the previous 
studies use NAFLD criteria and require reinterpretation.3 Although fatty liver disease 
has a complex phenotype and has a complicated etiology, a substantial proportion of 
existing data on in the overweight or obese population might be repurposed for 
assessing MAFLD epidemiology. It is well-recognized that body mass index (BMI) is 
closely associated with the risk of fatty liver disease and is a critical determinant of 
adverse clinical outcomes.4 In this study, we aim to estimate the global prevalence of 
MAFLD specifically in overweight and obese adults by performing a systematic review 
and meta-analysis through mining the existing epidemiological data on fatty liver 
disease.  
 
Materials and Methods 
A systematic search was conducted in Medline, Embase, Web of Science, Cochrane 
and google scholar database. We searched English articles from January, 2000 to May, 
2020 (Supplementary methods 1).  
Inclusion criteria for the meta-analysis were as follows: (1) hepatic steatosis detected 
by imaging (ultrasound, computed tomography, and magnetic resonance 
imaging/spectroscopy, transient elastography), liver biopsy, or blood predictive indices 
(fatty liver index); (2) the study included overweight or obese individuals; and (3) the 
study provided information on disease prevalence. Exclusion criteria were as follows: 
(1) the study was a review article, abstract, case report, correspondence, or conference 
paper; (2) did not identify individuals with MAFLD; (3) individuals <18 years; (4) 
performed in patients from outpatient service; (5) no sufficient information for data 
extraction. Data extraction, quality assessment as well as statistics analysis are 
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Figure 1. Global prevalence of MAFLD in overweight or obese adults. (A) Forest plot of MAFLD 
prevalence regardless of diagnostic techniques. (B) MAFLD prevalence in 27 countries and regions.  
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Results 
Among the retrieved 30745 records, 113 eligible studies comprising 2646231 
participants were finally included in the analysis (Supplementary Figure S1A, Table 
S1). Based on the updated definition, we identified 1911077 overweight or obese 
adults who could be diagnosed as MAFLD. This resulted in an overall prevalence rate 
of 51.32% (95% CI 47.53-55.11) regardless of diagnostic techniques (Figure 1). 
Stratified by different continents, South America led the highest prevalence (65.42%, 
95% CI 54.63-75.47), followed by Asia (52.51%, 95% CI 48.38-56.63), Europe 
(47.53%, 95% CI 41.00-54.11) and North America (43.50%, 95% CI 25.50-62.43). 
MAFLD prevalence varied substantially among countries and regions, from 22.28% 
(Thailand, 95% CI 18.85-25.92) to 81.47% (Poland, 95% CI 79.35-83.51). Among 
countries or regions containing at least five relevant studies, Japan had the highest 
(55.46%, 95% CI 47.28-63.49) and Netherlands had the lowest (43.02%, 95% CI 
27.03-59.79) of MAFLD prevalence in this population. Considering the diagnostic 
methods, one study used liver biopsy (51.36%, 95% CI 45.64-57.07), 10 with fatty liver 
index (54.38%, 95% CI 39.11-69.24), 4 used computed tomography (23.06%, 95% CI 
18.42-28.06), one used proton magnetic resonance spectroscopy (53.18%, 95% CI 
47.64-58.69), 3 used transient elastography (31.99%, 95% CI 19.20-46.33) and 92 
studies used ultrasound (52.72%, 95% CI 50.38-55.06, Supplementary Figure S1B). 
Since ultrasound was the most commonly used diagnostic technique, only these 
studies were included for the remaining analysis (Supplementary Figure S1C). The 
prevalence was higher in developing countries (54.08%, 95% CI 49.84-58.29) than 
developed countries (50.99%, 95% CI 48.27-53.71). MAFLD was more prevalent in 
lower-middle income countries (57.98%, 95% CI 31.80-81.99) than that of upper-
middles (53.60%, 95% CI 49.19-57.98) or high-income ones (51.51%, 95% CI 48.58-
54.43). Notably, those diagnosed from 2010 to 2020 (56.11%, 95% CI 51.80-60.38) 
had a higher prevalence of MAFLD in overweight and obese adults than those 
diagnosed from 2000 to 2009 (51.50%, 46.80-51.69). Egger’s test showed significant 
publication bias in the overall analyses (P<0.05) but not in subgroup analyses (P=0.59, 
Supplementary Figure S1D-F). 
 
Discussion 
To our knowledge, this is the first comprehensive meta-analysis on the global 
epidemiology of MAFLD in overweight and obese population. We estimate that the 
global prevalence of MAFLD among overweight or obese adults is over 50%. 
Alarmingly, the prevalence rate shows signs of even further increase, when older data 
is compared to more recent data.  
Within the NAFLD population, it was recently estimated that 60% are lean or non-obese 
individuals,5 and by inference 40% of this population should be overweight or obese. 
In the general population, global prevalence of NAFLD has been estimated as 25% 
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based on data from 1989 to 2015,6 and a recent study calculated the prevalence of 
lean and non-obese NAFLD as 17%.5 The estimation of NAFLD prevalence in obese 
population is far from accurate and ranges from 50-90%.7 One study based on liver 
histology reported a prevalence of steatosis of 15% in non-obese individuals, 65% in 
persons with obesity, and 85% in extremely obese patients.8 Because liver biopsy is 
only indicated for specific patients, these results cannot be generalized. Distinct from 
these historical studies, we now made a first step to quantify MAFLD epidemiology in 
overweight and obese adults. It is important to keep in mind that the relationship 
between MAFLD and BMI is complex and influenced by many factors, such as 
racial/ethnic background and genetic variations in specific genes and thus requires 
further in depth investigation.  
There are some limitations in this study. The limited data available from Africa and 
Oceania might be a serious impediment with respect to the accuracy of the estimations. 
Furthermore, only little information is available with regard to the demographic and 
genetic characteristics in the included studies. High heterogeneity was observed in 
pooled estimates. Moreover, we could not perform subgroup analysis between 
overweight and obese individuals due to the scarcity of the available data. 
In conclusion, MAFLD has a strikingly high prevalence rate in overweight and obese 
individuals. This calls for attention and dedicated action from primary care physicians, 
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Supplementary methods 1. Searching strategy for metabolic dysfunction-associated 
fatty liver disease in overweight or obese adults. 
 
Database searched via Years of 
coverage 
Records Records after 
duplicates 
removed 
Embase  Embase.com 2000 - 
Present 
11248 11075 
Medline ALL  Ovid  2000 - 
Present 
10390 3157 







Cochrane Central Register of 
Controlled Trials 
Wiley  2000 - 
Present 
349 182 
Other sources: Google Scholar (200 top ranked) 200 32 
Total 30745 16706 
 
Embase 
('fatty liver'/exp OR 'metabolic liver disease'/de OR 'steatohepatitis'/de OR (hepatosteato* OR 
steatohepat* OR AFLD OR NAFLD OR FLD OR ((fatty OR steato*) NEAR/3 (liver OR hepat*)) OR 
((metabol*) NEAR/3 (liver OR hepat*) NEAR/3 (diseas* OR syndrom*))):ab,ti,kw) AND ('epidemiological 
data'/de OR 'epidemiology'/de OR 'geographic distribution'/de OR 'patient volume'/de OR 
prevalence/exp OR geography/de OR 'geographic names'/exp OR 'cross-sectional study'/de OR 
(epidemiolog* OR ((geograph* OR global*) NEAR/3 (distribut*)) OR (patient* NEAR/3 volume*) OR 
prevalen* OR population-based* OR cross-sectional*):ab,ti,kw) NOT ([animals]/lim NOT [humans]/lim) 
NOT ('case report'/de OR 'case report*':ti) NOT ([Conference Abstract]/lim) AND [english]/lim 
Medline 
(exp Fatty Liver/ OR Liver Diseases/me OR (hepatosteato* OR steatohepat* OR AFLD OR NAFLD OR 
FLD OR ((fatty OR steato*) ADJ3 (liver OR hepat*)) OR ((metabol*) ADJ3 (liver OR hepat*) ADJ3 
(diseas* OR syndrom*))).ab,ti,kw.) AND (Epidemiological Monitoring/ OR Epidemiology/ OR 
Epidemiology.fs. OR exp Incidence/ OR exp Prevalence/ OR Geography/ OR exp Geographic 
Locations/ OR Epidemiologic Studies OR Cross-Sectional Studies/ OR (epidemiolog* OR ((geograph* 
OR global*) ADJ3 (distribut*)) OR (patient* ADJ3 volume*) OR prevalen* OR population-based* OR 
cross-sectional*).ab,ti,kw.) NOT (exp Animals/ NOT Humans/) NOT (Case Reports/ OR case report*.ti.) 
NOT (news OR congres* OR abstract* OR book* OR chapter* OR dissertation abstract*).pt. AND 
english.la.  
Cochrane 
((hepatosteato* OR steatohepat* OR AFLD OR NAFLD OR FLD OR ((fatty OR steato*) NEAR/3 (liver 
OR hepat*)) OR ((metabol*) NEAR/3 (liver OR hepat*) NEAR/3 (diseas* OR syndrom*))):ab,ti) AND 
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((epidemiolog* OR ((geograph* OR global*) NEAR/3 (distribut*)) OR (patient* NEAR/3 volume*) OR 
prevalen* OR population-based* OR cross-sectional*):ab,ti) 
Web of Science 
TS=(((hepatosteato* OR steatohepat* OR AFLD OR NAFLD OR FLD OR ((fatty OR steato*) NEAR/2 
(liver OR hepat*)) OR ((metabol*) NEAR/2 (liver OR hepat*) NEAR/2 (diseas* OR syndrom*)))) AND 
((epidemiolog* OR ((geograph* OR global*) NEAR/2 (distribut*)) OR (patient* NEAR/2 volume*) OR 
prevalen* OR population-based* OR cross-sectional*)) NOT ((animal* OR rat OR rats OR mouse OR 
mice OR murine OR dog OR dogs OR canine OR cat OR cats OR feline OR rabbit OR cow OR cows 
OR bovine OR rodent* OR sheep OR ovine OR pig OR swine OR porcine OR veterinar* OR chick* OR 
zebrafish* OR baboon* OR nonhuman* OR primate* OR cattle* OR goose OR geese OR duck OR 
macaque* OR avian* OR bird* OR fish*) NOT (human* OR patient* OR women OR woman OR men 
OR man))) AND DT=(Article OR Review) AND LA=(English) 
Google Scholar 
hepatosteatosis|steatohepatitis|AFLD|NAFLD|FLD|"fatty|steatotic liver"|"liver|hepatic 
steatosis"|"metabolic liver disease" epidemiology|prevalence|"geographic|global distribution"|"patient 
volume"|"population based"|"cross sectional" 
 
Supplementary methods 2. 
Studies were screened based on pre-specified decision rules. Initial title and abstract screening was 
done independently by two reviewers (JL and LW), with a random 10% of studies checked by another 
investigator (JS). Full-text review was done independently by two authors (JL and LW), with any 
discrepancies resolved by consensus or by a third reviewer (QP); consensus was reached in all 
instances. We extracted data at all levels reported in the study, including time of publication, study period, 
country or region, country or region income, the level of country development, study categories, 
diagnostic techniques and disease prevalence. Data were then crossly checked for accuracy against 
the original source by two authors (JL and LW). Two authors (JL and WL) independent reviewed and 
extracted data from the included studies by using a data extraction form specifically designed for current 
study. When duplicate data were identified, the duplicate with the smallest sample size or shortest 
duration of follow-up was excluded. We assessed the quality of included studies using an assessment 
scale based on the Newcastle-Ottawa Scale, which is comprised of three domains including selection, 
comparability and outcome. The Newcastle-Ottawa Scale assigns a maximum score of five for selection, 
two for comparability, and two for outcome. Studies scoring 1-3 were defined as low quality, 4-6 as 
average quality, and 7-9 as high quality (Supplementary Table S1). Studies were not excluded on the 
basis of their quality score to increase transparency and to ensure all available evidence in this area 
was reported. After checking for consistency, the Metaprop module in the R-3.5.3 statistical software 
package was used for meta-analysis. A 95% confidence interval (95% CI) was estimated using Wilson 
score method, and pooled prevalence was calculated with the DerSimonian-Laird random effects model 
with Free-Tukey double arcsine transformation. Heterogeneity across the included studies was 
assessed using the Cochran Q statistics and I2 statistics, with I2 statistics 25%-50%, 50%-75% and >75% 
considered as mild, moderate and severe heterogeneity, respectively. Egger regression test were used 
to assess potential publication biases. This study is reported in accordance with the Preferred Reporting 
Items for Systematic Reviews and Meta-Analysis (PRISMA). 
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Supplementary Figure 1. (A) Study selection. (B) MAFLD prevalence stratified by different diagnostic 
methods. (C) Subgroup analysis for MAFLD diagnosed by ultrasound. (D) Egger’s Test for all studies. 
(E) Egger’s Test for studies diagnosed by ultrasound. 
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Abstract 
The current understanding of cancer biology and development of effective treatments 
for cancer remain far from satisfactory. This in turn heavily relies on the availability of 
easy and robust model systems that resemble the architecture/physiology of the 
tumors in patients to facilitate research. Cancer research in vitro has mainly been 
based on the use of immortalized 2D cancer cell lines for, which deviate in many 
aspects from the original primary tumors. The recent development of the organoid 
technology allowing generation of organ-buds in 3D culture from adult stem cells has 
endowed the possibility of establishing stable culture from primary tumors. Although 
culturing organoids from liver tumors is thought to be difficult, we now convincingly 
demonstrate the establishment of organoids from mouse primary liver tumors. We 
have succeeded in culturing 91 lines from 129 liver tissue/tumors. These organoids 
can be grown in long-term cultures in vitro. About 20% of these organoids form tumors 
in immunodeficient mice upon (serial) transplantation, confirming their tumorigenic and 
self-renewal properties. Interestingly, single cells from the tumor organoids have high 
efficiency of organoid initiation, and a single organoid derived from a cancer cell is able 
to initiate a tumor in mice, indicating the enrichment of tumor-initiating cells in the tumor 
organoids. Furthermore, these organoids recapitulate, to some extent, the 
heterogeneity of liver cancer in patients, with respect to phenotype, cancer cell 
composition and treatment response. These model systems shall provide enormous 
opportunities to advance our research on liver cancer (stem cell) biology, drug 
development and personalized medicine.  
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Introduction 
Liver cancer is one of the most common cause of cancer-related death worldwide with 
limited treatment options available 1. Better understanding of the biology of liver cancer 
is urgently needed for facilitating the development of new therapies. However, this in 
turn heavily relies on the availability of easy and robust model systems that resemble 
the architecture and physiology of the tumors in patients. So far, the cancer research 
society has mainly used immortalized cancer cell lines that have been propagated in 
2D culture as in vitro model for decades. Obviously, these cell lines behave very 
different from the original tumor in many aspects and cost long time to establish2. 
Primary cell culture of liver cancer cells from either human or mouse has proven to be 
very difficul3. Thus, innovative approaches enabling in vitro propagation of primary liver 
cancer cells that maximize the modeling capacity of the patient disease and treatment 
response will be of particular importance. 
The recent development of the organoid technology has driven the stem cell research 
field moving forward4,5 . Organoids are initiated in vitro from one or a few adult Lgr5+ 
stem cells of a particular tissue/organ and self-organize into 3D structure6,7. They 
recapitulate the tissue architecture and lineage hierarchy, allow self-renewal and 
expansion of the stem cell population and empower different types of experimental 
manipulation8. Many types of cancers are believed to harbor a subset of cells, termed 
as tumor-initiating cells (TIC). Thus, it is conceivable that organoids could be cultured 
from tumor tissues, if sophisticated 3D cell culture techniques/conditions are employed. 
Indeed, tumor organoid models have been established from primary tumors of 
colorecta9, pancreatic10,11, prostate12 and liver cancer13 patients. This technology is 
now used to explore many aspects of cancer research, including studying oncogenic 
transformation, cancer stem cells, drug development and personalized treatment14,15. 
Our study has presented the successful establishment of malignant organoid models 
from mouse primary liver tumors, performed extensive characterization and 
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Method and material 
Tumor/healthy organoid culture  
Single cells were isolated from liver tumor tissues using a digestion solution: Collagenase type XI (0.5 
mg/ml, Sigma-Aldrich), Dispase (0.2 mg/ml, Gibco), 1 % FBS in DMEM medium (Lonza) (37 °C, 30 min), 
then centrifuged (600 rpm, 10 min) to collect the cell pellets. Cells were directly mixed with matrigel (BD 
Bioscience), seeded on 24/48 well plates and kept at 37 °C for at least 30 min. After the matrigel formed 
a solid gel, medium was slowly added. Organoid culture medium was based on advanced DMEM/F12 
(Invitrogen), which is supplemented with B27 (2% vol/vol) and N2 (1% vol/vol , Invitrogen), N-
acetylcysteine (1.25 μM, Sigma-Aldrich), gastrin (10 nM, Sigma-Aldrich), EGF (50 ng/ml, Peprotech), R-
spondin 1 (10% vol/vol, conditioned medium produced by 293T-H-RspoI-Fc cell line), FGF10 (100 ng/ml, 
Peprotech), nicotinamide (10 mM, Sigma-Aldrich) and HGF (50 ng/ml, Peprotech), as described 
previously5. For the initial 3 days, the organoids also need to be supplemented with Noggin (10% vol/vol, 
conditioned medium produced by 293T-HA-Noggin cell line) Wnt3a (30% vol/vol, conditioned medium 
produced by L-Wnt3a cell line)5. Medium was refreshed every 2-3 days and organoids were passaged 
in 1:2-1:10 split ratio once per week, or according to the growth of the organoids. The healthy liver-
derived organoids were also isolated and cultured by using the same methodology as tumor organoid 
culture (stemness-keeping culture condition, without further differentiation). 
 
Organoid allograft 
Cold advanced DMEM/F12 medium was used to collect the organoids. Organoids were mechanically 
dissociated into pieces by pipetting (5-10 times) (collect enough amount of organoids from an entire 24-
well plate, averagely 1 × 106-1 × 107). After centrifuging, organoids pellets (broken organoid pieces) 
were re-suspended in cold advanced DMEM/F12 medium and then mixed directly with matrigel in the 
ratio of 1:1 with a total volume of 100-200ul. 4-6 weeks old female NOG/JicTac (CIEA NOD.Cg-Prkdc-
scid Il2rg-tm1Sug) mice were purchased from Taconic, and subcutaneously injected with the collected 
tumor organoids. Tumor formation was monitored weekly and mice were sacrificed to harvest tumor 
after visualizing the tumor (the tumor size reached 1cm). Tumor tissues were stored or cultured as 
described above. All animal experiments were approved by the Committee on the Ethics of Animal 
Experiments of the Erasmus Medical Center. 
 
Single organoid formation assay and allograft assay 
Cold advanced DMEM/F12 medium was used to collect the organoids. Organoids were mechanically 
dissociated into small pieces by pipetting (20-30 times) and further digested into single cells by TrypLE 
(Gibco, 37̊C, 5-10 min). FACS sorter (BD FACSAriaTM II) was used to further isolate the single living 
cells. Propidiumiodide (PI) staining was used to exclude dead cells; FSC-Width with FSC-Area and then 
SSC-Width with SSC-Area gates were used to select the single cells. After mixing one single cell with 
matrigel, a droplet with in total volume of 5 µl was seeded in a well of 96-well plate for organoid initiation. 
After 1-3 weeks, single organoids were formed. Cold advanced DMEM/F12 medium was used to collect 
the single organoids. After removing the supernatant, matrigel was mixed with the organoid pellet and 
transplanted subcutaneously into the NOG mice directly. Tumor formation was monitored as described 
above. 
 
Metabolic activity analyses for drug treatment 
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Different organoid lines were seeded separately in a 24/48-well plate. Sorafenib (1 uM) and Regorafenib 
(1 uM) was added to the organoid culture since the initial day. Drugs were refreshed every 2 days. At 
the day 7, organoids were incubated with Alamar Blue (Invitrogen, 1:20 in DMEM) for four hours, and 
then medium was collected for analysis of the metabolic activity of the cells. Absorbance was determined 
by using fluorescence plate reader (CytoFluor® Series 4000, Perseptive Biosystems) at the excitation of 
530/25 nm and emission of 590/35. Each treatment condition was repeated for four times and matrigel 
only was used as blank control. 
 
Karyotyping 
Karyotyping was performed as previously described16. Briefly, cultures were incubated with 0.1 ug/ml 
Karyomax Colcemid (Gibco, 152120-012) for 24 h. Organoids were harvested by cold organoid basic 
medium and then kept on ice for 10 min. Then, TrypLE (Gibco) were added for digesting organoids into 
single cells. Cells were then incubated with KCL 0.0075 M hypotonic solution for 10 min in 37℃ incubator. 
Methanol: acetic acid (3:1, freshly prepared) was used for further fixation. Cells were dropped onto a 
microscope slide for visualization. Nuclei were mounted and stained using Vectashield with DAPI 
(Vector Labs). A minimum of 15 metaphases per sample were counted. 
 
Statistical Analysis 
Prism software (GraphPad Software) was used for all statistical analysis. For statistical significance of 
the differences between the means of two groups, we used Mann-Whitney U-test. For comparing two 
paired groups, we used Paired T-test. Differences were considered significant at a p value less than 
0.05. 
Results 
Successful culture of organoids from mouse primary liver tumors  
Diethylnitrosamine (DEN) is widely used as a carcinogen in experimental animal 
models, in particular for inducing liver tumors in mice. Similar to the gender disparity in 
patients, DEN also preferentially induce liver tumors in male mice17. Thus, we have 
mainly used male mice (53 male; 3 female) to induce liver tumor by DEN 
(Supplementary Figure 1 and Supplementary Figure 2). The livers were harvested for 
organoid culture (Figure 1A and Supplementary Figure 3). The numbers of visible 
tumors vary among the harvested mouse livers, ranging from zero to multiple tumors 
per liver (Supplementary Figure 1 and Supplementary Figure 4A). In total, we obtained 
129 individual tissue/tumors from these mice, which were subjected to organoid culture 
(Figure 1A and Supplementary Figure 3). In general, small organoids could be 
visualized since post day 2-7 and passage was required around 7-14 days. We have 
succeeded in establishing organoid culture from 91 out of the 129 tumors, representing 
an efficiency of 70.5% (Supplementary Figure 2 and Supplementary Figure 4). The 
initiation efficiency varied from 0% to 100% among individual livers (Supplementary 
Figure 4B). For the rest 38 tissues that failed to form into organoids, 12 samples did 
initiate organoids but stopped proliferation at an early stage (maintained less than 3-4 
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weeks, 1-3 passages); whereas the other tumors had extensive necrosis and did not 
initiate any organoid from the start.  
The successfully established lines could be maintained and propagated in 3D culture 
for at least 3 months, by passaging in the ratio of 1:2-1:4 for every 7 days. We further 
demonstrated that these tumor-derived organoids can be frozen, stored and re-
cultured again without affecting their growth rate. With respect to the morphology, we 
(Figure 1C) and others5 have observed that organoids derived from the healthy liver 
have a uniform bubble-like structure. In contrast, organoids derived from liver tumors 
presented diverse morphologies, ranging from bubble-like to condensed and flower-
like, as well as an irregular sheet-like structure (Figure 1D-H). Interestingly, some 
cultures contained a mixture of organoids with different morphology (Supplementary 
Figure 5), which may reflect the heterogeneity of cell types within the tumors.  
 
Tumorigenicity of expanded organoids in immunodeficient mice 
To functionally assess whether these tumor-derived organoids are malignant, we 
performed the allograft assay in NOG immunodeficient mice as described previously 
(Figure 1A and Supplementary Figure 3)18. We have subcutaneously engrafted all the 
established 91 organoid lines and assessed their tumor formation ability in vivo. Within 
4-16 weeks, 18 out of 91 (20%) lines initiated tumor formation in NOG mice (Figure 1A 
and Supplementary Table 1: The upper panel).  
Organoids could be cultured again from these allograft tumors (Figure 1A-B and 
Supplementary Figure 3). These tumor organoids needed to be passaged every 5 days 
in the ratio of 1:5-1:10, indicating an increased speed of growth. Importantly, when 
engrafting into NOG mice, these organoids are capable to initiate tumors again, with 
relatively shorter time compared to engraftment of the primary tumor organoids (Figure 
1B and Supplementary Table 1, allograft tumor vs. primary tumor: 35 days vs 40.6 
days). These results firmly demonstrated that liver tumor derived organoids are 
malignant and tumorigenic with self-renewal capability. Furthermore, we have 
performed karyotyping for the organoid strains (Figure 2). The majority of the strains 
from the primary tumors and all the strains derived from allograft showed irregular 
chromosome numbers. In contrast, organoids from healthy livers stably maintain 
diploid/tetraploid/octoploid chromosome numbers in culture. 
 
A single organoid derived from a single cancer cell is able to initiate tumor 
formation in mice  
To further consolidate the ability to initiate tumor growth of the organoids, we performed 
an organoid formation assay with isolated single cells. We found that isolated single 
cells from the tumor organoids can efficiently re-initiate organoids (Figure 1A). More 
importantly, subcutaneous transplantation of a single tumor organoid derived from a  
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Figure 1. Establishment and characterization of organoid cultures from mouse liver tumors. (A) The 
upper panel: An outline of the experimental strategy used to establish primary tumor organoids. The 
lower panel: Representative pictures showing tumor organoids cultured from mouse primary liver tumors, 
and the formation of allograft tumor in NOG mice. The allograft tumors can be cultured into tumor 
organoids again. (B) The upper panel: An outline of the experimental strategy used to investigate single 
tumor organoid. The lower panel: Representative pictures showing that allograft tumor can initiate tumor 
organoids again. A single cell isolated from the tumor organoid can initiate a single organoid and then 
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single cell into immunodeficient NOG mice rapidly initiated tumor around two weeks, 
confirming their malignant property (Figure 1B and Supplementary Table 1: the lower 
panel). Furthermore, organoids can be re-cultured from those allograft tumors and 
exhibited progressive expansion for over 4 months. These results indicate that 3D 
tumor organoid system enriches the cells with the capacity of tumor initiating.  
Classically, stem cell markers have been widely used to identify potential TIC, although 
it is an ever debating issue of defining qualified TIC markers19. Based on previous 
studies19,20, we have profiled a panel of potential TIC markers, in comparison with 
organoids from normal liver stem cells. We found that the expression profile for stem 
cell/tumor stem cell markers varied from different strains (Supplementary file 1). 
Several markers, including Bmi1, Lgr5, Oct4, Cd133, Hopx and Sox2 were upregulated 
in allograft strains compared to normal organoid or primary tumor-derived organoid 
strains (Figure 3). CD44 and Tert were downregulated in allograft strains. By paired 
analysis of the available paired strains, we observed the upregulation of Bmi1, Lgr5 
and Muc5ac and the downregulation of Sox9 and Ck7 (Supplementary Figure 6).  
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Figure 2. Karyotyping of normal and tumor organoids. (A-B) Representative images of organoid 
metaphases used for the ploidy analysis (A: normal chromosome number B: irregular chromosome 
number; Original magnification for organoids were 2800×). (C-D) Different analysis methods showing 
the percentage of ploidy per number of metaphases counted (at least 15 total), for normal organoid (N), 
allograft organoid (AL) and primary organoid (PT).   
 
Figure 3. Comparison of the expression of progenitor/stem cell markers. N: normal liver organoid strains; 
P: strains from primary liver tumors; A: strains from allograft liver tumors (*P < .05; **P < .01; ***P < .001). 
 
Tumor organoids express cholangiocyte and/or hepatocyte markers 
In patients, primary liver cancer has been traditionally classified into three main types 
based on the tumor cell type. These are hepatocellular carcinoma (HCC), 
cholangiocarcinoma (CC) and hepatocellular-cholangiocarcinoma (CHCs). Although it 
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remains a challenge to differentiate these types, hepatocyte (e.g. AFP, HNF4ɑ) or/and 
cholangiocyte (e.g. CEA, CK19, C-KIT, EpCAM) markers are often used as one of the 
approaches to distinguish these types of liver cancer21. In this respect, we have 
characterized the established tumor organoids and corresponding tissues by staining 
with HCC (AFP/HNF4ɑ), CC (EpCAM/CK19) marker, H&E staining and Gomori's 
reticulin staining respectively (Figure 4, supplementary file 1-3). Among the 91 strains 
which were transplanted into the NOG mice, 25 were lost due to infection in culture or 
storage issue later on (Supplementary Figure 4, marked by yellow). Thus, we mainly 
focused on the rest 66 strains, as well as the 18 allograft strains. We found distinct 
expression patterns among different lines of established tumor organoids. Some with 
a subset of cells express AFP and Hnf4a, some express EpCAM and CK19, and others 
express both markers (Supplementary file 1). More importantly, some allograft strains 
maintained the expression profile as well as the histology, compared to the primary 
tissue/strains (Figure 5A); whereas the other strains did not (Figure 5B). These data 
indicate that murine tumor organoids may recapitulate the heterogeneity of liver cancer 
types in patients to some extent. Of note, given that the etiology of liver is diverse, DEN 
induced liver tumors in mice do not fully represent liver cancer in patients17. 
 
Assessment of anti-cancer drugs in the tumor organoid model 
Current treatment options, in particular for advanced liver cancer, are very limited. 
Sorafenib is the only FDA-approved first-line systemic therapy for patients with 
advanced HCC, with improvement of patient survival for only 3 months1. Regorafenib 
is now emerging as a potential second-line therapy for HCC patients22. To explore the 
potential of using liver tumor organoid models for future drug development, we 
assessed the feasibility by testing the effects of Sorafenib and Regorafenib.  
We used organoid lines established from nine allograft tumors, as well as four primary-
tumor derived organoid strains. Overall, these two targeted therapies inhibited the 
growth of the organoids (Figure 6 and Supplementary figure 7). However, we also 
observed clear variations of the responsiveness among these organoids. Thus, we 
have classified the organoid strains into three groups. Group 1 is sensitive to both 
(Figure 6A and Supplementary figure 7A); whereas Group 2 is only sensitive to 
Sorafenib but not Regorafenib (Figure 6B and Supplementary figure 7B); and Group 3 
is not sensitive to both (Figure 6C and Supplementary figure 7C). We further compared 
the expression profile of stem cell/tumor stem cell markers between Group 1 with the 
rest strains. We have observed low expression of Oct4 and high expression of Sox9 in 
Group 1 (Supplementary Figure 8).  
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Figure 4. An example of the characterization of an organoid strain. (A) IHC straining for the allograft 
tissue of EpCAM (CC marker), SALL4 (poorly differentiated tumor marker) and AFP (HCC marker). (B) 
The morphology of organoid. (C) IF straining for the allograft organoid strain of CK19 (CC), EpCAM 
(CC), HNF4a(HCC) and AFP (HCC).(D) The expression profile for stem cell/tumor stem cell markers of 
the allograft organoid strains (n=3).  
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Figure 5. The characterization of organoid strains and corresponding tissue. (A) The tumor initiated by 
organoids showed similar histology and expression patterns of EpCAM and AFP compared to the 
primary tissue. Black box: the tumor organoid. (B) The tumor initiated by organoids showed different 
histology and expression profile of patterns of EpCAM and AFP compared to the primary tissue. 
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Figure 6. Tumor organoids in response to the treatment of the targeted therapeutics Sorafenib or 
Regorafenib. 13 tumor organoid lines (AL12, AL18, AL20, AL22, AL26, AL28, AL61, AL71, AL85, AL86, 
PT102, PT104 and PT105) were analyzed. At day 7, the Alamar blue assay was used to measure the 
growth of organoids. (*P < .05; **P < .01; ***P < .001, n=4). (A) Group 1: organoid strains which were 
both sensitive to Sorafenib and Regorafenib. (B) Group 2: organoid strains which were only sensitive to 
Sorafenib, but not Regorafenib. (C) Group 3: organoid strains which were not sensitive to both Sorafenib 
and Regorafenib.  
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Discussion 
This study has demonstrated the establishment of organoids from primary mouse liver 
tumors. These organoids can be expanded in long-term cultures and initiate tumors in 
immunodeficient mice. Importantly, these organoids recapitulate, to some extent, the 
heterogeneity of liver cancer as seen in patients, with respect to phenotype, cancer 
cell composition and treatment response. 
Classically, the in vitro investigation of liver cancer is based on cell lines, which have 
the following limitations: 1) limited number of established cell lines; 2) low efficiency of 
establishing new lines from primary tissues; 3) only aggressive tumors have high 
change to establish in vitro culture successfully. Thus, the majority of primary tissue 
(>90%) cannot be successfully culture in vitro, especially the benign or less aggressive 
tumors, which also should be further investigated. Except the traditional cell line culture 
model, several other methods have also been explored to model liver cancer in vitro. 
The rotating wall vessel bioreactor has been reported to be used to culture HCC cell 
lines. This system was further used to co-culture the liver tumor cells with colon 
carcinoma cells to form liver-tumor hybrid, as a model to mimic liver metastasis. In 
addition, 2D or 3D spheroid culture has been applied to culture HCC cell lines. 
However, the majority of those in vitro system focus on immortalized cell lines, rather 
than primary tissue.  
We here adopted matrigel based 3D organoid culture system. This model allows 
investigation of healthy adult stem cells, as well as various types of diseases, in 
particular cancer. Successful examples have been reported in establishing organoids 
from colon, pancreas and prostate tumor tissues. A very recent study has reported the 
culture of organoids from a few liver cancer patients13. Here we reported that we have 
succeeded in establishing 91 lines from 128 mouse liver tissues/tumors. These 
organoids are capable of long-term culture and expansion in vitro. They are capable of 
initiating tumors in immunodeficient mice upon (serial) transplantation, confirming their 
tumorigenic, malignant and self-renewal properties. However, a subset of the tumor 
organoid strains did not initiate tumor in the current allograft transplantation model. 
First of all, we cannot exclude the possible existence of normal organoids among these 
organoid lines established from primary tumors. Secondly, the mouse model used for 
allograft transplantation retains part of the immune system which may inhibit tumor 
initiation23.  
There is substantial heterogeneity among different organoid strains, in respect to 
organoid morphology, tissue histology and marker expression. The diversity of 
morphology has previously also been observed in other types of tumor organoids, such 
as those derived from colorectal9, pancreatic10,11 and prostate12 cancer. Interestingly, 
the tumor histology of the allograft and the corresponding primary tumor is not always 
matched (Supplementary Table 2, Supplementary Table 3 and Supplementary figure 
9). One possible explanation is that the current liver organoid culture protocol more 
favors the growth of stem cell/cholangiocyte like cells5,13,24. Secondly, trans-
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differentiation between hepatocyte and cholangiocyte has been well-recognized25. We 
speculate that with the current organoid culture approach we may drive the trans-
differentiation of primary HCC cells into cholangiocarcinoma cells. Last but not the least, 
in case of a small tumor, tissue was prioritized for organoid culture, left no 
representative primary tumor tissue for histology evaluation.  
Our results also support the notion that liver tumors contain TIC, and organoids may 
represent an innovative model system for studying these cancer cells. TIC is a rare 
cancer cell population, but is thought to be the engine of tumor formation, relapse, 
metastasis and chemo-resistance in many cancer types19, including in liver cancer26. 
We envision that these tumor organoid models have potential to circumvent a major 
bottleneck in the TIC field as these cells are usually not able to be cultured in vitro. The 
current research is largely based on phenotypic description and tumor formation 
assays in immunodeficient mice26. Sophisticated in vitro culture of liver tumor 
organoids that are capable of long-term propagation ex vivo, as demonstrated in our 
study, provides a unique tool for the research field to advance in-depth research of 
liver TIC.  
We further reveal the heterogeneity of individual lines as well as the differences in 
responsiveness between treatments. This provides proof-of-concept that organoids 
have the potential to be used as an in vitro model to study anti-cancer drug 
development in general, as well as for personalized medicine in cancer treatment. 
Furthermore, TIC have been proposed as attractive anti-cancer targets and recent 
studies have demonstrated the possibility and efficacy of targeting TIC in animal 
models. Different allograft organoid strains showed different expression patterns for 
the stem cell/tumor stem cell markers, which may be useful for further investigation of 
the specific tumor initiating cell/cancer stem cell populations (Supplementary figure 10). 
We believe that tumor organoid models have particular privileges as a platform for 
facilitating the development of TIC targeted therapies, given that these cells can be ex 
vivo cultured from primary tumor tissues. 
Organoid model system shall provide enormous opportunities to advance the research 
on liver cancer/stem cell biology, drug development and personalized medicine. Of 
note, organoid systems do not mutually exclude the use of the classical cancer cell 
lines, but in fact complement each other. Finally, more efforts are urgently required to 








Page | 175  
 
Reference 
1 Ohlund D, Handly-Santana A, Biffi G, Elyada E, Almeida AS, Ponz-Sarvise M, et al. Distinct populations of inflammatory 
fibroblasts and myofibroblasts in pancreatic cancer. J Exp Med 2017;214:579-96. 
2 Guo Y, Cordes KR, Farese RV, Jr., Walther TC. Lipid droplets at a glance. J Cell Sci 2009;122:749-52. 
3 Collaborators GBDO, Afshin A, Forouzanfar MH, Reitsma MB, Sur P, Estep K, et al. Health Effects of Overweight and 
Obesity in 195 Countries over 25 Years. N Engl J Med 2017;377:13-27. 
4 Gluchowski NL, Becuwe M, Walther TC, Farese RV, Jr. Lipid droplets and liver disease: from basic biology to clinical 
implications. Nat Rev Gastroenterol Hepatol 2017;14:343-55. 
5 Olzmann JA, Carvalho P. Dynamics and functions of lipid droplets. Nat Rev Mol Cell Biol 2019;20:137-55. 
6 Jackson CL. Lipid droplet biogenesis. Curr Opin Cell Biol 2019;59:88-96. 
7 Yen CL, Stone SJ, Koliwad S, Harris C, Farese RV, Jr. Thematic review series: glycerolipids. DGAT enzymes and 
triacylglycerol biosynthesis. J Lipid Res 2008;49:2283-301. 
8 Korber M, Klein I, Daum G. Steryl ester synthesis, storage and hydrolysis: A contribution to sterol homeostasis. Biochim 
Biophys Acta Mol Cell Biol Lipids 2017;1862:1534-45. 
9 Ben M'barek K, Ajjaji D, Chorlay A, Vanni S, Forêt L, Thiam AR. ER Membrane Phospholipids and Surface Tension 
Control Cellular Lipid Droplet Formation. Dev Cell 2017;41:591-604 e7. 
10 Salo VT, Belevich I, Li S, Karhinen L, Vihinen H, Vigouroux C, et al. Seipin regulates ER-lipid droplet contacts and cargo 
delivery. Embo J 2016;35:2699-716. 
11 Salo VT, Li S, Vihinen H, Hölttä-Vuori M, Szkalisity A, Horvath P, et al. Seipin Facilitates Triglyceride Flow to Lipid 
Droplet and Counteracts Droplet Ripening via Endoplasmic Reticulum Contact. Dev Cell 2019;50:478-93 e9. 
12 Chorlay A, Monticelli L, Veríssimo Ferreira J, Ben M'barek K, Ajjaji D, Wang S, et al. Membrane Asymmetry Imposes 
Directionality on Lipid Droplet Emergence from the ER. Dev Cell 2019;50:25-42 e7. 
13 Kory N, Farese RV, Jr., Walther TC. Targeting Fat: Mechanisms of Protein Localization to Lipid Droplets. Trends Cell 
Biol 2016;26:535-46. 
14 Wilfling F, Wang H, Haas JT, Krahmer N, Gould TJ, Uchida A, et al. Triacylglycerol synthesis enzymes mediate lipid 
droplet growth by relocalizing from the ER to lipid droplets. Dev Cell 2013;24:384-99. 
15 Kuerschner L, Moessinger C, Thiele C. Imaging of lipid biosynthesis: how a neutral lipid enters lipid droplets. Traffic 
2008;9:338-52. 
16 Prévost C, Sharp ME, Kory N, Lin Q, Voth GA, Farese RV, Jr., et al. Mechanism and Determinants of Amphipathic 
Helix-Containing Protein Targeting to Lipid Droplets. Dev Cell 2018;44:73-86 e4. 
17 Sztalryd C, Brasaemle DL. The perilipin family of lipid droplet proteins: Gatekeepers of intracellular lipolysis. Biochim 
Biophys Acta Mol Cell Biol Lipids 2017;1862:1221-32. 
18 Ozeki S, Cheng J, Tauchi-Sato K, Hatano N, Taniguchi H, Fujimoto T. Rab18 localizes to lipid droplets and induces 
their close apposition to the endoplasmic reticulum-derived membrane. J Cell Sci 2005;118:2601-11. 
19 Pataki CI, Rodrigues J, Zhang L, Qian J, Efron B, Hastie T, et al. Proteomic analysis of monolayer-integrated proteins 
on lipid droplets identifies amphipathic interfacial α-helical membrane anchors. Proc Natl Acad Sci U S A 2018;115:E8172-E80. 
20 Murphy DJ, Vance J. Mechanisms of lipid-body formation. Trends in Biochemical Sciences 1999;24:109-15. 
21 Thiam AR, Farese RV, Jr., Walther TC. The biophysics and cell biology of lipid droplets. Nat Rev Mol Cell Biol 
2013;14:775-86. 
22 Gong J, Sun Z, Wu L, Xu W, Schieber N, Xu D, et al. Fsp27 promotes lipid droplet growth by lipid exchange and transfer 
at lipid droplet contact sites. J Cell Biol 2011;195:953-63. 
23 Krahmer N, Guo Y, Wilfling F, Hilger M, Lingrell S, Heger K, et al. Phosphatidylcholine synthesis for lipid droplet 
expansion is mediated by localized activation of CTP:phosphocholine cytidylyltransferase. Cell Metab 2011;14:504-15. 
24 Guo Y, Walther TC, Rao M, Stuurman N, Goshima G, Terayama K, et al. Functional genomic screen reveals genes 
involved in lipid-droplet formation and utilization. Nature 2008;453:657-61. 
25 Valm AM, Cohen S, Legant WR, Melunis J, Hershberg U, Wait E, et al. Applying systems-level spectral imaging and 
analysis to reveal the organelle interactome. Nature 2017;546:162-7. 
26 Greenberg AS, Coleman RA, Kraemer FB, McManaman JL, Obin MS, Puri V, et al. The role of lipid droplets in metabolic 
disease in rodents and humans. J Clin Invest 2011;121:2102-10. 
27 Tauchi-Sato K, Ozeki S, Houjou T, Taguchi R, Fujimoto T. The surface of lipid droplets is a phospholipid monolayer 
with a unique Fatty Acid composition. J Biol Chem 2002;277:44507-12. 
28 Zehmer JK, Bartz R, Bisel B, Liu P, Seemann J, Anderson RGW. Targeting sequences of UBXD8 and AAM-B reveal 
that the ER has a direct role in the emergence and regression of lipid droplets. Journal of cell science 2009;122:3694-702. 
29 Olofsson S-O, Boström P, Andersson L, Rutberg M, Perman J, Borén J. Lipid droplets as dynamic organelles connecting 
storage and efflux of lipids. Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids 2009;1791:448-58. 
30 Bersuker K, Olzmann JA. Establishing the lipid droplet proteome: Mechanisms of lipid droplet protein targeting and 
degradation. Biochimica et biophysica acta Molecular and cell biology of lipids 2017;1862:1166-77. 
31 Wang H, Lei M, Hsia RC, Sztalryd C. Analysis of lipid droplets in cardiac muscle. Methods Cell Biol 2013;116:129-49. 
32 Tarnopolsky MA, Rennie CD, Robertshaw HA, Fedak-Tarnopolsky SN, Devries MC, Hamadeh MJ. Influence of 
endurance exercise training and sex on intramyocellular lipid and mitochondrial ultrastructure, substrate use, and mitochondrial 
enzyme activity. Am J Physiol Regul Integr Comp Physiol 2007;292:R1271-8. 
33 Shaw CS, Jones DA, Wagenmakers AJ. Network distribution of mitochondria and lipid droplets in human muscle fibres. 
Histochem Cell Biol 2008;129:65-72. 
34 Herms A, Bosch M, Reddy BJ, Schieber NL, Fajardo A, Rupérez C, et al. AMPK activation promotes lipid droplet 
dispersion on detyrosinated microtubules to increase mitochondrial fatty acid oxidation. Nat Commun 2015;6:7176. 
35 Rambold Angelika S, Cohen S, Lippincott-Schwartz J. Fatty Acid Trafficking in Starved Cells: Regulation by Lipid 
Droplet Lipolysis, Autophagy, and Mitochondrial Fusion Dynamics. Developmental Cell 2015;32:678-92. 
36 Benador IY, Veliova M, Liesa M, Shirihai OS. Mitochondria Bound to Lipid Droplets: Where Mitochondrial Dynamics 
Regulate Lipid Storage and Utilization. Cell Metabolism 2019;29:827-35. 
37 Benador IY, Veliova M, Mahdaviani K, Petcherski A, Wikstrom JD, Assali EA, et al. Mitochondria Bound to Lipid Droplets 
Have Unique Bioenergetics, Composition, and Dynamics that Support Lipid Droplet Expansion. Cell metabolism 2018;27:869-
85.e6. 
38 Wang H, Sztalryd C. Oxidative tissue: perilipin 5 links storage with the furnace. Trends in Endocrinology & Metabolism 
2011;22:197-203. 
Page | 176 
 
39 Wang H, Sreenivasan U, Hu H, Saladino A, Polster BM, Lund LM, et al. Perilipin 5, a lipid droplet-associated protein, 
provides physical and metabolic linkage to mitochondria. Journal of lipid research 2011;52:2159-68. 
40 Zhu Y, Ren C, Zhang M, Zhong Y. Perilipin 5 Reduces Oxidative Damage Associated With Lipotoxicity by Activating 
the PI3K/ERK-Mediated Nrf2-ARE Signaling Pathway in INS-1 Pancreatic β-Cells. Front Endocrinol (Lausanne) 2020;11:166-. 
41 Freyre CAC, Rauher PC, Ejsing CS, Klemm RW. MIGA2 Links Mitochondria, the ER, and Lipid Droplets and Promotes 
De Novo Lipogenesis in Adipocytes. Molecular Cell 2019;76:811-25.e14. 
42 Joshi AS, Nebenfuehr B, Choudhary V, Satpute-Krishnan P, Levine TP, Golden A, et al. Lipid droplet and peroxisome 
biogenesis occur at the same ER subdomains. Nature Communications 2018;9:2940. 
43 Shai N, Schuldiner M, Zalckvar E. No peroxisome is an island - Peroxisome contact sites. Biochim Biophys Acta 
2016;1863:1061-9. 
44 Joshi AS, Cohen S. Lipid Droplet and Peroxisome Biogenesis: Do They Go Hand-in-Hand? Front Cell Dev Biol 
2019;7:92. 
45 Zhou L, Yu M, Arshad M, Wang W, Lu Y, Gong J, et al. Coordination Among Lipid Droplets, Peroxisomes, and 
Mitochondria Regulates Energy Expenditure Through the CIDE-ATGL-PPARα Pathway in Adipocytes. Diabetes 2018;67:1935-
48. 
46 Singh R, Kaushik S, Wang Y, Xiang Y, Novak I, Komatsu M, et al. Autophagy regulates lipid metabolism. Nature 
2009;458:1131-5. 
47 Yang L, Li P, Fu S, Calay ES, Hotamisligil GS. Defective hepatic autophagy in obesity promotes ER stress and causes 
insulin resistance. Cell Metab 2010;11:467-78. 
48 Jaber N, Dou Z, Chen JS, Catanzaro J, Jiang YP, Ballou LM, et al. Class III PI3K Vps34 plays an essential role in 
autophagy and in heart and liver function. Proc Natl Acad Sci U S A 2012;109:2003-8. 
49 Settembre C, Ballabio A. Lysosome: regulator of lipid degradation pathways. Trends Cell Biol 2014;24:743-50. 
50 Velázquez AP, Tatsuta T, Ghillebert R, Drescher I, Graef M. Lipid droplet–mediated ER homeostasis regulates 
autophagy and cell survival during starvation. Journal of Cell Biology 2016;212:621-31. 
51 Eslam M, Newsome PN, Sarin SK, Anstee QM, Targher G, Romero-Gomez M, et al. A new definition for metabolic 
dysfunction-associated fatty liver disease: An international expert consensus statement. J Hepatol 2020. 
52 Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver 
disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology 2016;64:73-84. 
53 Zhang CH, Zhou BG, Sheng JQ, Chen Y, Cao YQ, Chen C. Molecular mechanisms of hepatic insulin resistance in 
nonalcoholic fatty liver disease and potential treatment strategies. Pharmacol Res 2020:104984. 
54 Chen K, Ma J, Jia X, Ai W, Ma Z, Pan Q. Advancing the understanding of NAFLD to hepatocellular carcinoma 
development: From experimental models to humans. Biochim Biophys Acta Rev Cancer 2019;1871:117-25. 
55 Straub BK, Stoeffel P, Heid H, Zimbelmann R, Schirmacher P. Differential pattern of lipid droplet-associated proteins 
and de novo perilipin expression in hepatocyte steatogenesis. Hepatology 2008;47:1936-46. 
56 Zhou L, Xu L, Ye J, Li D, Wang W, Li X, et al. Cidea promotes hepatic steatosis by sensing dietary fatty acids. 
Hepatology 2012;56:95-107. 
57 Tang P, Low HB, Png CW, Torta F, Kumar JK, Lim HY, et al. Protective Function of Mitogen-Activated Protein Kinase 
Phosphatase 5 in Aging- and Diet-Induced Hepatic Steatosis and Steatohepatitis. Hepatol Commun 2019;3:748-62. 
58 Su W, Wang Y, Jia X, Wu W, Li L, Tian X, et al. Comparative proteomic study reveals 17β-HSD13 as a pathogenic 
protein in nonalcoholic fatty liver disease. Proc Natl Acad Sci U S A 2014;111:11437-42. 
59 Su W, Peng J, Li S, Dai Y-b, Wang C-j, Xu H, et al. Liver X receptor α induces 17β-hydroxysteroid dehydrogenase-13 
expression through SREBP-1c. American Journal of Physiology-Endocrinology and Metabolism 2017;312:E357-E67. 
60 Kim KH, Shin HJ, Kim K, Choi HM, Rhee SH, Moon HB, et al. Hepatitis B virus X protein induces hepatic steatosis via 
transcriptional activation of SREBP1 and PPARgamma. Gastroenterology 2007;132:1955-67. 
61 Na TY, Shin YK, Roh KJ, Kang SA, Hong I, Oh SJ, et al. Liver X receptor mediates hepatitis B virus X protein-induced 
lipogenesis in hepatitis B virus-associated hepatocellular carcinoma. Hepatology 2009;49:1122-31. 
62 Yasumoto J, Kasai H, Yoshimura K, Otoguro T, Watashi K, Wakita T, et al. Hepatitis B virus prevents excessive viral 
production via reduction of cell death-inducing DFF45-like effectors. J Gen Virol 2017;98:1762-73. 
63 Miyanari Y, Atsuzawa K, Usuda N, Watashi K, Hishiki T, Zayas M, et al. The lipid droplet is an important organelle for 
hepatitis C virus production. Nature Cell Biology 2007;9:1089-97. 
64 Filipe A, McLauchlan J. Hepatitis C virus and lipid droplets: finding a niche. Trends Mol Med 2015;21:34-42. 
65 Lee JY, Cortese M, Haselmann U, Tabata K, Romero-Brey I, Funaya C, et al. Spatiotemporal Coupling of the Hepatitis 
C Virus Replication Cycle by Creating a Lipid Droplet- Proximal Membranous Replication Compartment. Cell Rep 2019;27:3602-
17 e5. 
66 Camus G, Schweiger M, Herker E, Harris C, Kondratowicz AS, Tsou C-L, et al. The hepatitis C virus core protein inhibits 
adipose triglyceride lipase (ATGL)-mediated lipid mobilization and enhances the ATGL interaction with comparative gene 
identification 58 (CGI-58) and lipid droplets. The Journal of biological chemistry 2014;289:35770-80. 
67 Boulant S, Douglas MW, Moody L, Budkowska A, Targett-Adams P, McLauchlan J. Hepatitis C Virus Core Protein 
Induces Lipid Droplet Redistribution in a Microtubule- and Dynein-Dependent Manner. Traffic 2008;9:1268-82. 
68 Tada T, Kumada T, Toyoda H, Sone Y, Takeshima K, Ogawa S, et al. Viral eradication reduces both liver stiffness and 
steatosis in patients with chronic hepatitis C virus infection who received direct-acting anti-viral therapy. Aliment Pharmacol Ther 
2018;47:1012-22. 
69 Hu B, Lin JZ, Yang XB, Sang XT. Aberrant lipid metabolism in hepatocellular carcinoma cells as well as immune 
microenvironment: A review. Cell Prolif 2020;53:e12772. 
70 Balci NC, Befeler AS, Bieneman BK, Fattahi R, Saglam S, Havlioglu N. Fat containing HCC: findings on CT and MRI 
including serial contrast-enhanced imaging. Acad Radiol 2009;16:963-8. 
71 Yamashita T, Honda M, Takatori H, Nishino R, Minato H, Takamura H, et al. Activation of lipogenic pathway correlates 
with cell proliferation and poor prognosis in hepatocellular carcinoma. Journal of Hepatology 2009;50:100-10. 
72 Björnson E, Mukhopadhyay B, Asplund A, Pristovsek N, Cinar R, Romeo S, et al. Stratification of Hepatocellular 
Carcinoma Patients Based on Acetate Utilization. Cell Reports 2015;13:2014-26. 
73 Menendez JA, Lupu R. Fatty acid synthase and the lipogenic phenotype in cancer pathogenesis. Nat Rev Cancer 
2007;7:763-77. 
74 Yasumoto Y, Miyazaki H, Vaidyan LK, Kagawa Y, Ebrahimi M, Yamamoto Y, et al. Inhibition of Fatty Acid Synthase 
Decreases Expression of Stemness Markers in Glioma Stem Cells. PLoS One 2016;11:e0147717. 
75 Nieman KM, Kenny HA, Penicka CV, Ladanyi A, Buell-Gutbrod R, Zillhardt MR, et al. Adipocytes promote ovarian 
cancer metastasis and provide energy for rapid tumor growth. Nat Med 2011;17:1498-503. 
 
 
Page | 177  
 
76 Cao W, Li M, Liu J, Zhang S, Noordam L, Verstegen MMA, et al. LGR5 marks targetable tumor-initiating cells in mouse 
liver cancer. Nature communications 2020;11:1961. 
77 Liu J, Dang H, Wang XW. The significance of intertumor and intratumor heterogeneity in liver cancer. Exp Mol Med 
2018;50:e416. 
78 Batlle E, Clevers H. Cancer stem cells revisited. Nat Med 2017;23:1124-34. 
79 Tuveson D, Clevers H. Cancer modeling meets human organoid technology. Science 2019;364:952-5. 
80 Broutier L, Mastrogiovanni G, Verstegen MM, Francies HE, Gavarro LM, Bradshaw CR, et al. Human primary liver 
cancer-derived organoid cultures for disease modeling and drug screening. Nat Med 2017;23:1424-35. 
81 Cao W, Liu J, Wang L, Li M, Verstegen MMA, Yin Y, et al. Modeling liver cancer and therapy responsiveness using 
organoids derived from primary mouse liver tumors. Carcinogenesis 2019;40:145-54. 
82 Giraldo NA, Becht E, Remark R, Damotte D, Sautes-Fridman C, Fridman WH. The immune contexture of primary and 
metastatic human tumours. Current Opinion in Immunology 2014;27:8-15. 
83 Kalluri R. The biology and function of fibroblasts in cancer. Nature Reviews Cancer 2016;16:582-98. 
84 Arnold JN, Magiera L, Kraman M, Fearon DT. Tumoral immune suppression by macrophages expressing fibroblast 
activation protein-alpha and heme oxygenase-1. Cancer Immunology Research 2014;2:121-6. 
85 Weissmueller S, Manchado E, Saborowski M, Morris JPt, Wagenblast E, Davis CA, et al. Mutant p53 drives pancreatic 
cancer metastasis through cell-autonomous PDGF receptor beta signaling. Cell 2014;157:382-94. 
86 Cadamuro M, Nardo G, Indraccolo S, Dall'olmo L, Sambado L, Moserle L, et al. Platelet-derived growth factor-D and 
Rho GTPases regulate recruitment of cancer-associated fibroblasts in cholangiocarcinoma. Hepatology 2013;58:1042-53. 
87 Koliaraki V, Pallangyo CK, Greten FR, Kollias G. Mesenchymal Cells in Colon Cancer. Gastroenterology 2017;152:964-
79. 
88 Sugimoto H, Mundel TM, Kieran MW, Kalluri R. Identification of fibroblast heterogeneity in the tumor microenvironment. 
Cancer Biol Ther 2006;5:1640-6. 
89 Record Owner NLM. Fibroblast-specific protein 1 identifies an inflammatory subpopulation of macrophages in the liver. 
90 Liu AY, Zheng H, Ouyang G. Periostin, a multifunctional matricellular protein in inflammatory and tumor 
microenvironments. Matrix Biol 2014;37:150-6. 
91 Multhaupt HA, Leitinger B, Gullberg D, Couchman JR. Extracellular matrix component signaling in cancer. Advanced 
Drug Delivery Reviews 2016;97:28-40. 
92 Record Owner NLM. CD10<ovid:sup>+</ovid:sup>GPR77<ovid:sup>+</ovid:sup> Cancer-Associated Fibroblasts 
Promote Cancer Formation and Chemoresistance by Sustaining Cancer Stemness. 
93 Fattovich G, Stroffolini T, Zagni I, Donato F. Hepatocellular carcinoma in cirrhosis: incidence and risk factors. 
Gastroenterology 2004;127:S35-50. 
94 Ren J, Smid M, Iaria J, Salvatori DCF, van Dam H, Zhu HJ, et al. Cancer-associated fibroblast-derived Gremlin 1 
promotes breast cancer progression. Breast Cancer Res 2019;21:109. 
95 Xiong S, Wang R, Chen Q, Luo J, Wang J, Zhao Z, et al. Cancer-associated fibroblasts promote stem cell-like properties 
of hepatocellular carcinoma cells through IL-6/STAT3/Notch signaling. Am J Cancer Res 2018;8:302-16. 
96 Fang T, Lv H, Lv G, Li T, Wang C, Han Q, et al. Tumor-derived exosomal miR-1247-3p induces cancer-associated 
fibroblast activation to foster lung metastasis of liver cancer. Nature communications 2018;9:191. 
97 Chen WJ, Ho CC, Chang YL, Chen HY, Lin CA, Ling TY, et al. Cancer-associated fibroblasts regulate the plasticity of 
lung cancer stemness via paracrine signalling. Nature communications 2014;5:3472. 
98 Ebbing EA, van der Zalm AP, Steins A, Creemers A, Hermsen S, Rentenaar R, et al. Stromal-derived interleukin 6 
drives epithelial-to-mesenchymal transition and therapy resistance in esophageal adenocarcinoma. Proc Natl Acad Sci U S A 
2019;116:2237-42. 
99 Hu G, Wang S, Xu F, Ding Q, Chen W, Zhong K, et al. Tumor-Infiltrating Podoplanin+ Fibroblasts Predict Worse 
Outcome in Solid Tumors. Cell Physiol Biochem 2018;51:1041-50. 
100 Su S, Chen J, Yao H, Liu J, Yu S, Lao L, et al. CD10(+)GPR77(+) Cancer-Associated Fibroblasts Promote Cancer 
Formation and Chemoresistance by Sustaining Cancer Stemness. Cell 2018;172:841-56 e16. 
101 Lenos KJ, Miedema DM, Lodestijn SC, Nijman LE, van den Bosch T, Romero Ros X, et al. Stem cell functionality is 
microenvironmentally defined during tumour expansion and therapy response in colon cancer. Nat Cell Biol 2018;20:1193-202. 
102 Clevers H. Modeling Development and Disease with Organoids. Cell 2016;165:1586-97. 
103 Seino T, Kawasaki S, Shimokawa M, Tamagawa H, Toshimitsu K, Fujii M, et al. Human Pancreatic Tumor Organoids 
Reveal Loss of Stem Cell Niche Factor Dependence during Disease Progression. Cell Stem Cell 2018;22:454-67 e6. 
104 Yamamura Y, Asai N, Enomoto A, Kato T, Mii S, Kondo Y, et al. Akt-Girdin signaling in cancer-associated fibroblasts 
contributes to tumor progression. Cancer Res 2015;75:813-23. 
105 Orimo A, Gupta PB, Sgroi DC, Arenzana-Seisdedos F, Delaunay T, Naeem R, et al. Stromal fibroblasts present in 
invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. Cell 
2005;121:335-48. 
106 Record Owner NLM. Hepatic myofibroblasts promote the progression of human cholangiocarcinoma through activation 
of epidermal growth factor receptor. 
107 Neufert C, Becker C, Tureci O, Waldner MJ, Backert I, Floh K, et al. Tumor fibroblast-derived epiregulin promotes 
growth of colitis-associated neoplasms through ERK. Journal of Clinical Investigation 2013;123:1428-43. 
108 Vaquero J, Lobe C, Tahraoui S, Claperon A, Mergey M, Merabtene F, et al. The IGF2/IR/IGF1R Pathway in Tumor 
Cells and Myofibroblasts Mediates Resistance to EGFR Inhibition in Cholangiocarcinoma. Clin Cancer Res 2018;24:4282-96. 
109 Grivennikov S, Karin E, Terzic J, Mucida D, Yu GY, Vallabhapurapu S, et al. IL-6 and Stat3 are required for survival of 
intestinal epithelial cells and development of colitis-associated cancer. Cancer Cell 2009;15:103-13. 
110 Record Owner NLM. Interleukin-11 is the dominant IL-6 family cytokine during gastrointestinal tumorigenesis and can 
be targeted therapeutically. 
111 Calon A, Espinet E, Palomo-Ponce S, Tauriello DV, Iglesias M, Cespedes MV, et al. Dependency of colorectal cancer 
on a TGF-beta-driven program in stromal cells for metastasis initiation. Cancer Cell 2012;22:571-84. 
112 Gaggioli C, Hooper S, Hidalgo-Carcedo C, Grosse R, Marshall JF, Harrington K, et al. Fibroblast-led collective invasion 
of carcinoma cells with differing roles for RhoGTPases in leading and following cells. Nat Cell Biol 2007;9:1392-400. 
113 Labernadie A, Kato T, Brugues A, Serra-Picamal X, Derzsi S, Arwert E, et al. A mechanically active heterotypic E-
cadherin/N-cadherin adhesion enables fibroblasts to drive cancer cell invasion. Nat Cell Biol 2017;19:224-37. 
114 Lau EY, Lo J, Cheng BY, Ma MK, Lee JM, Ng JK, et al. Cancer-Associated Fibroblasts Regulate Tumor-Initiating Cell 
Plasticity in Hepatocellular Carcinoma through c-Met/FRA1/HEY1 Signaling. Cell Reports 2016;15:1175-89. 
115 Chen X, Song E. Turning foes to friends: targeting cancer-associated fibroblasts. Nat Rev Drug Discov 2019;18:99-115. 
Page | 178 
 
116 Meads MB, Gatenby RA, Dalton WS. Environment-mediated drug resistance: a major contributor to minimal residual 
disease. Nature Reviews Cancer 2009;9:665-74. 
117 Paraiso KH, Smalley KS. Fibroblast-mediated drug resistance in cancer. Biochem Pharmacol 2013;85:1033-41. 
118 Kumari N, Dwarakanath BS, Das A, Bhatt AN. Role of interleukin-6 in cancer progression and therapeutic resistance. 
Tumour Biol 2016;37:11553-72. 
119 Roodhart JM, Daenen LG, Stigter EC, Prins HJ, Gerrits J, Houthuijzen JM, et al. Mesenchymal stem cells induce 
resistance to chemotherapy through the release of platinum-induced fatty acids. Cancer Cell 2011;20:370-83. 
120 Lotti F, Jarrar AM, Pai RK, Hitomi M, Lathia J, Mace A, et al. Chemotherapy activates cancer-associated fibroblasts to 
maintain colorectal cancer-initiating cells by IL-17A. J Exp Med 2013;210:2851-72. 
121 Wong PF, Wei W, Gupta S, Smithy JW, Zelterman D, Kluger HM, et al. Multiplex quantitative analysis of cancer-
associated fibroblasts and immunotherapy outcome in metastatic melanoma. J Immunother Cancer 2019;7:194. 
122 Nazareth MR, Broderick L, Simpson-Abelson MR, Kelleher RJ, Jr., Yokota SJ, Bankert RB. Characterization of human 
lung tumor-associated fibroblasts and their ability to modulate the activation of tumor-associated T cells. J Immunol 
2007;178:5552-62. 
123 Pinchuk IV, Saada JI, Beswick EJ, Boya G, Qiu SM, Mifflin RC, et al. PD-1 ligand expression by human colonic 
myofibroblasts/fibroblasts regulates CD4+ T-cell activity. Gastroenterology 2008;135:1228-37, 37 e1-2. 
124 Joyce JA, Fearon DT. T cell exclusion, immune privilege, and the tumor microenvironment. Science 2015;348:74-80. 
125 Tsai S, McOlash L, Palen K, Johnson B, Duris C, Yang Q, et al. Development of primary human pancreatic cancer 
organoids, matched stromal and immune cells and 3D tumor microenvironment models. BMC Cancer 2018;18:335. 
126 Villanueva A. Hepatocellular Carcinoma. N Engl J Med 2019;380:1450-62. 
127 White DL, Kanwal F, El-Serag HB. Association between nonalcoholic fatty liver disease and risk for hepatocellular 





Page | 179  
 
Supplementary data for 
Modeling liver cancer and therapy responsiveness using organoids 
derived from primary mouse liver tumors 
 
Table of contents 
Supplementary Figure 1 
Supplementary Figure 2 
Supplementary Figure 3 
Supplementary Figure 4 
Supplementary Figure 5 
Supplementary Figure 6 
Supplementary Figure 7 
Supplementary Figure 8 
Supplementary Figure 9 
Supplementary Figure 10 
Supplementary Table 1 
Supplementary Table 2 
Supplementary Table 3 
 
Page | 180 
 
 
Supplementary Figure 1. The livers. The black squares are pictures of the corresponding livers which 
missed due to technical issue.  
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Supplementary Figure 2. Tumor organoid lines. All the 91 tumor organoid lines, for the genetic 
background, gender and primary tumor formation time (counted since the time of first Den injection until 
the time to sacrifice the mice). 
  




Supplementary Figure 3. The flowchart of the experimental design.   
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Supplementary Figure 4. The organoid strains grouped according to the mice. (A) The organoid strains 
which were successfully initiated and maintained are marked by green; The organoid strains which were 
successfully initiated (maintained over 3 months), transplanted into NOG mice for tumor initiation but 
lost afterward due to storage issue/infection are marked by yellow. (B) The distribution of the organoid 
initiation efficiency for individual mouse liver.  
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Supplementary Figure 5. Tumor organoids show mixed morphology. Red arrow: “tumor organoid” 
morphology; Blue arrow: “normal organoid” morphology.  
 
Supplementary Figure 6. The panel of progenitor cell markers which compared between paired primary 
organoid strains and corresponding allograft organoid strains (*P < .05; **P < .01; n = 8).                
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Supplementary Figure 7. Tumor organoids in response to the treatment of the targeted therapeutics 
Sorafenib or Regorafenib. (A) Representative pictures taken at day 7, showing that tumor organoids 
respond differently to the treatment (n=4). (A) Group 1: organoid strains which were both sensitive to 
Sorafenib and Regorafenib. (B) Group 2: organoid strains which were only sensitive to Sorafenib, but 
not Regorafenib. (C) Group 3: organoid strains which were not sensitive to both Sorafenib and 
Regorafenib.  
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Supplementary figure 8: The panel of progenitor cell markers which compared between Group 1 
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Supplementary figure 9: (A) Group 3: The organoid strains showed normal organoid morphology, normal 
tissue histology but liver tumor morphology. (B) Group 5: The organoid strains showed tumor organoid 
morphology but with normal histology.   
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Supplementary Table 1. Liver tumor organoid can initiate tumor. The upper panel: The primary tumor 
organoid lines which formed tumor in the NOG mice, and the corresponding information of tumor 
harvesting time and mouse strain; The middle panel: Tumor organoids derived from the allograft (1st 
allograft) can re-initiate tumor again (2nd allograft) in the NOG mice; The lower panel: The 
corresponding tumor harvesting time of single cell formed organoid derived allograft tumors. 
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Supplementary Table 2: The histology for paired primary organoid strain (PT) and allograft organoid 
strain (AL). The green mark: the strains which showed consistent histology between primary and 
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Supplementary Table 3: Different groups of organoids which grouped by liver morphology, histology, 
organoid morphology. Group 1: 17 out of 55 strains showed normal for all three aspect, thus considering 
as “Normal group” (30.9%); Group 2: 16 out of 55 showed tumor organoid morphology with 
tumor/”normal” histology, considering as tumor organoid group (29.1%). Group 3: 4 out of 55 showed 
normal organoid morphology with tumor liver morphology (7.3%); Group 4: 8 out of 55 showed “normal” 
organoid morphology but with normal/other disease histology (14.5%); Group 5: 10 out of 55 showed 
tumor organoid morphology but with normal/other disease histology (18.2%);  
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Cancer stem cells (CSCs) or tumor-initiating cells (TICs) are thought to be the main 
drivers for disease progression and treatment resistance across various cancer types. 
Identifying and targeting these rare cancer cells, however, remains challenging and 
unproven with respect to therapeutic benefit. Here, we report the enrichment of LGR5 
expressing cells, a well-recognized stem cell marker, in mouse liver tumors, and the 
upregulation of LGR5 expression in human hepatocellular carcinoma. Isolated LGR5 
expressing cells from mouse liver tumors are superior in initiating organoids in 3D 
culture and forming tumors in immunodeficient mice upon engraftment compared to 
LGR5- cells, featuring candidate TICs. These cells are resistant to conventional 
treatment including sorafenib and 5-FU. Importantly, LGR5 lineage ablation 
significantly inhibits organoid initiation and tumor growth. The combination of LGR5 
ablation with 5-FU, but not sorafenib, further augments the therapeutic efficacy in vivo. 
Thus, we have identified the LGR5+ compartment as an important TIC population, 
representing a viable therapeutic target for combating liver cancer. 
 
Keyword: LGR5; Tumor-initiating cells, Liver cancer; Anti-cancer target. 
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Introduction  
The key concept underlying the cancer stem cell (CSC) or tumor-initiating cell (TIC) 
theory is that tumors are maintained through a hierarchical structure in which different 
cell populations have different functionalities in pathophysiology1. The bulk of a tumor 
is thought to consist of CSCs/TICs as well as rapidly proliferating cells. CSCs/TICs are 
responsible for tumor initiation, resistance to conventional treatment and distant 
metastasis. Rapidly proliferating cancer cells, thought to be derived from the tumor 
stem cell pool, are responsible for volume increment of the tumor2. A prediction based 
on this model is that ablation of the relatively small CSC compartment would ultimately 
result in cessation of tumor growth and metastasis, and provoke sensitization of the 
tumor to conventional treatment as well. 
Within the framework of this theory, CSCs/TICs would be characterized by a large 
capacity for self-renewal, a potential for differentiation into different cell types that 
constitute the tumor, and a resistance to conventional treatment1. These key features 
largely overlap with those of normal stem cells, making it extremely difficult to 
specifically identify CSCs/TICs, but on the other hand would allow techniques 
traditionally used for identifying normal stem cells also to be applied for CSCs/TICs3. 
LGR5 (leucine-rich repeat-containing G protein-coupled receptor 5) evokes special 
interest as a potential marker for the CSC/TIC compartment in this respect. LGR5 is a 
well-characterized stem cell marker in several tissues/organs, including the small 
intestine, the colon and the liver4,5,6. In colon and intestine, the LGR5 stem cell pool 
constantly proliferates and differentiates into mature cell types to compensate for the 
loss of functional epithelial cells. Interestingly, these LGR5 stem cells also participate 
in the process of oncogenesis, acting as the cells-of-origin of intestinal cancer7. 
Importantly, LGR5 marks CSCs in colon cancer8,9,10, intestinal cancer11 and basal cell 
carcinoma12. In intestinal adenoma as well as malignant carcinoma, LGR5 cells 
account consistently for a ratio of 5-10% of tumor cells and fuel tumor growth8,13. Proof-
of-concept showing that specific elimination of LGR5 cells delays tumor growth in colon 
cancer has been provided9. Given the essential role of CSCs/TICs, these cells are 
attractive targets for anti-cancer treatment, whereas their resistance to conventional 
therapies impedes the therapeutic development. 
In contrast to the colon and intestine, LGR5 stem cells are absent in the homeostatic 
liver, but emerge upon tissue injury4,14. These liver LGR5 cells are likely to be an 
intermediate stem/progenitor cell population that responds to injury but they may have 
a limited contribution to tissue repair14. Whether an LGR5+ compartment exists in liver 
cancer remains obscure and the possible importance of such a compartment in this 
disease is unexplored. Nevertheless, research into this possibility is urgently needed 
as liver cancer is one of the most common forms of malignancy worldwide, with nearly 
800,000 cases reported yearly and it is characterized by a depressing lack of treatment 
options15. Hepatocellular carcinoma (HCC) and cholangiocarcinoma (CC) are the two 
main types of primary liver cancer. Currently, surgery remains the only potentially 
curative therapeutic strategy available but is well-known for its high recurrence rate 
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following tumor resection. Chemotherapy and targeted treatment are generally 
ineffective, with sorafenib providing some extension of life expectancy to HCC patients. 
The unusual treatment resistance of liver cancer is thought to be associated with the 
presence of CSCs/TICs, but this notion remains largely unproven16. Thus, we aimed 
to investigate whether LGR5 marks CSCs/TICs in liver cancer, and to explore the 
potential for therapeutic targeting of these cells. Our results show that in liver cancer 
an LGR5+ compartment exists that is superior in tumor initiation and mediates therapy 
resistance. Targeting this compartment constitutes a rational novel avenue for 
combating this disease.
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Results 
Enrichment of LGR5 expressing cells in primary liver tumors  
Homeostatic livers are reported to be devoid of LGR5+ cells, but injury does induce 
such cells14. Whether LGR5+ cells are present in liver cancer is largely unknown. By 
adopting Lgr5-DTR-GFP knock-in mice (Fig. 1a), we first investigated the presence of 
LGR5+ cells (GFP co-expressing cells) in the healthy and injured liver, and during 
carcinogenesis. Carbon tetrachloride (CCl4) was used to trigger liver injury. 
Diethylnitrosamine (DEN) was used to induce primary liver tumor formation (Fig. 1b, 
and Supplementary Fig. 1). Although LGR5 cells are absent in the homeostatic liver 
(Fig. 1c), either a single course or repeated administration of DEN can rapidly trigger 
the emergence of LGR5-GFP+ cells (post DEN induction day 7; relative size of the 
LGR5-GFP+ compartment following 1 X DEN: 0.025 ± 0.05%, n = 3 [mean ± SEM]; 
Supplementary Fig. 2a-b). Animals were monitored for liver tumor formation from 4 
to 14 months post DEN induction (Supplementary File. 1). Analysis of the resulting 
hepatic neoplasms revealed stable presence of an LGR5+ compartment in these liver 
tumors (Fig. 1c). The relative abundance of LGR5 cells in the tumors (Supplementary 
File. 1 and Supplementary Fig. 2c-d) are significantly higher as compared to those 
in the tumor surrounding tissues (Fig. 1d) or as detected in CCl4 injured livers (Fig. 1c). 
The LGR5 expression levels in the tumor cells show substantial variation, but are 
substantially and significantly higher compared to that in injured liver (Fig. 1e). 
Immunohistochemistry (IHC) and immunofluorescence (IF) staining of GFP expression 
further confirms the presence of an LGR5+ compartment and enables detailed analysis 
of spatial distribution of LGR5-GFP+ cells in the liver (IF: Fig. 1f; IHC: Supplementary 
Fig. 2e-f). Co-staining with hepatocyte marker (HNF4α) or cholangiocyte marker 
(CK19) revealed that a proportion of LGR5 cells in the tumor express HNF4α or CK19 
(Fig. 1g-h), suggesting that LGR5+ cells may give rise to both a HCC-like and a CC-
like phenotype, the two main types of primary liver cancer. Thus, these data have 
demonstrated the presence of an LGR5+ compartment in primary murine liver cancer. 
To examine the clinical relevance, we investigated LGR5 expression in human HCC 
tumors from our patient cohort (Erasmus MC cohort). We found that LGR5 expression 
is significantly elevated in tumor tissues compared to the paired tumor free liver tissues 
(Fig. 2a), and also in some subpopulations of patients with specific etiologies of HCC 
(Fig. 2b). Survival analysis by predicting Kaplan-Meier curves revealed a tendency 
towards worse clinical outcome in patients with higher LGR5 expression (Fig. 2c). 
Further analysis of online publically available datasets confirmed the upregulation of 
LGR5 expression in HCC (Supplementary Fig. 3a), and possible association with 
clinical outcome especially in subpopulations of specific patients (Supplementary Fig. 
3b). Interestingly, with data from the TCGA database and International Cancer 
Genome Consortium-France (LICA-FR) and International Cancer Genome 
Consortium-Japan (LIRI-JP), we found that the upregulation of LGR5 expression is 
more pronounced in HCC tumors with β-catenin mutation (Supplementary Fig. 4). 
This is in line with LGR5 being a β-catenin target gene both in the intestine and liver5,17. 
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Taken together, LGR5 cells are enriched in both mouse and human liver tumors, and 
bear substantial clinical relevance.  
 
 
Fig. 1 Primary murine liver tumors are enriched with LGR5 expressing cells. a Principle of Lgr5-DTR-
GFP transgenic mouse strategy used in this study. b Principle of the experimental strategy used to 
induce primary murine tumors in the context of this study. c The percentage of LGR5+ cells, as 
determined by flow cytometry, is significantly higher in liver tumors from DEN-treated (7.29 ± 1.76%, n 
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= 55) as compared to livers from untreated animals (0 ± 0 %, n = 8) or injured livers from CCl4-treated 
animals (0.11 ± 0.022 %, n = 17) (Welch test, P = 0.0001). d The percentage of LGR5-GFP+ cells is 
significantly increased in liver tumors (7.29 ± 1.76%, n = 55) as compared to the tumor-surrounding 
tissues (2.93 ± 1.15%, n = 34) of the same mice (Welch test, P = 0.0407). e Liver tumor-derived LGR5-
GFP+ cells showed increased fluorescence intensity when compared to LGR5-GFP+ cells derived from 
CCl4-injured livers. f Representative images showing LGR5-GFP+ cells as present in liver tumors. Yellow 
arrow: LGR5-GFP+ cell. DAPI: blue. g-h Representative confocal images showing the expression of the 
cholangiocyte marker (g, CK19, yellow) and the hepatocyte-specific marker (h, HNF4α, red) in LGR5-
GFP expressing cells. Source data are provided as a Source Data file. 
 
 
Fig. 2 The expression of LGR5 is upregulated in human HCC tissues. a Upregulation of LGR5 
expression in HCC tissues (n = 74) compared with tumor free liver tissues (TFL, n = 75) from the 
Erasmus MC cohort (Paired T-test, P = 0.0066). GUSB (Beta-glucuronidases), HPRT1 (hypoxanthine 
phosphoribosyltransferase 1) and PMM1 (phosphomannomutase 1) were used as reference genes for 
normalization. b The expression of LGR5 in HCC tissues compared with TFL stratified based on the 
etiologies of HCC (Paired T-test). FHCC: Fibrolamellar carcinoma; HBV: Hepatitis B virus; HCV: 
Hepatitis C virus; NASH: Non-alcoholic steatohepatitis. Alc: Alcohol. Patient number: Alcohol (n = 16); 
FHCC (n = 3); HBV (n = 9); HCV (n = 5); HCV + Alcohol (n = 6); NASH (n = 8); Unknown (n = 21); HBV 
+ Alc/NASH/HCV (n = 5). c Kaplan-Meier curve of HCC patient survival with high (n = 37) and low (n = 
37) LGR5 expression (cut-off value based on median value – 0.047). Source data are provided as a 
Source Data file. 
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Preservation of LGR5 cells in liver tumor-derived organoids and allograft 
tumors  
3D organoid cultures are robust model systems for studying the properties of (cancer) 
stem cells18,19,20. We have successfully established routine procedures21 for creating 
organoid cultures from primary liver tumors of DEN-induced mice (Supplementary Fig. 
1). In total, 89 tissues were obtained from 41 individual murine livers (Supplementary 
File. 1). 63 out of 89 (70.8%) tumor/tumor surrounding tissues successfully initiated 
organoids (8 out of 34 tumor surrounding tissues did not initiate organoid, 23.5%; 18 
out of 55 tumor tissues did not initiate organoids, 32.7%). These organoids can be 
maintained and propagated in 3D culture for at least 5 months. Staining for CK19 and 
HNF4α demonstrates that these organoids either display a CC or HCC-like phenotype 
(Fig. 3a-b). Importantly, these cultured organoids maintain a population of LGR5 
positive cells (Fig. 3c). 
To investigate whether these organoid lines are malignant, we transplanted all the 63 
strains into immunodeficient NOG mice (Fig. 3d). One to six months after allografting, 
eleven out of 63 organoid-strains formed palpable tumors in the immune deficient mice 
(17.5%). All contained an LGR5-GFP+ compartment as determined by FACS analysis 
of the tumors (Fig. 3e). 
Following re-culture of cells obtained from these allograft tumors as organoids, we 
observed substantial diversity of the morphology (Supplementary Fig. 5a-c) and 
CK19/HNF4α expression in the corresponding allograft tumors (Fig. 3f and 
Supplementary File. 2). A population of LGR5-expressing cells were again observed 
in these organoid cultures (Supplementary Fig. 5d), in line with the existence of such 
a compartment in the allograft tumors from which these organoid cultures originated 
(IF: Supplementary Fig. 5e; IHC: Supplementary Fig. 5f and Supplementary File. 
2). In addition, genome-wide transcriptomic analysis revealed a distinct gene 
expression signature between LGR5+ and LGR5- cells, including TATA-box binding 
protein associated factor 7 like (Taf7l), Sialophorin (Spn), SRY-box 2 (Sox2), Nidogen-
1(Nid1), Paralemmin 3 (Palm3), Alpha-1-microglobulin/bikunin precursor (Ambp), 
Membrane bound O-acyltransferase domain containing 4 (Mboat4) and Chymase 1 
(Cma1), which had higher expression levels in LGR5+ compared with LGR5- population. 
Kaplan-Meier curve analysis revealed that all these genes are associated with the 
survival of liver cancer patients (Supplementary Fig. 6 and Supplementary File. 3-
4). Especially, Sox2 as a transcription factor is essential for maintaining self-renewal 
or pluripotency of undifferentiated embryonic stem cells, and has been reported as a 
marker for cancer stem cells in breast cancer and squamous-cell carcinoma22. Gene 
enrichment analysis of the 196 differentially expressed genes further revealed the 
involvement of metabolism-related pathways, including “Oxidation by Cytochrome 
P450”, “Calcium Regulation”, “Metapathway biotransformation” and “Purine 
metabolism”. There are also differentially expressed genes involved in immune 
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regulation, including “Macrophage markers pathway”, “Kit Receptor Signaling Pathway” 
and “IL-6 signaling Pathway”. Furthermore, LGR5+ cells had significantly differentially 
expressed genes involved in cell proliferation/migration, including “Chemokine 
signaling pathway”, “Matrix Metalloproteinases” and “PPAR signaling pathway”. 
Interestingly, there are differentially expressed genes enriched in “Wnt Signaling 
Pathway” and “G Protein Signaling Pathways”. Subsequent experiments were initiated 
to assess the exact functionality of LGR5 expressing cells. 
 
 
Fig. 3 Maintenance of LGR5 expressing cells in liver tumor organoids and allograft tumors. a-b 
Representative pictures showing organoid lines that predominately express the hepatocyte marker 
HNF4ɑ (a) or the cholangiocyte marker CK19 (b) (Upper panels: IF staining; lower panels bright-field 
microscopic pictures). c Representative pictures showing the presence of LGR5 expressing cells in 
organoids. LGR5-driven GFP: Green. d An outline of the experimental strategy used to transplant tumor 
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organoid lines into immunodeficient mice. e The percentages of LGR5 expressing cells in allograft 
tumors and the corresponding primary tumors (Primary vs. Allograft: 2.8 ± 0.8% vs. 6.8 ± 5.6%, n = 11, 
P = 0.3577). f-g Representative pictures of allograft tumors that mainly express either the hepatocyte 
marker HNF4ɑ (f) or the cholangiocyte marker CK19 (g). Source data are provided as a Source Data 
file. 
 
Dissociated LGR5+ cells from liver tumors are superior in organoid and tumor 
initiation compared to LGR5- cells 
For functional comparison of LGR5+ and LGR5- liver cancer cells, we first assessed 
their relative clonogenic ability using an organoid initiation assay. Employing FACS 
(the sorting strategy: Supplementary Fig. 7a), LGR5-GFP+ and LGR5-GFP- cells 
were collected from 71 individual primary murine liver tissues, and cultured in 3D 
matrigel (Fig. 4a and Supplementary File. 5). After 2-3 weeks, we observed organoid 
formation from single cells (Fig. 4b-d). Importantly, LGR5-GFP+ cells have stronger 
organoid formation ability compared to LGR5-GFP- cells (2.13 ± 0.67% vs. 0.07 ± 
0.02%, n = 30) (Supplementary File. 5: detailed organoid initiation efficiency). In 
addition, we also observed that the initiation ability of LGR5+ cells showed close 
correlation to collected cell number. The average numbers of LGR5+ cells collected 
from tissues that did initiate organoid (1906 ± 442, n = 25) were significantly higher 
compared to the number that did not (171 ± 47, n = 46). This was not the case for 
LGR5- cells (28350 ± 8914, n = 60 vs. 13860 ± 3654, n = 11) (Supplementary Fig. 
7b-d). This indicates that a sufficient cell number (>1000) is essential for successful 
organoid initiation of LGR5 expressing cells from liver tumors. 
We next performed organoid initiation for cells derived from the allograft tumors (Fig. 
4e). Similar as observed with primary tumors, LGR5+ cells of allograft tumors initiate 
more organoids as compared to LGR5- cells (40.5 ± 10.2% vs. 9.8 ± 3.9%, n = 10) (Fig. 
4f). Compared to cells isolated from primary tissues, allograft tumor cells are more 
potent with respect to their potential for organoid initiation (Supplementary Fig. 7e-g). 
Interestingly, organoids formed from a single LGR5-GFP+ or LGR5-GFP- cell produce 
both LGR5 positive and negative offspring, suggesting possible self-formation of a 
hierarchical organization sustaining organoid growth and differentiation 
(Supplementary Fig. 7h).  
The ultimate measure of potential functionality of LGR5+ cells in pathophysiology is 
their capacity to form allograft tumors in vivo (Fig. 4g). Hence identical numbers of 
FACS sorted LGR5-GFP+ and LGR5-GFP- cells derived from primary liver tumors were 
subcutaneously engrafted into NOG mice and tumor formation was monitored 
(Supplementary File. 6). As expected, LGR5+ cells display a stronger capacity for 
tumor initiation as compared to LGR5- cells (LGR5+ vs LGR5-: 33.3% vs 11.1% ) (Fig. 
4h, Supplementary File. 6). Moreover, tumors initiated from LGR5+ cells contain both 
LGR5 positive and negative populations (Fig. 4i-n). Additionally, we have performed a 
tumor formation assay for the cells that were derived from the allograft tumors (Fig. 
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4o). Again the LGR5+ compartment proved markedly more potent in this respect 
relative to the LGR5-GFP- compartment (Fig. 4p-q and Supplementary Table. 1). 
Collectively, our results are best interpreted that liver tumor-derived LGR5+ cells 
constitute a bona fide TIC compartment. 
 
 
Fig. 4 Single LGR5+ cells from liver tumors are superior in organoid and tumor initiation. a An outline of 
the experimental strategy for studying ex vivo organoid initiation of cells derived from primary murine 
liver tumors. b A representative picture of organoids derived from single LGR5+ cells. c Representative 
confocal micrograph of a single LGR5+ cell-initiated organoid dominated by LGR5 expressing cells. 
LGR5-driven GFP: Green. d Organoid initiation efficiency of LGR5-GFP+ and LGR5-GFP- cells, isolated 
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from primary liver tumors (LGR5+ cells: 25 out of 71 tissues, 35.2%; LGR5- cells: 11 out of 71 tissues, 
15.5%) (Paired T test, 2.13 ± 0.67 % vs. 0.065 ± 0.023 %, n = 30, P = 0.0048). e An outline of the 
experimental strategy used to study ex vivo organoid initiation of allograft tumor-derived cells. f 
Efficiency of organoid initiation by allograft liver tumor-derived LGR5-GFP+ and LGR5-GFP- cells (Paired 
T test, 40.46 ± 10.19 % vs. 9.84 ± 3.93 %, n = 10, P = 0.0187). g Outline of the experimental strategy 
used to assess in vivo tumor initiation of cells isolated from primary murine liver tumors. h Weight of 
tumors initiated by LGR5+ and LGR5- cells (LGR5+ vs. LGR5-: 0.46 ± 0.046 g vs. 0.10 ± 0.10 g, n = 
3)(Formed tumor number: LGR5+ cells--3 out of 9; LGR5- cells--1 out of 9). i LGR5 expression in single 
LGR5+ cell-derived allograft tumors and corresponding primary tumors (17.42 ± 15.29 % vs. 2.47 ± 
1.27 %, n = 3). j-n Representative pictures showing that LGR5-GFP+ and LGR5-GFP- cells (k) were 
isolated from DEN-induced primary liver tumors (j). Then, LGR5-GFP+ cells (green arrow) initiated 
allograft tumors in immunodeficient mouse (l-n). The initiated allograft tumors sustained LGR5 
expression (n). o An outline of the experimental strategy for in vivo tumor initiation assay of cells isolated 
from allograft murine liver tumors. p Tumor weight of allografts initiated by LGR5-GFP+ cells and LGR5-
GFP- cells (isolated from allograft tumors). (0.64 ± 0.19 g vs. 0.27 ± 0.08 g, n = 11, P = 0.0418). q 
Macroscopic aspect of the tumors initiated by LGR5-GFP+ cells and LGR5-GFP- cells (isolated from 
allograft tumors). Source data are provided as a Source Data file. 
 
Anti-cancer treatment enriches LGR5 expressing cells  
CSCs or TICs are presumed to be relatively resistant to conventional anti-cancer 
treatment. A prediction would thus be that in liver cancer the LGR5+ cells would be 
more resistant to anti-cancer treatment as compared to the LGR5- cells. Hence we 
challenged tumor organoids with sorafenib, the FDA-approved drug for treating 
advanced HCC, and compared the relative potential of LGR5-GFP+ and LGR5-GFP- 
cells to withstand such treatment (Fig. 5a). Treatment of tumor organoids with 
sorafenib significantly increased the percentage of LGR5 positive cells in the 
population (Fig. 5b-d). This effect became even more profound when the organoids 
were treated with the chemotherapeutic agent, 5-fluoro-uracil (5-FU) (Fig. 5a-d).  
Subsequently the relative size of the LGR5+ compartment following in vivo treatment 
with these therapeutic agents was assessed (Fig. 5e). Treatment with either sorafenib 
or 5-FU to mice bearing allograft tumors, formed by engrafting tumor organoids, 
substantially increased the fraction of the LGR5-GFP+ cells in the tumors (Fig. 5f). Also 
when LGR5-GFP+ and LGR5-GFP- cells were isolated from tumor organoids and used 
for organoid re-initiation, while subsequently being treated with 5-FU, the resulting 
cultures were dominated by LGR5-GFP+ expressing cells, independent from whether 
LGR5-GFP+ or LGR5-GFP- were used as starting material (Fig. 5g). Of note, LGR5+ 
cells isolated from 5-FU-treated tumors retained the ability of organoid and tumor 
initiation (Supplementary Fig. 8). Interestingly, 5-FU treatment effectively rewired the 
transcriptome of LGR5+ cells (Fig. 5h; Supplementary Fig. 6 and 9). Gene 
enrichment analysis of the 1464 differentially expressed genes between 5-FU treated 
compared to untreated LGR5+ cells revealed the involvement of stem cell-related 
pathways, including “Wnt Signaling”, “Notch Signaling Pathway”, “ErbB signaling 
pathway”, “Hedgehog Signaling Pathway” and “BMP Signaling Pathway” (Fig. 5i and 
Supplementary File. 3). These pathways are commonly activated in many types of 
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solid tumors, associated with cancer initiation, progression and metastasis23. 
Interestingly, there are several pathways, including “TGF Beta Signaling Pathway”, 
“EGFR1 Signaling Pathway”, “PPAR signaling pathway”, “G1 to S cell cycle control”, 
“Mismatch repair”, “p53 signaling” and “Apoptosis Modulation/Apoptosis pathway”, are 
known to be implicated in anti-cancer treatment response and DNA damage 
response24. These results may partially explain the enrichment of LGR5 expressing 
cells upon 5-FU treatment. In conclusion, besides resistance, conventional anti-cancer 
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Fig. 5 Anti-cancer treatment selects for LGR5+ cells. a Outline of the ex vivo experimental strategy used 
to assess the effects of drug treatment on the size of the LGR5+ compartment. b The fraction of LGR5-
GFP+ cells is significantly increased upon treatment with sorafenib or 5-FU (vehicle control vs. 10 µM 
sorafenib vs. 10 µM 5-FU: 2.6 ± 0.5 % vs. 4.6 ± 0.4 % vs. 21.3 ± 1.9 %). c-d Representative FACS plots 
(c) and confocal pictures (d) demonstrating that the fraction of LGR5-GFP+ cells is increased upon 
treatment with sorafenib or 5-FU. e An outline of the experimental strategy used for testing the effects 
of drug administration in vivo. f The percentages of LGR5-GFP+ cells is increased upon administration 
of sorafenib or 5-FU to allografted animals (vehicle control vs. sorafenib vs. 5-FU: 0.13 ± 0.04 %, n = 6 
vs. 0.42 ± 0.13 %, n = 8 vs. 0.66 ± 0.17 %, n = 7). g Representative confocal pictures showing that both 
single LGR5-GFP+ and LGR5-GFP- cell-initiated organoids contain LGR5 expressing cells and the 
relative fraction of LGR5 expressing cells is increased in treatment resistant organoids. LGR5-driven 
GFP: Green. h A Volcano plot showing the most significantly differentially expressed genes between 5-
FU treated/untreated LGR5+ cells. i Gene enrichment analysis (with the library of Wiki2019) within the 
differentially expressed genes. Source data are provided as a Source Data file. 
 
LGR5 lineage ablation inhibits organoid and tumor growth  
From the results described above, we inferred that ablation of the LGR5+ compartment 
should impair liver cancer growth. To experimentally test this notion, we exploited the 
co-expression of the diphtheria toxin receptor (DTR) in the Lgr5-DTR-GFP mice. This 
would allow us to specifically deplete the Lgr5-DTR-GFP+ compartment through 
diphtheria toxin (DT) administration (Fig. 1a). We have previously optimized the 
concentrations of DT treatment (1-10 ng/ml) for LGR5 depletion, with organoids 
derived from healthy Lgr5-DTR-GFP mice14. Accordingly, we evaluated the effects on 
organoid initiation and proliferation (Fig. 6a-b), and sorafenib treatment served as a 
positive control. DT treatment inhibited the growth of tumor organoids in an effect that 
showed close correlation as to the effects on the numbers of LGR5-GFP+ cells (Fig. 
6c-e). DT treatment did not influence the growth of tumor organoids of genetically wild 
type (Fig. 6c: left panel).  
We further assessed therapeutic targeting of LGR5 liver cancer cells in vivo. We first 
evaluated the effect of DT treatment after formation of visible tumors, following 
transplantation of tumor organoids into immunodeficient mice (Supplementary Fig. 
10a). 5-FU and sorafenib served as the positive controls. The effects of LGR5 cell 
depletion on the growth of formed tumors was minor (Supplementary Fig. 10c: right 
panel and 10d: right panel). In contrast, administration of DT immediately after 
transplantation of tumor organoids (Fig. 6f) efficiently delayed tumor initiation and 
inhibited their growth (Fig. 6h; Supplementary Fig. 10c: left panel and 10d: left panel). 
Further analysis of the tumors confirmed the depletion of the LGR5-GFP+ compartment 
in the DT treated animals (Fig. 6g). Also using absolute tumor size as a measure, DT-
mediated depletion of the LGR5+ compartment impaired tumor growth (Fig. 6i). The 
enrichment of stem cell markers also differed in control and DT-treated LGR5+/- cells 
(Supplementary Fig. 11). Interestingly, there was an inverse correlation between 
tumor size and the relative size of the LGR5-GFP+ compartment at the end of the 
experiment (Supplementary Fig. 10e-f), indicating that LGR5 expressing cells are 
probably more active in the tumor initiation period. As control, DT treatment did not 
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influence initiation and growth of tumors formed from the wild type tumor organoids 
(Supplementary Fig. 12a-b). Thus, LGR5 lineage ablation impedes organoid and 
tumor initiation and further growth.  
 
Fig. 6 LGR5 lineage ablation inhibits organoid and tumor growth. a-b The outlines of the ex vivo 
experimental strategy to assess the effects of anti-cancer drug treatment on (a)organoid initiation and 
delineate its temporal aspect (b) or during organoid expansion. c The response of wild type tumor 
organoids (Left) and Lgr5-DTR-GFP mice derived tumor organoids, with relatively high LGR5 expression 
(the percentage of LGR5 expression is higher than 1%)(Middle) or low LGR5 expression (the percentage 
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of LGR5 expression is lower than 1%) (Right) during regular expansion, to DT/sorafenib treatment. -/+: 
drug treatment during the expansion period; +/+: DT treatment since the initial culture day. d-e 
Representative FACS plots showing that LGR5-GFP+ cells are depleted by DT treatment, for high LGR5 
expression organoid strains (d) and low LGR5 expression organoid strains (e). f Outlines of the 
experimental strategy used to assess the efficacy of DT/sorafenib/5-FU administration on allograft 
tumors in mice. g Representative FACS plots from experiments validating the strategy to deplete LGR5+ 
cells. h A representative growth curve showing the volumes of tumors derived from the vehicle control 
group and the DT-administrated group (n = 8). i, The weight of tumors from vehicle control, DT, 5-FU or 
sorafenib-treated groups, on the day of mice sacrifice (Control vs. sorafenib vs. 5-FU vs. DT: 0.34 ± 
0.078 g, n = 18 vs. 0.18 ± 0.047g, n = 15 vs. 0.19 ± 0.033 g, n = 15 vs. 0.15 ± 0.027 g, n = 19). Source 
data are provided as a Source Data file. 
 
Combination of LGR5 lineage ablation with chemotherapy enhances the anti-
cancer efficacy  
As LGR5+ cells appear to mediate resistance against conventional anti-cancer 
treatment, it is rational to evaluate the combination of LGR5+ lineage ablation with 
conventional anticancer treatment.  
To experimentally test this notion, we first combined DT with sorafenib treatment. 
However, with different strategies of combination therapy, no enhanced anti-tumor 
activity was observed on allografted tumors (Fig. 7). We next tested the combination 
of 5-FU and DT. Allograft tumor-bearing mice were first subjected to 5-FU (which 
increases the relative size of the LGR5+ compartment) followed by cessation of 5-FU 
therapy and start of DT treatment as to kill the LGR5+ cells (Fig. 8a and 
Supplementary Fig. 13a-c). Indeed this approach is effective in combating allograft 
tumor formation (Fig. 8b) and is substantially superior to monotherapy with 5-FU, 
stand-alone DT treatment (Fig. 8c-d and Supplementary Fig. 14a) or initial treatment 
with DT followed by 5-FU therapy (Supplementary Fig. 13d-h). Simultaneous 
administration of 5-FU and DT (Fig. 8e) also resulted in robust anti-cancer effects (Fig. 
8f-h and Supplementary Fig. 14b). Thus targeting the LGR5+ compartment markedly 
enhances efficacy of conventional treatment aimed at combating liver cancer. 
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Fig. 7 Combination of LGR5 lineage ablation with sorafenib does not enhance the anti-cancer efficacy. 
a Outline of the experimental strategy to assess the combinatory effect of LGR5 lineage ablation with 
sorafenib. sorafenib and DT were administrated every other day for in total 10 days since visualization 
of tumor formation after organoid engraftment. b Representative growth curves showing tumor volumes 
in the vehicle control (CTR), sorafenib, DT, and sorafenib + DT treated groups. Black arrow: onset of 
administration. c Tumor masses from these four groups (CTR vs. sorafenib vs. DT. vs. sorafenib + DT: 
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0.45 ± 0.09 g, n = 8, vs. 0.25 ± 0.06 g, n = 8 vs. 0.28 ± 0.043 g, n = 8 vs. 0.29 ± 0.09, n = 8). d Images 
showing tumors from these four groups. e Outlines of the experimental strategy for assessing the effects 
of combining LGR5 lineage ablation and sorafenib treatment. sorafenib, DT or the combination were 
administered immediately since transplantation of the organoids every other day, for in total ten days. f, 
Representative growth curves showing tumor volumes of the four groups. Black arrow: onset of 
administration. g The tumor masses of these four groups (CTR vs. sorafenib vs. DT. vs. sorafenib + DT: 
0.21 ± 0.03 g, n = 8 vs. 0.16 ± 0.03 g, n = 8 vs. 0.09 ± 0.02 g, n = 8 vs. 0.12 ± 0.03 g, n = 8). h Images 
showing the tumors from the different groups. Source data are provided as a Source Data file. 
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Fig. 8 Combination of LGR5 lineage ablation with 5-FU results in enhanced anti-cancer efficacy. a 
Outline of the experimental strategy to assess the combinatory effect of LGR5 lineage ablation with 5-
FU. Following tumor organoid allografting, 5-FU was administrated for the first half of the experiment 
(every other day, for in total six days). DT was administrated for the second half of the experiment (every 
other day, for in total 6 days). b Representative growth curves showing tumor volumes in the vehicle 
control group (CTR), the 5-FU monotherapy group, the DT administration-only group, and the hybrid 5-
FU/DT group. Black arrow: onset of administration. c Tumor masses from these four groups (Control vs. 
5-FU vs. DT. vs. 5-FU-DT: 0.33 ± 0.076 g, n = 12 vs. 0.25 ± 0.066 g, n = 8 vs. 0.29 ± 0.052 g, n = 8 vs. 
0.13 ± 0.020 g, n = 8). d Representative images showing tumors from these four groups. e Outlines of 
the experimental strategy for assessing the effects of combined LGR5 lineage ablation and 5-FU 
treatment. 5-FU, DT or the combination were administered since organoid engraftment every other day, 
for in total twelve days. f Representative growth curves showing tumor volumes of the four groups. Black 
arrow: onset of administration. g The tumor masses of these four groups (Control vs. 5-FU vs. DT. vs. 
5-FU+DT: 0.28 ± 0.050 g, n = 15 vs. 0.21 ± 0.048 g, n = 8 vs. 0.16 ± 0.027 g, n = 11 vs. 0.069 ± 0.007 
g, n = 8). h Representative images showing the tumors from the different groups. Source data are 
provided as a Source Data file. 
 
Discussion 
This study has demonstrated that liver cancer contains an LGR5+ compartment that 
has various hallmarks of TICs/CSCs, including an increased capacity for tumor 
organoid formation in culture and allograft formation in mice as well as resistance 
against conventional anti-cancer therapy. Functionally, these cells seem more 
important in tumor initiation, whereas the LGR5- compartment appears to bear the 
proliferative burden. Simultaneously targeting both compartments as demonstrated in 
this study by 5-FU treatment in combination with DT-mediated ablation of the LGR5+ 
compartment was effective in combating experimental liver cancer. Thus, combining 
conventional therapy and LGR5+-targeted therapy deserve to be further explored for 
the treatment of liver cancer in the clinic. Conceivably, this approach could be more 
effective for subset of patients with high levels of LGR5 expression, such as CTNNB1 
mutated or alcohol-related HCC patients25,26. Although LGR5+-targeting therapies are 
still largely in their infancy, the analogy with neuroendocrine tumors, which are 
successfully combated by radioactive somatostatin analogues (e.g. 177Lu-Dotate) that 
target receptors with homology to LGR527, suggests that radioactive drugs (e.g. R-
spondin) may be an option for treating liver cancer28. Our results, however, indicate 
that such therapy will be more effective when combined with particular conventional 
anti-cancer therapies. 
Overexpression of LGR5 has been previously reported in patient HCC17, and we 
confirmed that this is more pronounced in β-catenin mutated liver tumors. Although the 
elevation of LGR5 expression and potential association with clinical outcome have 
been observed in HCC patients, whether it can serve as an independent prognostic 
biomarker remains to be further investigated in specifically designed tumor marker 
prognostic studies in patients29. 
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Of note, these early observations are based on mRNA expression, due to the lack of 
a reliable anti-LGR5 antibody. We now used transgenic mice in which LGR5-
expressing cells co-express GFP and we can conditionally ablate these cells with the 
DT-DTR system30. This model allows for the identification and direct visualization of 
LGR5 expressing cells based on GFP expression, as well as isolation of LGR5-GFP+ 
cells for further functional analyses and detailed characterization.  
In intestinal adenomas, LGR5 marks 5-10% of the cells, which keep fueling the growth 
of established mouse adenomas13. We found that the percentages of LGR5-GFP+ cells 
in murine liver tumors vary from 0.1% up to 55% (7.3 ± 1.8%, n = 55). Over 32% of the 
primary liver tumors harbor relatively high percentages (over 5%) (Supplementary Fig. 
2c). In colon cancer, the percentage of LGR5 expressing cells has been reported to 
be associated with different background of the tumors, especially the accumulation of 
certain oncogenic mutations8. Thus, we speculate that the large variation of the 
abundance of LGR5 cells in liver tumors may also be related to different types of 
oncogenic mutations, although this hypothesis requires further investigation. Of note, 
DEN was used to induce primary liver cancer in this study and this compound is 
associated with the accumulation of liver β-catenin mutations31. Therefore, it is possible 
that our results are mainly relevant to liver cancers with deregulated Wnt/ß-catenin 
signaling and their importance requires future investigation in other mutational 
backgrounds (e.g. deregulated TSC/mTOR signaling)32 as well. 
Through a series of functional assays, in particular in vitro organoid initiation and in 
vivo tumor formation, we have demonstrated the importance of these LGR5 TICs in 
liver cancer. To define the potential for therapeutic targeting, we have performed LGR5 
lineage ablation in organoids in vitro and in the tumor-bearing mouse model. Of note, 
the presence of LGR5 cells in tumors is likely dynamic. We observed large variations 
of their percentages among different primary liver tumors and allograft tumors 
generally contain lower numbers of LGR5 cells (less than 1%). In colorectal cancer, 
advanced stages compared to the early stages contain less LGR5 cells33. A 
speculative explanation could be that the tumors are derived from LGR5-positive stem 
cells, yet these cells are suppressed thereafter during tumor progression33. The 
dynamics could be essential for determining at which stage to target LGR5 TICs. When 
we performed LGR5 ablation in established tumors, we only observed a minor effect, 
probably due to a low percentage of LGR5 cells as well as their dispensable function 
at that stage, while depletion at the early stage yielded optimal anti-tumor effects. This 
result is in line with previous findings showing that LGR5 cells play distinct roles in 
primary and metastatic colon cancer8.  
Although we have demonstrated the feasibility and value of targeting LGR5 TICs in 
liver cancer, therapeutic ablation of these cells remains challenging. Resistance to 
conventional therapy is a common feature of CSCs2. We found that treatment with 
sorafenib or 5-FU enriches LGR5 cells, consistent with the findings in gastric34 and 
colorectal cancer35. Different mechanisms may contribute to treatment resistance. 
Although LGR5 stem cells are generally fast-cycling in the intestine36, the existence of 
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quiescent LGR5 cells have been reported in basal cell carcinoma, which mediate 
relapse after treatment12. Cell plasticity could be one of the potential mechanisms of 
treatment resistance. The loss of LGR5 stem cells in the intestine can be compensated 
by trans-differentiation from other stem cell pools30, or through plasticity of their 
enterocyte-lineage daughters37. Cancer cell plasticity, shifting dynamically between a 
differentiated and a stemness state, has also been proposed as an important feature 
contributing to tumor progression, metastasis and therapeutic response38. We now 
have observed the induction of LGR5+ from LGR5- liver cancer cells. This may 
implicates cell plasticity of LGR5 CSCs, but there could also be other mechanisms 
regulating the origin and expansion of LGR5 cells. Eventually, these LGR5 liver cancer 
cells may partially contribute to treatment resistance. 
Currently, several innovative scenarios are being explored to therapeutically target 
CSCs, including antibody-drug conjugates9, targeting quiescent CSCs39 and inhibiting 
CSC-related pathways2. However, as discussed, different mechanisms could lead to 
treatment resistance8. Thus, combined therapies are likely necessary for this respect. 
With the intention to fully expand the stem cell pool, cetuximab has been used to first 
trigger the LGR5 population, followed by the ablation of these CSCs. This combined 
therapy has resulted in potent efficacy against colorectal cancer10. Similarly, we have 
observed that the combination of LGR5 lineage ablation with 5-FU chemotherapy can 
also lead to enhanced anti-liver cancer activity. However, combination of LGR5 lineage 
ablation with sorafenib did not yield enhanced anti-tumor activity. This is probably 
related to the mild effect of sorafenib in triggering the LGR5 CSC pool.  
Lastly, a potential concern of such strategies is the possible harmful effects on normal 
LGR5 stem cells. In intestine, colon and skin, although LGR5 stem cells essentially 
contribute to tissue renewal at a daily basis5,6, their loss can be compensated by trans-
differentiation from other reserve stem cell pools30,40 or through plasticity of their 
daughter cells37. Importantly, antibody conjugated drug targeting LGR5 CSCs in colon 
cancer has no major impact on the function of normal LGR5 stem cells9. In liver, LGR5 
stem cells are absent during homeostasis, but only transiently activated upon injury 
likely without major contribution towards tissue repair4,14. Thus, we envision that our 
identification of targetable LGR5 TICs in liver cancer bears important implications for 
future therapeutic development.   
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Materials and Methods 
Primary liver tumor model 
Lgr5-DTR-GFP transgenic mice (kindly provided by Genentech) specifically co-express the diphtheria 
toxin (DT) receptor (DTR) and green florescent protein (GFP) under the control of the Lgr5 promotor30. 
Thus, LGR5+ cells can be identified by GFP expression, and LGR5-GFP+ cells can be specifically 
depleted by DT administration. Lgr5-DTR-GFP transgenic mice (3-4 weeks) were administered with 
Diethylnitrosamine (DEN) by intraperitoneal injection (Sigma-Aldrich, i.p., 100 mg/kg) weekly for 6-17 
weeks41 . DEN is used to induce liver tumor in Lgr5-DTR-GFP transgenic mice and wild type mice, which 
could cause liver disease from basophilic foci, hyperplasic nodules, hepatocellular adenoma and finally 
lead to HCC31,42,43. Mice were sacrificed 3-16 months after the last DEN injection and livers/tumors were 
collected for further experiments (Supplementary File. 1: In total, 41 mice were monitored; 80.5%, 33 
out of 41, mice formed liver tumors; the expression of LGR5 in each tumor/tumor surrounding tissues 
were also listed; Supplementary Fig. 2g-h). For each liver, biopsies were taken from the tumor and 
tumor surrounding tissue. If livers contain more than one tumors, individual tumors were collected and 
analyzed separately. For CCl4 induced liver injury, Lgr5-DTR-GFP transgenic mice were weekly 
repeated administered with (6 or 17 weeks) intraperitoneal CCl4 injection (10 µl/20 g body weight of 10% 
CCl4 solution in corn oil or corn oil as control). All animal experiments were approved by the Committee 
on the Ethics of Animal Experiments of the Erasmus Medical Center.  
 
HCC specimens and patient information 
HCC specimens (paired tumor tissue and adjacent tumor free liver tissue) were collected from HCC 
patients undergoing tumor resection at the Erasmus Medical Center, The Netherlands. Samples were 
stored at -80℃ and then used for RNA extraction. 74 specimens were obtained from HCC patients and 
the corresponding clinica-pathological data are summarized in Supplementary Table. 2. HCC-specific 
survival was assessed in all patients and patients were stratified according to relative LGR5 expression 
(below and above median – 0.047). The Kaplan-Meier method was used to estimate survival outcome 
curves and the log-rank test was used to compare the survival between the two groups. The hazard 
ratio (HR) for HCC-specific survival was estimated using the Cox proportional hazards regression model. 
The study was approved by the medical ethical committee of Erasmus Medical Center. In addition, the 
study protocol conforms to the ethical guidelines of the 1975 Declaration of Helsinki.  
 
Online database 
For analysis of Lgr5 mRNA expression, data were retrieved from three independent HCC cohorts 
including The Cancer Genome Atlas (TCGA), Wurmbach44, and Roessler45. For survival analysis based 
on Lgr5 mRNA expression, the TCGA cohort was used. For analysis of the relationship between gene 
mutation and Lgr5 expression, three independent cohorts were investigated, including TCGA, 
International Cancer Genome Consortium-France (LICA-FR) and International Cancer Genome 
Consortium-Japan (LIRI-JP).  
 
Tumor organoid culture 
Digestion solution II (37°C, 30 min, 500 µg/ml of collagenase type XI, 200 µg/ml of Dnase-1, 1% FBS in 
DMEM medium) (collagenase type XI: Sigma-Aldrich; Dnase-1: Sigma-Aldrich) was used to digest liver 
or tumor tissues into single cell suspension. Single cell suspension was directly mixed with matrigel 
(Corning BV) and then used for culturing, or sorted for further experiments. Sorted cells were also mixed 
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with matrigel and seeded for organoid initiation. Cells were cultured in organoid culture medium as 
previously described4,14. For the first 8-12 days, organoids were supplemented with 10 μM Y-27632 
(Sigma-Aldrich), Noggin and Wnt3a conditioned medium. Medium was refreshed every 2 days and 
passage was performed in split ratios of 1:2-1:15 weekly. The proposed tumor organoid phenotypes is 
based on the expression of EpCAM/CK19 positive for CC-like and HNF4ɑ/AFP positive for HCC-like 
phenotype. 
 
Histology, immunohistochemistry and immunofluorescence 
Liver or tumor was fixed in 4% paraformaldehyde (PFA) overnight at 4 °C. For immunofluorescence, 
samples were further dehydrated with 30% sucrose (Sigma-Aldrich, 4 °C, overnight), stored at -80 °C 
and then sectioned at 8 μm for further analysis. Images were acquired with a Zeiss LSM510META 
confocal microscope. For histology and immunohistochemistry, materials were dehydrated with 70% 
ethanol, embedded with paraffin, and sectioned at 4 μm for staining. Images were acquired with a Zeiss 
Axioskop 20 microscope. All antibodies are listed in Supplementary Table. 3. 
 
Organoid-based allograft tumor model 
Cold advanced DMEM/F12 medium was used to collect the organoids. After centrifuging, supernatant 
was discarded and organoid pellets (organoid fragmentation size: range from 5 ~ 150 µm) were mixed 
directly with matrigel in a ratio of 1:1 with a total volume of 200 µl. 4-6 weeks old female NOD.Cg-
PrkdcSCIDIl2rgtm1Wjl/SzJ (NSG) mice, NOG/JicTac (CIEA NOD.Cg-Prkdc-scid Il2rg-tm1Sug) mice or 
nude mice (NMRI:BomTac-Nude) were purchased from Taconic, and subcutaneously injected with the 
collected tumor organoids. The characterization of phenotypes for murine allograft tumor is based on 
the expression of EpCAM/CK19 for CC-like and HNF4ɑ/AFP for HCC-like phenotype (Supplementary 
File 2). Tumor dimensions were measured using calipers and tumor volume was calculated as 0.523 × 
length × width × width9. Tumor formation was monitored every other day and mice were sacrificed to 
harvest tumors after the tumor diameter reached approximately 2 cm. Tumor tissues were stored or 
cultured as described above. 
 
Cell ablation by diphtheria toxin and treatment of 5-FU/sorafenib  
To ablate LGR5+ cells in organoids, DT (Calbiochem, 1-10 ng/ml) was added to organoid 
expansion/initiation medium, followed by further analysis14. For in vivo ablation, DT was administrated 
via intraperitoneal injection every other day (50 µg per kg body weight). If mice suffering from weight 
loss ≥ 10%, compared to the previous injection, the injection was omitted. 5-FU/sorafenib were also 
administrated via intraperitoneal injection every other day (5-FU/sorafenib: 30 mg per kg body weight) 
(sorafenib: Bio-Connect BV; 5-FU: Sigma-Aldrich).  
 
qRT–PCR  
For freshly FACS-sorted cells and HCC specimens, RNeasy Micro Kit (QIAGEN) was used to isolate 
RNA. For organoids, Machery-NucleoSpin RNA II kit (Bioké) was used. Quantification was measured 
with Nanodrop ND-1000 (Wilmington). RNA was then converted to cDNA by using a cDNA Synthesis 
kit (TAKARA BIO INC.). Real-time PCR reactions were performed with SYBRGreen-based real-time 
PCR (Applied Biosystems®) and amplified in a thermal cycler (GeneAmp PCR System 9700). For cells 
collected from murine tissues, glyceraldehyde 3-phosphate dehydrogenase (Gapdh) gene was used as 
reference. For quantification of LGR5 mRNA in human tumors and tumor-free liver tissues, Gusb (Beta-
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glucuronidases), Hprt1 (hypoxanthine phosphoribosyltransferase 1) and Pmm1 (phosphomannomutase 
1) were used as reference genes. All primers are listed in Supplementary Table. 4. 
 
RNA sequencing 
Total RNA was isolated using RNeasy Micro Kit (QIAGEN). The quantity of RNA was measured by a 
NanoDrop 2000. The collected RNA was further amplified by using SMARTer kit. Then, RNA sequencing 
was performed by Novogene with the paired-end 150bp (PE 150) sequencing strategy. Gene expression 
was analyzed. The identification of differentially expressed genes is based on P < 0.05 and absolute 
values of logFc > 1.5. GSEA with the library of Wiki2019 was performed to reveal the alteration of 
signaling pathways.  
 
FACS analysis  
For FACS analysis, single cells derived from liver tumors/tumor surrounding tissues or organoids were 
suspended in DMEM plus 2% FBS. Cell suspensions were analyzed using a BD FACSCalibur or BD 
FACSAriaTM II. For FACS sorting, a BD FACSAriaTM II cell sorter was used to isolate the target cell 
population. Propidium iodide (PI) staining was performed to exclude dead cells and CD45 staining was 
adopted for excluding leucocytes. 
 
Metabolic activity analysis of organoids 
Different organoid lines were seeded separately in a 24/48-well plate. sorafenib (10 µM) or 5-FU (10 µM) 
was added to the organoid culture since the initial day or post-initiation day 3, respectively. Drugs were 
refreshed every other day. At the day 6-7, organoids were incubated with Alamar Blue (Invitrogen, 1:20 
in DMEM) for four hours (37 °C), and then medium was collected for analysis of the metabolic activity 
of the cells. Absorbance was determined by using fluorescence plate reader (CytoFluor® Series 4000, 
Perseptive Biosystems) at the excitation of 530/25 nm and emission of 590/35. Each treatment condition 
was repeated for four times and matrigel with medium only was used as blank control. 
 
Statistical analysis. 
Prism software (GraphPad Software) was used for all statistical analysis. For statistical significance of 
the differences between the means of groups, we used Mann-Whitney U-test; For statistical significance 
of the differences between groups with inequivalent sample sizes, we used Welch test (indicated in the 
legends); For statistical significance of the differences between paired samples, we used Paired T-test 
(indicated in the legends); For statistical significance of the differences between multiple independent 
groups, we used two-way ANOVA. Differences were considered significant at a P value less than 0.05. 
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Supplementary Figure 1 | General flowchart of the experimental design. 
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Supplementary Figure 2 | LGR5 expressing cells are present in the DEN-induced primary liver 
tumor. a, LGR5+ cells are present in the liver upon DEN administration (Post DEN induction day 7). b, 
Representative FACS plots showing that LGR5+ cells are present in the liver following DEN 
administration (Post DEN induction day 7). c, Relative LGR5+ fraction in DEN-induced liver tumors. d, 
Relative LGR5+ fraction in tissue bordering the DEN-induced liver tumors (denominated as surrounding). 
e-f, Representative immunohistochemistry pictures showing the microscopic aspect of the LGR5+ cells 
in liver cancer. Two types of LGR5+ cell distribution patterns are apparent, scattered LGR5+ cell 
distribution (e) and LGR5+ island-like clusters (f). The pictures show an anti-GFP immunohistochemistry 
staining in which LGR5+ cells are brown and nuclei are blue. Scale bar = 50µm. g, The percentage of 
LGR5-expressing cells within each tissue, grouped by tumor collection month (the month is counted 
since the first administration of DEN). Mean ± SEM. (h) Relative mice number fraction in all DEN-induced 
mice, grouped by tumor collection month. Source data are provided as a Source Data file.  
 
 
Page | 223  
 
 
Supplementary Figure 3 | LGR5 expression in HCC tissues and relation to patient outcome. a, 
The upregulated expression of LGR5 in HCC tissues compared with normal tissues from TCGA Liver 
cohort (Normal vs. HCC: n = 115 vs. n = 97, P = 0.085, Fold change: 1.013), Wurmbach liver cohort 
(Normal vs. HCC: n = 10 vs. n = 35, P = 4.31E-5, Fold change: 5.174) and Roessler liver cohort (Normal 
vs. HCC: n = 200 vs. n = 225, P = 6.72E-14, Fold change: 2.034). b, Kaplan-Meier curve for HCC of 
patients based on different etiology/tumor stage of HCC from TCGA Liver cohort. AJCC_T: American 
Joint Committee on Cancer (AJCC) tumor staging system; Stage: Barcelona Clinic Liver Cancer (BCLC) 
tumor staging system. Source data are provided as a Source Data file.   
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Supplementary Figure 4 | The expression level of LGR5 is upregulated in Ctnnb1 mutated HCC 
tumors. a-b, Upregulation of LGR5 expression in Ctnnb1 mutated compared to non-Ctnnb1 mutated 
patient HCC tumors, in ICGC-France, ICGC-Japan and TCGA cohort. c-d, No significant difference of 
LGR5 expression in Braf mutated compared to non-Braf mutated HCC tumors, in ICGC-France and 
ICGC-Japan cohort. e-f, No significant difference of LGR5 expression in Egfr mutated compared to non-
Egfr mutated HCC tumors, in ICGC-France, ICGC-Japan and TCGA cohort. Mean ± SEM. Source data 
are provided as a Source Data file.  
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Supplementary Figure 5 | Allograft liver tumors maintain an LGR5+ compartment. a-c, 3-7 days 
after initiation of allograft tumor-derived cultures, small organoids were observed and subsequently 
passage was performed every 4-7 days, employing splitting ratios ranging from 1:4 to 1:10 as 
appropriate. Representative pictures show the different morphologies of the tumor organoids obtained, 
which include but also flower-like, irregular sheet-like structures (a), and grape-like, condensed 
phenotypes (b), and. relative normal hollow sphere-like aspects (c). d, Representative confocal pictures 
showing the maintenance of an LGR5+ compartment in tumor organoids (LGR5-driven GFP: green). e, 
Representative immunofluorescent pictures showing an LGR5+ compartment in allograft tumors (LGR5-
driven GFP: green; DAPI: blue). f, Representative immunohistochemistry pictures showing expression 
of LGR5 promotor-driven GFP in allograft tumors (anti-GFP immunohistochemistry: brown; nuclei: blue). 
Scale bar = 50µm.  
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Supplementary Figure 6 | Genome-wide transcriptomic analysis of LGR5+ and LGR5- cells by 
RNA-Seq. a, Hierarchical clustering showed a separation of all four different groups (Untreated LGR5+ 
cells, Untreated LGR5- cells, 5-FU-treated LGR5+ cells, 5-FU-treated LGR5- cells). b, A Volcano plot 
showing the most significantly differentially expressed genes between untreated LGR5+ and LGR5- cells. 
c, GSEA with the library of Wiki2019 was performed to reveal the alteration of signaling pathways 
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Supplementary Figure 7 | LGR5+ cells have stronger organoid initiation ability. a, The FACS 
test/sort strategy for isolating LGR5-GFP+ and LGR5-GFP- cells obtained from liver/allograft 
tumors/organoids. b, The numbers of sorted LGR5-GFP+ and LGR5-GFP- cells yielding successful 
(black dots) or failure of organoid initiation (green dots), employing material obtained from DEN-induced 
murine livers (LGR5+-non-initiation vs. LGR5--non-initiation vs. LGR5+-initiation vs. LGR5--initiation: 
171.4 ± 47.1, n = 46 vs. 28350 ± 8914, n = 60 vs. 1906 ± 441.6, n = 25 vs. 13860 ± 3654, n = 11, Mean 
± SEM). c, The distribution showing the percentage of the number of LGR5+ cells which were isolated 
from primary liver tumors. d, The cell number distribution for the sorted LGR5+ cells which can initiate 
organoid, from primary tumors. e, The exact sorted numbers for LGR5+ cells and LGR5- cells , for 
organoid initiated (black dots) and non-organoid initiated (green dots), from allograft tumors (LGR5+-
non-initiated vs. LGR5--non-initiated vs. LGR5+-initiated vs. LGR5--initiated: 2.0 ± 0.6, n = 3 vs. 24.3 ± 
22.9, n = 4 vs. 453.7 ± 220.3, n = 9 vs. 524.3 ± 182.9, n = 8). f, Frequency distribution of the relative 
number of LGR5+ cells obtained from allograft liver tumors. g, Frequency distribution of the number of 
LGR5+ cells that display successful organoid initiation from material obtained from allograft tumors. h, 
Representative pictures tracing organoids initiation and growth from LGR5+ or LGR5- cells. Black arrow: 
LGR5 expressing cells. Day0/5/7: Scale bar = 50µm; Month1/2: Scale bar = 1000µm. Source data are 
provided as a Source Data file.  




Supplementary Figure 8 | LGR5+ cells from 5-FU treated tumors can initiate organoid and tumor. 
a, The organoid initiation ability of untreated LGR5+ cells (39.5 ± 4.8 %, n = 6, Mean ± SEM), untreated 
LGR5- cells (5.0 ± 2.9 %, n = 6), 5-FU-treated LGR5+ cells (31.2 ± 14.0 %, n = 6) and 5-FU-treated 
LGR5- cells (0.8 ± 0.8 %, n = 6). b, The tumor initiation ability of untreated LGR5+ cells (0.50 ± 0.15 g, 
n = 15), untreated LGR5- cells (0.21 ± 0.06 g, n = 15), 5-FU-treated LGR5+ cells (0.18 ± 0.05 g, n = 8) 
and 5-FU-treated LGR5- cells (0.31 ± 0.19 g, n = 8). c, Representative picture showing the organoid 
initiation ability of above four groups. Black arrow: initiated organoids. Scale bar = 1000µm. d, Pictures 
showing 5-FU-treated LGR5+ cells and 5-FU-treated LGR5- cells initiated tumors. Source data are 
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Supplementary Figure 9 | Genome-wide transcriptomic analysis of 5-FU treatment on LGR5+/- 
cells. a, A Volcano plot showing the most significantly differentially expressed genes between 5-FU 
treated LGR5+ cell/LGR5- cells. b, Gene enrichment analysis (Wiki2019) of the differentially expressed 
genes between 5-FU treated LGR5+ cell/LGR5- cells. c, A Volcano plot showing the most significantly 
differentially expressed genes between 5-FU treated/untreated LGR5- cells. d, Gene enrichment 
analysis (Wiki2019) of the differentially expressed genes between 5-FU treated/untreated LGR5- cells. 
Source data are provided as a Source Data file. 
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Supplementary Figure 10 | Targeting LGR5 impedes the tumor growth. a-b, Outline of the 
experimental strategies used to test the effect of DT administration during tumor growth (a) and at tumor 
initiation (b). c-d, Growth curves showing the effects of DT administration during the entire experimental 
period (Left, DT-I) and following DT intervention during tumor growth (Right, DT-M) for organoid strain 
1 (c) and strain 2 (d). Mean ± SEM. Red arrow: onset of DT administration (n = 4 for each time point). 
e, Representative FACS pictures (upper channel, with LGR5-GFP+ expression) and tumor pictures 
(lower channel, with tumor weights) showing that the same tumor strains, collected from a single mouse, 
shows variable LGR5 expression. f, tumors collected from six individual mice (transplanted with same 
strain and same amount of organoid; collected on the same day, non-treated tumors) showing that 
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Supplementary Figure 11 | The expression profile of untreated/DT-treated LGR5+ and LGR5- cells. 
a-p, The expression of stem cell/tumor stem cell markers in LGR5+/LGR5- and DT treated tumor isolated 
LGR5+/LGR5- cells was analyzed using qRT-PCR and related to a reference gene. Mean ± SEM. Source 
data are provided as a Source Data file. 
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Supplementary Figure 12 | Wide type tumor organoids do not respond to DT administration. a, 
The weight of tumors initiated by wild type organoids from control, the DT-treated group following 
sacrifice of the animals involved (Control vs. DT: 0.19 ± 0.042 g vs. 0.23 ± 0.018 g, n = 8, P = ns, Mean 
± SEM). b, Representative growth curve showing tumor volume in the control group and the DT-treated 
group (n = 4). c, Representative pictures showing the tumors from the control group and DT 
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Supplementary Figure 13 | Effects of combining DT treatment with conventional anti-cancer 
therapy. a, 5-FU control: 5-FU was administrated during the first half of the experiment period and tumor 
volume was assessed continuously. b, DT control: animals were treated with DT during the second half 
of the experiment period and tumor volume was assessed continuously. c, Combination strategy 1: 5-
FU was administrated during the first half and DT was treated during the second half of the experiment 
period. Tumor volume was assessed continuously. (a and b are the relevant control groups for c). d, DT 
control: DT was administrated during the first half of the experiment period and tumor volume was 
assessed continuously. e, 5-FU control: 5-FU was administrated during the second half of the 
experiment period and tumor volume was assessed continuously. f, Combination strategy 2: First DT 
was applied (first half of the experiment) followed by 5-FU treatment (second half of the experiment) (d 
and e are the relevant control groups for f). g, Representative growth curve showing tumor volumes of 
the control, Combination strategy 1 (5-FU--DT) and Combination strategy 2 (DT--5-FU) group (n = 4). h, 
Weight of tumors from the different groups described above at the end of the experiment. +/-: Treatment 
was administrated for the first half of the experiment; -/+: Treatment was administrated for the second 
half of the experiment; -/-: No treatment. Mean ± SEM. Source data are provided as a Source Data file. 
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Supplementary Figure 14 | Combination of LGR5 lineage ablation with conventional therapy. a-
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Supplementary Table 1 | Allograft tumor 
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Supplementary Table 2 | Clinical-pathological data of Erasmus cohort 
Table. Patient characteristics  
Characteristic HCC patients (n=74) 
Age at surgery (years)  
Mean ± SD 60 ± 15,9 
Median (range) 63 (11-82) 
Sex – no. (%)  
Male 45 (60,8) 
Female 29 (39,2) 
Race – no. (%)  
White 61 (82,4) 
African 6 (8,1) 
Asian 6 (8,1) 
Not reported 1 (1,4) 
Etiology – no. (%)  
No known liver disease 21 (28,4) 
Alcohol 16 (21,6) 
Hepatitis B 9 (12,2) 
NASH 8 (10,8) 
Hepatitis C + Alcohol 6 (8,1) 
Hepatitis B + Alc/HepC/NASH 5 (6,8) 
Hepatitis C 5 (6,8) 
Fibrolamellar HCC 3 (4,1) 
Hemochromatosis + NASH 1 (1,4) 
Hepatitis status – no. (%)  
Hepatitis B or C positive 25 (33,8) 
Chronic Hepatitis B  14 (18,9) 
Chronic Hepatitis C 12 (16,2) 
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Cirrhosis – no. (%)  
Yes 21 (28,4) 
No 53 (71,6) 
Tumor differentiation – no. (%)  
Good 8 (10,8) 
Moderate 40 (54,1) 
Poor 14 (18,9) 
Unknown 12 (16,2) 
Vascular invasion – no. (%)  
Yes 29 (39,2) 
No 38 (51,4) 
Unknown 7 (9,5) 
Number of lesions – no. (%)  
1 40 (54,1) 
>1 34 (45,9) 
Size of largest lesion (cm)  
Mean ± SD 7,7 ± 5,6 
Median (range) 6,1 (1-24) 
AFP level before resection (ug/l)  
Mean ± SD 6661,1 ± 407289,4 
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Supplementary Table 3 | Antibody 
Antibody Antibody clone/ 
reference 
Raised Origin 













Cytokeratin 19 ab52625 Rabbit Abcam 
GFP A-11122 Rabbit Invitrogen/Life 
Technologies 
 
Alexa Fluor® 488 
AffiniPure Donkey Anti-
Goat IgG (H+L) 
705-545-147 Donkey Bio-Connect 
 
Donkey anti-Rabbit IgG 
(H+L) Secondary 
Antibody, Alexa Fluor® 
594 conjugate 
R37119 Donkey Thermo fisher 
Donkey anti-mouse IgG 
(H+L) Secondary 
Antibody, Alexa Fluor® 
594 conjugate 
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Supplementary Table 4 | Primer 




G-protein coupled receptor 5 
Mouse-Lgr5 
 
Fw CTG ACT TTG AAT GGT GCC 
TCG 
Re ATG TCC ACT ACC GCG ATT AC 
Cytokeratin-19 Mouse-Krt19 
 
Fw GTG AAG ATC CGC GAC TGG T 
Re AGG CGA GCA TTG TC AAT CTG 
Transcription factor SOX-9 Mouse-Sox9 
 
Fw CGA CTA CGC TGA CCA TCA GA 
Re GAC TGG TTG TTC CCA GTG CT 
CD133 
 
Mouse-Prom1 Fw TCT GTT CAG CAT TTC CTC AC 





Fw CGT CCA ACA CCT CCC ACT AT 
Re AGC CGC TGC TGA CAT CGT 
Keratin, type II cytoskeletal 7 Mouse-Ck7 Fw ATC CGC GAG ATC ACC ATC 
Re ATG TGT CTG AGA TCT GCG 
ACT 
Leucine-rich repeats and 
immunoglobulin-like domains 
protein 1 
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RNA-binding protein MEX3A Mouse-Mex3a Fw ACACCACGGAGTGCGTTC 
Re GTTGGTTTTGGCCCTCAGA 






Epithelial cell adhesion molecule Mouse-Epcam Fw CGCAGCTCAGGAAGAATGTG 
Re TGAAGTACACTGGCATTGACG 
SRY-box 17 Mouse-Sox17 Fw GGCGCAGCAGAATCCAGA 
Re CCACGACTTGCCCAGCAT 
Cell surface associated or 
polymorphic epithelial mucin 




Mouse-Gapdh Fw TCACCACCATGGAGAAGGC 
Re GCTAAGCAGTTGGTGGTGCA 








Phosphomannomutase 1 Human-PMM1 Fw CGAGTTCTCCGAACTGGAC 
Re CTGTTTTCAGGGCTTCCAC 
Leucine-rich repeat-containing 
G-protein coupled receptor 5 
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Supplementary Note: 
Description for Supplementary Data 
[1]   Supplementary Data 1  
Content:  
The detailed information for Lgr5-DTRGFP mice which used to induce liver cancer, including:  
1)The mice code  
2)The mice background  
3)Primary Code: The corresponding code of initiated primary organoid strain. Black mark: the tissue did 
not initiate an organoid strain or the strain was already lost due to infection in the following culture.  
4)Post Den Time (Month): The sacrifice time after the induction of DEN.  
5)DEN Administration (Week): Time passed between administration of DEN and sacrifice.  
6)Tissue Type: S: tumor surrounding tissue; T: tumor tissue. S—T: initially marked with tumor 
surrounding tissue and then characterized as tumor.  
7)Percentage of LGR5-expressing cells (%): The percentage of LGR5-expressing cells within each 
tissue.  
8)Allograft Strains: The strain code which initiated allograft tumor in the immunodeficient mice. 
Remarks: In total, 41 mice were monitored. 10 (mice code: 8,12,17,18,21,22,29,31,35,41) out of 41 mice 
liver did not show obvious tumor formation. After the following characterization, 2 (mice code: 8, 22) out 
of 10 were proven to be liver tumor. 
Mouse 
Code 











M1 B6 PT1 7 6 S 0,28 
 
PT2 T 0,16 
 
M2 B6 PT3 7 6 S 0,79 
 
PT4 T 1,1 
 
M3 B6 PT5 12 6 S 0,16 
 
PT6 T 0,18 
 
M4 B6 PT7 9 6 S 0,57 
 
PT8 T1 5,66 AL8 
PT9 T2 0,32 
 
PT10 T3 5,61 AL10 
M5 B6 PT11 9 6 S 0,22 
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PT12 T 2,5 
 
M6 B6&C3H PT13 5 17 S 0 AL13 
PT14 T 2,75 
 
M7 B6 PT15 13 6 S 0,4 
 
PT16 T 2,07 
 
M8 B6 PT17 13 6 S--T 0,31 AL17 
M9 B6 PT18 12 6 S 1,1 
 
PT19 T 3,05 
 
M10 B6 PT20 15 6 S 0,85 
 
PT21 T1 2,85 
 
PT22 T2 1,43 
 
M11 B6 PT23 15 6 S 0,89 
 




Mice backgroud Primary code Post Den time DEN  Lgr5 expression Allograft 
strains 
M12 B6&C3H PT25 3 11 S 0,18  
M13 B6 PT26 10 17 S 0,062 
 
PT27 T 0,3 
 
M14 B6 PT28 13 6 S 0,33 
 
PT29 T1 0,47 
 
PT30 T2 2,15 
 
M15 B6 PT31 13 6 S 0 
 
PT32 T1 0,45 
 
PT33 T2 0,5 
 
M16 B6 PT34 13 6 S 0,12 
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M17 B6 PT36 13 6 S 0,72 
 
M18 B6 PT37 13 6 S 0,24 
 
M19 B6 PT38 13 6 S 3,41 AL38 
PT39 T 1,11 
 
M20 B6 PT40 16 6 S 0,15 
 
PT41 T 0,22 
 
M21 B6 PT42 14 6 S 0,33 
 
M22 B6&C3H PT43 7 17 S--T 0,77 AL43 
M23 B6&C3H PT44 7 17 S 3,08 
 
PT45 T1 3,29 
 
PT46 T2 0,05 AL46 
Mouse 
Code 
Mice backgroud Primary code Post Den time DEN  Lgr5 expression Allograft 
strains 
M24 B6&C3H PT47 7 17 S 25 
 
PT48 T1 46,1 
 
PT49 T2 55,6 
 
PT50 T3 51,2 
 
M25 B6 PT51 14 6 T 4,63 
 
M26 B6 PT52 14 6 S 0,021 
 
PT53 T 0 
 
M27 B6&C3H PT54 7 17 T 7,73 
 
M28 B6 PT55 8 17 S 20,3 
 
PT56 T1 10,7 
 
PT57 T2 1,67 
 
PT58 T3 0,48 
 
PT59 T4 4,66 
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M29 B6 PT60 15 6 S 0,4 
 
M30 B6&C3H PT61 8 17 T1 2,62 AL61 
PT62 T2 7,01 AL62 
PT63 T3 10,5 
 
M31 B6&C3H PT64 8 17 S 0,3 
 
M32 B6 PT65 15 6 S 20,3 
 
PT66 T1 1,04 
 
PT67 T2 8,03 
 
M33 B6 PT68 15 6 T1 47,9 
 
PT69 T2 17,4 
 




Mice backgroud Primary code Post Den time DEN  Lgr5 expression Allograft 
strains 
M34 B6 PT71 15 6 S 17,4 
 
PT72 T1 3,86 
 
PT73 T2 21,6 
 
M35 B6 PT74 15 6 S 0,22 
 
M36 B6 PT75 15 6 S 0,25 
 
PT76 T 3,41 
 
M37 B6 PT77 15 6 T1 1,41 
 
PT78 T2 0,23 
 
PT79 T3 0,65 
 
M38 B6&C3H PT80 8 17 S 0,26 
 
PT81 T 0,14 
 
M39 B6 PT82 13 6 T1 0,29 
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PT84 T3 0,18 AL84 
PT85 T4 8.90 AL85 
M40 B6&C3H PT86 7 17 T1 14,6 
 
PT87 T2 6,82 
 
PT88 T3 13,9 
 
M41 B6&C3H PT89 8 17 S 0,21 
 
 
Group Code Group  Tissue Number Lgr5 Expression 
A The collected mice liver tissue  89 5.583%  
B The mice liver which did not initiate tumor  8 0.325% 
C Tumor surrounding tissue 34 2.930% 
D Tumor tissue 55 7.294% 
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[2]   Supplementary Data 2  
Content:  
The H&E/Gomori/EpCAM/AFP/CK19/GFP staining of primary/allograft tissues for all 
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[3]   Supplementary Data 3 
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Content:  
Gene enrichment analysis of the differentially expressed genes between Untreated 
LGR5+ Vs. LGR5-, 5-FU-treated LGR5+ Vs. LGR5-, 5-FU-treated Vs. Untreated 
LGR5+ and 5-FU-treated Vs. Untreated LGR5- cells.  
 
Treated LGR5+ Vs. LGR5-
Pathway Genes
Matrix Metalloproteinases WP441 MMP12;MMP9;MMP21
Glucocorticoid & Mineralcorticoid Metabolism WP495 HSD11B2;CYP21A1
Microglia Pathogen Phagocytosis Pathway WP3626 C1QA;FCER1G;NCF1
Striated Muscle Contraction WP216 TPM2;TCAP;TNNI3
Inflammatory Response Pathway WP458 COL1A1;CD28
Prostaglandin Synthesis and Regulation WP374 HSD11B2;ANXA8
Irinotecan Pathway WP475 UGT1A1
Osteoblast WP238 COL1A1
Estrogen metabolism WP1264 UGT1A1
Heart Development WP2067 HEY1;VEGFC
Calcium Regulation in the Cardiac Cell WP553 PRKCG;KCNB1;GJB6;ATP1B2;ADRB2
Glucuronidation WP1241 UGT1A1
Complement Activation, Classical Pathway WP200 C1QA
Eicosanoid Synthesis WP318 LTC4S
Hedgehog Signaling Pathway WP116 HHIP
GPCRs, Class B Secretin-like WP456 ADGRE1
Signal Transduction of S1P Receptor WP57 S1PR5
Spinal Cord Injury WP2432 MMP12;OMG;MMP9
Endochondral Ossification WP1270 COL10A1;MMP9
Dysregulated miRNA Targeting in Insulin/PI3K-AKT Signaling WP3855 COL1A1
Oxidative Stress WP412 UGT1A1
One Carbon Metabolism WP435 FOLH1
Peptide GPCRs WP234 CXCR3;CCR9
Eicosanoid metabolism via Lipo Oxygenases (LOX) WP4348 LTC4S
Monoamine GPCRs WP570 ADRB2
Retinol metabolism WP1259 NPC1L1
Parkinsons Disease Pathway WP3638 SNCAIP
Oxidation by Cytochrome P450 WP1274 CYP21A1
Oxidative Damage WP1496 C1QA
Non-odorant GPCRs WP1396 ADGRE1;CXCR3;CCR9;KISS1R;ADRB2;S1PR5
Metapathway biotransformation WP1251 UGT1A1;CYP21A1;HS3ST5
Wnt Signaling Pathway and Pluripotency WP723 PRKCG;HNF1A
Chemokine signaling pathway WP2292 NCF1;CXCR3;CCR9;PPBP
Wnt Signaling Pathway WP403 PRKCG
Lung fibrosis WP3632 MMP9
Complement and Coagulation Cascades WP449 C1QA
Alpha6-Beta4 Integrin Signaling Pathway WP488 COL17A1
GPCRs, Class A Rhodopsin-like WP189 GPR12;CXCR3;CCR9;ADRB2
Focal Adhesion WP85 COL1A1;VEGFC;THBS2
Adipogenesis genes WP447 PNPLA3;HNF1A
IL-2 Signaling Pathway WP450 CD53
Delta-Notch Signaling Pathway WP265 HEY1
GPCRs, Other WP41 ADRB2;S1PR5
Cytoplasmic Ribosomal Proteins WP163 RPL24
G Protein Signaling Pathways WP232 PRKCG
Amino Acid metabolism WP662 TAT
IL-6 signaling Pathway WP387 HNF1A
IL-3 Signaling Pathway WP373 MMP9
Neural Crest Differentiation WP2074 SNAI2
ESC Pluripotency Pathways WP339 HNF1A
Odorant GPCRs WP1397 GPR12;GPR61
Focal Adhesion-PI3K-Akt-mTOR-signaling pathway WP2841 COL1A1;ANGPT2;VEGFC;THBS2
Myometrial Relaxation and Contraction Pathways WP385 PRKCG
MAPK signaling pathway WP493 PRKCG









Untreated LGR5+ Vs. LGR5-
Pathway Genes
Peptide GPCRs WP234 FPR1;SSTR1;TSHR
Myometrial Relaxation and Contraction Pathways WP385 MYL4;RGS5;ADCY4;RLN1
Macrophage markers WP2271 LYZ2
Matrix Metalloproteinases WP441 MMP8
Dopaminergic Neurogenesis WP1498 PITX3
Non-odorant GPCRs WP1396 FPR1;SSTR1;TSHR;CELSR3
Oxidation by Cytochrome P450 WP1274 CYP4X1
Striated Muscle Contraction WP216 MYL4
GPCRs, Class A Rhodopsin-like WP189 FPR1;SSTR1;TSHR
Metapathway biotransformation WP1251 CYP4X1;FMO2
Calcium Regulation in the Cardiac Cell WP553 RGS5;ADCY4
TYROBP Causal Network WP3625 HLX
Lung fibrosis WP3632 CMA1
Kit Receptor Signaling Pathway WP407 FGR
Purine metabolism WP2185 PNP2;ADCY4
PPAR signaling pathway WP2316 FABP2
Chemokine signaling pathway WP2292 FGR;ADCY4
G Protein Signaling Pathways WP232 ADCY4
Wnt Signaling Pathway and Pluripotency WP723 NKD2
IL-6 signaling Pathway WP387 FGR
GPCRs, Other WP41 CELSR3
Focal Adhesion WP85 FGR
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[4]   Supplementary Data 4 
Content: 
Gene: The differentially expressed genes between untreated LGR5+ cells and LGR5- 
cells. 
Gene description: The gene description. 
Survival Analyses: Online database (The Human Protein Atlas, 
http://www.proteinatlas.org/). 
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[5]   Supplementary Data 5  
Content:  
The detailed information for single cells isolated from DEN induced murine livers and allograft tumors, 
then used for organoid initiation, including:  
1) Code: The corresponding tissues of DEN induced murine livers or allograft tumors. Green mark: the 
groups did initiate organoids after sorting.  
2) Initiated organoid number for each group.  
3) Organoid initiated efficiency (%) for each group. 
Remarks: In total 89 tissues were collected. Among them, 71 tissues were sorted for following single cell 




























PT1 0 0 0 1 0 0 
PT2 1 0 0 7 0 0 
PT3 10 1 10 17 0 0 
PT11 307 0 0 8124 0 0 
PT12 787 2 0.25 39066 20 0.05 
PT13 24 0 0 332457 0 0 
PT14 140 0 0 44901 0 0 
PT15 58 0 0 186498 0 0 
PT16 49 0 0 21632 0 0 
PT17 59 0 0 221656 0 0 
PT18 51 0 0 185640 0 0 
PT19 81 0 0 8985 0 0 
PT20 379 1 0.26 26090 75 0.29 
PT21 611 1 0.16 13775 39 0.28 
PT22 20 0 0 475 0 0 
PT23 322 0 0 27748 0 0 
PT24 3 0 0 8951 0 0 
PT26 32 0 0 87 0 0 
PT27 17 0 0 19104 30 0.16 
PT28 17 0 0 8643 3 0.035 
PT29 62 0 0 10809 22 0.20 
PT30 124 0 0 6680 5 0.075 
PT31 140 0 0 2692 0 0 
PT32 41 0 0 6430 0 0 
PT33 141 0 0 23853 10 0.042 
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PT34 36 0 0 2355 0 0 
PT35 540 0 0 26689 0 0 
PT36 265 0 0 86774 0 0 
PT37 109 0 0 90979 0 0 
PT38 1253 10 8.00 131695 0 0 
PT39 1073 0 0 250982 0 0 
PT40 115 0 0 1329 0 0 
PT41 20 0 0 1464 0 0 
PT42 181 0 0 1193 0 0 
PT43 131 0 0 5998 0 0 
PT44 71 0 0 76 0 0 
PT45 740 3 0.41 1348 0 0 
PT46 22 0 0 1485 0 0 
PT47 2304 5 0.22 5356 0 0 
PT48 845 1 0.12 859 0 0 
PT49 482 1 0.21 418 1 0.24 
PT50 385 2 0.52 444 0 0 
PT51 140 5 3.57 189 1 0.53 
PT52 12 0 0 594 0 0 
PT53 1 0 0 180 0 0 
PT54 6062 50 0.82 5767 0 0 
PT55 407 0 0 2121 0 0 
PT56 2282 364 16.0 3841 2 0.05 
PT57 288 3 1.04 960 0 0 
PT58 120 0 0 1613 0 0 
PT59 821 23 2.8 758 0 0 
PT60 30 0 0 1299 0 0 
PT61 1879 0 0 2242 0 0 
PT62 2881 10 3.5 4514 0 0 
PT63 3510 27 7.7 1262 0 0 
PT64 6 0 0 16 0 0 
PT65 340 0 0 281 0 0 
PT66 1425 0 0 1222 0 0 
PT67 4404 3 0.00068 1026 0 0 
PT68 9386 25 2.7 5129 0 0 
PT69 93 0 0 128 0 0 
PT70 1694 10 0.59 728  0 0 
PT71 1526 14 0.92 1792 0 0 
PT72 4482 6 0.13 4482 0 0 
PT73 1101 4 0.36 1097 0 0 
PT80 103 0 0 729 0 0 
PT81 58 0 0 51 0 0 
PT82 129 0 0 37 0 0 
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PT83 627 14 2.23 616 0 0 
PT84 31 0 0 18 0 0 




























AL17 70 64 91.4 513 46 9,0 
AL13 1026 233 22.7 663 5 0,8 
SAL1 7 7 100 38 7 18,4 
AL43 39 15 38.5 54 18 33,3 
AL46 13 5 38.5 1 0 0,0 
AL13.1 1646 180 10.9 1373 176 12,8 
AL17.2 21 11 52.4 366 11 3,0 
AL8.1 62 17 27.4 100 3 3,0 
AL8.2 107 12 11.2 181 7 3,9 
AL8.3 138 16 11.6 178 0 0,0 
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[6]   Supplementary Data 6  
Content:  
The detailed information for single cells isolated from DEN induced murine livers, then injected directly 
into immunodeficient mice for tumor formation, including:  
1) Code: The corresponding tissues of DEN induced murine livers and initiated allograft tumors. Green 
mark: the groups did initiate tumors after sorting.  
2) Injected cell number for each group.  
3) Pictures of primary tumors and corresponding allograft tumors. 
 






  1         PT47 
LGR5+ cells 3000 no 
LGR5- cells 3000 no 
2 PT50 
LGR5+ cells 2000 SAL1 
LGR5- cells 2000 SAL2 
3 PT63 
LGR5+ cells 2000 SAL3 
LGR5- cells 2000 no 
4 PT65 
LGR5+ cells 6000 no 
LGR5- cells 6000 no 
5 PT67 
LGR5+ cells 1000 no 
LGR5- cells 1000 no 
6 PT68 
LGR5+ cells 16000 SAL4 
LGR5- cells 16000 no 
7 PT72 
LGR5+ cells 5000 no 
LGR5- cells 5000 no 
8 PT73 
LGR5+ cells 1000 no 
LGR5- cells 1000 no 
 PT85 LGR5+ cells 3000 no 
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9 LGR5- cells 3000 no 
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Abstract 
Background & Aims: Cancer associated fibroblasts (CAFs) play a key role in cancer process, 
but the research progress is hampered by the paucity of preclinical models essential for 
mechanistic dissection of cancer cell-CAF interactions. Here, we aim to establish a 3D 
organotypic co-cultures of primary liver tumor-derived organoids with CAFs, and to understand 
their interactions and the response to treatment.  
Methods: Liver tumor organoids and CAFs were cultured from murine and human primary 
liver tumors. 3D co-culture models of tumor organoids with CAFs and trans-well culture 
systems were established in vitro. A xenograft model was used to interrogate the cell-cell 
interactions in vivo. Gene expression analysis of CAF markers in our hepatocellular carcinoma 
(HCC) cohort and an online liver cancer database indicated the clinical relevance of CAFs.  
Results: To functionally investigate the interactions of liver cancer cells with CAFs, we have 
successfully established murine and human 3D co-culture models of liver tumor organoids with 
CAFs. CAFs promoted tumor organoid growth in co-culture with direct cell-cell contact and in 
trans-well system via paracrine signaling. Vice versa, cancer cells secret paracrine factors 
regulating CAF physiology. Co-transplantation of CAFs with liver tumor organoids of mouse or 
human origin promoted tumor growth in xenograft models. Moreover, tumor organoids 
conferred resistance to clinically used anti-cancer drugs including Sorafenib, Regorafenib and 
Fluorouracil (5-FU) in the presence of CAFs, or the conditioned medium of CAFs.  
Conclusions: We have successfully established murine and human 3D co-culture models and 
have revealed robust effects of CAFs in liver cancer nurturing and treatment resistance.  
Key words: Liver tumor organoids; stromal cells; co-culture; cell-cell contact; paracrine effect. 
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Introduction  
Liver cancer is one of the most common and deadly malignancies worldwide, and currently 
there are limited treatment options available. Heterogeneity within and between liver tumors 
greatly complicates disease progression and treatment response.[1] A subpopulation of cancer 
cells within tumors, termed cancer stem cells (CSCs), have been recognized to possess 
capacity for both self-renewal but also the potential for differentiation. This population of cells 
appears responsible for resistance to treatment in addition to tumor initiation and 
progression.[2] Although tumor biology of liver cancer in general remains poorly understood, 
hopes for obtaining better understanding of this disease have been fostered by the recent 
development of 3D organoids culture technology. Such cultures, initially derived from tissue-
resident stem/progenitor cells, embryonic stem cells or induced pluripotent stem cells, has 
emerged as a new technology for stem cell research as they are capable of self-renewal and 
self-organization that recapitulate the functionality of the tissue-of-origin. Interestingly, this 3D 
culture system has been extended to culture a variety of primary cancer cells, providing insight 
into the role of CSCs in the cancer progress.[3] For liver cancer, tumor organoids that resemble 
hepatocellular carcinoma (HCC) or cholangiocarcinoma (CCA) have been successfully 
cultured from human tumor[4] or mouse tumor models.[5] In general, organoids are much 
easier to be cultured from CCA than HCC.  
Cancer cells, in particular CSCs, actively interact with the tumor microenvironment. This 
microenvironment contains numerous cell types, including immune cells, fibroblasts and 
endothelial cells, and various factors including signaling molecules and extracellular matrix 
(ECM).[6] Among these components, a specialized group of fibroblasts called cancer 
associated fibroblasts (CAFs) are considered to be of unusual importance to tumor 
development. Previous studies have identified several CAF markers including alpha-smooth 
muscle actin (α-SMA), fibroblast associated protein (FAP), Vimentin, fibroblast specific protein 
1 (FSP1), CD29, Caveonin 1 (CAV1), Desmin, platelet-derived growth factor receptor alpha 
(PDGFRA), platelet-derived growth factor receptor beta (PDGFRB), Gremlin1, Collagen, type 
I, alpha 1 (COL1A1), Periostin and C-X-C motif chemokine 12 (CXCL12).[7-14] CAFs can 
support tumor growth, metastasis and formation of cancer stem cell niches, and mediate 
immunosuppression and drug resistance by directly interacting with cancer cells or secreting 
a panel of factors and nutrients.[15] More than 80% of HCC patients have the background of 
liver cirrhosis,[16] and these livers are enriched with activated fibroblasts due to the chronic 
inflammation that characterize this disease. Thus, CAFs are assumed to play a prominent role 
in liver cancer even in the absence of formal proof.  
In this study, we first develop a 3D co-culture system of primary liver tumor-derived organoids 
with CAFs of mouse or human origin. By using this system, we investigated the reciprocal 
interactions of cancer cells and CAFs, and the role that the CAF niche provided with respect 
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Figure 1. Bioinformatics analysis between FAP, CD29 and Periostin gene expression and clinical 
relevance in liver cancer. (A-C) Gene expression of CAF markers FAP, CD29 and Periostin in tumors 
compared to paired adjacent tumor free liver tissues in our HCC cohort (n = 75 HCC, Mann-Whitney U 
tests. ***p < 0.001). (D, I, N) Gene expression of CAF markers FAP, CD29 and Periostin in CCA 
compared to normal liver tissues in an online TCGA database (n = 9 for normal liver tissue; n = 36 for 
tumor tissue; One-way ANOVA; *p < 0.05). (F, K, P) Gene expression of CAF markers FAP, CD29 and 
Periostin in HCC compared to normal liver tissues in an online TCGA database (n = 160 for normal liver 
tissue; n = 369 for tumor tissue; One-way ANOVA; *p < 0.05). (E, J, O) The expression of FAP, CD29 
and Periostin in different tumor stage of CCA (n = 36, One-way ANOVA). (G, L, Q) The expression of 
FAP, CD29 and Periostin in different tumor stage of HCC (n = 369, One-way ANOVA). (H, M, R) Overall 
survival assessed using the online TCGA database at www.gepia.com. The differences in survival 
related to CAFs markers CD29, FAP and Periostin mRNA expression were compared in each group 
involving in all patients (Log-rank test, FAP [n = 36 for CCA, n = 358 for HCC]; CD29 [n = 36 for CCA, 
n = 364 for HCC]; Periostin [n = 36 for CCA, n = 364 for HCC]). Dotted line indicated the 95% confidence 
interval. T, tumor tissues; N, normal liver tissue; CAF, cancer associated fibroblast; CCA, 
cholangiocarcinoma; HCC, hepatocellular carcinoma; FAP, fibroblast associated protein. 
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Figure 2. Survival and recurrence analysis based on the gene expression of CD29, FAP and 
Periostin in our HCC cohort and bioinformatics analysis of other CAFs markers in GEPIA online 
database. (A-L) Overall survival and disease free rate based on the gene expression of CD29, FAP and 
Periostin in tumor tissue or tumor free liver tissue of our HCC patients (Kaplan-Meier analysis, n = 75). 
(M) Bioinformatics analysis of PDGFRB, α-SMA,S100A4, COL1A1, PDGFRA, CXCL12, CAV1, 
VIMENTINE in GEPIA database. The gene expression of these markers in tumor and normal liver tissue 
(CCA: n = 9 for normal liver tissue; n = 36 for tumor tissue; HCC: n = 160 for normal liver tissue; n = 369 
for tumor tissue; One-way ANOVA). Gene expression of these markers in different stages of liver tumors 
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(CCA: n = 36; HCC: n = 369, One-way ANOVA). The differences in survival related to CAFs markers 
PDGFRB, Alpha-SMA, FSP1, COL1A1, PDGFRA, CXCL12, CAV1 and Vimentin mRNA expression 
were compared in each group involving in all patients (Log-rank test, n = 36 for CCA, n = 364 for HCC). 
(-) Without statistical significant difference. CAF, cancer associated fibroblast; CCA, 
cholangiocarcinoma; HCC, hepatocellular carcinoma; FAP, fibroblast associated protein; FSP1, 
fibroblast-specific protein1; PDGFRA, platelet-derived growth factor receptor alpha; PDGFRB, platelet-
derived growth factor receptor beta; COL1A1, collagen , type I, alpha 1; CXCL12, C-X-C motif 
chemokine ligand 12; CAV1, Caveolin 1; T, tumor tissues; N, normal liver tissue; OS, overall survival 
rate. 
Results 
Evidence for potential clinical significance of CAFs in liver cancer 
We first examined the potential clinical relevance of CAFs in liver cancer patients. We 
quantified the mRNA expression of three well-recognized CAF markers including FAP[17, 18], 
CD29[19, 20] and Periostin[21, 22] in our HCC patient cohort. Their expression is significantly 
elevated in tumors compared to adjacent liver tissues of the same patients (n = 75, Figure 1A-
C). We next analyzed the expression of these CAF markers using the online TCGA database. 
Consistently, FAP, CD29 and Periostin are upregulated in tumor compared to normal liver 
tissues (n = 196 for normal liver tissue; n = 405 for tumor tissue, including 369 HCC and 36 
CCA, Figure 1D, F, I, K, N, P). This upregulation is more apparent in late stage of liver cancer 
(Figure 1E, G, J, L, O, Q). Importantly, high expression of FAP, CD29 or Periostin in tumor 
tissues is significantly associated with poor overall survival of the patients (Figure 1H, M, R). 
The patient number in our HCC cohort is too small for powerful statistical analysis of CAF 
markers in association with cancer-specific survival. Some of these markers showed similar 
trends in relation to patient survival in our cohort as observed in TCGA dataset, although they 
are not fully in accordance with the results from TCGA database (Figure 2A-L). Analysis of 
additional CAF markers revealed the upregulation of several other markers in tumor, although 
their expression is not associated with patient survival (Figure 2M). These results provided 
some evidence for potential clinical relevance of CAFs in liver cancer and promoted us to 
establish experimental models for further investigation.   
Construction of 3D co-culture systems of liver tumor organoids with CAFs  
For studying the interaction between cancer cells and CAFs, we first explored the construction 
of 3D organotypic co-culture systems of liver tumor organoids with CAFs. We have established 
6 mouse tumor organoids from carcinogen N-nitrosodiethylamine (DEN) induced mouse liver 
tumors and 4 human CCA tumor organoids from resected patient CCA tumors as previously 
described.[4, 5] CAFs were isolated and cultured from DEN-induced liver tumors of red 
fluorescence-expressing Rosa 26-mT mice (Figure 3A), and tumors of HCC and CCA patients 
(Figure 3B). As a result, 2 mouse CAFs (2 out of 6 mice), 6 human CAFs (2 out of 3 CCA and 
4 out of 10 HCC) were established. CAFs were enriched by plastic adherence and propagated 
in culture. Both mouse and human CAFs display an elongated, spindle-like morphology (Figure 
3C). Immunofluorescence staining confirmed that most CAFs were positive for α-SMA and 
FAP (Figure 3D). We excluded the presence of other cell types including cancer cells, immune 
cells and endothelial cells by staining with the corresponding makers AFP, EpCAM, CD45 and 
CD31 (Figure 3D).  
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We have successfully established the murine and human 3D co-cultures of tumor organoids 
and CAFs. (Figure 4A-E). However, the co-cultured organoids and CAFs were not derived from 
the same mice or patients. After three days in co-culture, CAFs become further elongated and 
gradually formed net-like structure which encircled organoids (Figure 4E). Corresponding 
immunofluorescence images of the culture system of mouse origin are displayed, as these  
 
Figure 3. Establishment of cancer associated fibroblasts. (A) Rosa26-mT mouse treated with 
diethylnitrosamine (DEN) for 17 weeks, and waited 30 weeks for tumor formation. Then mouse CAFs 
were cultured according to our protocol. (B) Representative IHC staining of α-SMA in mouse and human 
primary tissue (magnification 400X). (C) Representative image of established human and mouse CAFs 
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(magnification 100X). (D) Representative IF staining of α-SMA, FAP, EpCAM, AFP, CD45 and CD31 in 
mouse and human CAFs (magnification 400X). IHC, immunohistochemistry; α-SMA, alpha smooth 
muscle actin; CAFs, cancer associated fibroblasts; IF, immunofluorescence; FAP, fibroblast associated 
protein; AFP, Alpha-fetoprotein; EpCAM, epithelial cell adhesion molecule. 
CAFs were derived from red fluorescent protein (RFP) expression murine liver tumor (Figure 
4F). By using immunofluorescence staining and 3D reconstructing the Z-stack of confocal 
images, we further confirmed that CAFs closely surrounded the organoids (Figure 4G and H).   
 
Figure 4. Establishment of organoids and CAFs co-culture models of mouse and human origins. (A-B) 
Schematic illustration of the co-culture models of murine and human origins. (C-D) Representative image of human 
CAFs, human organoids and co-cultures at day 10 (C, magnification 20X; D, magnification 100X). (E) 
Representative image of mouse CAFs, mouse organoids and co-cultures from day 0 to day 7 (magnification 20X, 
inset magnification 100X). (F) Representative IF staining of mouse CAFs, mouse organoids and co-cultures 
(magnification 400X). (G) Representative confocal image of mouse organoids and CAFs co-culture model 
(magnification 400X). (H) Representative 3D reconstruction of Z-stack of mouse organoids and CAFs co-culture 
model. CAFs, cancer associated fibroblasts; IF, immunofluorescence.  
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Figure 5. The effects of CAFs on tumor organoids formation and growth. (A-B) Measuring the 
diameter of organoids under immunofluorescence and bright field vision (n = 6. Five organoids for each 
well were randomly measured). (C) Mouse or human tumor organoids cultured with or without 
corresponding CAFs. (D) Diameters of mouse organoids cultured with or without mouse CAFs (n = 8 
experimental settings with 3 biological replicates for each. Five organoids for each well were randomly 
measured). (E) Number of mouse organoids cultured with or without mouse CAFs (n = 8 experimental 
settings with 3 biological replicates for each) (F) Diameters of human organoids cultured with or without 
human CAFs (n = 7 experimental settings with 3 biological replicates for each. Five organoids for each 
well were randomly measured). (G) Number of human organoids cultured with or without mouse CAFs 
(n = 7 experimental settings with 3 biological replicates for each). (H-I) Diameters of formed organoids 
in mono- or co-cultures with different concentration between organoids and CAFs (n = 6; Five organoids 
for each well were randomly measured). (J-K) The number of formed organoids in mono- or co-cultures 
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with different concentration between organoids and CAFs (n = 6). (L) Ki67 staining for mouse organoids 
mono-culture (magnification 400X). (M) Ki67 staining for mouse organoids and CAFs co-culture 
(magnification 400X). (N) Ki67 staining for human organoids mono-culture (magnification 400X). (O) 
Ki67 staining for human organoids and CAFs co-culture (magnification 400X). (B, D-K) Data are 
expressed as means ± SD; Mann-Whitney U tests; **p < 0.01, ***p < 0.001. 
 
 
Figure 6. The effects of CAFs on organoids in trans-well platform. (A) Schematic illustration of trans-well culture 
platform for mouse cells. (B) Diameters of mouse organoids in trans-well platform with or without CAFs (n = 6; 
Five organoids for each well were randomly measured). (C) Number of mouse organoids in trans-well platform 
with or without CAFs (n = 6). (D) Representative images of mono-, co-cultured mouse organoids. (E) Growth of 
mouse liver tumor organoids determined by CellTiter (n = 9) and Alamar Blue Assay (n = 6). (F) Schematic 
illustration of trans-well culture platform for human cells. (G) Diameters of human organoids in trans-well 
platform with or without CAFs (n = 6; Five organoids for each well were randomly measured). (H) Number of 
human organoids in trans-well platform with or without CAFs (n = 6). (I) Representative images of mono-, co-
cultured human organoids in trans-well platform. (J) Growth of human organoids determined by CellTiter and 
Alamar Blue Assay (n = 9). (K) The number of formed mouse tumor organoids in the presence or absence of CAFs 
in a trans-well system (n = 4 experimental settings with 3 biological replicates for each, Mann-Whitney U tests). 
(L) The size of formed mouse tumor organoids in the presence or absence of CAFs in a trans-well system (n = 4 
experimental settings with 3 biological replicates for each. Five organoids for each well were randomly measured. 
(M) Growth of mouse liver tumor organoids determined by Alamar Blue Assay (n = 4 experimental settings with 
3 biological replicates for each). (N) The number of formed human tumor organoids in the presence or absence 
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of CAFs in a trans-well system (n = 3 experimental settings with 3 biological replicates for each, Mann-Whitney 
U tests). (O) The size of formed human tumor organoids in the presence or absence of CAFs in a trans-well system 
(n = 3 experimental settings with 3 biological replicates for each. Five organoids for each well were randomly 
measured. (P) Growth of mouse liver tumor organoids determined by Alamar Blue Assay (n = 3 experimental 
settings with 3 biological replicates for each). (B, C, E, G, H, J, L, M, O, P) Data are expressed as means ± SD; Mann-
Whitney U tests; *p < 0.05, **p < 0.01, ***p < 0.001. CAFs, cancer associated fibroblast. 
 
Figure 7. The expression profile of stem cell markers in tumor organoids. (A) Stem cell markers 
expression of mouse organoids in the presence or absence of CAFs conditioned medium (n = 9). (B) 
Stem cell markers expression of human organoids in the presence or absence of CAFs conditioned 
medium (n = 6). (A-B) Data are expressed as means ± SD; Mann-Whitney U tests; *p < 0.05, **p < 0.01. 
CAFs, cancer associated fibroblast; CTR, control; CON, conditioned. 
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Figure 8. Supernatant of organoids on the growth, morphology and gene expression of CAFs. (A-
B) Growth of mouse CAFs in the presence or absence of organoids conditioned medium (n = 9). (C-D) 
Growth of human CAFs in the presence or absence of organoids conditioned medium (n = 9). (E) 
Expression profile of mouse CAFs markers in the presence or absence of organoids conditioned 
medium (n = 8). (F) Expression profile of human CAFs markers in the presence or absence of organoids 
conditioned medium (n = 8). (B, D, E, F) Data were presented as Mean ± SD. Mann-Whitney U tests. *p 
< 0.05, **p < 0.01, ***p < 0.001. CAFs, cancer associated fibroblast; CTR, control; CON, conditioned. 
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CAFs promote the growth of organoids in co-culture 
After co-culturing digested single murine organoid cells with CAFs for 7 days and those of 
human origin for 14 days, we counted the number of formed organoids and randomly 
measured the diameter of five organoids in each well (Figure 5A). We verified the accuracy of 
our measurement by measuring the diameter both under immunofluorescence and bright field 
vision (Figure 5B). We found that co-culturing CAFs enlarged the size of formed organoids, 
but did not affect the number (Figure 5C-G). This effect was already apparent at a 1:1 ratio 
input of organoid and CAF cells, but was not enhanced by further increasing the input of CAFs 
(Figure 5H-K). Enhanced expression of the cell proliferation marker Ki67 in co-cultured 
organoids further supports this promoting effect (Figure 5L-O). Therefore, these results 
suggest that CAFs may not regulate the efficiency of organoid initiation, but promote the growth 
of formed organoids in the co-culture system.  
 
Reciprocal enhancement of CAFs and tumor organoids growth through paracrine 
signaling 
The aforementioned results were demonstrated in the co-culture system, but this does not 
exclude the possibility of paracrine effects. To investigate this, we established a trans-well 
system in which CAFs were seeded on the top and organoids on the bottom layer (Figure 6A). 
After incubation for 10 days, we found that CAFs did not affect the number, but, reminiscent to 
co-culture, increased the diameter of formed organoids in the setting of cells of mouse origin 
(Figure 6B-D). Cell Titer Assay and Alamar Blue Assay further confirmed these results (Figure 
6E). Same results were observed in the setting of other combination of mouse cells as well as 
cells of human origin (Figure 6F-P). Interestingly, several stem cell markers including Lrig1, 
Muc5ac, CD133, TERT, NANOG were upregulated in mouse organoids by the paracrine effect 
of CAFs (Figure 7A). But this was not observed in human organoids (Figure 7B).  
Next, we examined the reverse effect by exposing CAFs to the conditioned medium of tumor 
organoids (Figure 8A and C). We found that education with soluble factors from tumor 
organoids significantly promoted the growth of CAFs (Figure 8B and D). Profiling a panel of 
potential CAFs makers revealed that gremlin1 was upregulated in both mouse and human 
CAFs (Figure 8E and F). Previous studies have documented that gremlin1 suppresses the 
function of bone morphogenetic proteins which may support cancer stemness.[23] Thus, CAFs 
and organoids reciprocally facilitate their growth at least partially through paracrine signaling.  
CAFs promote the growth of organoids-formed tumors in mice  
We have previously demonstrated that liver tumor organoids are capable of forming tumors 
upon subcutaneous transplantation in immunodeficient mice.[5] We thus investigated the 
effects of CAFs on organoids-based tumor formation and growth in vivo (Figure 9A). We found 
that co-transplantation of organoids with CAFs lead to more efficient tumor formation (12/12) 
than transplanting mouse organoids alone (9/12) (Figure 9B). More importantly, co-
transplantation resulted in much larger tumors compared to transplanting organoids alone 
(tumor weight 0.60 ± 0.31g, n=12, VS. 0.33 ± 0.13g, n=9, p<0.05, Figure 9C). 
Immunohistochemistry and immunofluorescence staining confirmed the presence of CAFs in 
the tumor tissue of mice co-transplanted with CAFs (Figure 9D-F). Interestingly, CAFs are also 
abundantly present in the tumors of control mice transplanted with organoids alone (Figure 9D  
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Figure 9. Mouse CAFs promote the growth of mouse organoids formed tumors in vivo. (A) 2.5*105 
mouse tumor organoids together with or without 2.5*105 mouse CAFs were transplanted into NSG 
mouse. (B) Representative pictures showed the tumors from mono- and co-transplantation. (C) The 
weight of tumors from mono- or co-transplantation (n = 9 for xenografts from organoids transplantation 
only, n = 12 for xenografts from CAFs and organoids co-transplantation, *P < 0.05). (D) The 
representative immunohistochemistry staining of EpCAM, α-SMA, H&E and Gomori for tumors from 
mono- or co-transplantation (magnification 400X). (E) The representative confocal image of α-SMA 
expression for tumors from mono- or co-transplantation (magnification 400X, inset magnification 2000X). 
(F) The representative confocal image of EpCAM expression for tumors from mono- or co-
transplantation (magnification 400X, inset magnification 2000X). (G) Expression profile of CAF markers 
for transplanted and endogenously recruited mouse CAFs (Endogenous, n = 4; Transplanted, n = 8). 
(C, G) Data were presented as mean ± SD, Mann-Whitney U tests. CAFs, cancer associated fibroblasts; 
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NSG, NOD scid gamma mouse; EpCAM, epithelial cell adhesion molecule; α-SMA, alpha smooth actin; 
H&E, hematoxylin and eosin; Endo, endogenous; Trans, transplant. 
and E), suggesting that tumor organoids and the formed tumors can efficiently recruit 
endogenous CAFs. As the transplanted CAFs express RFP, we were able to separate the 
transplanted CAFs and endogenous CAFs by using FACS. The expression levels of some 
CAF markers are indeed substantially different but the pattern is not very clear (Figure 9G).  
Consistently, co-transplantation with human CAFs also promoted tumor formation and growth 
of patient CCA organoids in mice (Figure 10A-C). Immunohistochemistry and 
immunofluorescence staining confirmed the presence of CAFs in the tumors (Figure 10D and 
F). We next isolated the in vivo educated human CAFs from the tumors and compared their 
gene expression with in vitro cultured CAFs. We found a distinct expression pattern of the CAF 
markers, showing a trend of enhanced expression of CAF markers in tumor educated CAFs 
(Figure 10G). Taken together, CAFs support organoids-based tumor formation and growth in 
vivo.  
CAFs protect tumor organoids from drug treatment 
We next examined the effects of CAFs on the response of tumor organoids to the anti-cancer 
drugs including Sorafenib, Regorafenib and Fluorouracil (5-FU). Mouse liver tumor organoids 
were treated with Sorafenib, Regorafenib or 5-FU in the presence or absence of CAFs (Figure 
11A). Although the number of formed organoids are not significantly different, the diameters of 
organoids are significantly larger when co-culturing with CAFs compared with organoids alone 
(Figure 11B-H). Of note, most of the organoids that survived from the treatment were surround 
by CAFs (Figure 11I and J). These results were further confirmed in human liver tumor 
organoids, treated with Sorafenib, Regorafenib or 5-FU in the presence or absence of human 
CAFs (Figure 12A-H). Of note, treatment of Sorafenib, Regorafenib or 5-FU at 5 uMol/ml 
exerted moderate inhibition on cultured CAFs (Figure 11K, 12I).  
To investigate whether these effects are related to paracrine signaling, both mouse and human 
organoids were exposed to conditioned medium of CAFs and treated with Sorafenib, 
Regorafenib or 5-FU (Figure 13A and K). Interestingly, organoids in the presence of CAF 
conditioned medium are more resistant to the treatment, as shown by higher half maximal 
inhibitory concentrations (IC50) (Figure 13B, E, H, L, O, R), and the morphological appearance 
(Figure 13C, F, I, M, P, S). A dynamic response of treatment at different time points revealed 
similar pattern of resistance in the presence of CAF conditioned medium (Figure 13D, G, J, N, 
Q, T). Taken together, these findings demonstrate that CAFs protect tumor organoids from 
anti-cancer treatment.   
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Figure 10. Human CAFs promote the growth of patient CCA organoids formed tumors in vivo. (A) 
2.5*105 human tumor organoids together with or without 2.5*105 human CAFs were transplanted into 
NSG mouse. (B) Representative pictures showed the tumors from mono- and co-transplantation. (C) 
The weight of tumors from mono- or co-transplantation (n = 10 for both groups, **P < 0.01). (D) The 
representative immunohistochemistry staining of EpCAM, α-SMA, H&E and Gomori for tumors from 
mono- or co-transplantation (magnification 400X). (E) The representative confocal image of α-SMA 
expression for tumors of mono- or co-transplantation (magnification 400X, inset magnification 2000X). 
(F) The representative confocal image of EpCAM expression for tumors from mono- or co-
transplantation (magnification 400X, inset magnification 2000X). (G) Expression profile of CAF markers 
for in vivo educated human CAFs from xenograft tumors compared to in vitro cultured CAFs (Educated 
n = 10, in-vitro n = 8). (C, G) Data were presented as mean ± SD, Mann-Whitney U tests. CAFs, cancer 
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associated fibroblasts; CCA, cholangiocarcinoma; NSG, NOD scid gamma mouse; EpCAM, epithelial 
cell adhesion molecule; α-SMA, alpha smooth actin; H&E, hematoxylin and eosin. 
 
Figure 11. Mouse organoids in the presence or absence of CAFs in response to anti-cancer drugs. (A) An outline 
of the experimental strategy used to illustrate the drug administration on mouse tumor organoids with or 
without CAFs. (B-G) Mouse organoids in response to treatment of Sorafenib (4 uM/ml), Regorafenib (3 uM/ml) 
or 5-FU (3.5 uM/ml) with or without CAFs (n = 6). (H) Representative image of treatment for mouse mono-culture 
and co-culture (Magnification 20X). (I-J) Representative confocal image of mouse CAFs, organoids and co-cultures 
in response to treatment of Sorafenib and Regarafenib (Magnification 400X). (K) Mouse CAFs in response to anti-
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cancer drugs (Sorafenib [5 uM/ml], Regorafenib [5 uM/ml], 5-FU [5 uM/ml]; n = 8). (B, D, F) Five organoids for 
each well were randomly measured. (B-G, K) Data were presented as mean ± SD, Mann-Whitney U tests, *p < 
0.05, ***p < 0.001. CAFs, cancer associated fibroblast; 5-FU, Fluorouracil, CTR, control. 
 
Figure 12. Human organoids in the presence or absence of CAFs in response to anti-cancer drugs. 
(A) An outline of the experimental strategy used to illustrate the drug treatment on human tumor 
organoids with or without CAFs. (B-G) Human organoids in response to treatment of Sorafenib (4 uM/ml), 
Regorafenib (3 uM/ml) or 5-FU (3.5 uM/ml) with or without CAFs. (H) Representative image of human 
mono-culture and co-culture with or without treatment (Magnification 20X). (I) Human CAFs in response 
to anti-cancer drugs (Sorafenib [5 uM/ml], Regorafenib [5 uM/ml], 5-FU [5 uM/ml]; n = 8). (B, D, F) Five 
organoids for each well were randomly measured. (B-G, I) Data were presented as mean ± SD, Mann-




CAFs as a vital component of the tumor microenvironment have been extensively 
demonstrated to support cancer development and progression, and to promote treatment 
resistance.[24, 25] The clinical significance of CAFs in disease progression, therapeutic 
response and patient outcome has been widely reported in various types of cancer.[26-28] In 
this study, we found that enhanced expression of CAF markers in liver tumors are associated 
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with poor patient outcome. Contemporary, a major challenge is how to dissect the interactions 
of cancer cells with CAFs in robust experimental models. We successfully established 3D co-
culture systems of liver tumor organoids and CAFs of both mouse and human origins to study 
the interactions between these two cell types. 
 
 
Figure 13. Organoids in the presence or absence of CAFs conditioned medium in response to 
the anti-cancer treatment. (A, K) An outline of the experimental strategy used to illustrate drug 
treatment on tumor organoids with or without conditioned medium of pretreated CAFs. (B, E, H, L, O, R) 
Organoids in the presence or absence of conditioned medium of pretreated CAFs were treated with a 
serial concentration of Sorafenib, Regorafenib or 5-FU, and the IC50 was determined (n = 9; Data were 
presented as mean ± SD). (C, F, I, M, P, S) Representative image of mouse or human tumor organoids 
in the presence or absence of conditioned medium of pretreated CAFs, treated with a serial 
concentrations of Sorafenib, Regorafenib or 5-FU for 10 days of mouse cells and 14 days of human 
cells (Magnification 20X). (D, G, J, N, Q, T) Cell viability assays were performed and measured at the 
indicated times, using mouse or human tumor organoids incubated with indicated anti-cancer drugs and 
parenthesized concentration in the presence or absence of conditioned medium of pretreated CAFs. n 
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= 9. Graphs show means ± SD of data normalized to t = 0,. Mann-Whitney U tests, *P < 0.05, **P < 0.01, 
***P < 0.001. CAF, cancer associated fibroblasts; IC50, half maximal inhibitory concentration; 5-FU, 
Fluorouracil. 
A prominent role of CAFs is thought to shape the stem cell niche to nurture CSCs, whereas 
the conventional 2D culture of immortalized cancer cell lines is far from satisfactory in 
recapitulating the properties of CSCs.[29, 30] The recent development of organoids technology 
that grows embryonic or adult mammalian stem cells-derived 3D organotypic structures in vitro 
has greatly facilitated stem cell research. This now has been extended to the culture of primary 
cancer cells that recapitulates the genomic and structural architecture of the tumor-of-origin, 
and especially CSC compartment.[31] Tumor organoids have been successfully established 
across variety of cancer types, including liver cancer.[4, 5, 32] The co-culture model of 
organoids with CAFs was first pioneered in pancreatic cancer, as pancreatic cancer has the 
most extensive stromal reaction accounting for up to 90% of the tumor volume.[33, 34] In this 
study, we established the co-culture of liver tumor organoids with CAFs. We first cultured 
organoids and CAFs from DEN-induced mouse liver tumors. We have recently shown that 
these organoids can recapitulate the heterogeneity of patient liver cancer types to some 
extent.[5] For patient liver cancer, organoids are much easier to be cultured from CCA 
compared to HCC,[4] and therefore we used CCA organoids for establishing the model. Our 
model systems shall enable the detailed study of interactions between liver cancer cells, 
especially CSCs, with CAFs.  
CAFs secrete a variety of cytokines, chemokines and growth factors to create a tumor-
permissive microenvironment.[35] Many factors like chemokine ligand 5 (CCL-5), CXCL12, 
transforming growth factor beta (TGFβ), insulin-like growth factors (IGF), epidermal growth 
factors (EGF), fibroblast growth factors (FGF), IL-6, IL-8, IL-10 and IL-11 secreted by CAFs 
have an essential role in regulating cancer development.[26, 29, 36-42] In addition to 
biochemical crosstalk, direct contact between CAFs and cancer cells also play a critical role in 
tumor progression. By extracellular matrix remodeling, CAFs facilitate the migration of cancer 
cells.[20] On the other hand, CAFs directly exert a pulling force on cancer cells through 
epithelial to mesenchymal transition (EMT) by mediating N-cadherin and E-cadherin 
expression.[43] These results are in accordance with our findings that CAFs confer growth 
advantages of tumor organoids in co-culture with cell-cell contact and in a trans-well system 
via paracrine signaling. Furthermore, co-transplantation with CAFs promotes organoids-based 
tumor formation and growth in mice. In pancreatic tumor organoids, a Wnt-non-producing 
subtype requires Wnt ligands from CAFs.[33] CAF-derived HGF has been reported to regulate 
liver tumor initiating cells via activation of FRAI in an Erk1, 2-dependent manner.[17] In our 
model, the exact contribution of paracrine signaling and physical interaction, and the underline 
molecular mechanisms, remain to be further explored. 
Recruitment of fibroblasts to tumor stroma is regulated by multiple factors, which is highly 
context-dependent but remains not fully understood. It has been suggested that during tumor 
initiation, CAFs can be differentiated from the local fibroblast population of the epithelial stroma 
up on stimulation by transforming growth factor, whereas at later tumor progression stages, 
CAFs are mainly recruited from distal locations.[44-46] Thus, the origin of CAFs appears 
diverse and can be derived from different sources, such as tissue residual fibroblasts, bone 
marrow-derived cells, endothelial cells, pericytes, vascular smooth muscle cells, or even 
cancer cells that undergo EMT.[47-49] However, most of the previous studies suggest CAFs 
are non-cancer cells. In our study, we found our CAFs are negative for AFP and EpCAM, the 
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markers that are expressed by liver tumor organoids. Furthermore, we did not observe tumor 
formation by transplanting a large number of CAFs into flank of NSG immunodeficient mice. 
These results suggest that phenotypically and functionally our CAFs are not cancer cells. The 
different origin and different context may endow distinct phenotypes and functions of CAFs. 
This may partially explain our exploratory observation that in vitro cultured, transplanted and 
in vivo spontaneously recruited CAFs express different patterns of CAF markers. 
Development of drug-resistance is a relentless clinical challenge for cancer treatment.[50] This 
re-enables tumor growth, cancer cell dissemination and early onset of metastasis. Studies on 
the mechanisms of therapy resistance have primarily focused on the intrinsic properties of 
tumor cells. Emerging evidence has redirected to the role of the organ/tumor-specific 
microenvironment for developing drug resistance. CAFs contribute to treatment resistance 
mainly through impaired drug delivery and biochemical signaling. Remodeled ECM by CAFs 
acts as a physical barrier to inhibit the uptake of anti-cancer drugs by increasing intratumoral 
interstitial fluid pressures and inducing vascular collapse.[51, 52] CAFs-derived soluble factors 
including IL-6, IL-17A, IGF1, IGF2 and nitric oxide can indirectly mediate the development of 
cancer treatment resistance.[51, 53-55] Our study revealed that co-culture with CAFs confer 
resistance of liver tumor organoids to the clinically used anti-cancer drugs including 5-FU, 
Sorafenib and Regorafenib. This effect was recapitulated by adding conditioned medium from 
CAFs. However, whether this effect occurs in vivo and the involved molecular mechanisms 
remain to be further studied.  
A recent study has shown that the CAF population is implicated in immune dysregulation and 
associated with immunotherapy outcome in melanoma patients.[56] Interestingly, cultured 
CAFs from colon tumor, as well as lung cancer, have been reported to express immune 
checkpoint molecule programmed death 1 ligand 1/2, which strongly induce T cell 
exhaustion.[57, 58] CAFs may also indirectly regulate the immune response through ECM 
remodeling by acting as a barrier which block the access of immune cells to cancer cells.[59] 
A co-culture model with human pancreatic cancer organoids, matched stromal and immune 
cells has been recently developed. Thus, we call the further advance of our models by 
incorporating immune cells that shall enable the study of tumor-stroma and tumor immune 
interaction and the assessment of immunotherapeutic such as checkpoint inhibitors in the 
context of T-cell infiltration.[60] Because the clinical benefits of immune-based therapies for 
HCC are evident, and ongoing clinical trials will soon establish their role in management of 
HCC patients.  
In summary, we have successfully established 3D co-culture models of liver tumor organoids 
with CAFs of mouse or human origin. We have revealed the robust effects of CAFs in liver 
cancer nurturing and treatment resistance. These model systems will be helpful for future 
research on the interactions of liver cancer cells with the stromal compartment and facilitate 
therapeutic development.   
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Materials and methods 
 
Mouse liver tumor organoid culture 
Mouse liver tumor organoids were cultured from DEN-treated LGR5-DTR-EGFP mice with histologically 
verified liver tumors. Tumor tissue was minced and digested with a digestion solution: Collagenase type 
XI (0.5 mg/ml, Sigmal Alrich, C9407), Dispase (0.2 mg/ml, Gibco, 17105041), 1% fetal bovine serum in 
Dulbecco’s modified Eagle’s medium (DMEM, 37°C, 30 mins, Lonza,). The tissue debris was allowed 
to settle, and the dissociated cells were pelleted and washed in Advanced DMEM/F12 (Invitrogen) and 
seeded in Matrigel (BD bioscience, 356231). After the Matrigel became solid, expansion medium was 
slowly added in. Mouse organoid expansion medium (OEM) was based on mouse organoid basic 
medium (OBM, Advanced DMEM/F12 supplemented with 1% Penicillin/Streptomycin [Life technologies, 
15140122], 1% Glutamax [Westburg BV, BE-17-605E/U1], 10 mM HEPES [Westburg BV, be-17-737E]), 
B27 (2% vol/vol, Life Technologies Europe BV, 17504-001), N2 (1%, vol/vol, Life Technologies Europe 
BV, 17502001), N-acetylcysteine (1.25 μM, Sigma–Aldrich, A7250), gastrin (10 nM, Sigma Aldrich, 
G9145), epidermal growth factor (EGF, 50 ng/ml, PeproTech, AF-100-15), R-spondin 1 (10% vol/vol, 
conditioned medium produced by 293T-H-RspoI-Fc cell line), fibroblast growth factor 10 (FGF10, 100 
ng/ml, PeproTech, 100-26), nicotinamide (10 mM, Sigma–Aldrich, N0636) and hepatocyte growth factor 
(HGF, 50 ng/ml, PeproTech, 167100-39-0500). For the initial 3 days, the organoids were cultured with 
organoid initiation medium (OIM) supplemented with Noggin (10% vol/vol, conditioned medium 
produced by 293T-HA-Noggin cell line), Wnt3a (10% vol/vol, conditioned medium produced by L-Wnt3a 
cell line), and Y-27632 (10.5 μM, Sigma-Aldrich, Y0503).  
To passage, cold OBM was used to collect the organoids. Organoids were mechanically dissociated 
into small pieces by pipetting, and then seeded back into fresh Matrigel again. Passaging was performed 
at a ratio from 1:6~1:10 per week according to the growth of the organoids. To create frozen stocks, 
organoids were passaged and mixed with Freeze medium (90% FBS supplemented with 10% DMSO) 
using standard procedures. Cultures were thawed using standard thawing procedures, washed once 
with OBM, and seeded in Matrigel (Corning BV, 356231) with OIM for the first passage. 
 
Isolation and culture of mouse CAFs 
Mouse CAFs were isolated from DEN-induced Rosa26-mT mice with histologically verified liver tumors. 
CAFs were isolated by using an outgrowth isolation. Tissue from tumor edge was minced and digested 
with a digestion solution: Collagenase type XI (0.5 mg/ml, Sigmal Alrich, C7657), Dispase (0.2 mg/ml, 
Gibco, 17105041), 1% fetal bovine serum in Dulbecco’s modified Eagle’s medium (DMEM, Lonza) for 
30 mins to 2 hours at 37°C in a water bath. Then the sample was filtered by using a filter tip and 
subsequently quenched in 10% FCS RPMI 1640 medium. The pellet that contained tumor debris was 
plated in a T25 flask and fibroblast was allowed to grow out and attached to the wall of the flask. To 
avoid cancer cell contamination, established cell culture was passed at least 3 generations. The medium 
was changed every 2 days. CAFs were sub-cultured when reaching 80% confluent, banked and used 
for experimental studies at passages 4-8. The fibroblasts were checked by using immunofluorescence 
of staining of the fibroblast markers α-SMA (1:1000, Abcam, ab124964), FAP (1:500, Abcam, ab28244) 
and negative staining for the HCC cell (AFP, 1:50, Sigma-Aldrich, SAB3500533), epithelial cell marker 
(EpCAM, 1:1000, Abcam, ab71916), endothelial marker (CD31, 1:50, Abcam, ab28364) and immune 
cell marker (CD45, 1:200, cell signalling, 13917) to exclude contamination of other cells types before 
subjected to experiments.  
 
Human CCA organoids and CAF culture 
OEM for culturing human CCA organoids was based upon OBM, B27(2% vol/vol), N2 (1% vol/vol, 
Invitrogen), N-acetylcysteine (1.25 μM), gastrin (10 nM), Rspo-1 conditioned medium (10% vol/vol), 10 
mM nicotinamide, recombinant human EGF (50 ng/ml), recombinant human FGF10 (100 ng/ml), 
recombinant human HGF (25 ng/ml), 10 μM Forskolin (Bio-Techn, 1099), 5 μM A8301 (Bio-Techne, 
2939/10), and 10 μM Y27632. Upon attainment of dense tumor-derived organoids (2-3 weeks after 
isolation), they were passaged by mechanical dissociation into small fragments via trituration with pipet, 
and transferred to fresh Matrigel in the previously defined OEM. Medium was refreshed every 2-3 days 
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and organoids were passaged in 1:2-1:10 split ratio according to the growth of the organoids. For 
isolation and culture of human CAFs from HCC and CCA tumors, the protocol was similar as isolation 
and culture of mouse CAFs.  
The study was approved by the medical ethical committee of Erasmus Medical Center. In addition, the 
study protocol conforms to the ethical guidelines of the 1975 Declaration of Helsinki. 
 
Co-culture of tumor organoids and CAFs 
Cold organoid basic medium (OBM) was used to collect the organoids. Organoids were mechanically 
dissociated into small pieces by pipetting (20-30 times) and further digested into single cells by Trypsin-
EDTA (gibco, 37°C, 2 mins). Fluorescence-activated cell sorting sorter (BD FACS AriaTM II) was used 
to further isolate the single living cells. Propidium iodide staining was used to exclude dead cells. 
Forward scattered light-width (FSC-Width) with FSC-Area and then side scattered light-width (SSC-
Width) with SSC-Area gates were used to select the single cells. CAFs were collected when they were 
80% confluent in the flask. After digesting into single cells, fluorescence-activated cell sorting sorter was 
used to further isolate the single living cells. For co-cultures, different concentrations between CAFs and 
tumor organoids cells were sorted into 48 wells or 96 wells plates with OBM contained 1% Matrigel. 
Then the cells were centrifuged in 1000rpm for three minutes and incubated in the plate overnight. The 
supernatant was removed on the second day and plastic surface of the wells was coated with Matrigel 
to provide biomatrix for 3D organoid growth. When Matrigel became solid, mouse OEM or human OEM 
were added. After co-culturing organoid cells with CAFs of mouse origin for 7 days and those of human 
origin for 14 days, the diameters of organoids was measured by using scale tool from ZenLightEdition 
Software. 
 
Trans-well culture  
For Trans-well culture, 1000 CAF cells were seeded on top of the trans-well membrane (1 μm pore size, 
Greiner Bio-One, 662610) and 500 single organoid cells growing in the lower compartment in 24-well 
plates for 10 days for mouse cells and 14 days for human cells.  
 
Alamar blue assay  
CAFs or organoids were incubated with Alamar Blue (Invitrogen, 1:20 in DMEM, DAL1100) for two hours 
(37°C), and then medium was collected for analysis of the metabolic activity of the cells. Absorbance 
was determined by using fluorescence plate reader (CytoFluor Series 4000, Perseptive Biosystems) at 
the excitation of 530/25 nm and emission of 590/35 nm. Matrigel with medium only was used as blank 
control.  
 
Cell titer assay  
After culturing organoids 10 days for mouse cells or 14 days for human cells in trans-well, a volume of 
CellTiter-Glo 3D reagent (Promega, G9681) equal to the volume of cell culture medium was added in 
each well. The contents were mixed vigorously for 5 minutes to induce cell lysis. The plate was incubated 
at room temperature for an additional 25 minutes to stabilize the luminescent signal, then luminescence 
was recorded.  
 
Quantitative real-time RT-PCR  
Total RNA was isolated using Macherey-Nagel NucleoSpin RNA II kit (Bioke, Leiden, Netherlands) and 
quantified using a Nanodrop ND-1000 (Wilmington, DE, USA). Quantification was measured with 
Nanodrop ND-1000 (Wilmington). RNA was then converted to cDNA by using a cDNA Synthesis kit 
(TAKARA BIO INC.). Real-time PCR reactions were performed with SYBRGreen-based real-time PCR 
(Applied Biosystems®) and amplified in a thermal cycler (GeneAmp PCR System 9700). For cells 
collected from murine tissues, glyceraldehyde 3-phosphate dehydrogenase (Gapdh) gene was used as 
reference. All qRT-PCR primers are listed in Table 1. 
Organoids-based tumor formation assay in NSG mice  
Five to six weeks old NSG immunodeficient mice were used for in vivo tumorigenesis assay. 2.5*105 
mouse or human organoids together with or without 2.5*105 CAFs in 100 ul Matrigel subcutaneously 
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inoculated into the flanks of the mice. 2.5 million CAFs alone were injected as control. Tumor formation 
and tumor weight were examined and determined after 1-2 months. Mice were housed in a room 
maintained on a 12h light/dark cycle (light on at 6 a.m.) with food and water provided ad libitum. All 
animal experiments were approved by the Committee on the Ethics of Animal Experiments of the 
Erasmus Medical Center.  
 
Flow cytometry assay and cell sorting  
For FACS analysis, single cells derived from liver and organoids were suspended in DMEM plus 2% 
FBS. Cell suspensions were analyzed using a BD FACSCalibur or BD FACSAriaTM II. For FACS sort, 
a BD FACSAriaTM II cell sorter was used to isolate the target cell population. Single cell suspensions 
of tumor cells were labelled with PE anti-human CD140a Antibody (PDGFRα, 5 µl per million cells in 
100 µl volume, Biolegend, 323506), Pacific Blue anti-human CD31 Antibody (2 µl per million cells in 100 
µl volume Biolegend, 102422), FITC anti-human CD326 Antibody (EpCAM, 5 µl per million cells in 100 
µl volume, Biolegend, 324204), Alexa Fluor 700 anti-human CD45 Antibody (1 µl per million cells in 100 
µl volume, Biolegend, 135906) and PE anti-mouse CD140a Antibody (PDGFRα, 5 µl per million cells in 
100 µl volume, Biolegend, 135906). For cell sorting, PDGFRα+ for CAFs were collected and processed 
for RNA extraction and qRT-PCR.  
 
Immunofluorescence  
CAFs were fixed in 4% paraformaldehyde (PFA) for 1 hour and permeabilised by incubation in PBS 0.2% 
Triton 100 (Sigma-Aldrich, X100) at room temperature for 20 minutes. Samples were blocked for 1 hour 
at room temperature in blocking buffer: 5% BSA PBS 0.05% Tween 20 (Sigma, P9416). Then cells were 
incubated with primary antibody anti-alpha-SMA (1:1000, Abcam, ab124964), anti-FAP (1:500, Abcam, 
ab28244), anti-EpCAM (1:1000, Abcam, Ab71916), anti-AFP (1:50, Sigmal-Aldrich, SAB3500533), anti-
CD31 (1:50, Abcam, ab28364) and anti-CD45 (1:200, Cell signaling, 13917s) in blocking solution in a 
wet chamber overnight at 4°C. After three washes of 15 minutes in PBS, the samples were mounted 
and analyzed by using a Zeiss LSM510meta confocal. 
 
Tissue histology, immunohistology and immunofluorescence  
For histological analysis, tumors were dissected into 10% neutral buffered formalin, embedded in 
paraffin blocks and serial sections were taken. Paraffin-embedded tissue sections were rehydrated 
before antigen retrieval using pH 6 sodium citrate buffer. After blocking endogenous peroxidase (DAKO 
peroxidase block), sections were incubated with primary antibodies anti-Alpha-SMA (1:1000, Abcam, 
ab124964), anti-EpCAM (1:1000, Abcam, Ab71916) overnight. Then sections were incubated with 
second antibody for 1 h at room temperature. The slides were placed in DAB substrate (Abcam, ab64238) 
and incubated until desired color is achieved (30s - 3mins). Consequently, the slides were 
counterstained with haematoxylin. Images were acquired with a Zeiss Axioskop 20 microscope.  
For immunofluorescence, samples were further dehydrated with 30% sucrose (Sigma-Aldrich, S0389, 
4°C, overnight), stored at -80°C and then sectioned at 8 μm for further analysis. Images were acquired 
with a Zeiss LSM510meta confocal microscope.  
 
Drug treatment  
Organoids and CAFs were digested by using trypsin-EDTA into single cells. By using FACS sorting, 
2000 mouse organoids or 4000 human organoids cells with or without CAFs in a 1:10 ratio were seeded 
and treated with Sorafenib (4 uMol/ml, Bi-connect BV, SC-357801A), Regorafenib (3 uMol/ml, Bio-
connect BV, S1178) and 5-FU (3.5 uMol/ml, Sigmal Aldrich, F-6627) for 7 days. The number of formed 
organoids were counted and their diameters were measured.  
To investigate the paracrine effect of CAFs on tumor organoids, Conditional medium of CAFs (about 
70% confluent) was collected. In order to recapitulate the effects of anti-cancer drugs on CAFs in co-
culture models, CAFs were primed by pretreating with 5 uM Sorafenib, 5 uM Regorafenib or 5 uM 5-FU 
in 10% FCS RMPI1640 medium for 12 h. Then the supernatant was removed and the cells were washed 
by PBS for three times. CAFs were then cultured in 0% FCS RMPI 1640 medium for another 12 h. After 
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removing medium and washing three times with PBS, 10 ml OBM was added and conditioned for 12 h. 
The supernatant were then collected and filtered by a 40um filter.  
For IC50 analysis, 5000 mouse organoids or 10000 human organoids cells were cultured with 
conditioned or unconditioned medium with a series of concentrations of Sorafenib, Regorafenib or 5-FU 
for 10 days of mouse cells and 14 days of human cells. Cell viability was measured by Alamar blue 
assay. To study the dynamic response of treatment at different time points, 5000 mouse or human 
organoids cells were cultured with conditioned or unconditioned medium with Sorafenib (3.5 uMol/ml), 
Regorafenib (3 uMol/ml) and 5-FU (3.5 uMol/ml) for 0-192 h. Alamar blue assay was used to determine 
cell viability.  
 
Online database  
We used a database of GEPIA gene expression profiling interactive analysis (http://gepia.cancer-
pku.cn/)[61] to evaluate the association of patient overall survival with the expression of target genes in 
tumor and normal liver tissue as well as at different stages of tumors. 
 
Statistics analysis 
Prism software (GraphPad Software 8.0) was used for all statistical analysis. Data were presented as 
mean ± standard deviation (SD). For comparing gene expression in tumor tissue and surrounding tissue 
from online database, One-way ANOVA was used to compare the difference between groups. For 
overall survival rate between high and low expression of genes, Log-Rank or Kaplan-Meier was used to 
compare the difference between groups. For statistical significance of the differences between groups, 
we used Mann-Whitney U-test. For Differences were considered significant at a P value less than 0.05. 
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In this thesis I have focussed on diverse but to certain extents related liver diseases. 
A common denominator might be that they either predispose or constitute cancer of 
the liver. Liver cancer, which mainly includes the disease entities cholangiocarcinoma 
(CCA) and hepatocellular carcinoma (HCC) display a rapid increase on an already high 
incidence and hence liver cancer has become a member of the group of most prevalent 
types of cancers globally.1, 2 In view of the inadequacy of current options with respect 
to clinical management, it is not surprising to note that liver cancer constitutes one of 
the most common causes of oncological death and as a consequence this group of 
diseases is considered to be a major global public health challenge.3 Progress with 
respect to better therapeutic options is frustratingly inadequate and slow.4 The body of 
work in this dissertation was started from the idea that improved prevention and 
treatment of liver cancer needs improved understanding of not only the molecular and 
cellular factors governing its initiation and that determine treatment success, including 
side effects, but also the epidemiological factors driving nosidynamics (temporal 
changes in disease incidence). In this respect one should take into account that some 
inflammatory conditions like hepatitis C virus (HCV) infection, hepatitis E virus (HEV) 
or fatty liver disease predispose to cancer development. Thus I also undertook to start 
a quest for obtaining a better understanding of inflammatory disease in the liver. The 
preceding chapters have described the fruits resulting from all these endeavors, while 
in the present discussion, I strive to summarize these results and to discuss the main 
discoveries made in the light of the body of contemporary biomedical literature. 
Full comprehension the overall approach taken requires an overview of existing 
relevant literature and thus prior providing an outline of this thesis, in Chapter 1, I 
provide a concise review on selected aspects of inflammatory disease and stem cells 
in the liver. In chapter 2, I further elaborate on this by interrogating the compendium of 
currently available biomedical literature on establishing how droplet dynamically 
interact with other cellular organelles to exert a variety of biological functions. This 
relates to chapter 3,4,5 where I investigate direct acting antiviral drugs (DAAs) for the 
treatment of Hepatitis C. Hepatitis C is an important inflammatory condition of the liver, 
and a precursor to cirrhosis and HCC. DAAs are highly effective and target viral RNA 
replication at the stage the virus co-localizes with lipid droplets. Unfortunately, in this 
thesis I was not able to study how my results on DAA and HCV replication relate to the 
co-localization of HCV core protein with lipid droplets, but I feel my results on the 
effectiveness and safety of direct-acting antivirals in eradicating HCV-GT1 in transplant 
recipients provide important groundwork for a future successor Ph.D student in this 
respect. Also my work on the proliferation promoted effect of direct-acting antivirals in 
hepatocellular carcinoma cells might be seen in this light. Moreover fatty liver disease 
(chapters 6,7,8) closely relates to lipid droplet formation and their growth, and thus my 
efforts on the prevalence, incidence, disease progression and clinical outcome of fatty 
liver disease may provide a solid foundation for a future successor to my work. As a 
future post doc in my host laboratory I might even be able to guide some of the efforts 
involved. As stated the final consequence of both viral hepatitis and fatty liver disease 
is cancer development and I attempted to make progress here as well. To this end I 
studied the role of cancer-associated fibroblasts (CAFs), the major component of tumor 
microenvironment, in proliferation and drug-resistant of liver tumor cells and the role of 
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LGR5-marked tumor initiating cells in liver cancer (chapter 9,10,11). Together I hope 
this thesis constitutes a valuable contribution to the scientific field of hepatic disease.  
Hepatitis 
HCV has either direct or indirect roles in carcinogenesis and is thought to act mainly 
through fibrosis in this respect, although viral effect on ß-catenin signaling in 
hepatocytes have also been proposed to be relevant.5 Patients with advanced fibrosis 
or cirrhosis are at increased risk for carcinogenesis because chromosomal alterations 
that occur in fibrotic tissue are associated with tumor formation.6 In addition, HCV may 
promote carcinogenesis through chronic inflammation or stimulation of hepatic stellate 
cells with subsequent fibrosis as a result. Chronic liver inflammation has been 
associated with a shift in the aspect of signaling by transforming growth factor beta 
resulting in a change from tumor suppression to fibrosis and carcinogenesis in 
response to this morphogen.7 Ongoing inflammation provokes repeated cycles of cell 
death and regeneration in hepatic tissue 8 Such repeated cell cycling, especially in an 
inflammatory environment, is associated with accumulation of mutations that may 
transform hepatocytes to malignant cells through a multistage process. However, 
chronic inflammation by itself does not seem to promote carcinogenesis because 
patients with autoimmune liver disease, who have persistent chronic liver inflammation 
from the autoimmune process, rarely develop HCC. HCV nonstructural protein genes 
promote fibrosis partly through inducing transforming growth factor beta expression 
and activating hepatic stellate cells.9 This has been demonstrated in cell culture 
systems where sera from HCV patients stimulate hepatic stellate cell proliferation, 
which subsequently leads to fibrosis.9 In addition, HCV core protein may promote 
carcinogenesis. In a transgenic mouse model HCV core protein led to the development 
of HCC without the genetic aberrations typically seen in carcinogenesis, such as in 
colon cancer.10 Previously, work in my host laboratory had shown that Hepatitis E virus 
infection induces mitochondrial fusion to facilitate viral replication by interfering with 
cell-autonomous innate immunity (Yijin Wang, thesis, ISBN: 978-94-6169-903-9). 
Interestingly, some studies also indicated that moderate tissue damage provoked by 
HEV infection could be in certain circumstances responsible of the progression of the 
chronic liver disease toward HCC. The importance of virus-induced inflammation in the 
context of liver cancer had, however, not been addressed prompting my further 
investigations in this respect.  
To this end in Chapter 3, we compared the different combinations of DAAs in 
eradication of HCV GT1 recurrence for post-transplant organ recipients. Reinfection of 
liver allografts is universal in patients with pre-transplantation viremia and occurs at 
reperfusion, only a few hours after transplantation HCV RNA levels increase reaching 
peak levels by the fourth postoperative month. Changes induced by HCV infection of 
the graft can be demonstrated in 70-90% of recipients after 1 year and in 90-95% after 
5 years, illustrating the universality of post-transplant HCV infection. Clinical course, 
severity of recurrent disease and outcome though are highly variable.11 The most 
common pathological course is a kind of progressive chronic liver disease not 
dissimilar to that seen in the immunocompetent population (transplantation patients 
are routinely place on immunosuppressive regimens to prevent graft rejection), but are 
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characterized by higher viral loads and faster progression of fibrosis (which is a 
consequence of an early activation of stellate cells).12 It is generally assumed that the 
immune response is the mediator of hepatocyte injury, but how this relates to 
immunosuppressive regimens these patients receive remains little understood and 
requires further investigation. The mean time interval from transplantation to the 
establishment of cirrhosis is 9.5 years. Due to this high speed of liver disease 
progression in these transplanted patients, re-transplantation is often necessary and 
hence HCV recurrence accounts for about 30-40% of elective re-transplantation. My 
results show that DAA treatment is clinically effective with respect to GT1 HCV 
recurrence in liver transplantation recipients. Of note, an unbalanced application of 
DAAs for GT1 HCV recurrence appears to exist when different regions are compared. 
There is a trend that use of first-class of DAAs is confined to European and North 
American countries. For many countries, even Japan is an example, cost-effectiveness 
more as achieving a sustained virological response (SVR) per se is the first 
consideration for clinicians.13, 14 However, in Asian, Pacific, or African countries, HCV 
has a distinct epidemiology, also due to that DAA availability is subject to economic 
constraints and regulatory rules.15 In our subgroup analysis of liver transplant 
recipients with SVR12 rate and fibrosis data (METAVIR Fibrosis Score), our detailed 
analysis supports the latest evidence-based guidelines that DAAs also can be 
effectively used in eradicating HCV in patients with advanced fibrosis or cirrhosis post 
LT.16 We observed a higher SVR12 pooled estimate proportion in patients with mild 
fibrosis compared with those of advanced fibrosis or cirrhosis, with a trend favoring 
SVR12 in patients with mild fibrosis. Our results indicated that the capability of HCV 
eradication by DAAs may be correlated with the levels of liver fibrosis or cirrhosis. 
Therefore, I recommend DAA treatment early after transplantation. 
In Chapter 4, I further explore this line of research and show that the DAA drug 
Sofosbuvir may induce a proliferation promoting effect of liver cancer cells in vitro. I 
observed increased single cell-based clonogenic capability in all four HCC cell lines. 
This is reflected by the significantly increased number and size of formed colonies. I 
interpret these unexpected results as having important implications and explaining as 
yet not-understood clinical observations. In fact, higher risk of HCC development has 
been observed in HCV patients with advanced diseases (e.g. cirrhosis),17 or previously 
treated for HCC (e.g. ablation, resection, chemoembolization18 or liver 
transplantation19). Although the effects seen in such studies are often poo-pooed by 
attributing such results to bias in selection, my results may indicate a direct promoting 
effect of DAAs on the rare preexisting transformed tumor cells in the cirrhotic liver, the 
residual HCC cells that are not completely eradicated by treatment, or the circulating 
tumor cells in the transplant patients. Despite the low number of these tumor cells, they 
are likely resemble the so called cancer stem cells that are resistance to chemo- or 
radiotherapy but responsible for tumor initiation, treatment relapse and recurrence after 
surgical operation.20 Thus, DAAs are likely not to have a universal but rather specific 
effects on particular patients in respect to the risk of HCC development; whereas the 
current clinical studies are unable to fully resolve the ongoing debate. Complicating 
matters here is various studies indicate a role for immune cell dysfunction,21-25, 
changes in the immune cytokine milieu 26, 27 and activation of angiogenesis 28 as well. 
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Thus, the distinct not mutually exclusive interpretations are possible and further 
investigations are necessary to address this issue. 
 
Chapter 5 is a bit of the odd man out in this thesis as I discuss in this chapter global 
HEV seroprevalence. Although one-third of global population live in HEV endemic 
areas at risk of infection, the true burden of HEV among the world remains largely 
unknown. By retrieving data from 75 countries of the six inhabited continents, I 
estimated that 12.47% of the global population, corresponding to approximately 939 
million individuals, has experienced past infection of HEV based on their seropositivity 
of anti‐HEV IgG antibody. Our study reconfirms high seroprevalence of HEV in Asia 
and Africa.29, 30 However, the HEV prevalence in Europe was lower than observed in 
a previous study.31 The possible explanation for these disparities could be that these 
other reports involved collecting fewer studies and included relatively small size 
populations and were thus prone to more bias. Substantial differences in sensitivity 
and specificity of the anti‐HEV IgG ELISA kits from different manufacturers is an 
important consideration as well.32, 33 I largely agree with others that the Wantai assay 
has the highest sensitivity and fortunately this assay is the one that has been most 
widely used. Accumulating knowledge on HEV biology and transmission routes has 
facilitated the identification of risk factors for the infection. A wide range of domestic or 
wild animals have been recognized as reservoirs for the zoonotic strains. As expected, 
consumption of raw meat is an important risk factor revealed by my meta‐analysis. 
This is in line with previous reports that humans with occupational exposure to pigs are 
at a high risk for HEV infection.34, 35 The host range for HEV is ever expanding and 
cross‐species infections commonly occur.36 Intriguingly, recent evidence has indicated 
that companion animals including dogs, cats, rabbits and horses might be accidental 
hosts for HEV and might constitute a source for HEV transmission to human.37-39 In 
this study, we found that people who frequently contact with dogs have higher anti‐
HEV IgG seropositivity. This was not found in people who contact with cats, but the 
number of studies is very limited. Previous studies have indicated the differences of 
HEV seroprevalence between rural and urban areas.40-42 We found that rural compared 
to urban residents have higher risk of HEV infection. This largely agrees with our 
findings that high exposure to soil is also a risk factor. Thus, my results bear important 
implications for assessing the global burden and devising preventive measures for 
controlling HEV infection.  
 
Fatty liver disease 
Non-alcoholic fatty liver disease (NAFLD) was first described as a distinct clinical entity 
four decades ago. However, the condition has become the center of attention within 
hepatology owing to its high prevalence and growing contribution to the burden of end-
stage liver disease in the general population. It is estimated that the burden of end-
stage liver disease will increase 2–3 fold in both Western nations as well as in several 
Asian countries by 2030. Although fatty liver associated with metabolic dysfunction is 
common, there is no approved drug therapy. While pharmacotherapies are in 
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development, response rates appear unfortunately modest. The heterogeneous 
pathogenesis of metabolic fatty liver diseases and inaccuracies in terminology and 
definitions necessitate a reappraisal of nomenclature to inform clinical trial design and 
drug development. The old terminology NAFLD does not reflect current knowledge and 
metabolic (dysfunction) associated fatty liver disease “MAFLD” was suggested as a 
more appropriate overarching term. This opens the door for efforts from the research 
community to update the nomenclature and sub-phenotype the disease in order to 
accelerate the translational path to new treatments and this consideration drove import 
a significant part of the research effort described in this thesis.  
In chapter 6, I included 578 studies and ventured to comprehensively estimate the 
global prevalence, incidence, disease progression and outcomes of NAFLD. The 
overall prevalence of NAFLD in the general population is 29.38% (95% CI 28.09-30.69) 
regardless of the diagnostic techniques employed to reach diagnosis. Extensive earlier 
work, however, suggested a principle importance of technique when diagnosing 
NAFLD. Arguments have been raised against the application of liver enzymes for 
diagnosing NAFLD because normal levels of these enzymes have been widely 
observed over the entire clinical spectrum of NAFLD and thus use of enzymes leads 
to underdiagnoses.43 In line with this, I also observed that the prevalence of NAFLD 
diagnosed by elevation of liver enzymes yielded a substantially lower rate compared 
to that of liver biopsy and imaging modality based diagnosis. Ultrasound was the most 
commonly used diagnostic technique for NAFLD diagnosis with an observed rate of 
prevalence rate of 30.49% (95% CI 29.55-31.43). My pooled estimates of the odds 
ratios for risk factors are largely in line with previous studies with some subtle 
differences being noted by me.44 Obesity, male sex, obesity, development of metabolic 
syndrome as well as hypertension appear major risk factors. More importantly, I 
observed an annual increase in the incidence of NAFLD-associated HCC which 
exceeded previously published estimates. However, exact HCC incidences are difficult 
to estimate because in some cases of NAFLD-related HCC there is no preceding 
cirrhosis.45 Also, some NAFLD/NASH patients that are co-infected with hepatitis B 
virus, hepatitis C virus or have other metabolic diseases cannot be included in this 
estimate of NAFLD-related HCC incidence. Given the already high and ever increasing 
burden of NAFLD and NASH, the incidence of related HCC is expected to grow. 
In chapter 7, a systematic review and a meta-analysis based on existing 
epidemiological data on fatty liver disease in overweight or obese children and 
adolescents, were pooled for estimating for MAFLD prevalence. The prevalence of 
obesity has nearly tripled since 1975, and this parallels the growth of the fatty liver 
disease epidemic. Strong associations between obesity and prevalence of fatty liver 
disease have been well-documented, both in children and adolescents.46 A previous 
study attempted to visualize the dynamics in NAFLD prevalence in adolescents aged 
12 to 19 years using data from different periods from the NHANES database. Strikingly, 
the prevalence of NAFLD has substantially risen from 3.9% in 1988-1994 to 10.7% in 
2007-2010.47 A recent meta-analysis estimated that the NAFLD prevalence rate in 
overweight or obese children from general population was 12.5% and 36%, 
respectively. NAFLD prevalence among children based on child obesity clinics has 
been reported to be 34%,48 but we observed a much higher (1.5 fold) rate of MAFLD 
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in this population. This discrepancy may be attributed to differences in disease 
definition between NALFD and MAFLD, and/or population selection. NAFLD could 
represent an umbrella term for multiple underlying sub-types which underestimates the 
prevalence of fatty liver disease.49 
In chapter 8, I attempted to estimate the global prevalence of MAFLD among 
overweight or obese adults and my results suggested that this prevalence exceeds 
50%. Alarmingly, the prevalence rate is rising further even still, at least when the latest 
10 years are compared to the preceding decade. Within the NAFLD population, recent 
estimates suggest that 60% are lean or non-obese individuals 50 and thus 40% are 
expected to be overweight or obese people. In the general population, global 
prevalence of NAFLD has been estimated to be 25%, as based on data from 1989 to 
2015,43. A recent study calculated the prevalence of lean and non-obese NAFLD to be 
17%.50 Apparently, estimations of NAFLD prevalence in the obese population are far 
from accurate as these estimates range from 50% to 90%.51 One study based on liver 
histology reported the prevalence of steatosis as being 15% in non-obese individuals, 
65% in persons with obesity, and 85% in extremely obese patients.52 Because liver 
biopsy is only indicated for specific patients, these results cannot be generalized. 
Distinct from these historical studies, I now made a first step to quantify MAFLD 
epidemiology in overweight and obese adults. Nevertheless, the relationship between 
MAFLD and BMI is complex influenced by many factors, such as racial/ethnic 
background and genetic variations in specific genes, thus requiring further in depth 
investigation. 
Cancer stem cells 
Comprehending the medical biology of cancer stem cells remains difficult, but may 
ultimately also lead to improved clinical management. In this thesis I tried to use 
organoids to obtain better understanding of cancer stem cells. To this end I exploited 
the still relatively new organoid technology. Organoids denominate stem cell derived 
organ-like 3D structures. Such organoids system do not only provide a promising 
platform for stem cell biology research, but might be used for modeling a wide range 
of diseases.53 Stem cells in cancer are thought to underlie tumor initiation and growth, 
therapy resistance and tumor recurrence.54 In my thesis I concentrated on LGR5, the 
leucine-rich-repeat-containing G-protein-coupled receptor 5, that marks a group of 
stem cells proliferating after liver injury induced by carbon tetrachloride (CCL4).55 In 
intestinal and colorectal carcinoma, LGR5 marks a cancer stem cell population. The 
role of this group of stem cells in liver cancer remained, however, obscure at best. 
My study established that LGR5 cells were induced by DEN injection (a procedure that 
evokes pre-cancerous liver damage often showing further progression). Furthermore, 
I observed that these LGR5 cells have a much stronger ability for tumor initiation (i.e. 
the capacity to form new organoids but also in vivo. I describe the findings involved in 
Chapter 9 and Chapter 10. I also reported that the fraction of LGR5 cells was 
significantly higher in tumor tissue when compared to the tissue surrounding the tumor 
(Chapter 10). To further demonstrate the function of LGR5 cells, we established a 
organoid culture system from primary liver tumors (Chapter 9). Employing this model, 
we observed that tumor LGR5 cells have stronger in vitro organoid initiation ability and 
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in vivo tumor initiation capability. We also revealed that LGR5 positive cells were more 
resistant to treatment, compared to LGR5 negative cells. More interestingly, the 
ablation of the LGR5 expression cells in liver tumor would impede the in vivo tumor 
formation. Studies in colon cancer have indicated that the reduction of the size of the 
LGR5 compartment impedes both the growth of the primary tumors as well as their 
metastasis.56  
Cancer associated fibroblasts 
Following my investigations of the liver cancer cells proper, I decided to explore the 
dependency of these cells on their environment. The cancer-associated fibroblasts 
(CAFs), which constitute a major component of tumor microenvironment, play a role in 
cancer progression but also in drug resistance of these cells in general.57, 58 I attempted 
to determine their role in liver cancer by creating a model that is in essence a co-culture 
system of these CAFs and the cancer cells. I reasoned that by employing such cultures, 
I might be able to establish a ‘more clinically relevant’ tumor model that better mimics 
the actual situation as it occurs in vivo. Among the multitude of possible intercellular 
interactions of the cancer cells with their tumor microenvironment, the reciprocal 
interaction between fibroblasts and cancer cells is postulated to contribute to tumor 
initiation, but also progression and eventual metastasis, in many cancer types, 
although its role in liver cancer stays largely uncharacterized.59, 60 Enticingly, these 
models could also be used to test anticancer agents.61 Thus I decided to explore this 
angle of the liver cancer process. 
In Chapter 11, I present an organoid-based co-culture model that combines tumor 
organoids with CAFs. I do observe that proliferation of tumor cells is significantly 
stimulated in these co-cultures when I compare these to the control group. Because I 
feel that the in vivo is more alike to co-cultures as compared to competing technologies, 
I think that the reciprocal interaction between the tumor organoids with the fibroblasts 
that I uncovered is best interpreted as that the co-culture system is more suitable for 
drug screening when compared to conventional technology. I addition, this system 
should help me dissecting the role of the tumor microenvironment in the liver cancer 
process. The mechanisms that may explain the trophic effects of co-culture include the 
induction of epithelial-to-mesenchymal transition (EMT) in the cancer cell compartment 
and this may predispose to metastasis. Furthermore, induction of increased stemness 
(which is associated with therapy resistance) and a metabolic reprogramming (which 
is a hallmark of cancer cells) are important here as well, I feel. In conjunction these 
CAF-mediated effects on the tumor cells can explain tumor progression and therapy 
failure.62, 63 Disregarding the progress made in understanding CAF biology, I also feel 
my model can be of further importance to the field because most of the current 
investigations are based on in vitro assays and work involving a limited number of 
immortalized cell lines, whereas my model can work directly with cells obtained from 
patients and may also capture the variety in cell subtypes better. I thus hope that these 
studies may give more insight to the activity of CAFs and interaction between CAFs 
and cancer cells in turn producing superior therapy. 
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However, despite the large amount of work that has been done, more efforts are 
needed in this area. If, however, they prove successful, it may well prove possible to 
translate CAF-directed anti-cancer strategies from the bench to the clinic. 
A further important point emerging from my studies is that the targeting of the cancer 
stem cell system is useful as it hampers the potential of the cancer for recovering from 
a chemotherapeutic insult. The apparent advantage of the specific targeting of cancer 
stem cells such as the LGR5 cells employed in this thesis is that it opens a window to 
a more superior clinical effect of patient management and potentially leads to long-
term therapeutic benefit. If these observations can be extrapolated to other forms of 
oncological disease well, my studies might foster the generation a framework that 
allows developing novel therapeutic approaches for oncological disease in general. 
Overall I have tried in this thesis to address many aspects of cancer and also 
inflammation in the field of hepatology and I hope the studies described in the above 
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De lever, een groot lichtbruin orgaan dat rechtsboven in de buik onder het middenrif 
gelegen is, vormt één van de belangrijkste structuren van het lichaam. Het orgaan dat 
vaak terecht beschreven wordt als de biochemische fabriek van het lichaam, vervult 
talrijke functies, met name bij de verwerking en afvoer van afvalstoffen, de productie 
en opslag van energie en de productie van belangrijke eiwitten. Ongelukkigerwijze, 
kan de lever ook ziek worden en zo dan ook de bron zijn van veel menselijke ellende 
en verdriet. Met mijn promotieonderzoek en dit proefschrift heb ik een bijdrage 
proberen te leveren aan het gevecht van de mensheid tegen ziekte in de lever. Met 
name concentreer ik mij hierbij op twee vormen van virale infectie van de lever 
(Hepatitis C en Hepatitis E), ziekte door vervetting van de lever en leverkanker. Ik doe 
dit middels literatuur studies, epidemiologische analyses en biologische 
experimentatie.  
In dit proefschrift geef ik eerst een rechtvaardiging van de gekozen strategie 
(hoofdstuk één) en probeer ik met name de keuzes die ik heb gemaakt in dit 
onderzoek uit te leggen. Vervolgens voer ik een literatuurstudie uit naar functie en 
belang van intracellulaire vetdruppeltjes voor het functioneren van de levercellen (de 
zogenaamde hepatocyten). In de darm wordt voedsel opgenomen en dit wordt 
vervolgens door de lever verwerkt. Een gedeelte van de energie die vervolgens 
beschikbaar komt in de levercel, wordt dan omgezet in triglyceriden en die worden of 
afgegeven aan het lichaam, of opgeslagen in vetdruppeltjes in de levercel. In 
hoofdstuk twee beschrijf ik een literatuurstudie naar het belang van deze vetdruppels 
voor het functioneren van de lever in gezondheid en ziekte. Het blijkt dat sommige 
virussen deze vetdruppeltjes gebruiken als een stellage waarop zij gedurende hun 
levenscyclus nieuwe virusdeeltjes kunnen bouwen. Daarmee worden dergelijke 
vetdruppeltjes ook meteen een interessant aangrijppunt bij de behandeling van 
virusziekten in de lever. 
In hoofdstuk drie werk ik het probleem van virusinfectie van de lever verder uit. Hier 
concentreer ik mij in eerste instantie op het Hepatitis C virus. Zo’n hepatitis C-infectie 
is meestal asymptomatisch en wordt in de meerderheid van de gevallen (70%) 
ongemerkt chronisch. Bij een kwart van de mensen die de chronische vorm van 
Hepatitis C hebben, ontwikkelt zich verlittekening van de lever en uit deze groep krijgt 
dan weer ongeveer 2-5% per jaar leverkanker. Mensen krijgen pas 20 of 30 jaar na de 
initiële besmetting klachten, wanneer de lever al onherstelbaar is aangetast. Er zijn 
verschillende virusstammen, maar in dit hoofdstuk concentreer ik mij op het 
zogenaamde genotype 1 en beperk ik mij tot die patiënten die vanwege verlittekening 
van de lever door het hepatitis C virus een levertransplantatie hebben ondergaan. De 
nieuw lever van dergelijke patiënten wordt vrijwel altijd geherinfecteerd door het virus 
en ik onderzoek welke antivirale middelen het best toegepast kunnen worden. De 
resultaten werden gepubliceerd in het vaktijdschift Transplantation Infectious Disease. 
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In hoofdstuk vier bouw ik op deze resultaten verder. Merkwaardigerwijze helpen 
antivirale middelen niet bij het beschermen tegen het ontstaan van leverkanker, zelfs 
al wordt de virale infectie wel efficiënt bestreden. In dit hoofdstuk doe ik experimenten 
waarbij ik levercellen behandel met een antiviraal middel en ik laat zien dat dergelijke 
middelen zelf het kankerproces kunnen bevorderen. Het gunstig effect van het 
bestrijden van het virus zou dus wel eens teniet kunnen worden gedaan door effecten 
van het medicijn zelf op het kankerproces. Deze resultaten publiceerde ik in het 
vaktijdschrift Clinics and Research in Hepatology and Gastroenterology. 
In hoofdstuk vijf richt ik mijn aandacht op een ander virus dat de lever infecteert, het 
Hepatitis E virus. Het hepatitis E-virus veroorzaakt meestal milde klachten maar kan 
zich tot een chronische infectie ontwikkelen bij sterk verminderde weerstand zoals 
transplantatiepatiënten. Daarnaast wordt in ontwikkelingslanden tot ernstige ziekte en 
sterfte tijdens de zwangerschap gezien. In dit hoofdstuk, dat gepubliceerd in het 
vooraanstaande vaktijdschrift Liver International, breng ik de ernst van het probleem 
middels een wereldwijde epidemiologische analyse in kaart.  
In de volgende drie hoofdstukken richt ik mijn pijlen dan op leververvetting. 
Leververvetting is de meest voorkomende aandoening van de lever in de Westerse 
wereld. Door een slechte voeding en een ongezonde levensstijl hoopt vet zich op in 
de lever. Als er niets gebeurt aan de onderliggende oorzaken, vervet de lever steeds 
verder, met leverontsteking tot gevolg. Uiteindelijk leidt dit weer tot ernstige schade 
aan de lever en soms tot levensbedreigend leverfalen, met een levertransplantatie nog 
als enige behandelmogelijkheid. Hoofdstuk zes is een algemene epidemiologische 
analyse van dit probleem, terwijl in hoofdstuk zeven meer naar kinderen en pubers 
wordt gekeken, terwijl in hoofdstuk acht specifiek naar volwassen met overgewicht 
worden onderzocht. Samen geven ze een goed beeld van de betrokken problematiek. 
Zowel virale leverinfectie alsook leververvetting kunnen leiden tot leverkanker en de 
laatste experimentele hoofdstukken uit dit proefschrift gaan hierover. In hoofdstuk 
negen laat ik zien hoe je organoïden kan gebruiken bij ontwerpen van betere therapie 
voor leverkanker. Organoïden zijn in een kweekschaal uit stamcellen gegroeide 
structuren die belangrijke aspecten van organen kunnen modelleren, maar ook kanker 
uit dergelijke organen. Ik laat zien dat dit ook voor leverkanker kan. Ik kon deze 
resultaten publiceren in het vooraanstaande vaktijdschrift Carcinogenesis. Vervolgens 
heb ik dit systeem geëxploiteerd om te onderzoeken of het uitschakelen van een 
bepaald stamceltype, de zogenaamde LGR5-positieve cel, waarde had bij het 
behandelen van leverkanker. Ik liet zien dat chemotherapie alleen niet in staat was 
leverkanker te bestrijden. Ook louter het uitschakelen van de LGR5-positieve cel had 
weinig effect. Werden beide behandelingen gecombineerd, dan werd de leverkanker 
wel effectief bestreden. Deze veelbelovende resultaten, te vinden in hoofdstuk tien, 
werden gepubliceerd in het vooraanstaande wetenschappelijke tijdschrift Nature 
Communications. Een laatste studie (hoofdstuk 11) richt zich niet op de kankercellen 
zelf, maar juist op de bindweefselcellen die de kankercellen omringen. Ik kon laten zien 
dat deze cellen een belangrijke rol vervullen bij het voeden en verzorgen van de 
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kankercellen, vooral tijdens chemotherapie. Deze cellen vormen dus een verder 
aangrijpingspunt voor mogelijke nieuwe therapie. Deze resultaten heb ik ook 
gepubliceerd en wel in het vooraanstaande vaktijdschrift Cellular and Molecular 
Gastroenterology and Hepatology. 
In hoofdstuk 12 probeer ik alle data die ik heb verzameld tijdens mijn 
promotieonderzoek te integreren en te bediscussiëren in het licht van het corpus aan 
contemporaine biomedische wetenschappelijke literatuur. Ik hoop daarmee een 
bijdrage te hebben geleverd aan betere behandeling van ziekten van de lever, of 
althans een fundament te hebben geschapen waarmee een opvolger van mij aan de 
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